<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40177579</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-3835</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta pharmaceutica Sinica. B</Title><ISOAbbreviation>Acta Pharm Sin B</ISOAbbreviation></Journal><ArticleTitle>Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>962</EndPage><MedlinePgn>947-962</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apsb.2024.12.030</ELocationID><Abstract><AbstractText>Booster vaccinations are highly recommended in combating the SARS-CoV-2 Omicron variant and its subvariants. However, the optimal booster vaccination strategies and related immune mechanisms with different prior vaccinations are under-revealed. In this study, we systematically evaluated the immune responses in mice and hamsters with different prime-boost regimens before their protective efficacies against Omicron were detected. We found that boosting with Ad5-nCoV, S<sub>WT</sub>-2P or S<sub>Omicron</sub>-6P induced significantly higher levels of neutralization activities against Omicron variants than CoronaVac and ZF2001 by eliciting stronger germinal center (GC) responses. Specifically, S<sub>Omicron</sub>-6P induced even stronger antibody responses against Omicron variants in CoronaVac and Ad5-nCoV-primed animals than non-Omicron-specific vaccines but with limited differences as compared to Ad5-nCoV and S<sub>WT</sub>-2P. In addition, boosting with a specific vaccine has the potential to remodel the existing immune profiles. These findings indicated that adenovirus-vectored vaccines and mRNA vaccines would be more effective than other types of vaccines as booster shots in combating Omicron infections. Moreover, the protective efficacies of the vaccines in booster vaccinations are highly related to GC reactions in secondary lymphatic organs. In summary, these findings provide timely important information on prime-boost regimens and future vaccine design.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Namei</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinghai</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Minmin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yanqiong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>RNAlfa Biotech, Hefei 230088, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Entao</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei 230026, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430062, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Jiaming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yucai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RNAlfa Biotech, Hefei 230088, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei 230031, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei 230026, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Pharm Sin B</MedlineTA><NlmUniqueID>101600560</NlmUniqueID><ISSNLinking>2211-3835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Booster vaccination</Keyword><Keyword MajorTopicYN="N">Commercial vaccines</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Omicron-specific mRNA vaccine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Subvariants</Keyword></KeywordList><CoiStatement>Yucai Wang is the inventor on pending patent applications related to the Omicron mRNA vaccine. The other authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>3</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40177579</ArticleId><ArticleId IdType="pmc">PMC11959960</ArticleId><ArticleId IdType="doi">10.1016/j.apsb.2024.12.030</ArticleId><ArticleId IdType="pii">S2211-3835(24)00487-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Med. 2022 Mar;28(3):477-480</Citation><ArticleIdList><ArticleId IdType="pubmed">35046572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2021 Jan;21(1):39-51</Citation><ArticleIdList><ArticleId IdType="pubmed">33069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2022 Dec 31;18(1):2027160</Citation><ArticleIdList><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2022 Apr;94(4):1261-1263</Citation><ArticleIdList><ArticleId IdType="pubmed">34927258</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Jul 8;385(2):179-186</Citation><ArticleIdList><ArticleId IdType="pubmed">34161052</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2022 May 16;14(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">35632800</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Jun 10;384(23):2187-2201</Citation><ArticleIdList><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Immunol. 2022 Nov 25;7(77):eade2283</Citation><ArticleIdList><ArticleId IdType="pubmed">36125366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Aug 15;396(10249):467-478</Citation><ArticleIdList><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6639-E6648</Citation><ArticleIdList><ArticleId IdType="pubmed">27702895</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2022 Feb 15;327(7):628-629</Citation><ArticleIdList><ArticleId IdType="pubmed">35061011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Oct;586(7830):567-571</Citation><ArticleIdList><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2022 Dec;11(1):1058-1071</Citation><ArticleIdList><ArticleId IdType="pubmed">35311493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2023 Jan;23(1):25-28</Citation><ArticleIdList><ArticleId IdType="pubmed">36480944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2022 Jul;28(7):1501-1508</Citation><ArticleIdList><ArticleId IdType="pubmed">35725921</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2022 Apr;94(4):1255-1256</Citation><ArticleIdList><ArticleId IdType="pubmed">34850421</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Jul 3;369(6499):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">32376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2021 Jun;21(6):803-812</Citation><ArticleIdList><ArticleId IdType="pubmed">33548194</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2016 May 20;34:335-68</Citation><ArticleIdList><ArticleId IdType="pubmed">26907215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2022 Aug;608(7923):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2022 Oct;32(10):949-952</Citation><ArticleIdList><ArticleId IdType="pubmed">35915244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2015 Mar;15(3):160-71</Citation><ArticleIdList><ArticleId IdType="pubmed">25698678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2023 Jan;29(1):247-257</Citation><ArticleIdList><ArticleId IdType="pubmed">36265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2022 Feb;28(2):401-409</Citation><ArticleIdList><ArticleId IdType="pubmed">35087233</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2020 Dec 15;53(6):1281-1295.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">33296685</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2023 Jan 4;8(1):6</Citation><ArticleIdList><ArticleId IdType="pubmed">36596766</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2022 Mar 17;386(11):1046-1057</Citation><ArticleIdList><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2021 Jul 10;398(10295):121-130</Citation><ArticleIdList><ArticleId IdType="pubmed">34181880</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2021 Aug 10;54(8):1652-1664</Citation><ArticleIdList><ArticleId IdType="pubmed">34380063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2015 Mar;15(3):149-59</Citation><ArticleIdList><ArticleId IdType="pubmed">25677494</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Feb 4;384(5):403-416</Citation><ArticleIdList><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2022 Apr 13;30(4):485-488.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">35245438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2022 Aug 24;13(1):4958</Citation><ArticleIdList><ArticleId IdType="pubmed">36002453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2018 Jun 4;215(6):1571-1588</Citation><ArticleIdList><ArticleId IdType="pubmed">29739835</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2022 Apr 21;386(16):1579-1580</Citation><ArticleIdList><ArticleId IdType="pubmed">35294809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">35921836</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2110105119</Citation><ArticleIdList><ArticleId IdType="pubmed">35994646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2023 Jan;23(1):30-32</Citation><ArticleIdList><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2022 Mar 4;375(6584):1048-1053</Citation><ArticleIdList><ArticleId IdType="pubmed">35133176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2022 Feb 3;185(3):457-466.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2021 Dec 10;374(6573):1343-1353</Citation><ArticleIdList><ArticleId IdType="pubmed">34672695</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2022 Sep;32(5):e2381</Citation><ArticleIdList><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 Apr;592(7853):283-289</Citation><ArticleIdList><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2022 Nov;28(11):2398-2405</Citation><ArticleIdList><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2022 Apr 28;185(9):1572-1587.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">35452622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2021 Dec;21(12):1654-1664</Citation><ArticleIdList><ArticleId IdType="pubmed">34324836</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2019 May 21;50(5):1132-1148</Citation><ArticleIdList><ArticleId IdType="pubmed">31117010</ArticleId></ArticleIdList></Reference><Reference><Citation>MedComm (2020). 2023 Dec 15;4(6):e460</Citation><ArticleIdList><ArticleId IdType="pubmed">38107058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2023 Mar;21(3):162-177</Citation><ArticleIdList><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2012 Mar 12;209(3):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">22370719</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2022 Feb 25;375(6583):864-868</Citation><ArticleIdList><ArticleId IdType="pubmed">35076256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2022 Apr;32(4):401-403</Citation><ArticleIdList><ArticleId IdType="pubmed">35165421</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 May;581(7807):215-220</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2022 Jun 2;386(22):2097-2111</Citation><ArticleIdList><ArticleId IdType="pubmed">35507481</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Dec 31;383(27):2603-2615</Citation><ArticleIdList><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 Sep;27(9):1525-1529</Citation><ArticleIdList><ArticleId IdType="pubmed">34262158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40174256</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority &amp; lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol&#xae;) in comparison to Shanchol&#x2122;.</ArticleTitle><Pagination><StartPage>126998</StartPage><MedlinePgn>126998</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.126998</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00295-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cholera is a vaccine-preventable disease that has faced a surge in outbreaks and a shortage of vaccines. The new generation oral cholera vaccine (OCV) BBV131, featuring a simplified single stable O1 Hikojima strain, aims to enhance production efficiency and affordability. This study evaluates BBV131's immune profile, safety, and non-inferiority compared to Shanchol&#x2122; in healthy adults and children. Adding BBV131 to the vaccine stockpile could improve supply, simplify logistics, and ease administration efforts.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomised, modified, double-blind, multi-centre, phase III trial, 1800 participants were recruited across 10 clinical trial sites across India. Participants were stratified into three age groups (adults &gt;18&#xa0;years, children &#x2265;5 to &lt;18&#xa0;years, and infants &#x2265;1 to &lt;5&#xa0;years) and were randomised in a 3:1 ratio to receive either BBV131 or Shanchol&#x2122;. All participants received two doses of the vaccine orally on days 0 and 14. Immunogenicity was assessed through blood samples collected at baseline, two weeks after each dose, and follow-ups at days 28, 56, 90, and 180. The primary endpoint focused on the proportion of participants achieving &gt;4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14&#xa0;days post two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety. Safety was evaluated throughout the study, reporting solicited and unsolicited adverse events (AEs). Another cohort of 1800 was added to the above study as an addendum to expand the safety database.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of the 1800 enrolled participants, 1794 completed the study. Post-vaccination, the percentage of participants in the BBV131 group who exhibited a&#xa0;&gt;&#xa0;4-fold increase in anti-V. cholerae antibody titres were 68.25&#xa0;% for Ogawa and 69.52&#xa0;% for Inaba-demonstrating non-inferiority to Shanchol&#x2122;, with a lower limit of 95&#xa0;% CI above the non-inferiority margin. The safety profile revealed 257 AEs among 236 participants (13.1&#xa0;%), with similar incidence across age groups and between vaccines; common AEs included dry mouth and headache.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The findings indicate that BBV131 demonstrates non-inferior immunogenicity and comparable safety to Shanchol&#x2122; in healthy Indian adults and children, supporting its potential as an effective OCV.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">CTRI/2022/01/039734.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vadrevu</LastName><ForeName>Krishna Mohan</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India. Electronic address: kmohan@bharatbiotech.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavan</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jeevan Rekha Hospital, Belagavi, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chawla</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Prakhar Hospital, Kanpur, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarthy</LastName><ForeName>B S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>King George Hospital, Vizag, Vishakapatnam, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Chandramani</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>All India Institute of Medical Sciences, Patna, Bihar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redkar</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Redkar Hospital and Research Centre, Pernem, Goa, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Savita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yandapally</LastName><ForeName>Sriharsha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Induss Hospital, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suma Priya</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Malla Reddy Narayana Multispeciality Hospital, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalatkar</LastName><ForeName>Vasant</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Khalatkar Hospital, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Vishal</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rana Hospital, Gorakhpur, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganneru</LastName><ForeName>Brunda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Siddharth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Bhargav</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmgren</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, Department of Microbiology and Immunology, University of Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patnaik</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Sai D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ella</LastName><ForeName>Raches</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bharat Biotech International Limited, Hyderabad, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BBV131</Keyword><Keyword MajorTopicYN="N">Cholera</Keyword><Keyword MajorTopicYN="N">Hikojima</Keyword><Keyword MajorTopicYN="N">Hillchol&#xae;</Keyword><Keyword MajorTopicYN="N">Inaba</Keyword><Keyword MajorTopicYN="N">Ogawa</Keyword><Keyword MajorTopicYN="N">Shanchol&#x2122;</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40174256</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.126998</ArticleId><ArticleId IdType="pii">S0264-410X(25)00295-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40172023</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice.</ArticleTitle><Pagination><StartPage>2486635</StartPage><MedlinePgn>2486635</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2025.2486635</ELocationID><Abstract><AbstractText>Emulsion-based antigen delivery systems have emerged as a novel approach to enhance the effectiveness of subunit vaccines. This study presents the development of a newly formulated oil-in-water (o/w) nanoemulsion adjuvant (NEA) composed of squalene oil and &#x3b1;-tocopheryl polyethylene glycol 1000 succinate (TPGS), which serves dual roles as an emulsifier and an immunostimulator. In comparison to AS03, an FDA-approved emulsion adjuvant that includes &#x3b1;-tocopherol, squalene, and polysorbate 80, NEA is devoid of &#x3b1;-tocopherol and exhibits comparable physicochemical properties, including particle size, polydispersity index, morphology, pH, zeta potential, and viscosity. Stability assessments conducted using Turbiscan Lab indicated that NEA undergoes an uplift process without experiencing flocculation, agglomeration or delamination. Model subunit antigens of recombinant glycoprotein E (gE) targeting the varicella-zoster virus (VZV) and highly purified hemagglutinin (HA) protein against trivalent seasonal influenza viruses (TIV) were employed to assess the adjuvanticity of NEA. It was revealed that the specific anti-gE IgG titers induced by the gE/NEA were markedly higher than those generated by gE alone, with titers of 13,000 <i>vs</i> 3,000 for the primary vaccination, and 5&#x2009;&#xd7;&#x2009;10<sup>6</sup> <i>vs</i> 5&#x2009;&#xd7;&#x2009;10<sup>4</sup> for the booster vaccination. Additionally, the TIV/NEA group exhibited a significantly improved immunogenic response relative to TIV alone across all three HA antigens at six-week after immunization, as evidenced by anti-HA titers of 256 <i>vs</i> 32. Furthermore, the NEA demonstrated no significant difference in efficacy compared to AS03 in both the VZV and TIV vaccines. Consequently, NEA presents a promising alternative to AS03 for the development of effective subunit vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Quanyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Shuoyao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhilei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co. Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004655">Emulsions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>O03S90U1F2</RegistryNumber><NameOfSubstance UI="C014225">tocophersolan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>A7YT618XBV</RegistryNumber><NameOfSubstance UI="C550253">AS03 adjuvant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089582">Adjuvants, Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber><NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="Y">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004655" MajorTopicYN="Y">Emulsions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="Y">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="Y">Squalene</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="Y">Vitamin E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="Y">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089582" MajorTopicYN="N">Adjuvants, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055598" MajorTopicYN="N">Chemical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AS03</Keyword><Keyword MajorTopicYN="N">Emulsion adjuvant</Keyword><Keyword MajorTopicYN="N">Turbiscan stability</Keyword><Keyword MajorTopicYN="N">dual-functional emulsifier</Keyword><Keyword MajorTopicYN="N">subunit vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>7</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40172023</ArticleId><ArticleId IdType="doi">10.1080/21645515.2025.2486635</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40169810</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>T-cell-derived IFN-&#x3b3; suppresses T follicular helper cell differentiation and antibody responses.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s44318-025-00414-3</ELocationID><Abstract><AbstractText>CD4<sup>+</sup> T cells play a critical role in antiviral humoral and cellular immune responses. We have previously reported that subcutaneous lymphocytic choriomeningitis virus (s.c. LCMV) infection is characterized by a stark compartmentalization of CD4<sup>+</sup> T cells, leading to strong T<sub>H</sub>1 cell polarization but virtually absent T follicular helper (T<sub>FH</sub>) cells, key drivers of humoral immunity. Here, we investigate the mechanisms responsible for this impaired T<sub>FH</sub> differentiation. We show that T-bet<sup>+</sup> cells induced by LCMV infection encompass a T<sub>H</sub>1 cell subset expressing granzyme&#xa0;B (GzmB), and a Tcf-1<sup>+</sup> cell subset that retains the potential for T<sub>FH</sub> differentiation without expressing mature T<sub>FH</sub> markers. Notably, IFN-&#x3b3; blockade enables full differentiation of Tcf-1<sup>+</sup> cells into T<sub>FH</sub> cells, formation of germinal centers, and increased antibody production. Suppression of T<sub>FH</sub> cells by IFN-&#x3b3; is not directly mediated by CD4<sup>+</sup> T cells but rather involves another cell type, likely dendritic cells (DCs). Our study provides novel insights into the mechanisms underlying early CD4<sup>+</sup> T-cell polarization and humoral responses to viruses, with the potential to facilitate the development of effective vaccine strategies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Sala</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nelli</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0004-5006-0201</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laura</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Lucia</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beccaria</LastName><ForeName>Cristian Gabriel</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-9682-4415</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>Elisa B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangione</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marotta</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0009-3160-824X</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grillo</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9064-2274</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giustini</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0005-4509-0227</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daehong</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1253-8946</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furiato</LastName><ForeName>Giuliana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malpighi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Consolo</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becher</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Merav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology and Immunology, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amit</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosselut</LastName><ForeName>Remy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guidotti</LastName><ForeName>Luca G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0002-0205-2678</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Iannacone</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9370-2671</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. iannacone.matteo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. iannacone.matteo@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy. iannacone.matteo@hsr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kuka</LastName><ForeName>Mirela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9418-1559</Identifier><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. kuka.mirela@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. kuka.mirela@hsr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PRIN-20209Y5YFZ</GrantID><Agency>Ministero dell'Universit&#xe0; e della Ricerca (MUR)</Agency><Country/></Grant><Grant><GrantID>PRIN-P2022YKH9R</GrantID><Agency>Ministero dell'Universit&#xe0; e della Ricerca (MUR)</Agency><Country/></Grant><Grant><GrantID>PRIN-20224NMLXK</GrantID><Agency>Ministero dell'Universit&#xe0; e della Ricerca (MUR)</Agency><Country/></Grant><Grant><GrantID>PRIN-P2022Z8HNC</GrantID><Agency>Ministero dell'Universit&#xe0; e della Ricerca (MUR)</Agency><Country/></Grant><Grant><GrantID>PRIN-2017ZXT5WR</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca (MIUR)</Agency><Country/></Grant><Grant><GrantID>SIR-RBSI14BAO5</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca (MIUR)</Agency><Country/></Grant><Grant><GrantID>PE00000007,INF-ACT</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca (MIUR)</Agency><Country/></Grant><Grant><GrantID>GR-2021-12372615</GrantID><Agency>Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (AIFA)</Agency><Country/></Grant><Grant><GrantID>RF-2018-12365801</GrantID><Agency>Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (AIFA)</Agency><Country/></Grant><Grant><GrantID>Consolidator Grant 725038</GrantID><Agency>EC | European Research Council (ERC)</Agency><Country/></Grant><Grant><GrantID>Proof of Concept Grant 957502</GrantID><Agency>EC | European Research Council (ERC)</Agency><Country/></Grant><Grant><GrantID>Sponsored Research Agreements</GrantID><Agency>Gilead Sciences (Gilead)</Agency><Country/></Grant><Grant><GrantID>Sponsored Research Agreements</GrantID><Agency>Asher Biotherapeutics</Agency><Country/></Grant><Grant><GrantID>Sponsored Research Agreements</GrantID><Agency>Vir Biotechnology (Vir)</Agency><Country/></Grant><Grant><GrantID>19891</GrantID><Agency>Italian Association for Cancer Research (AIRC)</Agency><Country/></Grant><Grant><GrantID>22737</GrantID><Agency>Italian Association for Cancer Research (AIRC)</Agency><Country/></Grant><Grant><GrantID>Donation</GrantID><Agency>Fondazione SAME</Agency><Country/></Grant><Grant><GrantID>Fellowship</GrantID><Agency>Fondazione Prossimo Mio</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell Responses</Keyword><Keyword MajorTopicYN="N">CD4+ T Cells</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword><Keyword MajorTopicYN="N">Viral Infection</Keyword></KeywordList><CoiStatement>Disclosure and competing interests statement. MI participated in advisory boards/consultantship for Asher Biotherapeutics, GentiBio, Clexio Biosciences, Sybilla Biotech, BlueJay Therapeutics, Bristol Myers Squibb, Aligos Therapeutics and receives funding from Asher Biotherapeutics and VIR Biotechnology. LGG participated in boards, advisory boards and consultantships for Genenta Science, Epsilen Bio, Gilead Sciences, Antios Therapeutics, Aligos Therapeutics, Medicxi, Chroma Medicine and Ananda Immunotherapies. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40169810</ArticleId><ArticleId IdType="doi">10.1038/s44318-025-00414-3</ArticleId><ArticleId IdType="pii">10.1038/s44318-025-00414-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abed NS, Chace JH, Cowdery JS (1994) T cell-independent and T cell-dependent B cell activation increases IFN-gamma R expression and renders B cells sensitive to IFN-gamma-mediated inhibition. J Immunol 153:3369&#x2013;3377</Citation><ArticleIdList><ArticleId IdType="pubmed">7523492</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.153.8.3369</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo-D&#xed;az NM, Bachus H, Papillion A, Randall TD, Akther J, Rosenberg AF, Le&#xf3;n B, Ballesteros-Tato A (2023) Interferon-&#x3b3; production by Tfh cells is required for CXCR3<sup>+</sup> pre-memory B cell differentiation and subsequent lung-resident memory B cell responses. Immunity 56:2358&#x2013;2372.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">37699392</ArticleId><ArticleId IdType="pmc">10592015</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2023.08.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM (2004) Sustained IL-12 signaling is required for Th1 development. J Immunol 172:61&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">14688310</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.172.1.61</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstr&#xe5;hle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L et al (2018) Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun 9:2419</Citation><ArticleIdList><ArticleId IdType="pubmed">29925878</ArticleId><ArticleId IdType="pmc">6010471</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04724-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley LM, Dalton DK, Croft M (1996) A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 157:1350&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pubmed">8759714</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.157.4.1350</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US et al (2018) Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest 128:4588&#x2013;4603</Citation><ArticleIdList><ArticleId IdType="pubmed">30091725</ArticleId><ArticleId IdType="pmc">6159997</ArticleId><ArticleId IdType="doi">10.1172/JCI121960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Chow RD, Song E, Mao T, Israelow B, Kamath K, Bozekowski J, Haynes WA, Filler RB, Menasche BL et al (2022) High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. Sci Immunol 7:eabl5652</Citation><ArticleIdList><ArticleId IdType="pubmed">34914544</ArticleId><ArticleId IdType="pmc">8977051</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abl5652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chodisetti SB, Fike AJ, Domeier PP, Singh H, Choi NM, Corradetti C, Kawasawa YI, Cooper TK, Caricchio R, Rahman ZSM (2020) Type II but not type I IFN signaling is indispensable for TLR7-promoted development of autoreactive B cells and systemic autoimmunity. J Immunol 204:796&#x2013;809</Citation><ArticleIdList><ArticleId IdType="pubmed">31900342</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1901175</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, Lao C, Crotty S (2011) ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 34:932&#x2013;946</Citation><ArticleIdList><ArticleId IdType="pubmed">21636296</ArticleId><ArticleId IdType="pmc">3124577</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2011.03.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousens LP, Orange JS, Su HC, Biron CA (1997a) Interferon-&#x3b1;/&#x3b2; inhibition of interleukin 12 and interferon-&#x3b3; production in vitro and endogenously during viral infection. Proc Natl Acad Sci USA 94:634&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pubmed">9012836</ArticleId><ArticleId IdType="pmc">19565</ArticleId><ArticleId IdType="doi">10.1073/pnas.94.2.634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousens LP, Orange JS, Su HC, Biron CA (1997b) Interferon-&#x3b1;/&#x3b2; inhibition of interleukin 12 and interferon-&#x3b3; production in vitro and endogenously during viral infection. Proc Natl Acad Sci USA 94:634&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pubmed">9012836</ArticleId><ArticleId IdType="pmc">19565</ArticleId><ArticleId IdType="doi">10.1073/pnas.94.2.634</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S (2011) Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pubmed">21314428</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101400</ArticleId></ArticleIdList></Reference><Reference><Citation>Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, McCarthy SA, Davies RM, Li H (2021) Twelve years of SAMtools and BCFtools. Gigascience, 10:giab008</Citation></Reference><Reference><Citation>De Giovanni M, Cutillo V, Giladi A, Sala E, Maganuco CG, Medaglia C, Di Lucia P, Bono E, Cristofani C, Consolo E et al (2020) Gene Expression Omnibus GSE130009 ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130009 ) [DATASET]</Citation></Reference><Reference><Citation>De Giovanni M, Cutillo V, Giladi A, Sala E, Maganuco CG, Medaglia C, Di Lucia P, Bono E, Cristofani C, Consolo E et al (2020) Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4<sup>+</sup> T cells. Nat Immunol 21:321&#x2013;330</Citation><ArticleIdList><ArticleId IdType="pubmed">32066949</ArticleId><ArticleId IdType="pmc">7043938</ArticleId><ArticleId IdType="doi">10.1038/s41590-020-0596-6</ArticleId></ArticleIdList></Reference><Reference><Citation>DiToro D, Winstead CJ, Pham D, Witte S, Andargachew R, Singer JR, Wilson CG, Zindl CL, Luther RJ, Silberger DJ et al (2018) Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells. Science 361:eaao2933</Citation><ArticleIdList><ArticleId IdType="pubmed">30213884</ArticleId><ArticleId IdType="pmc">6501592</ArticleId><ArticleId IdType="doi">10.1126/science.aao2933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29:15&#x2013;21</Citation></Reference><Reference><Citation>Eisenbarth SC (2019) Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol, 19:89&#x2013;103</Citation></Reference><Reference><Citation>Elsner RA, Smita S, Shlomchik MJ (2024) IL-12 induces a B cell-intrinsic IL-12/IFN&#x3b3; feed-forward loop promoting extrafollicular B cell responses. Nat Immunol 25:1283&#x2013;1295</Citation><ArticleIdList><ArticleId IdType="pubmed">38862796</ArticleId><ArticleId IdType="doi">10.1038/s41590-024-01858-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallet B, Narr K, Ertuna YI, Remy M, Sommerstein R, Cornille K, Kreutzfeldt M, Page N, Zimmer G, Geier F (2016) Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci Immunol 1:eaah6817</Citation><ArticleIdList><ArticleId IdType="pubmed">27872905</ArticleId><ArticleId IdType="pmc">5115616</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aah6817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore A, Sala E, Laura C, Riba M, Nelli M, Fumagalli V, Oberrauch F, Mangione M, Cristofani C, Provero P et al (2023) A fluorescent reporter model for the visualization and characterization of T<sub>DC</sub>. Eur J Immunol 53:e2350529</Citation><ArticleIdList><ArticleId IdType="pubmed">37741290</ArticleId><ArticleId IdType="doi">10.1002/eji.202350529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli V, Rav&#xe0; M, Marotta D, Di Lucia P, Laura C, Sala E, Grillo M, Bono E, Giustini L, Perucchini C et al (2021) Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Sci Immunol 7:eabl9929</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl9929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli V, Rav&#xe0; M, Marotta D, Di Lucia P, Bono EB, Giustini L, De Leo F, Casalgrandi M, Monteleone E, Mouro V et al. (2024) Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat Immunol, 25:633&#x2013;643</Citation></Reference><Reference><Citation>Hale JS, Youngblood B, Latner DR, Mohammed AUR, Ye L, Akondy RS, Wu T, Iyer SS, Ahmed R (2013) Distinct memory CD4+ T cells with commitment to T follicular helper-and T helper 1-cell lineages are generated after acute viral infection. Immunity 38:805&#x2013;817</Citation><ArticleIdList><ArticleId IdType="pubmed">23583644</ArticleId><ArticleId IdType="pmc">3741679</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2013.02.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231&#x2013;243</Citation><ArticleIdList><ArticleId IdType="pubmed">16498452</ArticleId><ArticleId IdType="doi">10.1038/nri1783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DS, Obeng-Adjei N, Ly A, Ioannidis LJ, Crompton PD (2017) Emerging concepts in T follicular helper cell responses to malaria. Int J Parasitol 47:105&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">27866903</ArticleId><ArticleId IdType="doi">10.1016/j.ijpara.2016.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26:659&#x2013;668</Citation><ArticleIdList><ArticleId IdType="pubmed">8605935</ArticleId><ArticleId IdType="doi">10.1002/eji.1830260323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O&#x2019;Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547&#x2013;549</Citation><ArticleIdList><ArticleId IdType="pubmed">8097338</ArticleId><ArticleId IdType="doi">10.1126/science.8097338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, Mildner A, Cohen N, Jung S, Tanay A, Amit I (2014) Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343:776&#x2013;779</Citation><ArticleIdList><ArticleId IdType="pubmed">24531970</ArticleId><ArticleId IdType="pmc">4412462</ArticleId><ArticleId IdType="doi">10.1126/science.1247651</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S (2009) Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325:1006&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="pubmed">19608860</ArticleId><ArticleId IdType="pmc">2766560</ArticleId><ArticleId IdType="doi">10.1126/science.1175870</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F et al (2002) In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17:211&#x2013;220</Citation><ArticleIdList><ArticleId IdType="pubmed">12196292</ArticleId><ArticleId IdType="pmc">3689299</ArticleId><ArticleId IdType="doi">10.1016/S1074-7613(02)00365-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced aligner with low memory requirements. Nat Methods, 12:357&#x2013;360</Citation></Reference><Reference><Citation>Komai-Koma M, Ji Y, Cao H, Liu Z, McSharry C, Xu D (2021) Monophosphoryl lipid A directly regulates Th1 cytokine production in human CD4+ T-cells through Toll-like receptor 2 and 4. Immunobiology 226:152132</Citation><ArticleIdList><ArticleId IdType="pubmed">34478947</ArticleId><ArticleId IdType="doi">10.1016/j.imbio.2021.152132</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger PD, Goldberg MF, Hong SW, Osum KC, Langlois RA, Kotov DI, Dileepan T, Jenkins MK (2021) Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells. Immunity 54:687&#x2013;701.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">33773107</ArticleId><ArticleId IdType="pmc">8495663</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2021.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuka M, Iannacone M (2022) Heterogeneity in antiviral B cell responses: Lessons from the movies. Immunol Rev, 306:224&#x2013;233</Citation></Reference><Reference><Citation>Kuka M, Munitic I, Ashwell JD (2012) Identification and characterization of polyclonal &#x3b1;&#x3b2;-T cells with dendritic cell properties. Nat Commun 3:1223</Citation><ArticleIdList><ArticleId IdType="pubmed">23187623</ArticleId><ArticleId IdType="doi">10.1038/ncomms2223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-M, Fleige A, Forman R, Cho S, Khan AA, Lin L-L, Nguyen DT, O&#x2019;Hara-Hall A, Yin Z, Hunter CA et al (2015a) Gene Expression Omnibus GSE64594 ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64594 ) [DATASET]</Citation></Reference><Reference><Citation>Lee H-M, Fleige A, Forman R, Cho S, Khan AA, Lin L-L, Nguyen DT, O&#x2019;Hara-Hall A, Yin Z, Hunter CA et al (2015b) IFN&#x3b3; signaling endows DCs with the capacity to control type I inflammation during parasitic infection through promoting T-bet+ regulatory T cells. PLoS Pathog 11:e1004635</Citation><ArticleIdList><ArticleId IdType="pubmed">25658840</ArticleId><ArticleId IdType="pmc">4450074</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1004635</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30:923&#x2013;930</Citation></Reference><Reference><Citation>Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, O&#x2019;Shea JJ (2001) T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 98:15137&#x2013;15142</Citation><ArticleIdList><ArticleId IdType="pubmed">11752460</ArticleId><ArticleId IdType="pmc">64996</ArticleId><ArticleId IdType="doi">10.1073/pnas.261570598</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;nnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, Soon MSF, Fogg LG, Nair AS, Liligeto U et al (2017) Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria. Sci Immunol 2:eaal2192</Citation><ArticleIdList><ArticleId IdType="pubmed">28345074</ArticleId><ArticleId IdType="pmc">5365145</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aal2192</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628&#x2013;1632</Citation><ArticleIdList><ArticleId IdType="pubmed">17569868</ArticleId><ArticleId IdType="doi">10.1126/science.1138963</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Melville J (2018) Umap: uniform manifold approximation and projection for dimension reduction. Preprint at https://arxiv.org/abs/1802.03426</Citation></Reference><Reference><Citation>Mempel TR, Henrickson SE, Von Andrian UH (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154&#x2013;159</Citation><ArticleIdList><ArticleId IdType="pubmed">14712275</ArticleId><ArticleId IdType="doi">10.1038/nature02238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza A, Yewdell WT, Hoyos B, Schizas M, Bou-Puerto R, Michaels AJ, Brown CC, Chaudhuri J, Rudensky AY (2021) Assembly of a spatial circuit of T-bet-expressing T and B lymphocytes is required for antiviral humoral immunity. Sci Immunol 6:eabi4710</Citation><ArticleIdList><ArticleId IdType="pubmed">34117110</ArticleId><ArticleId IdType="pmc">8418793</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abi4710</ArticleId></ArticleIdList></Reference><Reference><Citation>Miro F, Nobile C, Blanchard N, Lind M, Filipe-Santos O, Fieschi C, Chapgier A, Vogt G, de Beaucoudrey L, Kumararatne DS et al (2006) T cell-dependent activation of dendritic cells requires IL-12 and IFN-gamma signaling in T cells. J Immunol 177:3625&#x2013;3634</Citation><ArticleIdList><ArticleId IdType="pubmed">16951322</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.177.6.3625</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagi T, Gil MP, Wang X, Louten J, Chu W-M, Biron CA (2007) High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med 204:2383&#x2013;2396</Citation><ArticleIdList><ArticleId IdType="pubmed">17846149</ArticleId><ArticleId IdType="pmc">2118450</ArticleId><ArticleId IdType="doi">10.1084/jem.20070401</ArticleId></ArticleIdList></Reference><Reference><Citation>Myles A, Gearhart PJ, Cancro MP (2017) Signals that drive T-bet expression in B cells. Cell Immunol 321:3&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">28923237</ArticleId><ArticleId IdType="pmc">6191851</ArticleId><ArticleId IdType="doi">10.1016/j.cellimm.2017.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S, Kanno Y, Takahashi H, Jankovic D, Lu KT, Johnson TA, Sun HW, Vahedi G, Hakim O, Handon R et al (2011) Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 35:919&#x2013;931</Citation><ArticleIdList><ArticleId IdType="pubmed">22195747</ArticleId><ArticleId IdType="pmc">3244883</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2011.11.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA (2000) Interferon &#x3b1;/&#x3b2;-mediated inhibition and promotion of interferon &#x3b3;: STAT1 resolves a paradox. Nat Immunol 1:70&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">10881178</ArticleId><ArticleId IdType="doi">10.1038/76940</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O&#x2019;Shea JJ, Biron CA (2002) Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297:2063&#x2013;2066</Citation><ArticleIdList><ArticleId IdType="pubmed">12242445</ArticleId><ArticleId IdType="doi">10.1126/science.1074900</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeng-Adjei N, Portugal S, Holla P, Li S, Sohn H, Ambegaonkar A, Skinner J, Bowyer G, Doumbo OK, Traore B et al (2017) Malaria-induced interferon-&#x3b3; drives the expansion of Tbethi atypical memory B cells. PLoS Pathog 13:e1006576</Citation><ArticleIdList><ArticleId IdType="pubmed">28953967</ArticleId><ArticleId IdType="pmc">5633206</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1006576</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeng-Adjei N, Portugal S, Tran TM, Yazew TB, Skinner J, Li S, Jain A, Felgner PL, Doumbo OK, Kayentao K et al (2015) Circulating Th1-cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children. Cell Rep 13:425&#x2013;439</Citation><ArticleIdList><ArticleId IdType="pubmed">26440897</ArticleId><ArticleId IdType="pmc">4607674</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SA, Seki A, Rutz S (2019) Ribonucleoprotein transfection for CRISPR/Cas9-mediated gene knockout in primary T cells. Curr Protoc Immunol 124:e69</Citation><ArticleIdList><ArticleId IdType="pubmed">30334617</ArticleId><ArticleId IdType="doi">10.1002/cpim.69</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H (1998) Virus&#x2010;specific major MHC class II&#x2010;restricted TCR&#x2010;transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 28:390&#x2013;400</Citation><ArticleIdList><ArticleId IdType="pubmed">9485218</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199801)28:01&lt;390::AID-IMMU390&gt;3.0.CO;2-O</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxenius A, Karrer U, Zinkernagel RM, Hengartner H (1999) IL-12 is not required for induction of type 1 cytokine responses in viral infections. J Immunol 162:965&#x2013;973</Citation><ArticleIdList><ArticleId IdType="pubmed">9916721</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.162.2.965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pien GC, Biron CA (2000) Compartmental differences in NK cell responsiveness to IL-12 during lymphocytic choriomeningitis virus infection. J Immunol 164:994&#x2013;1001</Citation><ArticleIdList><ArticleId IdType="pubmed">10623849</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.164.2.994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J (2014) Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity 40:367&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pubmed">24631156</ArticleId><ArticleId IdType="pmc">3992517</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2014.02.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt RL, Liang H-E, Locksley RM (2009) Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 10:385&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pubmed">19252490</ArticleId><ArticleId IdType="pmc">2714053</ArticleId><ArticleId IdType="doi">10.1038/ni.1715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov AV, Marrack P, Rubtsova K (2017) T-bet expressing B cells&#x2014;novel target for autoimmune therapies. Cell Immunol 321:35&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">28641866</ArticleId><ArticleId IdType="doi">10.1016/j.cellimm.2017.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P (2017) B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest 127:1392&#x2013;1404</Citation><ArticleIdList><ArticleId IdType="pubmed">28240602</ArticleId><ArticleId IdType="pmc">5373868</ArticleId><ArticleId IdType="doi">10.1172/JCI91250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryg-Cornejo V, Ioannidis LJ, Ly A, Chiu CY, Tellier J, Hill DL, Preston SP, Pellegrini M, Yu D, Nutt SL et al (2016) Severe malaria infections impair germinal center responses by inhibiting T follicular helper cell differentiation. Cell Rep 14:68&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">26725120</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammicheli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C, Maganuco CG, Fallet B, Ganzer L et al (2016) Inflammatory monocytes hinder antiviral B cell responses. Sci Immunol 1:eaah6789</Citation><ArticleIdList><ArticleId IdType="pubmed">27868108</ArticleId><ArticleId IdType="pmc">5111729</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aah6789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schijns VECJ, Haagmans BL, Wierda CMH, Kruithof B, Heijnen IAFM, Alber G, Horzinek MC (1998) Mice lacking IL-12 develop polarized Th1 cells during viral infection. J Immunol 160:3958&#x2013;3964</Citation><ArticleIdList><ArticleId IdType="pubmed">9558103</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.160.8.3958</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pubmed">17981204</ArticleId><ArticleId IdType="doi">10.1016/S0065-2776(07)96002-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz EG, Mariani L, Radbruch A, H&#xf6;fer T (2009) Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity 30:673&#x2013;683</Citation><ArticleIdList><ArticleId IdType="pubmed">19409816</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2009.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sercan O, Stoycheva D, H&#xe4;mmerling GJ, Arnold B, Sch&#xfc;ler T (2010) IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation. J Immunol 184:2855&#x2013;2862</Citation><ArticleIdList><ArticleId IdType="pubmed">20164422</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0902708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AA, Groom JR (2021) Transcription tipping points for T follicular helper cell and T-helper 1 cell fate commitment. Cell Mol Immunol, 18:528&#x2013;538</Citation></Reference><Reference><Citation>Smith T, Heger A, Sudbery I (2017) UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res, 27:491&#x2013;499</Citation></Reference><Reference><Citation>Snell LM, Osokine I, Yamada DH, De la Fuente JR, Elsaesser HJ, Brooks DG (2016) Overcoming CD4 Th1 cell fate restrictions to sustain antiviral CD8 T cells and control persistent virus infection. Cell Rep 16:3286&#x2013;3296</Citation><ArticleIdList><ArticleId IdType="pubmed">27653690</ArticleId><ArticleId IdType="pmc">5669380</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.08.065</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone SL, Peel JN, Scharer CD, Risley CA, Chisolm DA, Schultz MD, Yu B, Ballesteros-Tato A, Wojciechowski W, Mousseau B et al (2019) T-bet transcription factor promotes antibody-secreting cell differentiation by limiting the inflammatory effects of IFN-&#x3b3; on B cells. Immunity 50:1172&#x2013;1187.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">31076359</ArticleId><ArticleId IdType="pmc">6929688</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, Satija R (2019) Comprehensive integration of single-cell data. Cell 177:1888&#x2013;1902.e21</Citation><ArticleIdList><ArticleId IdType="pubmed">31178118</ArticleId><ArticleId IdType="pmc">6687398</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655&#x2013;669</Citation><ArticleIdList><ArticleId IdType="pubmed">10761931</ArticleId><ArticleId IdType="doi">10.1016/S0092-8674(00)80702-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuzlak S, Dejean AS, Iannacone M, Quintana FJ, Waisman A, Ginhoux F, Korn T, Becher B (2021) Repositioning T<sub>H</sub> cell polarization from single cytokines to complex help. Nat Immunol 22:1210&#x2013;1217</Citation><ArticleIdList><ArticleId IdType="pubmed">34545250</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01009-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger S, Seidl M, van Schouwenburg P, Rakhmanov M, Bulashevska A, Frede N, Grimbacher B, Pfeiffer J, Schrenk K, Munoz L et al (2018) The T<sub>H</sub>1 phenotype of follicular helper T cells indicates an IFN-&#x3b3;-associated immune dysregulation in patients with CD21low common variable immunodeficiency. J Allergy Clin Immunol 141:730&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pubmed">28554560</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2017.04.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinuesa CG, Linterman MA, Yu D, MacLennan IC (2016) Follicular helper T cells. Annu Rev Immunol 34:335&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">26907215</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakil AE, Wang ZE, Ryan JC, Fowell DJ, Locksley RM (1998) Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development. J Exp Med 188:1651&#x2013;1656</Citation><ArticleIdList><ArticleId IdType="pubmed">9802977</ArticleId><ArticleId IdType="pmc">2212510</ArticleId><ArticleId IdType="doi">10.1084/jem.188.9.1651</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KP, Mills KH (2013) Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol 34:521&#x2013;530</Citation><ArticleIdList><ArticleId IdType="pubmed">23973621</ArticleId><ArticleId IdType="doi">10.1016/j.it.2013.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein JS, Laidlaw BJ, Lu Y, Wang JK, Schulz VP, Li N, Herman EI, Kaech SM, Gallagher PG, Craft J (2018) STAT4 and T-bet control follicular helper T cell development in viral infections. J Exp Med 215:337&#x2013;355</Citation><ArticleIdList><ArticleId IdType="pubmed">29212666</ArticleId><ArticleId IdType="pmc">5748849</ArticleId><ArticleId IdType="doi">10.1084/jem.20170457</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmire JK, Benning N, Whitton JL (2005) Cutting edge: early IFN-gamma signaling directly enhances primary antiviral CD4+ T cell responses. J Immunol 175:5624&#x2013;5628</Citation><ArticleIdList><ArticleId IdType="pubmed">16237051</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.175.9.5624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Thurman A, Pezzulo AA, Szachowicz PJ, Li P et al (2022) Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605:146&#x2013;151</Citation><ArticleIdList><ArticleId IdType="pubmed">35314834</ArticleId><ArticleId IdType="pmc">9783543</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04630-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, Sandor K, Pai JA, Daniel B, Raju S, Wu R, Hsiung S, Qi Y, Yangdon T, Okamoto M et al (2022) BCL6-dependent TCF-1<sup>+</sup> progenitor cells maintain effector and helper CD4<sup>+</sup> T cell responses to persistent antigen. Immunity 55:1200&#x2013;1215.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">35637103</ArticleId><ArticleId IdType="pmc">10034764</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Cao Y, Xie Z, Huang Q, Bai Q, Yang X, He R, Hao Y, Wang H, Zhao T (2015) The transcription factor TCF-1 initiates the differentiation of TFH cells during acute viral infection. Nat Immunol 16:991&#x2013;999</Citation><ArticleIdList><ArticleId IdType="pubmed">26214740</ArticleId><ArticleId IdType="doi">10.1038/ni.3229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Apilado R, Coleman J, Ben-Sasson S, Tsang S, Hu-Li J, Paul WE, Huang H (2001) Interferon gamma stabilizes the T helper cell type 1 phenotype. J Exp Med 194:165&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">11457891</ArticleId><ArticleId IdType="pmc">2193457</ArticleId><ArticleId IdType="doi">10.1084/jem.194.2.165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations Annu Rev Immunol 28:445&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pubmed">20192806</ArticleId><ArticleId IdType="pmc">3502616</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-030409-101212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumaquero E, Stone SL, Scharer CD, Jenks SA, Nellore A, Mousseau B, Rosal-Vela A, Botta D, Bradley JE, Wojciechowski W et al (2019) IFN&#x3b3; induces epigenetic programming of human T-bet<sup>hi</sup> B cells and promotes TLR7/8 and IL-21 induced differentiation. Elife 8:e41641</Citation><ArticleIdList><ArticleId IdType="pubmed">31090539</ArticleId><ArticleId IdType="pmc">6544433</ArticleId><ArticleId IdType="doi">10.7554/eLife.41641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40143922</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2950-1334</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JHLT open</Title><ISOAbbreviation>JHLT Open</ISOAbbreviation></Journal><ArticleTitle>Evaluating longitudinal cytomegalovirus-specific humoral immune responses and association with DNAemia risk in seropositive lung transplant recipients.</ArticleTitle><Pagination><StartPage>100113</StartPage><MedlinePgn>100113</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100113</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhlto.2024.100113</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cytomegalovirus (CMV) is the most common viral infection among lung transplant recipients and is associated with chronic lung allograft dysfunction. There is a need for better therapeutics as well as biomarkers to enable effective stratification of CMV seropositive patient risk for developing CMV DNAemia to inform prophylaxis duration.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">CMV-specific immunoglobulin G (IgG) binding and functional responses were evaluated in a discovery cohort of longitudinal plasma samples from 51 CMV seropositive human lung transplant recipients, collected as part of the clinical trials in organ transplantation (CTOT)-20 and CTOT-22 consortium studies. Pre-transplant plasma from an additional 43 CMV seropositive lung transplant recipients was evaluated as a validation cohort.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the discovery cohort with longitudinal samples, pre-transplant plasma IgG binding to CMV surface glycoproteins glycoprotein H (gH)/glycoprotein L (gL), gH/gL/glycoprotein O (gO), and pentameric complex, as well as neutralization of CMV in epithelial cells, is associated with increased risk of CMV DNAemia post-prophylaxis. However, these results were not confirmed by the validation cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">While quantification of pre-transplant CMV-specific antibody responses showed association with DNAemia in the discovery cohort, additional clinical variables and/or known risk factors for CMV, such as patient CMV-specific T-cell responses, may need to be considered in combination with humoral immunity to effectively stratify risk of CMV DNAemia.</AbstractText><CopyrightInformation>&#xa9; 2024 International Society for Heart and Lung Transplantation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harnois</LastName><ForeName>Melissa J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Immunology, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barfield</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Systems Immunology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollara</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spies</LastName><ForeName>Connor S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Laurie D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Cliburn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Systems Immunology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Annette M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Immunology, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Permar</LastName><ForeName>Sallie R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JHLT Open</MedlineTA><NlmUniqueID>9918716187806676</NlmUniqueID><ISSNLinking>2950-1334</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CMV</Keyword><Keyword MajorTopicYN="N">CMV DNAemia</Keyword><Keyword MajorTopicYN="N">cytomegalovirus</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword><Keyword MajorTopicYN="N">lung transplant</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Melissa J. Harnois reports financial support was provided by the 10.13039/100000060National Institute of Allergy and Infectious Diseases T32 (2T32AI052077-16A1). Cliburn Chan reports financial support was provided by 10.13039/100000002NIH U01AI113315. Scott M. Palmer reports financial support was provided by the National Institute of Allergy and Infectious Diseases (U01AI113315). Scott M. Palmer reports financial support was provided by 10.13039/100000897Cystic Fibrosis Foundation (PALMER19AB0). Scott M. Palmer reports a relationship with Incyte that includes funding grants. Scott M. Palmer reports a relationship with 10.13039/100004325AstraZeneca that includes funding grants. Scott M. Palmer reports a relationship with 10.13039/100008021Bristol Myers Squibb that includes funding grants and speaking and lecture fees. Scott M. Palmer reports a relationship with 10.13039/100016477CareDx that includes funding grants. Scott M. Palmer reports a relationship with Boehringer Ingelheim Pharmaceuticals Inc. that includes funding grants and speaking and lecture fees. Scott M. Palmer reports a relationship with Altavant Sciences, Inc. that includes speaking and lecture fees. Scott M. Palmer reports a relationship with Mallinckrodt Pharmaceuticals that includes speaking and lecture fees. Scott M. Palmer reports a relationship with Natera that includes speaking and lecture fees. Sallie Permar reports a relationship with Merck Vaccines that includes consulting or advisory and funding grants. Sallie Permar reports a relationship with Moderna Inc. that includes consulting or advisory and funding grants. Sallie Permar reports a relationship with Dynavax that includes consulting or advisory. Sallie Permar reports a relationship with Pfizer Inc. that includes consulting or advisory. Sallie Permar reports a relationship with GlaxoSmithKline Inc. that includes consulting or advisory. Sallie Permar reports a relationship with Hookipa Biotech GmbH that includes consulting or advisory. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors wish to acknowledge the CTOT-20 and CTOT-22 consortium sites with investigators and research coordinators for their instrumental effort toward patient enrollment, data collection, and sample collection and processing. Duke University: John M. Reynolds (principal investigator (PI)), Katelyn Arroyo, Erika Bush, Dongfeng Chen, Courtney Frankel, Annette Jackson, Fran Kelly, Allan Kirk, Stuart Knechtle, Justin Magin, Andrew Nagler, Megan Neely, Robyn Osborne, Scott Palmer, Elizabeth Pavlisko, Laurie Snyder, Jamie Todd, Daniel Turner, Jeremy Weber. University of Toronto: Lianne Singer (PI), Iva Avramov, Cecilia Chaparro, Noori Chowdhury, Marcelo Cuesta, Victor Ferreira, Atul Humar, Shahid Husain, David Hwang, Anam Islam, Stephen Juvet, Shaf Keshavjee, Deepali Kumar, Tereza Martinu, Max Niit, Dmitry Rozenberg, Alison Tian, Jussi Tikkanen, Kathryn Tinckam. Johns Hopkins University: Pali Shah (PI), Robin Avery, Maria Bettinotti, Peter Illei, Joby Mathew, Christian Merlo, Jonathan Orens, Jonathan Schenck. University of California, Los Angeles: John Belperio (PI), Eileen Callahan, Ariss DerHovanessian, Paul Lopez, Joseph Lynch III, Elman Punzalan, Elaine Reed, David Sayah, Michael Shino, Dean Wallace, Samuel Weigt. Cleveland Clinic: Marie Budev (PI), Valeria Arrosi, Adarsh Conjeevaram, Carol Farver, Stuart Houltham, Debra Kohn, Bette Maierson, Valerie Shaner, Wayne Tsuang, Aiwen Zhang. Duke Clinical Research Institute: Jerry Kirchner. Rho, Inc.: Brian Armstrong, Michele Cosgrove, David Ikle, Karen Kesler, Heather Kopetskie, Meghan McGinn, Michele Martin, Michelle Sever. NIAID: Julia Goldstein, Yvonne Morrison, Mark Robien, Nikki Williams. We wish to acknowledge funding support for CTOT-20 and CTOT-22 (NIH National Institute of Allergy and Infectious Disease, U01AI113315), the Cystic Fibrosis Foundation (awarded to S.M.P., PALMER19AB0), and T32 Training Grant (awarded to M.J.H., 2T32AI052077-16A1).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40143922</ArticleId><ArticleId IdType="pmc">PMC11935385</ArticleId><ArticleId IdType="doi">10.1016/j.jhlto.2024.100113</ArticleId><ArticleId IdType="pii">S2950-1334(24)00062-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Azevedo L.S., Pierrotti L.C., Abdala E., et al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70:515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4496754</ArticleId><ArticleId IdType="pubmed">26222822</ArticleId></ArticleIdList></Reference><Reference><Citation>Meesing A., Razonable R.R. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78:1085&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">29961185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurihara C., Fernandez R., Safaeinili N., et al. Long-term impact of cytomegalovirus serologic status on lung transplantation in the United States. Ann Thorac Surg. 2019;107:1046&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844363</ArticleId><ArticleId IdType="pubmed">30476471</ArticleId></ArticleIdList></Reference><Reference><Citation>Balthesen M., Messerele M., Reddehase M.J. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol. 1993;67:5360&#x2013;5366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237936</ArticleId><ArticleId IdType="pubmed">8394453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos S., Vos R., Van Raemdonck D.E., Verleden G.M. Survival in adult lung transplantation: where are we in 2020? Curr Opin Organ Transplant. 2020;25:268&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">32332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J., Benvenuto L.J., Sonett J.R. Long-term outcomes and management of lung transplant recipients. Best Pract Res Clin Anaesthesiol. 2017;31:285&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">29110800</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietzen H., Hartenberger S., Jaksch P., Puchhammer-Stockl E. Association between chronic lung allograft dysfunction and human Cytomegalovirus UL40 peptide variants in lung-transplant recipients. J Heart Lung Transplant. 2021;40:900&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">34183227</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable R.R., Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33</Citation><ArticleIdList><ArticleId IdType="pubmed">30817026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A., Musk M., Lavender M., et al. Cytomegalovirus viremia in lung transplantation during and after prophylaxis. Transpl Infect Dis. 2019;21</Citation><ArticleIdList><ArticleId IdType="pubmed">30884067</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam E., Lesnick T., Kremers W., Kennedy C.C., Razonable R.R. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transplant. 2016;30:270&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">26701733</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation. 2011;91:927&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">21358366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93:248&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">18245650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunde T., Kirchner A., Hoffmeister B., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201:1031&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213133</ArticleId><ArticleId IdType="pubmed">15795239</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash K., Chandorkar A., Saharia K.K. Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update. Diagnostics (Basel) 2021;11:2&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8153332</ArticleId><ArticleId IdType="pubmed">34068377</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye A.P., Babu T.M., Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2020;34:1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920732</ArticleId><ArticleId IdType="pubmed">33115722</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder L.D., Belperio J., Budev M., et al. Highlights from the clinical trials in organ transplantation (CTOT)-20 and CTOT-22 Consortium studies in lung transplant. Am J Transplant. 2020;20:1489&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323580</ArticleId><ArticleId IdType="pubmed">32342596</ArticleId></ArticleIdList></Reference><Reference><Citation>Harnois M.J., Dennis M., Stohr D., et al. Characterization of plasma immunoglobulin G responses in elite neutralizers of human cytomegalovirus. J Infect Dis. 2022;226:1667&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205896</ArticleId><ArticleId IdType="pubmed">35970817</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts M.R., Brenchley J.M., Price D.A., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">14580882</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson C.S., Huffman T., Jenks J.A., et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci USA. 2018;115:6267&#x2013;6272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004431</ArticleId><ArticleId IdType="pubmed">29712861</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Mangiafico S.rcompanion: Functions to support extension education program evaluation. R package version 2.4.1; 2021.</Citation></Reference><Reference><Citation>Kleiber C., Zeileis A. Applied Econometrics with R. 1 ed. Springer; New York, NY: 2008.</Citation></Reference><Reference><Citation>Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914998</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar G., Boeckh M., Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221:S23&#x2013;S31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7057778</ArticleId><ArticleId IdType="pubmed">32134486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes D., Hafferty J., Fulton L., et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol. 2008;41:92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581120</ArticleId><ArticleId IdType="pubmed">18032098</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bner M., Sauer J., Rhul L., et al. Longitudinal dynamics of SARS-CoV-2 spike-specific antibody responses in patients on waiting list and after lung transplantation. J Heart Lung Transplant. 2023;42:165.</Citation></Reference><Reference><Citation>Vietzen H., Gorzer I., Honsig C., Jaksch P., Puchhammer-Stockl E. Human cytomegalovirus (HCMV)-specific antibody response and development of antibody-dependent cellular cytotoxicity against HCMV after lung transplantation. J Infect Dis. 2020;222:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157310</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075549</ArticleId><ArticleId IdType="pubmed">21481708</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmes E.C., Miller I.G., Wimberly C.E., et al. Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection. J Clin Investig. 2022;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9374380</ArticleId><ArticleId IdType="pubmed">35763348</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhard S., Vietzen H., Gorzer I., Jaksch P., Puchhammer-Stockl E. Analysis and fine specificity of the HCMV-specific cell-free and cell-associated antibody-dependent cellular phagocytosis (ADCP) responses in lung transplant recipients. Int J Mol Sci. 2021;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8348747</ArticleId><ArticleId IdType="pubmed">34360986</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadeu L., Revilla-Lopez E., Jarque M., et al. CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients. J Infect Dis. 2021;224:526&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">33245359</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder L.D., Chan C., Kwon D., et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016;193:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731614</ArticleId><ArticleId IdType="pubmed">26372850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40135893</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.</ArticleTitle><Pagination><StartPage>e0208024</StartPage><MedlinePgn>e0208024</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.02080-24</ELocationID><Abstract><AbstractText>African swine fever virus (ASFV) is the pathogen of African swine fever (ASF), and its infection causes a lethal disease in pigs, with severe pathological lesions. These changes indicate excessive inflammatory responses in infected pigs, which is the main cause of death, but the ASFV proteins worked in this physiological process and the mechanisms underlying ASFV-induced inflammation remain unclear. Here, we identify that viral I177L works in these inflammatory responses. Mechanistically, I177L facilitates TRAF6 ubiquitination that enhances its binding to TAK1, which promotes TAK1 ubiquitination and phosphorylation. These processes depend on the E3 ubiquitin ligase activity of TRAF6. The upregulation of I177L to TRAF6-TAK1 interaction and TAK1 activation is responsible for I177L's activated effect on the NF-&#x3ba;B signaling pathway. Additionally, I177L promotes assembly of the NLRP3 inflammasome and ASC oligomerization, thus leading to the activation of the NLRP3 inflammasome and the production and secretion of mature IL-1&#x3b2;. TAK1 inhibition efficiently reverses ASFV-activated NF-&#x3ba;B signaling and inflammatory responses and suppresses ASFV replication. Furthermore, I177L-deficient ASFV induces milder inflammatory responses in pigs compared with parental ASFV, which still protects pigs against ASFV challenge. The finding confirms ASFV I177L as an important proinflammatory protein <i>in vitro</i> and <i>in vivo</i> and reveals a key mechanism underlying ASFV-mediated inflammatory responses for the first time, which enriches our knowledge of the complex ASFV, thus benefiting our understanding of the interplay between ASFV infection and the host's inflammatory responses.IMPORTANCEAfrican swine fever (ASF) is a devastating viral disease in pigs, and excessive inflammatory responses induced by ASFV mainly cause death. Thus, the study of the proinflammatory virulent proteins and the detailed mechanisms are important to ASF control. Here, I177L was demonstrated to be an essential protein in ASFV-mediated inflammation, which performs by simultaneously activating the NF-&#x3ba;B signaling and the NLRP3 inflammasome. The finding elucidates the molecular mechanism underlying ASFV-activated inflammatory responses for the first time. It provides a theoretical foundation for reducing the high mortality caused by excessive inflammation and opens new avenues for small-molecule drug development and vaccine design targeting ASFV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Pan-Xue</ForeName><Initials>P-X</Initials><Identifier Source="ORCID">0009-0004-2961-6789</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.</Affiliation><Identifier Source="RINGGOLD">34752</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Wen-Ping</ForeName><Initials>W-P</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Feng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guo-Qiang</ForeName><Initials>G-Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Xu-Guang</ForeName><Initials>X-G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.</Affiliation><Identifier Source="RINGGOLD">34752</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ru</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yao-Feng</ForeName><Initials>Y-F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.</Affiliation><Identifier Source="RINGGOLD">34752</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Sen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0764-6122</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.</Affiliation><Identifier Source="RINGGOLD">34752</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4831-5103</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hai-Xue</ForeName><Initials>H-X</Initials><Identifier Source="ORCID">0000-0001-6850-1379</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">African swine fever virus</Keyword><Keyword MajorTopicYN="N">I177L</Keyword><Keyword MajorTopicYN="N">NLRP3 inflammasome</Keyword><Keyword MajorTopicYN="N">TAK1</Keyword><Keyword MajorTopicYN="N">TRAF6</Keyword><Keyword MajorTopicYN="N">inflammatory response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>26</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>26</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>26</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40135893</ArticleId><ArticleId IdType="doi">10.1128/jvi.02080-24</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40122414</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0038</ISSN><JournalIssue CitedMedium="Internet"><Volume>953</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Gene</Title><ISOAbbreviation>Gene</ISOAbbreviation></Journal><ArticleTitle>Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.</ArticleTitle><Pagination><StartPage>149436</StartPage><MedlinePgn>149436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2025.149436</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1119(25)00224-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transmission Blocking Vaccines (TBVs) are critical for malaria eradication as they aim to interrupt the transmission cycle of Plasmodium parasites. However, the development of effective TBVs is challenged by the antigenic diversity of potential vaccine targets. This study investigates the fibrinogen-related protein 1 (frep1) gene, a promising candidate for TBVs, focusing on the genetic diversity of the frep1 gene and immunogenic potential in Anopheles stephensi from southern Iran.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Analysis of 30 An. stephensi isolates collected from three malaria-endemic cities was carried out using molecular amplification, sequencing, and bioinformatics tools. The haplotype and nucleotide diversity were assessed using the DnaSP, while predicted linear B-cell epitopes were evaluated through the ABCpred. Additionally, conformational epitopes were identified via DiscoTope analysis and visualized using the PyMOL. Furthermore, MHC II-peptide interactions were examined to evaluate the potential for effective immune responses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven distinct haplotypes of the frep1 domain were identified, with synonymous nucleotide variations indicating high genetic conservation. This conservation was complemented by the identification of 16 linear B-cell epitopes with high immunogenic scores (0.80-0.97). Conformational epitopes, prominently located at the N-terminus and C-terminus, were consistent across isolates. MHC II-binding analysis revealed peptides with strong affinities to prevalent HLA alleles in Iran, suggesting effective antigen presentation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">FREP1 demonstrates purifying selection, low genetic diversity and high immunogenic potential, highlighting the suitability of the protein as a TBV candidate. The presence of conserved epitopes and strong MHC II interactions supports the potential of this protein for inducing robust immune responses. However, regional haplotype diversity suggests that vaccine strategies may need to account for local variability. These findings underscore the promise of FREP1 for TBV development and emphasize the need for further validation in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kheirkhah</LastName><ForeName>Omolbani</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirahmadi</LastName><ForeName>Sakineh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrizi</LastName><ForeName>Akram Abouie</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raz</LastName><ForeName>Abbasali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran. Electronic address: raz.biotech@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gene</MedlineTA><NlmUniqueID>7706761</NlmUniqueID><ISSNLinking>0378-1119</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anopheles stephensi</Keyword><Keyword MajorTopicYN="N">Epitope prediction</Keyword><Keyword MajorTopicYN="N">FREP1 domain</Keyword><Keyword MajorTopicYN="N">Genetic diversity</Keyword><Keyword MajorTopicYN="N">MHC II interactions</Keyword><Keyword MajorTopicYN="N">Transmission Blocking Vaccine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>20</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40122414</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2025.149436</ArticleId><ArticleId IdType="pii">S0378-1119(25)00224-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40120437</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14&#xa0;years: A randomized and open-label clinical trial.</ArticleTitle><Pagination><StartPage>127015</StartPage><MedlinePgn>127015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00312-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The World Health Organization (WHO) urges global administration of at least one dose of the HPV vaccine, particularly for girls aged 9-14, to work towards the elimination of cervical cancer. However, data on the efficacy of a single dose of Cecolin&#xae;, a bivalent HPV vaccine, remain quite limited. Therefore, it is crucial to design studies investigating the protective effects of a single dose of Cecolin&#xae; in Chinese girls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The randomized clinical trial began on February 23, 2023 (NCT06345885). 198 Chinese girls aged 9-14 received a single dose of Cecolin&#xae; or Gardasil&#xae;. Seroconversion rates and geometric mean titers (GMTs) for HPV16 and HPV18 were assessed at one and two months post-vaccination. Non-inferiority was declared if the lower limit of the 95&#xa0;% confidence interval (CI) exceeded -5&#xa0;%. Safety of vaccine was evaluated in all vaccinated participants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At one month post-vaccination, both the Cecolin&#xae; and Gardasil&#xae; groups achieved 100&#xa0;% seroconversion for HPV16 antibodies. The seroconversion rates for HPV18 were 97.9&#xa0;% (95&#xa0;% CI: 92.5&#xa0;%, 99.7&#xa0;%) in the Cecolin&#xae; group and 95.6&#xa0;% (95&#xa0;% CI: 89.1&#xa0;%, 98.8&#xa0;%) in the Gardasil&#xae; group. The GMTs in the Cecolin&#xae; group were significantly higher than those in the Gardasil&#xae; group for both HPV types, with GMT ratios of 1.5 (1.1, 2.1) for HPV16 and 2.84 (2.0, 4.1) for HPV18. The seroconversion rates and GMT ratios one month after a single dose of Cecolin&#xae; were non-inferior to those of Gardasil&#xae;, with results remaining consistent at two months. The incidence of adverse events was similar between the two groups throughout the study, with no statistically significant differences.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The immunogenicity and safety of a single dose of Cecolin&#xae; in Chinese girls aged 9-14&#xa0;years were comparable to those of Gardasil. These findings support the use of single-dose Cecolin&#xae; to enhance HPV vaccination coverage for cervical cancer prevention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Fangqin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Kaili</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Junrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Sumei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Chun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Zhaofeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, school of Public Health, Xiamen University, Xiamen 361102, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiufen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zhangping Center for Disease Control and Prevention, Zhangping 364499, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Xiamen City Center for Disease Control and Prevention, Xiamen 361021, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongjuan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China. Electronic address: dongj8888@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Human papillomavirus vaccine</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Randomized controlled clinical trial</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Single dose</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dongjuan Zhang reports financial support was provided by Xiamen Innovax Biotech Co. Ltd. Kaili Du, Chun Fan and Qiufen Zhang reports a relationship with Xiamen Innovax Biotech Co. Ltd. that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>22</Day><Hour>19</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40120437</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127015</ArticleId><ArticleId IdType="pii">S0264-410X(25)00312-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40118915</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">55</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-025-01106-z</ELocationID><Abstract><AbstractText>Several human papillomavirus (HPV) L1-based virus-like particle (VLP) vaccines are in development to meet future global vaccination needs. Type-specific monoclonal antibodies with good reactivity to all types of vaccines are urgently needed to evaluate vaccine potency. In this study, binding activity, neutralizing activity, conformational sensitivity, immunodominance in human serum, and versatility were compared among antibodies. A broad-spectrum binding antibody (C4-F5-127) was selected as the capture antibody; four type-specific neutralizing antibodies (6-F5-77, 11-F5-187, 16-F5-196, and 18-F5-203) were selected as detection antibodies for HPV6, 11, 16, and 18, respectively. These antibodies formed a standardized and universal in vitro relative potency (IVRP) assay kit. High-resolution cryo-electron microscopy (cryo-EM) structures of HPV6-6-F5-77, HPV11-11-F5-187, HPV16-16-F5-196 and HPV18-18-F5-203 complexes define the location and nature of epitopes, revealing serotype specific binding modes and neutralization mechanisms. The IVRP results were correlated with potency data from mouse models, offering an efficient alternative to in vivo potency experiments.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hu</LastName><ForeName>Jinpan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jia</LastName><ForeName>Zijing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Wangjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qingfeng</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Haiyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jianhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co. Ltd, 210000, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lingjie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co. Ltd, 210000, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fengze</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co. Ltd, 210000, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yingping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Danfeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Guangxi Institute for Drug Control, Nanning, 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaowei</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3374-1038</Identifier><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ningshao</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0179-5266</Identifier><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiangxi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China. xiangxi@ibp.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4246-8889</Identifier><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), No. 31 Huatuo Street, Daxing District, 102629, Beijing, China. huangweijin@nifdc.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>22</Day><Hour>20</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>22</Day><Hour>20</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>22</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40118915</ArticleId><ArticleId IdType="pmc">PMC11928608</ArticleId><ArticleId IdType="doi">10.1038/s41541-025-01106-z</ArticleId><ArticleId IdType="pii">10.1038/s41541-025-01106-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.71, 209&#x2013;249 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Durst, M., Gissmann, L., Ikenberg, H. &amp; zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA80, 3812&#x2013;3815 (1983).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394142</ArticleId><ArticleId IdType="pubmed">6304740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer2, 342&#x2013;350 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12044010</ArticleId></ArticleIdList></Reference><Reference><Citation>Group, F. I. S. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356, 1915&#x2013;1927 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17494925</ArticleId></ArticleIdList></Reference><Reference><Citation>De Martel, C., Plummer, M., Vignat, J. &amp; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer141, 664&#x2013;670 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520228</ArticleId><ArticleId IdType="pubmed">28369882</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvolti, S. et al. The Global Demand and Supply Balance of the Human Papillomavirus Vaccine: Implications for the Global Strategy for the Elimination of Cervical Cancer. Vaccines12, 10.3390/vaccines12010004 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10820532</ArticleId><ArticleId IdType="pubmed">38276663</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser Sixty-first report, 1-267 (WHO, 2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">29144075</ArticleId></ArticleIdList></Reference><Reference><Citation>Shank-Retzlaff, M. et al. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum. Vaccin1, 191&#x2013;197 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">17012876</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlrich, S., Coppens, E., Moysan, F., Nelson, S. &amp; Nougarede, N. In Alternatives to Animal Testing Ch. 10, 76&#x2013;82 (Springer, Singapore, 2019).</Citation></Reference><Reference><Citation>Metz, B., Hendriksen, C. F., Jiskoot, W. &amp; Kersten, G. F. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine20, 2411&#x2013;2430 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12057596</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, W. et al. Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs. NPJ Vaccines5, 89 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511963</ArticleId><ArticleId IdType="pubmed">33042588</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, C. et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum. Vaccin Immunother.10, 2168&#x2013;2174 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896759</ArticleId><ArticleId IdType="pubmed">25424920</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. Emerg. Microbes Infect.8, 1721&#x2013;1733 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883418</ArticleId><ArticleId IdType="pubmed">31769733</ArticleId></ArticleIdList></Reference><Reference><Citation>He, M. et al. Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding. J. Virol.95, 10.1128/JVI.01587-20 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092703</ArticleId><ArticleId IdType="pubmed">33472937</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards, K. F., Bienkowska-Haba, M., Dasgupta, J., Chen, X. S. &amp; Sapp, M. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J. Virol.87, 11426&#x2013;11437 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807331</ArticleId><ArticleId IdType="pubmed">23966387</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck, C. B. et al. Arrangement of L2 within the papillomavirus capsid. J. Virol.82, 5190&#x2013;5197 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395198</ArticleId><ArticleId IdType="pubmed">18367526</ArticleId></ArticleIdList></Reference><Reference><Citation>Day, P. M. &amp; Schiller, J. T. The role of furin in papillomavirus infection. Fut. Microbiol.4, 1255&#x2013;1262 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829937</ArticleId><ArticleId IdType="pubmed">19995186</ArticleId></ArticleIdList></Reference><Reference><Citation>Leder, C., Kleinschmidt, J. A., Wiethe, C. &amp; Muller, M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol.75, 9201&#x2013;9209 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114488</ArticleId><ArticleId IdType="pubmed">11533183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastrana, D. V. et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology321, 205&#x2013;216 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15051381</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastrana, D. V. et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology337, 365&#x2013;372 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15885736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossadegh, N. et al. Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology326, 57&#x2013;66 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15262495</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, K. M. et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol.83, 2067&#x2013;2074 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643729</ArticleId><ArticleId IdType="pubmed">19073722</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc.4, 372&#x2013;384 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750034</ArticleId><ArticleId IdType="pubmed">19247287</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, M. J., Seitz, H., Towne, V., Muller, M. &amp; Finnefrock, A. C. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin. Vaccin. Immunol.21, 587&#x2013;593 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993119</ArticleId><ArticleId IdType="pubmed">24574536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, X. L., Zhang, C. T., Zhu, X. K. &amp; Wang, Y. C. Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. Virol. Sin.25, 8&#x2013;17 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227880</ArticleId><ArticleId IdType="pubmed">20960279</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie, J., Liu, Y., Huang, W. &amp; Wang, Y. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. Viruses8, 107 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848601</ArticleId><ArticleId IdType="pubmed">27120611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie, J., Huang, W., Wu, X. &amp; Wang, Y. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J. Med. Virol.86, 1542&#x2013;1555 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24895216</ArticleId></ArticleIdList></Reference><Reference><Citation>Matumoto, M. A note on some points of calculation method of LD50 by Reed and Muench. Jpn. J. Exp. Med.20, 175&#x2013;179 (1949).</Citation><ArticleIdList><ArticleId IdType="pubmed">15396956</ArticleId></ArticleIdList></Reference><Reference><Citation>Opalka, D. et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol.10, 108&#x2013;115 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145272</ArticleId><ArticleId IdType="pubmed">12522048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan, K. M. et al. Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types. mSphere8, e0096221 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10117101</ArticleId><ArticleId IdType="pubmed">36926984</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife7, 10.7554/eLife.42166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol.193, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani, A., Rubinstein, J. L., Fleet, D. J. &amp; Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods14, 290&#x2013;296 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukelbir, A., Sigworth, F. J. &amp; Tagare, H. D. Quantifying the local resolution of cryo-EM density maps. Nat. Methods11, 63&#x2013;65 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903095</ArticleId><ArticleId IdType="pubmed">24213166</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res.46, W296&#x2013;W303 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput Chem.25, 1605&#x2013;1612 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley, P. &amp; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr.60, 2126&#x2013;2132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr.66, 213&#x2013;221 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, C. &amp; Rossmann, M. G. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol.158, 182&#x2013;187 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978246</ArticleId><ArticleId IdType="pubmed">17116403</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci.27, 14&#x2013;25 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40117506</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-4602</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Biomacromolecules</Title><ISOAbbreviation>Biomacromolecules</ISOAbbreviation></Journal><ArticleTitle>Enhanced Whole Tumor Cell-Based Vaccines by a RAFT and Protein Fusion Strategy for Tumor Immunotherapy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biomac.5c00115</ELocationID><Abstract><AbstractText>Inactivated whole tumor cell-based vaccines (WTVs) are a promising strategy for tumor immunotherapy, but have exhibited limited antitumor effects clinically. Aiming at constructing enhanced WTVs, we developed glycopolymer-engineered WTVs (G-WTVs) using a Halo-Tag protein (HTP) fusion technique and reversible addition-fragmentation chain transfer (RAFT) polymerization. In our study, G-WTVs with varying molecular weights of glycopolymers were constructed. Compared to unmodified tumor cells, all G-WTVs effectively induced the polarization of macrophages toward the M1 phenotype and promoted the secretion of pro-inflammatory cytokines. This enhanced immune response was attributed to the improved interactions between G-WTVs and the macrophages. Among the G-WTVs, the medium molecular weight variant demonstrated the most pronounced enhancement of antitumor immune responses. Notably, the administration of optimized G-WTVs effectively inhibited the growth of B16 melanoma in mice. Our findings provide a new approach to enhance the antitumor efficacy of WTVs via cell membrane glycopolymer engineering, offering a promising strategy for tumor immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>He</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5514-2370</Identifier><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ruyan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Chemical and Environmental Engineering, Hunan Institute of Technology, Hengyang 421002, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heng</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Fangjian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yichen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Lihua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Sujian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Gaojian</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5877-3159</Identifier><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7799-4961</Identifier><AffiliationInfo><Affiliation>State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials College of Chemistry, Chemical Engineering and Materials Science Soochow University, 199 Ren'ai Road, Suzhou, Jiangsu 215123, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Biosurf Biotech Co., Ltd., Suzhou 215123, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biomacromolecules</MedlineTA><NlmUniqueID>100892849</NlmUniqueID><ISSNLinking>1525-7797</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40117506</ArticleId><ArticleId IdType="doi">10.1021/acs.biomac.5c00115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40113807</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.</ArticleTitle><Pagination><StartPage>54</StartPage><MedlinePgn>54</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">54</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-025-01107-y</ELocationID><Abstract><AbstractText>Personalized cancer vaccines (PCVs) largely leverage neoantigens arising from somatic mutations, limiting their application to patients with relatively high tumor mutational burden (TMB). This underscores the need for alternative antigens to design PCVs for low TMB cancers. To this end, we substantiate endogenous retroviral elements (EVEs) as tumor antigens through large-scale genomic analyses of healthy tissues and solid cancers. These analyses revealed that the breadth of EVE expression in tumors stratify checkpoint inhibitor-treated melanoma patients into groups with differential overall and progression-free survival. To enable the design of PCVs containing EVE-derived epitopes with therapeutic potential, we developed a computational pipeline, ObsERV. We show that EVE-derived peptides are presented as epitopes on tumors and can be predicted by ObsERV. Preclinical testing of ObsERV demonstrates induction of sustained poly-functional CD4+ and CD8+ T-cell responses as well as long-term tumor protection. As such, EVEs may facilitate and improve PCVs, especially for low-TMB patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garde</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark. cg@evaxion.ai.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlidis</LastName><ForeName>Michail A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-8942-8921</Identifier><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garces</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Emma J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramarathinam</LastName><ForeName>Sri H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology &amp; Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soka&#x10d;</LastName><ForeName>Mateo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Kirti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology &amp; Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faridi</LastName><ForeName>Pouya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahrenfeldt</LastName><ForeName>Johanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Shanzou</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology &amp; Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friis</LastName><ForeName>Stine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleine-Kohlbrecher</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birkbak</LastName><ForeName>Nicolai J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kringelum</LastName><ForeName>Jens V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf8;n&#xf8;</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0007-6197-2646</Identifier><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purcell</LastName><ForeName>Anthony W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology &amp; Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trolle</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0762-2198</Identifier><AffiliationInfo><Affiliation>Evaxion Biotech A/S, Dr Neergaards Vej 5F, H&#xf8;rsholm, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R272-2017-4040</GrantID><Agency>IngaBritt och Arne Lundbergs Forskningsstiftelse (Ingabritt and Arne Lundberg Research Foundation)</Agency><Country/></Grant><Grant><GrantID>AUFF-E-2018-7-14</GrantID><Agency>Aarhus Universitets Forskningsfond (Aarhus University Research Foundation)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: C.G., M.A.P., P.G., E.J.L., S.F., D.K.K., J.V.K., B.R., and T.T. are employed by Evaxion Biotech A/S which holds IP for identifying neoepitopes and personalized immunotherapy. AWP is on the scientific advisory board of Evaxion Biotech A/S. N.J.B. has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and a patent on methods for predicting anti-cancer response (US14/466,208). The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40113807</ArticleId><ArticleId IdType="pmc">PMC11926357</ArticleId><ArticleId IdType="doi">10.1038/s41541-025-01107-y</ArticleId><ArticleId IdType="pii">10.1038/s41541-025-01107-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med.371, 2189&#x2013;2199 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315319</ArticleId><ArticleId IdType="pubmed">25409260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science348, 124&#x2013;128 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993154</ArticleId><ArticleId IdType="pubmed">25765070</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey, J. D. &amp; Zhang, B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J.23, 39 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937597</ArticleId><ArticleId IdType="pubmed">33677681</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin, J. et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N. Engl. J. Med.381, 1535&#x2013;1546 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31562797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawbi, H. A. et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N. Engl. J. Med.386, 24&#x2013;34 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844513</ArticleId><ArticleId IdType="pubmed">34986285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott, P. A. et al. A Phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell183, 347&#x2013;362.e24 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33064988</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;rk, S. K. et al. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF&#xae;09b, in patients with metastatic melanoma. Oncoimmunology11, 2023255 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757480</ArticleId><ArticleId IdType="pubmed">35036074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature515, 572&#x2013;576 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25428506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong, Y. et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nat. Commun.10, 5228 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6864081</ArticleId><ArticleId IdType="pubmed">31745090</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltonen, K. et al. Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy. Cancers13, 3408 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306067</ArticleId><ArticleId IdType="pubmed">34298622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bont&#xe9;, P.-E. et al. Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. Cell Rep.39, 110916 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35675780</ArticleId></ArticleIdList></Reference><Reference><Citation>Capietto, A.-H., Hoshyar, R. &amp; Delamarre, L. Sources of cancer neoantigens beyond single-nucleotide variants. Int J. Mol. Sci.23, 10131 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9455963</ArticleId><ArticleId IdType="pubmed">36077528</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandi, N. &amp; Tramontano, E. Human endogenous retroviruses are ancient acquired elements still shaping innate immune responses. Front Immunol.9, 2039 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6139349</ArticleId><ArticleId IdType="pubmed">30250470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol.10, 168:1&#x2013;10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376112</ArticleId><ArticleId IdType="pubmed">30800125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrison, K. E. et al. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog.3, e165 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2065876</ArticleId><ArticleId IdType="pubmed">17997601</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonnard, J., Colau, D., Boon, T. &amp; Coulie, P. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res.62, 5510&#x2013;5516 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12359761</ArticleId></ArticleIdList></Reference><Reference><Citation>Rycaj, K. et al. Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin. Cancer Res21, 471&#x2013;483 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25370465</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini, S. K. et al. Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. Nat. Commun.11, 5660 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653045</ArticleId><ArticleId IdType="pubmed">33168830</ArticleId></ArticleIdList></Reference><Reference><Citation>Casares, N. et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol.31, 1780&#x2013;1789 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11385623</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringhini, M. et al. Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen. Cancer Immunol. Immunother.70, 3183&#x2013;3197 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505334</ArticleId><ArticleId IdType="pubmed">33796916</ArticleId></ArticleIdList></Reference><Reference><Citation>Neukirch, L. et al. Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. Oncotarget10, 1458&#x2013;1472 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402721</ArticleId><ArticleId IdType="pubmed">30858929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura, P. et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci. Adv.8, eabj3671 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791462</ArticleId><ArticleId IdType="pubmed">35080970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature520, 692&#x2013;696 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838069</ArticleId><ArticleId IdType="pubmed">25901682</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther.18, 843&#x2013;851 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862534</ArticleId><ArticleId IdType="pubmed">20179677</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsalloum, A., Shevchenko, J. A. &amp; Sennikov, S. The Melanoma-Associated Antigen Family A (MAGE-A): A promising target for cancer immunotherapy? Cancers15, 1779 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10046478</ArticleId><ArticleId IdType="pubmed">36980665</ArticleId></ArticleIdList></Reference><Reference><Citation>She, J. et al. The landscape of hervRNAs transcribed from human endogenous retroviruses across human body sites. Genome Biol.23, 231 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9632151</ArticleId><ArticleId IdType="pubmed">36329469</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopkins, N. et al. Ribosomal profiling of human endogenous retroviruses in healthy tissues. BMC Genomics25, 5 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10759522</ArticleId><ArticleId IdType="pubmed">38166631</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi, S. et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature403, 785&#x2013;789 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10693809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima-Junior, D. S. et al. Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota. Cell184, 3794&#x2013;3811.e19 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381240</ArticleId><ArticleId IdType="pubmed">34166614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangeney, M., de Parseval, N., Thomas, G. &amp; Heidmann, T. The full-length envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties. J. Gen. Virol.82, 2515&#x2013;2518 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker, E., Peckham-Gregory, E. C. &amp; Scheurer, M. E. HERVs and cancer&#x2014;a comprehensive review of the relationship of human endogenous retroviruses and human cancers. Biomedicines11, 936 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10046157</ArticleId><ArticleId IdType="pubmed">36979914</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med25, 1916&#x2013;1927 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898788</ArticleId><ArticleId IdType="pubmed">31792460</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science350, 207&#x2013;211 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5054517</ArticleId><ArticleId IdType="pubmed">26359337</ArticleId></ArticleIdList></Reference><Reference><Citation>Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell171, 934&#x2013;949.e16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685550</ArticleId><ArticleId IdType="pubmed">29033130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariathasan, S. et al. TGF&#x3b2; attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature554, 544&#x2013;548 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028240</ArticleId><ArticleId IdType="pubmed">29443960</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hm, W. et al. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J. Immunol.161, 897&#x2013;908 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9670968</ArticleId></ArticleIdList></Reference><Reference><Citation>Viborg, N. et al. DNA based neoepitope vaccination induces tumor control in syngeneic mouse models. npj Vaccines8, 1&#x2013;16 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10224666</ArticleId><ArticleId IdType="pubmed">37244905</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell162, 974&#x2013;986 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556003</ArticleId><ArticleId IdType="pubmed">26317466</ArticleId></ArticleIdList></Reference><Reference><Citation>Brocks, D. et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat. Genet.49, 1052&#x2013;1060 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6005702</ArticleId><ArticleId IdType="pubmed">28604729</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. et al. Dual Inhibition of DNA and Histone Methyltransferases increases viral mimicry in ovarian cancer cells. Cancer Res78, 5754&#x2013;5766 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191339</ArticleId><ArticleId IdType="pubmed">30185548</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay, P. et al. Recurrent transcriptional responses in AML and MDS patients treated with decitabine. Exp. Hematol.111, 50&#x2013;65 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833843</ArticleId><ArticleId IdType="pubmed">35429619</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, C. C. et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J. Clin. Invest128, 4804&#x2013;4820 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205406</ArticleId><ArticleId IdType="pubmed">30137025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 1&#x2013;11 10.1038/s41586-023-05771-9 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115647</ArticleId><ArticleId IdType="pubmed">37046094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, F. et al. Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget7, 84093&#x2013;84117 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5356647</ArticleId><ArticleId IdType="pubmed">27557521</ArticleId></ArticleIdList></Reference><Reference><Citation>Denne, M. et al. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J. Virol.81, 5607&#x2013;5616 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900259</ArticleId><ArticleId IdType="pubmed">17360752</ArticleId></ArticleIdList></Reference><Reference><Citation>Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature463, 899&#x2013;905 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826709</ArticleId><ArticleId IdType="pubmed">20164920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraehn, G. M. et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer84, 72&#x2013;79 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2363612</ArticleId><ArticleId IdType="pubmed">11139316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortezaee, K. &amp; Majidpoor, J. Transforming growth factor-&#x3b2; signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated. J. Cell Mol. Med27, 311&#x2013;321 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9889687</ArticleId><ArticleId IdType="pubmed">36625080</ArticleId></ArticleIdList></Reference><Reference><Citation>Attig, J. et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res29, 1578&#x2013;1590 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771403</ArticleId><ArticleId IdType="pubmed">31537638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte, V. et al. Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J. Immunol.171, 6396&#x2013;6405 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14662838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossendorp, F., Menged&#xe9;, E., Camps, M., Filius, R. &amp; Melief, C. J. M. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med.187, 693&#x2013;702 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212165</ArticleId><ArticleId IdType="pubmed">9480979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedoui, S., Heath, W. R. &amp; Mueller, S. N. CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. Immunol. Rev.272, 52&#x2013;64 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27319342</ArticleId></ArticleIdList></Reference><Reference><Citation>Laidlaw, B. J., Craft, J. E. &amp; Kaech, S. M. The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat. Rev. Immunol.16, 102&#x2013;111 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860014</ArticleId><ArticleId IdType="pubmed">26781939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, J. C. &amp; Perry-Lalley, D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J. Immunother.23, 177&#x2013;183 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10746543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kershaw, M. H. et al. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res61, 7920&#x2013;7924 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247477</ArticleId><ArticleId IdType="pubmed">11691813</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlroy, D. et al. DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol. Ther.17, 1473&#x2013;1481 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835232</ArticleId><ArticleId IdType="pubmed">19417740</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates, A. D. et al. Ensembl 2020. Nucleic Acids Res.48, D682&#x2013;D688 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145704</ArticleId><ArticleId IdType="pubmed">31691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa, S. &amp; Takahashi, M. U. gEVE: a genome-based endogenous viral element database provides comprehensive viral protein-coding sequences in mammalian genomes. Database2016, baw087 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4885607</ArticleId><ArticleId IdType="pubmed">27242033</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J.17, 10&#x2013;12 (2011).</Citation></Reference><Reference><Citation>Bolger, A. M., Lohse, M. &amp; Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics30, 2114&#x2013;2120 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, B. &amp; Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma.12, 323 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell, A. W., Ramarathinam, S. H. &amp; Ternette, N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat. Protoc.14, 1687&#x2013;1707 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31092913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey, K., Ramarathinam, S. H. &amp; Purcell, A. W. Isolation of HLA bound peptides by Immunoaffinity capture and identification by mass Spectrometry. Curr. Protoc.1, e92 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33769717</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res49, D480&#x2013;D489 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778908</ArticleId><ArticleId IdType="pubmed">33237286</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson, B., Alvarez, B., Paul, S., Peters, B. &amp; Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res48, W449&#x2013;W454 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319546</ArticleId><ArticleId IdType="pubmed">32406916</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell, T. J., Rubinsteyn, A. &amp; Laserson, U. MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-presented peptides by incorporating antigen processing. Cell Syst.11, 42&#x2013;48.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32711842</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedregosa, F. et al. Scikit-learn: Machine learning in Python. J. Mach. Learn. Res.12, 2825&#x2013;2830 (2011).</Citation></Reference><Reference><Citation>Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature547, 217&#x2013;221 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577644</ArticleId><ArticleId IdType="pubmed">28678778</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature565, 234&#x2013;239 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546179</ArticleId><ArticleId IdType="pubmed">30568305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol.6, 26 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319429</ArticleId><ArticleId IdType="pubmed">22115189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv: Genomics (2013).</Citation></Reference><Reference><Citation>Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience10, giab008 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931819</ArticleId><ArticleId IdType="pubmed">33590861</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res.20, 1297&#x2013;1303 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol.17, 122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson-Pilon, C. lifelines: survival analysis in Python. J. Open Source Softw.4, 1317 (2019).</Citation></Reference><Reference><Citation>Cancer Genome Atlas Research Network. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet45, 1113&#x2013;1120 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919969</ArticleId><ArticleId IdType="pubmed">24071849</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet45, 580&#x2013;585 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias, J. E. &amp; Gygi, S. P. Target-Decoy Search Strategy for Mass Spectrometry-Based Proteomics. in Proteome Bioinformatics (eds. Hubbard, S. J. &amp; Jones, A. R.) 55&#x2013;71 (Humana Press, Totowa, NJ, 2010). 10.1007/978-1-60761-444-9_5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922680</ArticleId><ArticleId IdType="pubmed">20013364</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods17, 261&#x2013;272 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7056644</ArticleId><ArticleId IdType="pubmed">32015543</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res.47, D442&#x2013;D450 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40101454</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.</ArticleTitle><Pagination><StartPage>126993</StartPage><MedlinePgn>126993</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.126993</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00290-7</ELocationID><Abstract><AbstractText>Developing an effective vaccine against malaria remains a prime goal of human health. The circumsporozoite protein (CSP) is a major surface protein of the sporozoites, and is the target of two licensed Plasmodium falciparum malaria vaccines, RTS,S/AS01, named Mosquirix and R21/Matrix-M. However, to improve the standards set by these vaccines we require a second-generation or prophylactic vaccine. Recently, monoclonal antibodies have emerged as essential biopharmaceutical prophylactic vaccines. The present study targeted recombinant Plasmodium falciparum CSP (rPfCSP) with a phage display of human single-fold scFv Tomlinson libraries I+J and picked fourteen scFvs that represented two independent clones after sequencing; CL1 and CL3. These phages were analysed for their binding to rPfCSP. The selected scFvs were cloned in a human IgG1 Fc tag vector, to generate scFv-Fc full-length antibody clones. CL1 bound rPfCSP protein with a K<sub>D</sub> of 3.8x10<sup>-6</sup>M and CL3 bound rPfCSP protein with a K<sub>D</sub> of 5.6 x 10<sup>-5</sup> M. These antibodies detected native PfCSP on the sporozoite surface. Molecular docking simulation revealed that rPfCSP residues interacting with CL1 and CL3 were downstream of the repeat region. These antibodies inhibited the sporozoite infectivity into HepG2 cells, similar to a gold standard monoclonal antibody, 2A10. Low-dose passive transfer of the CL1 and CL3 antibodies conferred high-level protection when challenged with PfCSP-Pb transgenic parasites in the mouse infection model. The high in vitro and in vivo efficacies of the CL1 and CL3 antibodies have applications in malaria immunoprophylaxis in protecting travellers and military servicemen or as a therapeutic vaccine in malaria elimination programmes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parveen</LastName><ForeName>Sadaf</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Malaria Biology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rath</LastName><ForeName>Pragyan Parimita</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Parasite Cell Biology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabrez</LastName><ForeName>Shams</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Summaiya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arkam</LastName><ForeName>Shaikh Zikra</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Sheenam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Structural Immunology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India; Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd milestone, Faridabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahnawaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Bioinformatics Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Susheel K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department for Congenital Diseases, Statens Serum Institut (SSI), DK 2300 Copenhagen, Denmark; Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, DK 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junaid</LastName><ForeName>Iqbal Taliy</ForeName><Initials>IT</Initials><AffiliationInfo><Affiliation>Malaria Biology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Dhiraj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cellular Immunology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theisen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Congenital Diseases, Statens Serum Institut (SSI), DK 2300 Copenhagen, Denmark; Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, DK 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Translational Bioinformatics Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohmmed</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Parasite Cell Biology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salunke</LastName><ForeName>Dinakar M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Structural Immunology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India. Electronic address: dinkar.salunke55@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Agam P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Infectious Diseases Laboratory, National Institute of Immunology, New Delhi, India.. Electronic address: singhap@nii.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Pawan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Malaria Biology Group, International Centre for Genetic Engineering &amp; Biotechnology (ICGEB), New Delhi, India. Electronic address: pawanmal@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunoglobulin G (IgG)</Keyword><Keyword MajorTopicYN="N">Monoclonal Antibody</Keyword><Keyword MajorTopicYN="N">Plasmodium</Keyword><Keyword MajorTopicYN="N">antibody engineering</Keyword><Keyword MajorTopicYN="N">phage display</Keyword></KeywordList><CoiStatement>Declaration of competing interest The following authors declare the following financial interests which may be considered as potential competing interests: Sadaf Parveen, Pawan Malhotra, Agam P. Singh, Dinakar M. Salunke, Asif Mohmmed has patent An Engineered Plasmodium falciparum Sporozoite Protein Fragment (PfCSP) Specific scFv-Fc Protein. The other authors declare that they have no known competing financial interests that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>18</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40101454</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.126993</ArticleId><ArticleId IdType="pii">S0264-410X(25)00290-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40095061</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-025-06359-w</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">The nPOD-Virus group collaboratively applied innovative technologies to detect and sequence viral RNA in pancreas and other tissues from organ donors with type 1 diabetes. These analyses involved the largest number of pancreas samples collected to date. The aim of the current work was to examine the presence of enterovirus RNA in pancreas and lymphoid tissues of organ donors with and without type 1 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed pancreas, spleen, pancreatic lymph nodes and duodenum samples from the following groups: (1) donors with type 1 diabetes (n=71) with (n=35) or without (n=36) insulin-containing islets; (2) donors with single or double islet autoantibody positivity without diabetes (n=22); and (3) autoantibody-negative donors without diabetes (control donors) (n=74). Five research laboratories participated in this collaborative effort using approaches for unbiased discovery of RNA viruses (two RNA-Seq platforms), targeted detection of Enterovirus A-D species using RT-PCR, and tests for virus growth in cell culture.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Direct RNA-Seq did not detect virus signal in pancreas samples, whereas RT-PCR detected enterovirus RNA confirmed by sequencing in low amounts in pancreas samples in three of the five donor groups: donors with type 1 diabetes with insulin-containing islets, 16% (5/32) being positive; donors with single islet autoantibody positivity, 53% (8/15) being positive; and non-diabetic donors, 8% (4/49) being positive. Detection of enterovirus RNA was significantly more frequent in single islet autoantibody-positive donors compared with donors with type 1 diabetes with insulin-deficient islets (p&lt;0.001) and control (non-diabetic) donors (p=0.004). In some donors, pancreatic lymph nodes were also positive. RT-PCR detected enterovirus RNA also in the spleen of a small number of donors and virus enrichment in susceptible cell lines before RT-PCR resulted in much higher rate in spleen positivity, particularly in donors with type 1 diabetes. Interestingly, the enterovirus strains detected did not cause a typical lytic infection, possibly reflecting their persistence-prone nature.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">This was the largest coordinated effort to examine the presence of enterovirus RNA in the pancreas of organ donors with type 1 diabetes, using a multitude of assays. These findings are consistent with the notion that donors with type 1 diabetes and donors with islet autoantibodies may carry a low-grade enterovirus infection in the pancreas and lymphoid tissues.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laiho</LastName><ForeName>Jutta E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-5443-4651</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. jutta.laiho@tuni.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikarinen</LastName><ForeName>Sami</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3901-6774</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfopoulou</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8181-4548</Identifier><AffiliationInfo><Affiliation>Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikarinen</LastName><ForeName>Maarit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1329-1508</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renner</LastName><ForeName>Ashlie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depledge</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4292-0599</Identifier><AffiliationInfo><Affiliation>Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-7621-8829</Identifier><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerling</LastName><ForeName>Ivan C</ForeName><Initials>IC</Initials><Identifier Source="ORCID">0000-0001-5097-6050</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuer</LastName><ForeName>Judith</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8246-0534</Identifier><AffiliationInfo><Affiliation>Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrosino</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-4046-6898</Identifier><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5597-9215</Identifier><AffiliationInfo><Affiliation>Genomics PLC, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7211-0319</Identifier><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes &amp; Metabolism Research Institute, Beckmann Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toniolo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3008-2126</Identifier><AffiliationInfo><Affiliation>Global Virus Network, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-6550-3237</Identifier><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hy&#xf6;ty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>nPOD-Virus Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AI50237</GrantID><Agency>National Institutes of Health, USA</Agency><Country/></Grant><Grant><GrantID>personal grant for JEL</GrantID><Agency>Diabetestutkimuss&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant><Grant><GrantID>personal grants for JEL</GrantID><Agency>Yrj&#xf6; Jahnssonin S&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant><Grant><GrantID>MO</GrantID><Agency>Yrj&#xf6; Jahnssonin S&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant><Grant><GrantID>Grant#2018PG-T1D053</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>G-2108-04793</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>97013</GrantID><Agency>European Foundation for the Study of Diabetes</Agency><Country/></Grant><Grant><GrantID>25-2012-770</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>JDRF 25-2012-516</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>nPOD: 5-SRA-2018-557-Q-R</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>RRID:SCR_014641</GrantID><Agency>network for Pancreatic Organ donors with Diabetes, nPOD</Agency><Country/></Grant><Grant><GrantID>personal grant for JEL</GrantID><Agency>Pirkanmaan Rahasto</Agency><Country/></Grant><Grant><GrantID>Persistent Virus Infection in Diabetes Network [PE</GrantID><Agency>Seventh Framework Programme</Agency><Country/></Grant><Grant><GrantID>for HH</GrantID><Agency>Sigrid Jus&#xe9;liuksen S&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant><Grant><GrantID>288671</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>personal grants for JEL</GrantID><Agency>P&#xe4;ivikki ja Sakari Sohlbergin S&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant><Grant><GrantID>MO</GrantID><Agency>P&#xe4;ivikki ja Sakari Sohlbergin S&#xe4;&#xe4;ti&#xf6;</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Sep 13:2024.09.11.24313112. doi: 10.1101/2024.09.11.24313112.</RefSource><PMID Version="1">39314969</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Islet autoimmunity</Keyword><Keyword MajorTopicYN="N">Lymph nodes</Keyword><Keyword MajorTopicYN="N">Organ donors</Keyword><Keyword MajorTopicYN="N">Pancreas</Keyword><Keyword MajorTopicYN="N">Persistent infection</Keyword><Keyword MajorTopicYN="N">Spleen</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword></KeywordList><CoiStatement>Acknowledgements: The authors wish to thank all families associated with organ donation for research purposes for their gift that made efforts like those in this programme possible. In addition, appreciation is given to the organ procurement organisations who make the nPOD programme possible. Part of the data has been included in the PhD thesis (2019) of J.E. Laiho (ISBN:978-952-03-1031-8).The authors would like to thank J. Ilom&#xe4;ki, T. Kuusela and M. Ovaskainen (Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland) for technical assistance. The authors thank all the members of the nPOD-Virus group. A list is included as electronic supplementary material (ESM). Data availability: Data generated and analysed during this study are available through the corresponding author upon request. Funding: This study was supported by Breakthrough T1D (formerly known as JDRF) grants for the nPOD-Virus Group, JDRF 25-2012-516 and JDRF 25-2012-770, as well as the European Commission (Persistent Virus Infection in Diabetes Network [PEVNET], Frame Programme 7, contract no. 261441). JEL and MO were supported by grants from Sakari and P&#xe4;ivikki Sohlberg&#x2019;s Foundation, Finland and Yrj&#xf6; Jahnsson&#x2019;s Foundation, Finland. JEL was also supported by the grants from The Diabetes Research Foundation in Finland and Finnish Cultural foundation. HH has additionally received funding from the Sigrid Juselius Foundation, European Foundation for the Study of Diabetes (grant no. 97013) and the Academy of Finland (grant no. 288671), which contributed to this work. REL also was funded by NIH grant R01-AI50237. The support of the Global Virus Network (GVN; University of Maryland, Baltimore, USA) is gratefully acknowledged. This research was performed with support from the Network for Pancreatic Organ donors with Diabetes (nPOD; RRID:SCR_014641), a collaborative type 1 diabetes research project supported by Breakthrough T1D (formerly known as JDRF) (nPOD: 5-SRA-2018-557-Q-R) and The Leona M. &amp; Harry B. Helmsley Charitable Trust (grant no. 2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at https://npod.org/for-partners/npod-partners/ . Authors&#x2019; relationships and activities: HH is a board member and stock owner of Vactech Oy, a Finnish biotech company that has contributed to the development of a coxsackie B virus vaccine. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: AP, SO, JEL, HH, VP, JFP and AT were responsible for the overall design of the study. SO was responsible for the virus PCR and sequencing analyses at Tampere laboratory, and AR and REL were responsible for the virus PCR and sequencing analyses at BCM. SM, DD, ICG, JB and VP contributed to the RNA-Seq analyses at UCL. MCR and JFP were responsible for the WGS sequencing at BCM. AT was responsible for the virus propagation studies at the Varese laboratory. MO and JEL performed the overall data analyses. JEL, SO, SM and MO were the primary contributors in the preparation of the manuscript. All authors contributed to data interpretation and discussion, reviewed the manuscript and approved the final version. JEL is the guarantor of this work and, as such, has full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40095061</ArticleId><ArticleId IdType="doi">10.1007/s00125-025-06359-w</ArticleId><ArticleId IdType="pii">10.1007/s00125-025-06359-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52(6):1143&#x2013;1151. https://doi.org/10.1007/s00125-009-1276-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1276-0</ArticleId><ArticleId IdType="pubmed">19266182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F, Censini S, van Halteren AGS et al (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 104(12):5115&#x2013;5120. https://doi.org/10.1073/pnas.0700442104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700442104</ArticleId><ArticleId IdType="pubmed">17360338</ArticleId><ArticleId IdType="pmc">1829272</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T et al (2015) Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64(5):1682&#x2013;1687. https://doi.org/10.2337/db14-1370</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylipaasto P, Klingel K, Lindberg AM et al (2004) Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 47(2):225&#x2013;239. https://doi.org/10.1007/s00125-003-1297-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-003-1297-z</ArticleId><ArticleId IdType="pubmed">14727023</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibasaki S, Imagawa A, Tauriainen S et al (2010) Expression of toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr J 57(3):211&#x2013;219. https://doi.org/10.1507/endocrj.K09E-291</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.K09E-291</ArticleId><ArticleId IdType="pubmed">20009359</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Krogvold L, Edwin B et al (2021) Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64(11):2491&#x2013;2501. https://doi.org/10.1007/s00125-021-05525-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05525-0</ArticleId><ArticleId IdType="pubmed">34390364</ArticleId><ArticleId IdType="pmc">8494699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenson AB, Rosenberg HS, Notkins AL (1980) Pancreatic islet-cell damage in children with fatal viral infections. Lancet 2(8190):354&#x2013;358</Citation><ArticleIdList><ArticleId IdType="pubmed">6105486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissel SJ, Winkler CC, DelTondo J, Wang G, Williams K, Wiley CA (2014) Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathology 34(5):429&#x2013;437. https://doi.org/10.1111/neup.12121</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12121</ArticleId><ArticleId IdType="pubmed">24702280</ArticleId><ArticleId IdType="pmc">4188796</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Genoni A, Puggioni A et al (2022) Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia 65(12):2108&#x2013;2120. https://doi.org/10.1007/s00125-022-05779-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05779-2</ArticleId><ArticleId IdType="pubmed">35953727</ArticleId><ArticleId IdType="pmc">9630231</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshebani A, Olsson A, Westman J, Tuvemo T, Korsgren O, Frisk G (2007) Effects on isolated human pancreatic islet cells after infection with strains of enterovirus isolated at clinical presentation of type 1 diabetes. Virus Res 124(1&#x2013;2):193&#x2013;203. https://doi.org/10.1016/j.virusres.2006.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.11.004</ArticleId><ArticleId IdType="pubmed">17169456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifie E, Russell MA, Dhayal S et al (2018) Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia 61(11):2344&#x2013;2355. https://doi.org/10.1007/s00125-018-4704-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4704-1</ArticleId><ArticleId IdType="pubmed">30074059</ArticleId><ArticleId IdType="pmc">6182664</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, Lynch KF, Wong MC et al (2019) Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med 25(12):1865&#x2013;1872. https://doi.org/10.1038/s41591-019-0667-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId><ArticleId IdType="pmc">6898786</ArticleId></ArticleIdList></Reference><Reference><Citation>Op de Beeck A, Eizirik DL (2016) Viral infections in type 1 diabetes mellitus&#x2013;why the &#x3b2; cells? Nat Rev Endocrinol 12(5):263&#x2013;273. https://doi.org/10.1038/nrendo.2016.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.30</ArticleId><ArticleId IdType="pubmed">27020257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S, Smithee S, Alhazmi A, Chapman N (2015) Coxsackievirus can persist in murine pancreas by deletion of 5 &#x2019; terminal genomic sequences. J Med Virol 87(2):240&#x2013;247. https://doi.org/10.1002/jmv.24039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24039</ArticleId><ArticleId IdType="pubmed">25111164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS (2008) Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol 323:275&#x2013;292. https://doi.org/10.1007/978-3-540-75546-3_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-75546-3_13</ArticleId><ArticleId IdType="pubmed">18357775</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Tauriainen S, Oikarinen S et al (2012) Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 61(3):687&#x2013;691. https://doi.org/10.2337/db11-1157</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1157</ArticleId><ArticleId IdType="pubmed">22315304</ArticleId><ArticleId IdType="pmc">3282798</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Tauriainen S, Honkanen T et al (2008) Detection of enteroviruses in the intestine of type 1 diabetic patients. Clin Exp Immunol 151(1):71&#x2013;75. https://doi.org/10.1111/j.1365-2249.2007.03529.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2007.03529.x</ArticleId><ArticleId IdType="pubmed">17991291</ArticleId><ArticleId IdType="pmc">2276929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercalli A, Lampasona V, Klingel K et al (2012) No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 55(9):2479&#x2013;2488. https://doi.org/10.1007/s00125-012-2591-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2591-4</ArticleId><ArticleId IdType="pubmed">22684312</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell-Thompson ML, Montgomery EL, Foss RM et al (2012) Collection protocol for human pancreas. J Vis Exp 63:e4039. https://doi.org/10.3791/4039-v</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/4039-v</ArticleId></ArticleIdList></Reference><Reference><Citation>Depledge DP, Palser AL, Watson SJ et al (2011) Specific capture and whole-genome sequencing of viruses from clinical samples. PloS One 6(11):e27805. https://doi.org/10.1371/journal.pone.0027805</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027805</ArticleId><ArticleId IdType="pubmed">22125625</ArticleId><ArticleId IdType="pmc">3220689</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG (2013) Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 56(1):185&#x2013;193. https://doi.org/10.1007/s00125-012-2745-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2745-4</ArticleId><ArticleId IdType="pubmed">23064357</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T, Laiho JE, Oikarinen M et al (2025) Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes. Diabetologia.&#xa0; https://doi.org/10.1007/s00125-025-06384-9</Citation></Reference><Reference><Citation>Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59(11):2448&#x2013;2458. https://doi.org/10.1007/s00125-016-4067-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4067-4</ArticleId><ArticleId IdType="pubmed">27506584</ArticleId><ArticleId IdType="pmc">5042874</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JR, Roy S, Ruis C, Yara Romero E et al (2016) Norovirus whole-genome sequencing by SureSelect target enrichment: a robust and sensitive method. J Clin Microbiol 54(10):2530&#x2013;2537. https://doi.org/10.1128/JCM.01052-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01052-16</ArticleId><ArticleId IdType="pubmed">27487952</ArticleId><ArticleId IdType="pmc">5035417</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmieder R, Edwards R (2011) Quality control and preprocessing of metagenomic datasets. Bioinforma Oxf Engl 27(6):863&#x2013;864. https://doi.org/10.1093/bioinformatics/btr026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr026</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215(3):403&#x2013;410. https://doi.org/10.1016/S0022-2836(05)80360-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(05)80360-2</ArticleId><ArticleId IdType="pubmed">2231712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18(5):821&#x2013;829. https://doi.org/10.1101/gr.074492.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.074492.107</ArticleId><ArticleId IdType="pubmed">18349386</ArticleId><ArticleId IdType="pmc">2336801</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357&#x2013;359. https://doi.org/10.1038/nmeth.1923</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId><ArticleId IdType="pmc">3322381</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfopoulou S, Plagnol V (2015) Bayesian mixture analysis for metagenomic community profiling. Bioinforma Oxf Engl 31(18):2930&#x2013;2938. https://doi.org/10.1093/bioinformatics/btv317</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv317</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries JJC, Brown JR, Fischer N et al (2021) Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samples. J Clin Virol 141:104908. https://doi.org/10.1016/j.jcv.2021.104908</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.104908</ArticleId><ArticleId IdType="pubmed">34273858</ArticleId><ArticleId IdType="pmc">7615111</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan CJA, Mohamad SMB, Young DF et al (2015) Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med 7(307):307ra154. https://doi.org/10.1126/scitranslmed.aac4227</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac4227</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId><ArticleId IdType="pmc">4926955</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfopoulou S, Brown JR, Davies EG et al (2016) Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 375(5):497&#x2013;498. https://doi.org/10.1056/NEJMc1509458</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1509458</ArticleId><ArticleId IdType="pubmed">27518687</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfopoulou S, Mee ET, Connaughton SM et al (2017) Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. Acta Neuropathol (Berl) 133(1):139&#x2013;147. https://doi.org/10.1007/s00401-016-1629-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1629-y</ArticleId><ArticleId IdType="pubmed">27770235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum SH, Turner A, Guiver M et al (2016) An emerging opportunistic infection: fatal astrovirus (VA1/HMO-C) encephalitis in a pediatric stem cell transplant recipient. Transpl Infect Dis 18(6):960&#x2013;964. https://doi.org/10.1111/tid.12607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.12607</ArticleId><ArticleId IdType="pubmed">27632248</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JR, Morfopoulou S, Hubb J et al (2015) Astrovirus VA1/HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised patients. Clin Infect Dis 60(6):881&#x2013;888. https://doi.org/10.1093/cid/ciu940</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu940</ArticleId><ArticleId IdType="pubmed">25572899</ArticleId><ArticleId IdType="pmc">4345817</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen H, Oikarinen S, Pakkanen O et al (2013) Human enterovirus 71 strains in the background population and in hospital patients in Finland. J Clin Virol 56(4):348&#x2013;353. https://doi.org/10.1016/j.jcv.2012.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.11.018</ArticleId><ArticleId IdType="pubmed">23261080</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoni A, Canducci F, Rossi A et al (2017) Revealing enterovirus infection in chronic human disorders: an integrated diagnostic approach. Sci Rep 7(1):5013. https://doi.org/10.1038/s41598-017-04993-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04993-y</ArticleId><ArticleId IdType="pubmed">28694527</ArticleId><ArticleId IdType="pmc">5504018</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccari G, Genoni A, Sansonno S, Toniolo A (2016) Properties of two enterovirus antibodies that are utilized in diabetes research. Sci Rep 6:24757. https://doi.org/10.1038/srep24757</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24757</ArticleId><ArticleId IdType="pubmed">27091243</ArticleId><ArticleId IdType="pmc">4835795</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Dhayal S et al (2014) Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 57(2):392&#x2013;401. https://doi.org/10.1007/s00125-013-3094-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3094-7</ArticleId><ArticleId IdType="pubmed">24190581</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch TC, Hitefield NL, Morris MA et al (2024) Proteomic and mass spectrometry-based identification of viral proteins in human tissue samples from the Network for Pancreatic Organ Donors with Diabetes. medRxiv. Available from: https://www.medrxiv.org/content/10.1101/2024.10.24.24315944v1 (Preprint) (accessed 11 Dec 2024)</Citation></Reference><Reference><Citation>Richardson SJ, Rodriguez-Calvo T, Laiho JE et al (2025) Joint analysis of the nPOD-virus group data: the association of enterovirus with type 1 diabetes is supported by multiple markers of infection in pancreas tissue. Diabetologia.&#xa0; https://doi.org/10.1007/s00125-025-06401-x</Citation></Reference><Reference><Citation>Manduchi E, Descamps HC, Schug J et al (2024) No evidence for persistent enteroviral B infection of pancreatic islets in patients with type 1 diabetes and prediabetes from RNA sequencing data. Diabetes 73(10):1697&#x2013;1704. https://doi.org/10.2337/db24-0076</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db24-0076</ArticleId><ArticleId IdType="pubmed">39083653</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S (2008) 5&#x2019; terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375(2):480&#x2013;491. https://doi.org/10.1016/j.virol.2008.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.02.030</ArticleId><ArticleId IdType="pubmed">18378272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Tracy S, Tapprich W et al (2005) 5&#x2019;-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol 79(11):7024&#x2013;7041. https://doi.org/10.1128/JVI.79.11.7024-7041.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.11.7024-7041.2005</ArticleId><ArticleId IdType="pubmed">15890942</ArticleId><ArticleId IdType="pmc">1112132</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Bertolet L, Toniolo A et al (2020) Differential detection of encapsidated versus unencapsidated enterovirus RNA in samples containing pancreatic enzymes&#x2014;relevance for diabetes studies. Viruses 12(7):747. https://doi.org/10.3390/v12070747</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12070747</ArticleId><ArticleId IdType="pubmed">32664501</ArticleId><ArticleId IdType="pmc">7411921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM (2022) Persistent enterovirus infection: little deletions, long infections. Vaccines 10(5):770. https://doi.org/10.3390/vaccines10050770</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050770</ArticleId><ArticleId IdType="pubmed">35632526</ArticleId><ArticleId IdType="pmc">9143164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PY, Hickey AC, Jamiluddin MF et al (2015) Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 33(44):6017&#x2013;6024. https://doi.org/10.1016/j.vaccine.2015.05.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel K, McManus BM, Kandolf R (1995) Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 16(Suppl O):42&#x2013;45. https://doi.org/10.1093/eurheartj/16.suppl_O.42</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/16.suppl_O.42</ArticleId><ArticleId IdType="pubmed">8682099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho-Yen DO, Hardie R, McClure J, Cunningham NE, Bell EJ (1989) Fatal outcome of echovirus 7 infection. Scand J Infect Dis 21(4):459&#x2013;461. https://doi.org/10.3109/00365548909167452</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365548909167452</ArticleId><ArticleId IdType="pubmed">2587948</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel K, Kandolf R (1996) Molecular in situ localization techniques in diagnosis and pathogenicity studies of enteroviral heart disease. Clin Diagn Virol 5(2&#x2013;3):157&#x2013;166. https://doi.org/10.1016/0928-0197(96)00217-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0928-0197(96)00217-6</ArticleId><ArticleId IdType="pubmed">15566874</ArticleId></ArticleIdList></Reference><Reference><Citation>Geravandi S, Richardson S, Pugliese A, Maedler K (2021) Localization of enteroviral RNA within the pancreas in donors with T1D and T1D-associated autoantibodies. Cell Rep Med 2(8):100371. https://doi.org/10.1016/j.xcrm.2021.100371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100371</ArticleId><ArticleId IdType="pubmed">34467248</ArticleId><ArticleId IdType="pmc">8385321</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkimaa A, Sioofy-Khojine AB, Oikarinen S, Bertin A, Hober D, Hy&#xf6;ty H (2020) Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. J Clin Virol 128:104334. https://doi.org/10.1016/j.jcv.2020.104334</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104334</ArticleId><ArticleId IdType="pubmed">32450550</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuorinen T, Vainionp&#xe4;&#xe4; R, Kettinen H, Hyypi&#xe4; T (1994) Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84(3):823&#x2013;829. https://doi.org/10.1182/blood.V84.3.823.823</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V84.3.823.823</ArticleId><ArticleId IdType="pubmed">8043865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL (1999) The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 155(4):1205&#x2013;1215. https://doi.org/10.1016/S0002-9440(10)65223-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65223-6</ArticleId><ArticleId IdType="pubmed">10514403</ArticleId><ArticleId IdType="pmc">1867001</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuorinen T, Vainionp&#xe4;&#xe4; R, Vanharanta R, Hyypi&#xe4; T (1996) Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection. J Virol 70(12):9018&#x2013;9023. https://doi.org/10.1128/jvi.70.12.9018-9023.1996</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.12.9018-9023.1996</ArticleId><ArticleId IdType="pubmed">8971035</ArticleId><ArticleId IdType="pmc">191003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Richardson SJ, Locke JM et al (2022) Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage. Diabetologia 65(10):1701&#x2013;1709. https://doi.org/10.1007/s00125-022-05753-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05753-y</ArticleId><ArticleId IdType="pubmed">35867130</ArticleId><ArticleId IdType="pmc">9477938</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker RE, Yang W, Vecchi GA, Takahashi S (2024) Increasing intensity of enterovirus outbreaks projected with climate change. Nat Commun 15(1):6466. https://doi.org/10.1038/s41467-024-50936-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-50936-3</ArticleId><ArticleId IdType="pubmed">39085256</ArticleId><ArticleId IdType="pmc">11291881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40090995</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-025-06384-9</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Earlier studies of pancreases from donors with type 1 diabetes demonstrated enteroviral capsid protein VP1 in beta cells. In the context of a multidisciplinary approach undertaken by the nPOD-Virus group, we assessed VP1 positivity in pancreas and other tissues (spleen, duodenum and pancreatic lymph nodes) from 188 organ donors, including donors with type 1 diabetes and donors expressing autoantibody risk markers. We also investigated whether VP1 positivity is linked to the hyperexpression of HLA class I (HLA-I) molecules in islet cells.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Organ donor tissues were collected by the Network for Pancreatic Organ Donors with Diabetes (nPOD) from donors without diabetes (ND, n=76), donors expressing a single or multiple diabetes-associated autoantibodies (AAb<sup>+</sup>, n=20; AAb<sup>++</sup>, n=9) and donors with type 1 diabetes with residual insulin-containing islets (T1D-ICIs, n=41) or only insulin-deficient islets (T1D-IDIs, n=42). VP1 was assessed using immunohistochemistry (IHC) and HLA-I using IHC and immunofluorescence, in two independent laboratories. We determined assay concordance across laboratories and overall occurrence of positive assays, on a case-by-case basis and between donor groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Islet cell VP1 positivity was detected in most T1D-ICI donors (77.5%) vs only 38.2% of ND donors (p&lt;0.001). VP1 positivity was associated with HLA-I hyperexpression. Of those donors assessed for HLA-I and VP1, 73.7% had both VP1 immunopositivity and HLA-I hyperexpression (p&lt;0.001 vs ND). Moreover, VP1<sup>+</sup> cells were detected at higher frequency in donors with HLA-I hyperexpression (p&lt;0.001 vs normal HLA-I). Among VP1<sup>+</sup> donors, the proportion with HLA-I hyperexpression was significantly higher in the AAb<sup>++</sup> and T1D-ICI groups (94.9%, p&lt;0.001 vs ND); this was not restricted to individuals with recent-onset diabetes. Critically, for all donor groups combined, HLA-I hyperexpression occurred more frequently in VP1<sup>+</sup> compared with VP1<sup>-</sup> donors (45.8% vs 16%, p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">We report the most extensive analysis to date of VP1 and HLA-I in pancreases from donors with preclinical and diagnosed type 1 diabetes. We find an association of VP1 with residual beta cells after diagnosis and demonstrate VP1 positivity during the autoantibody-positive preclinical stage. For the first time, we show that VP1 positivity and HLA-I hyperexpression in islet cells are both present during the preclinical stage. While the study of tissues does not allow us to demonstrate causality, our data support the hypothesis that enterovirus infections may occur throughout the natural history of type 1 diabetes and may be one of multiple mechanisms driving islet cell HLA-I hyperexpression.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez-Calvo</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1531-8583</Identifier><AffiliationInfo><Affiliation>Institute of Diabetes Research, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Munich-Neuherberg, Germany. teresa.rodriguez@helmholtz-munich.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laiho</LastName><ForeName>Jutta E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-5443-4651</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikarinen</LastName><ForeName>Maarit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1329-1508</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akhbari</LastName><ForeName>Pouria</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4127-9058</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaxman</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worthington</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2699-2074</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apaolaza</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7550-054X</Identifier><AffiliationInfo><Affiliation>Institute of Diabetes Research, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaddis</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-6752-7670</Identifier><AffiliationInfo><Affiliation>Department of Diabetes and Cancer Discovery Science, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusmartseva</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2614-0813</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tauriainen</LastName><ForeName>Sisko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell-Thompson</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Herrath</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute (DRI), University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrine, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Chief Medical Office, Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hy&#xf6;ty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Noel G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0003-1537-8113</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7211-0319</Identifier><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes &amp; Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-1160-6062</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK. s.richardson@exeter.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>nPOD-Virus group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>288671</GrantID><Agency>Sigrid Juselius Foundation and Academy of Finland</Agency><Country/></Grant><Grant><GrantID>MR/P010695/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UC24 DK104162</GrantID><Agency>Human Islet Research Network</Agency><Country/></Grant><Grant><GrantID>3-SRA-2017-492-A-N</GrantID><Agency>Juvenile Diabetes Research Foundation International</Agency><Country/></Grant><Grant><GrantID>3-SRA-2023-1417-S-B</GrantID><Agency>Juvenile Diabetes Research Foundation International</Agency><Country/></Grant><Grant><GrantID>3-SRA-25-2012-516</GrantID><Agency>Juvenile Diabetes Research Foundation International</Agency><Country/></Grant><Grant><GrantID>5-CDA-2014-221-A-N</GrantID><Agency>Juvenile Diabetes Research Foundation International</Agency><Country/></Grant><Grant><GrantID>5-CDA-2020-949-A-N</GrantID><Agency>Juvenile Diabetes Research Foundation International</Agency><Country/></Grant><Grant><GrantID>2018PG-T1D053</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>3-SRA-2023-1417-S-B</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>G-2108-04793</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>22/0006504</GrantID><Agency>Steve Morgan Foundation DUK/JDRF</Agency><Country/></Grant><Grant><GrantID>261441</GrantID><Agency>European comission frame programme 7</Agency><Country/></Grant><Grant><GrantID>97013</GrantID><Agency>European Foundation for the Study of Diabetes</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">HLA-I molecules</Keyword><Keyword MajorTopicYN="N">Immunofluorescence</Keyword><Keyword MajorTopicYN="N">Immunohistochemistry</Keyword><Keyword MajorTopicYN="N">Pancreas</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword></KeywordList><CoiStatement>Acknowledgements: The authors wish to thank all families associated with organ donation for research purposes for their gift that made efforts like those in this programme possible. In addition, appreciation is given to the Organ Procurement Organisations (OPO) who make the nPOD programme possible. The authors would like to thank E. Eskola and E. Tolvanen (Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland), N. Amirian (La Jolla Institute) and D. Balcacean (Helmholtz Munich) for technical assistance. The authors thank all the members of the nPOD-Virus group. A list is included as electronic supplementary material (ESM). Data availability: Data generated and analysed during this study are available through the corresponding author upon request. Funding: Open Access funding enabled and organized by Projekt DEAL. This research was performed with the support of the Network for Pancreatic Organ Donors with Diabetes (nPOD; RRID:SCR_014641), a collaborative type 1 diabetes research project supported by grants from Breakthrough T1D (formerly known as JDRF), The Leona M. &amp; Harry B. Helmsley Charitable Trust (3-SRA-2023-1417-S-B) and the Helmsley Charitable Trust (2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility of the authors and do not necessarily reflect the official view of nPOD. OPO partnering with nPOD to provide research resources are listed at https://npod.org/for-partners/npod-partners/ . The nPOD-Virus group was supported by Breakthrough T1D grants (3-SRA-25-2012-516 and 3-SRA-2017-492-A-N) awarded to AP, with sub-awards to members, and the European Commission (Persistent Virus Infection in Diabetes Network [PEVNET], Frame Programme 7, Contract No. 261441). SJR is grateful to Breakthrough T1D for a Career Development Award (5-CDA-2014-221-A-N), to MRC for Project Grant MR/P010695/1 (joint with NGM) and is supported by a Steve Morgan Foundation DUK/JDRF Grant Challenge Senior Research Fellowship (22/0006504). TRC is grateful to Breakthrough T1D for a Career Development Award (5-CDA-2020-949-A-N). JSK is also supported by a grant from the NIDDK-sponsored Human Islet Research Network (HIRN, RRID:SCR_014393; https://hirnetwork.org ; UC24 DK104162). JEL was supported by grants from Sakari and P&#xe4;ivikki Sohlberg&#x2019;s Foundation, Yrj&#xf6; Jahnsson&#x2019;s Foundation, The Diabetes Research Foundation in Finland and Finnish Cultural foundation. Studies from University of Exeter were supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The studies from Tampere University (HH) were also supported by the European Foundation for the Study of Diabetes (grant no. 97013), Sigrid Juselius Foundation and Academy of Finland (grant no. 288671) and the Diabetes Research Foundation in Finland. Authors&#x2019; relationships and activities: HH is a board member and stock owner of Vactech Oy, a Finnish biotech company that has contributed to the development of a coxsackie B virus vaccine. MvH is employed by Novo Nordisk A/S. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: TRC, JEL, JSK, MAA, MvH, HH, NGM, AP and SJR contributed to the original idea. TRC, JEL, MO, PAk, CF, TW, PAp, JSK, IK, ST, MCT, MAA, MvH, HH, NGM, AP and SJR contributed to the design, performance and interpretation of the experiments and formal analysis. TRC, JEL, JSK, AP and SJR wrote the manuscript and it was edited by TRC, JEL, JSK, IK, MAA, HH, NGM, AP and SJR. All authors have read and reviewed the manuscript critically for important intellectual content, and have approved the final version. SJR, TRC, JEL, JSK and AP are the guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>15</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>15</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>0</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40090995</ArticleId><ArticleId IdType="doi">10.1007/s00125-025-06384-9</ArticleId><ArticleId IdType="pii">10.1007/s00125-025-06384-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yeung WCG, Rawlinson WD, Craig ME (2011) Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342(Journal Article):d35. https://doi.org/10.1136/bmj.d35</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d35</ArticleId><ArticleId IdType="pubmed">21292721</ArticleId><ArticleId IdType="pmc">3033438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne JL, Richardson SJ, Atkinson MA et al (2019) Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 62(5):744&#x2013;53. https://doi.org/10.1007/s00125-019-4811-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-4811-7</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId><ArticleId IdType="pmc">6450860</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, Lynch KF, Wong MC et al (2019) Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med 25(12):1865&#x2013;72. https://doi.org/10.1038/s41591-019-0667-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId><ArticleId IdType="pmc">6898786</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Krogvold L, Edwin B et al (2021) Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64(11):2491&#x2013;501. https://doi.org/10.1007/s00125-021-05525-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05525-0</ArticleId><ArticleId IdType="pubmed">34390364</ArticleId><ArticleId IdType="pmc">8494699</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs SR, Roy A, Dance B et al (2023) Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol 11(8):578&#x2013;92. https://doi.org/10.1016/S2213-8587(23)00122-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00122-5</ArticleId><ArticleId IdType="pubmed">37390839</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Martiskainen M, Tauriainen S et al (2011) Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 60(1):276&#x2013;9. https://doi.org/10.2337/db10-0186</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0186</ArticleId><ArticleId IdType="pubmed">20943747</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen H, Oikarinen S, Nurminen N et al (2017) Detection of enteroviruses in stools precedes islet autoimmunity by several months: possible evidence for slowly operating mechanisms in virus-induced autoimmunity. Diabetologia 60(3):424&#x2013;31. https://doi.org/10.1007/s00125-016-4177-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4177-z</ArticleId><ArticleId IdType="pubmed">28070615</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Honkanen H, Pakkanen O et al (2014) Coxsackievirus B1 is associated with induction of &#x3b2;-cell autoimmunity that portends type 1 diabetes. Diabetes 63(2):446&#x2013;55. https://doi.org/10.2337/db13-0619</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Tauriainen S, Hober D et al (2014) Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes 63(2):655&#x2013;62. https://doi.org/10.2337/db13-0620</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0620</ArticleId><ArticleId IdType="pubmed">24009257</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52(6):1143&#x2013;51. https://doi.org/10.1007/s00125-009-1276-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1276-0</ArticleId><ArticleId IdType="pubmed">19266182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F, Censini S, van Halteren AGS et al (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 104(12):5115&#x2013;20. https://doi.org/10.1073/pnas.0700442104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700442104</ArticleId><ArticleId IdType="pubmed">17360338</ArticleId><ArticleId IdType="pmc">1829272</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T et al (2015) Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64(5):1682&#x2013;7. https://doi.org/10.2337/db14-1370</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG (2013) Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 56(1):185&#x2013;93. https://doi.org/10.1007/s00125-012-2745-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2745-4</ArticleId><ArticleId IdType="pubmed">23064357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR (1985) In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313(6):353&#x2013;60. https://doi.org/10.1056/NEJM198508083130604</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198508083130604</ArticleId><ArticleId IdType="pubmed">3159965</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59(11):2448&#x2013;58. https://doi.org/10.1007/s00125-016-4067-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4067-4</ArticleId><ArticleId IdType="pubmed">27506584</ArticleId><ArticleId IdType="pmc">5042874</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulis AK (1996) The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. APMIS Acta Pathol Microbiol Immunol Scand 104(3):161&#x2013;7. https://doi.org/10.1111/j.1699-0463.1996.tb00702.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1996.tb00702.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T, Richardson SJ, Pugliese A (2018) Pancreas pathology during the natural history of type 1 diabetes. Curr Diab Rep 18(11):124. https://doi.org/10.1007/s11892-018-1084-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-018-1084-3</ArticleId><ArticleId IdType="pubmed">30293191</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkahla MA, Sabouri S, Kiosses WB, Rajendran S, Quesada-Masachs E, von Herrath MG (2021) HLA class I hyper-expression unmasks beta cells but not alpha cells to the immune system in pre-diabetes. J Autoimmun 119:102628. https://doi.org/10.1016/j.jaut.2021.102628</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102628</ArticleId><ArticleId IdType="pubmed">33706238</ArticleId><ArticleId IdType="pmc">8044030</ArticleId></ArticleIdList></Reference><Reference><Citation>Apaolaza PS, Balcacean D, Zapardiel-Gonzalo J et al (2021) Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. Sci Adv 7(9):eabd6527. https://doi.org/10.1126/sciadv.abd6527</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd6527</ArticleId><ArticleId IdType="pubmed">33627420</ArticleId><ArticleId IdType="pmc">7904254</ArticleId></ArticleIdList></Reference><Reference><Citation>Marroqui L, Dos Santos RS, Op de Beeck A et al (2017) Interferon-&#x3b1; mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 60(4):656&#x2013;67. https://doi.org/10.1007/s00125-016-4201-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4201-3</ArticleId><ArticleId IdType="pubmed">28062922</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomans de Brach&#xe8;ne A, Dos Santos RS, Marroqui L et al (2018) IFN-&#x3b1; induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia 61(3):636&#x2013;40. https://doi.org/10.1007/s00125-017-4536-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4536-4</ArticleId><ArticleId IdType="pubmed">29305625</ArticleId></ArticleIdList></Reference><Reference><Citation>Knebel UE, Peleg S, Dai C et al (2024) Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes. Cell Metab 36(1):48-61.e6. https://doi.org/10.1016/j.cmet.2023.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2023.11.011</ArticleId><ArticleId IdType="pubmed">38128529</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Dhayal S et al (2014) Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 57(2):392&#x2013;401. https://doi.org/10.1007/s00125-013-3094-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3094-7</ArticleId><ArticleId IdType="pubmed">24190581</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Tauriainen S, Honkanen T et al (2008) Analysis of pancreas tissue in a child positive for islet cell antibodies. Diabetologia 51(10):1796&#x2013;802. https://doi.org/10.1007/s00125-008-1107-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-008-1107-8</ArticleId><ArticleId IdType="pubmed">18696046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwet KL (2010) Handbook of inter-rater reliability. The Definitive Guide to Measuring the Extent of Agreement Among Raters. Advanced Analytics, LLC, Gaithersburg, MD, USA</Citation></Reference><Reference><Citation>Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159&#x2013;74. https://doi.org/10.2307/2529310</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529310</ArticleId><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwet KL (2019) irrCAC: Computing chance-corrected agreement coefficients (CAC).&#xa0;R package version 1</Citation></Reference><Reference><Citation>Roivainen M, Rasilainen S, Ylipaasto P et al (2000) Mechanisms of coxsackievirus-induced damage to human pancreatic beta-cells. J Clin Endocrinol Metab 85(1):432&#x2013;40. https://doi.org/10.1210/jcem.85.1.6306</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.85.1.6306</ArticleId><ArticleId IdType="pubmed">10634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Lehtonen J, Nurminen N et al (2018) Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 61(5):1193&#x2013;202. https://doi.org/10.1007/s00125-018-4561-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4561-y</ArticleId><ArticleId IdType="pubmed">29404673</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniolo A (2023) Islet autoimmunity and type 1 diabetes associated with enterovirus infections. Lancet Diabetes Endocrinol 11(8):530&#x2013;2. https://doi.org/10.1016/S2213-8587(23)00133-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00133-X</ArticleId><ArticleId IdType="pubmed">37390840</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T, Suwandi JS, Amirian N et al (2015) Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase. J Histochem Cytochem Off J Histochem Soc 63(8):626&#x2013;36. https://doi.org/10.1369/0022155415576543</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155415576543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N et al (2017) Increase in pancreatic proinsulin and preservation of &#x3b2;-cell mass in autoantibody-positive donors prior to type 1 diabetes onset. Diabetes 66(5):1334&#x2013;45. https://doi.org/10.2337/db16-1343</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db16-1343</ArticleId><ArticleId IdType="pubmed">28137793</ArticleId><ArticleId IdType="pmc">5399615</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiho JE, Oikarinen S, Morfopoulou S et al (2025) Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes. Diabetologia. https://doi.org/10.1007/s00125-025-06359-w</Citation></Reference><Reference><Citation>Richardson SJ, Rodriguez-Calvo T, Laiho JE et al (2025) Joint analysis of the nPOD-Virus Group data: the association of enterovirus with type 1 diabetes is supported by multiple markers of infection in pancreas tissue. Diabetologia. https://doi.org/10.1007/s00125-025-06401-x</Citation></Reference><Reference><Citation>Geravandi S, Richardson S, Pugliese A, Maedler K (2021) Localization of enteroviral RNA within the pancreas in donors with T1D and T1D-associated autoantibodies. Cell Rep Med 2(8):100371. https://doi.org/10.1016/j.xcrm.2021.100371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100371</ArticleId><ArticleId IdType="pubmed">34467248</ArticleId><ArticleId IdType="pmc">8385321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Richardson SJ, Locke JM et al (2022) Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage. Diabetologia 65(10):1701&#x2013;1709. https://doi.org/10.1007/s00125-022-05753-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05753-y</ArticleId><ArticleId IdType="pubmed">35867130</ArticleId><ArticleId IdType="pmc">9477938</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S (2008) 5&#x2019; terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375(2):480&#x2013;91. https://doi.org/10.1016/j.virol.2008.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.02.030</ArticleId><ArticleId IdType="pubmed">18378272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS (2008) Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol 323(Journal Article):275&#x2013;92. https://doi.org/10.1007/978-3-540-75546-3_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-75546-3_13</ArticleId><ArticleId IdType="pubmed">18357775</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S, Smithee S, Alhazmi A, Chapman N (2015) Coxsackievirus can persist in murine pancreas by deletion of 5 &#x2019; terminal genomic sequences. J Med Virol 87(2):240&#x2013;7. https://doi.org/10.1002/jmv.24039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24039</ArticleId><ArticleId IdType="pubmed">25111164</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American Diabetes Association. Diabetes Care 38(10):1964&#x2013;74. https://doi.org/10.2337/dc15-1419</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-1419</ArticleId><ArticleId IdType="pubmed">26404926</ArticleId><ArticleId IdType="pmc">5321245</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive &#x3b1;-interferon in insulin-secreting &#x3b2; cells in type 1 diabetes mellitus. Lancet 330(8573):1423&#x2013;7. https://doi.org/10.1016/S0140-6736(87)91128-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(87)91128-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomans de Brach&#xe8;ne A, Alvelos MI, Szymczak F et al (2024) Interferons are key cytokines acting on pancreatic islets in type 1 diabetes. Diabetologia 67(5):908&#x2013;27. https://doi.org/10.1007/s00125-024-06106-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06106-7</ArticleId><ArticleId IdType="pubmed">38409439</ArticleId></ArticleIdList></Reference><Reference><Citation>Marroqui L, Dos Santos RS, Fl&#xf8;yel T et al (2015) TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic &#x3b2;-cells. Diabetes 64(11):3808&#x2013;17. https://doi.org/10.2337/db15-0362</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db15-0362</ArticleId><ArticleId IdType="pubmed">26239055</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40090994</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Joint analysis of the nPOD-Virus Group data: the association of enterovirus with type 1 diabetes is supported by multiple markers of infection in pancreas tissue.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-025-06401-x</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Previous pathology studies have associated enterovirus infections with type 1 diabetes by examining the enterovirus capsid protein 1 (VP1) in autopsy pancreases obtained near diabetes diagnosis. The Network for Pancreatic Organ Donors with Diabetes (nPOD) has since obtained pancreases from organ donors with type 1 diabetes (with broad age and disease duration) and donors with disease-associated autoantibodies (AAbs), the latter representing preclinical disease. Two accompanying manuscripts from the nPOD-Virus Group report primary data from a coordinated analysis of multiple enterovirus indices. We aimed to comprehensively assess the association of multiple enterovirus markers with type 1 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The nPOD-Virus Group examined pancreases from 197 donors, recovered between 2007 and 2019, classified into five groups: donors with type 1 diabetes, with residual insulin-containing islets (T1D-ICI group, n=41) or with only insulin-deficient islets (T1D-IDI, n=42); donors without diabetes who are AAb-negative (ND, n=83); and rare donors without diabetes expressing a single AAb (AAb<sup>+</sup>, n=22) or multiple AAbs (AAb<sup>++</sup>, n=9). We assessed the overall association of multiple indicators of enterovirus infection, case-by-case and between donor groups, as well as assay agreement and reproducibility, using various statistical methods. We examined data from 645 assays performed across 197 nPOD donors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Detection of enterovirus indices by independent laboratories had high reproducibility, using both enterovirus-targeted and unbiased methods. T1D-ICI donors had significantly higher (p&lt;0.001) proportions of positive assay outcomes (58.4%) vs T1D-IDI (10.3%), ND (17.8%) and AAb-positive donors (AAb<sup>+</sup> 24.6%; AAb<sup>++</sup> 35.0%). Head-to-head comparisons revealed increased proportions of donors positive in two independent assays among T1D-ICI vs ND donors (VP1/HLA class I [HLA-I], p&lt;0.0001; VP1/enterovirus-specific RT-PCR (EV-PCR), p=0.076; EV-PCR/HLA-I, p=0.016; proteomics/HLA-I, p&lt;0.0001; VP1/proteomics, p=0.06). Among 110 donors examined for three markers (VP1, EV-PCR and HLA-I), 83.3% of T1D-ICI donors were positive in two or more assays vs 0% of ND (p&lt;0.001), 26.7% of AAb<sup>+</sup> (p=0.006), 28.6% of AAb<sup>++</sup> (p=0.023) and 0% of T1D-IDI (p&lt;0.001) donors.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">The nPOD-Virus Group conducted, to date, the largest and most comprehensive analysis of multiple indices of pancreatic enterovirus infections in type 1 diabetes; these were more prevalent in T1D-ICI and AAb<sup>++</sup> donors than in other groups. Their preferential detection of these indices in donors with residual beta cells and autoimmunity implicates enterovirus infections across disease progression stages and supports a contribution to beta cell loss, directly or indirectly, even after diagnosis. The relatively small number of infected cells and the low amount of viral RNA support the existence of non-acute, low level, possibly persistent enterovirus infections in the pancreas.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-1160-6062</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Calvo</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1531-8583</Identifier><AffiliationInfo><Affiliation>Institute of Diabetes Research, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laiho</LastName><ForeName>Jutta E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-5443-4651</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaddis</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-6752-7670</Identifier><AffiliationInfo><Affiliation>Department of Diabetes and Cancer Discovery Science, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyalwidhe</LastName><ForeName>Julius O</ForeName><Initials>JO</Initials><Identifier Source="ORCID">0000-0003-2854-7510</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusmartseva</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2614-0813</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfopoulou</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8181-4548</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrosino</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-4046-6898</Identifier><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5597-9215</Identifier><AffiliationInfo><Affiliation>Genetics Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maedler</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7436-1197</Identifier><AffiliationInfo><Affiliation>Centre for Biomolecular Interactions Bremen, University of Bremen, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-9063-9777</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Autoimmunity and Primary Immunodeficiency Disease Section, Autoimmunity and Mucosal Immunology Branch, DAIT NIAD NIH DHHS, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadler</LastName><ForeName>Jerry L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>UC Davis School of Medicine, Sacramento, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ACOS-Research Northern California VA Health System, Mather, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-8489-4782</Identifier><AffiliationInfo><Affiliation>Diabetes Institute, Department of Pathology, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Herrath</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-6550-3237</Identifier><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyoty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Noel G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0003-1537-8113</Identifier><AffiliationInfo><Affiliation>Islet Biology Exeter (IBEx), Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7211-0319</Identifier><AffiliationInfo><Affiliation>Department of Diabetes Immunology, Arthur Riggs Diabetes &amp; Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, USA. apugliese@coh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>nPOD-Virus Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>261441</GrantID><Agency>FP7 Health</Agency><Country/></Grant><Grant><GrantID>22/0006504</GrantID><Acronym>DUK_</Acronym><Agency>Diabetes UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P010695/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UC24 DK104162</GrantID><Agency>Human Islet Research Network</Agency><Country/></Grant><Grant><GrantID>3-SRA-2017-492-A-N</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>3-SRA-2023-1417-S-B</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>3-SRA-25-2012-516</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>5-CDA-2014-221-A-N</GrantID><Agency>JDRF</Agency><Country>United States</Country></Grant><Grant><GrantID>2018PG-T1D053</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant><Grant><GrantID>G-2108-04793</GrantID><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Pancreas</Keyword><Keyword MajorTopicYN="N">Pancreatic beta cell</Keyword><Keyword MajorTopicYN="N">Pancreatic islet</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword></KeywordList><CoiStatement>Acknowledgements: The authors wish to thank all families associated with organ donation for research purposes whose gift was invaluable for this research. The authors are grateful to JDRF Program Officers who envisioned the formation of and provided programmatic guidance to the nPOD-Virus Group (R. Insel, J. Greenstein, T. Staeva, M. Nierras, J. Dunne). The authors thank all the members of the nPOD-Virus group. A list is included as electronic supplementary material (ESM). Data availability: Data generated and analysed during this study are available through the corresponding author upon request. Funding: This research was performed with the support of the Network for Pancreatic Organ donors with Diabetes (nPOD; RRID:SCR_014641), a collaborative type 1 diabetes research project supported by grants from JDRF/The Leona M. &amp; Harry B. Helmsley Charitable Trust (3-SRA-2023-1417-S-B) and the Helmsley Charitable Trust (2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at https://npod.org/for-partners/npod-partners/ . The nPOD-Virus Group was supported by Breakthrough T1D (formerly JDRF) grants (3-SRA-25-2012-516 and 3-SRA-2017-492-A-N awarded to AP). This work was supported by a Breakthrough T1D Career Development Award (5-CDA-2014-221-A-N) to SJR, an MRC Project Grant MR/P010695/1 awarded to SJR and NGM, and a Steve Morgan Foundation Grand Challenge Senior Research Fellowship awarded to SJR (22/0006504). The studies from the University of Exeter were supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Part of the studies were supported by the European Union program Frame Programme 7 (Persistent Virus Infection in Diabetes Network [PEVNET], contract no. 261441). JSK is also supported by a grant from the NIDDK-sponsored Human Islet Research Network (HIRN, RRID:SCR_014393; https://hirnetwork.org ; UC24 DK104162). KM was supported by a German Research Foundation grant (DFG). Authors&#x2019; relationships and activities: HH is a board member and stock owner of Vactech Oy, a Finnish biotech company that has contributed to the development of a CVB vaccine. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: SJR, TRC, JEL, JSK, REL, JON, JLN, IK, MAA, MvH, NGM, HH and AP made substantial contributions to the conception and design of the work. Assays were performed by SJR, TRC, JEL, JON, SM, KM, JFP and REL and interpretation of the individual specific assay experiments was performed by SJR, TRC, JEL, JON, REL, KM, MAM, VP, JFP, NGM, HH and AP. Formal combined analysis and interpretations were completed by SJR, TRC, JEL, JSK, JON, REL, HH and AP. MAM helped in sample selection, coordination, and procurement for proteomics assays, as well as editing of the manuscript. SJR, TRC, JEL, JSK and AP wrote the first draft of the manuscript. All authors reviewed critically the manuscript for important intellectual content and edited the manuscript. All authors have read and approved the final version of the manuscript. SJR, TRC, JL, JSK and AP are the guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>15</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>15</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>0</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40090994</ArticleId><ArticleId IdType="doi">10.1007/s00125-025-06401-x</ArticleId><ArticleId IdType="pii">10.1007/s00125-025-06401-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salminen K, Sadeharju K, Lonnrot M et al (2003) Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol 69(1):91&#x2013;98. https://doi.org/10.1002/jmv.10260</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10260</ArticleId><ArticleId IdType="pubmed">12436483</ArticleId></ArticleIdList></Reference><Reference><Citation>Stene LC, Oikarinen S, Hyoty H et al (2010) Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 59(12):3174&#x2013;3180. https://doi.org/10.2337/db10-0866</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0866</ArticleId><ArticleId IdType="pubmed">20858685</ArticleId><ArticleId IdType="pmc">2992780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HS, Briese T, Winkler C et al (2013) Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Diabetologia 56(8):1705&#x2013;1711. https://doi.org/10.1007/s00125-013-2924-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-2924-y</ArticleId><ArticleId IdType="pubmed">23657799</ArticleId><ArticleId IdType="pmc">4019381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HC, Wang CH, Tsai FJ et al (2015) Enterovirus infection is associated with an increased risk of childhood type 1 diabetes in Taiwan: a nationwide population-based cohort study. Diabetologia 58(1):79&#x2013;86. https://doi.org/10.1007/s00125-014-3400-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3400-z</ArticleId><ArticleId IdType="pubmed">25335440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton MP, Eugster A, Walther D et al (2016) Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin. Sci Rep 6:32899. https://doi.org/10.1038/srep32899</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32899</ArticleId><ArticleId IdType="pubmed">27604323</ArticleId><ArticleId IdType="pmc">5015062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyoty H (2016) Viruses in type 1 diabetes. Pediatric diabetes 17(Suppl 22):56&#x2013;64. https://doi.org/10.1111/pedi.12370</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12370</ArticleId><ArticleId IdType="pubmed">27411438</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen DW, Kim KW, Rawlinson WD, Craig ME (2018) Maternal virus infections in pregnancy and type 1 diabetes in their offspring: Systematic review and meta-analysis of observational studies. Rev Med Virol 28(3):e1974. https://doi.org/10.1002/rmv.1974</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1974</ArticleId><ArticleId IdType="pubmed">29569297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung WC, Rawlinson WD, Craig ME (2011) Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342:d35. https://doi.org/10.1136/bmj.d35</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d35</ArticleId><ArticleId IdType="pubmed">21292721</ArticleId><ArticleId IdType="pmc">3033438</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen H, Oikarinen S, Nurminen N et al (2017) Detection of enteroviruses in stools precedes islet autoimmunity by several months: possible evidence for slowly operating mechanisms in virus-induced autoimmunity. Diabetologia 60(3):424&#x2013;431. https://doi.org/10.1007/s00125-016-4177-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4177-z</ArticleId><ArticleId IdType="pubmed">28070615</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Honkanen H, Pakkanen O et al (2014) Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes 63(2):446&#x2013;455. https://doi.org/10.2337/db13-0619</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Martiskainen M, Tauriainen S et al (2011) Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 60(1):276&#x2013;279. https://doi.org/10.2337/db10-0186</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0186</ArticleId><ArticleId IdType="pubmed">20943747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, Lynch KF, Wong MC et al (2019) Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med 25(12):1865&#x2013;1872. https://doi.org/10.1038/s41591-019-0667-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId><ArticleId IdType="pmc">6898786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F, Censini S, van Halteren AG et al (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104(12):5115&#x2013;5120. https://doi.org/10.1073/pnas.0700442104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700442104</ArticleId><ArticleId IdType="pubmed">17360338</ArticleId><ArticleId IdType="pmc">1829272</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52(6):1143&#x2013;1151. https://doi.org/10.1007/s00125-009-1276-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1276-0</ArticleId><ArticleId IdType="pubmed">19266182</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG (2013) Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 56(1):185&#x2013;193. https://doi.org/10.1007/s00125-012-2745-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2745-4</ArticleId><ArticleId IdType="pubmed">23064357</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T et al (2015) Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64(5):1682&#x2013;1687. https://doi.org/10.2337/db14-1370</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Leete P, Dhayal S et al (2014) Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 57(2):392&#x2013;401. https://doi.org/10.1007/s00125-013-3094-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3094-7</ArticleId><ArticleId IdType="pubmed">24190581</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59(11):2448&#x2013;2458. https://doi.org/10.1007/s00125-016-4067-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4067-4</ArticleId><ArticleId IdType="pubmed">27506584</ArticleId><ArticleId IdType="pmc">5042874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Nishida Y, Tanaka S, Aida K (2011) Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM): innate immunity in fulminant type 1 diabetes and SPIDDM. Diabetes Metab ResRev 27(8):965&#x2013;970. https://doi.org/10.1002/dmrr.1237</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.1237</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch TC, Hitefield NL, Morris MA, Pugliese A, Nadler JL, Nyalwidhe JO (2024) Proteomic and mass spectrometry-based identification of viral proteins in human tissue samples from the Network for Pancreatic Organ Donors with Diabetes. medRxiv. https://doi.org/10.1101/2024.10.24.24315944 (preprint)</Citation></Reference><Reference><Citation>Laiho JE, Oikarinen S, Morfopoulou S et al (2025) Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes. Diabetologia. https://doi.org/10.1007/s00125-025-06359-w</Citation></Reference><Reference><Citation>Rodriguez-Calvo T, Laiho JE, Oikarinen M et al (2025) Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes. Diabetologia. https://doi.org/10.1007/s00125-025-06384-9</Citation></Reference><Reference><Citation>Geravandi S, Richardson S, Pugliese A, Maedler K (2021) Localization of enteroviral RNA within the pancreas in donors with T1D and T1D-associated autoantibodies. Cell Rep Med 2(8):100371. https://doi.org/10.1016/j.xcrm.2021.100371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100371</ArticleId><ArticleId IdType="pubmed">34467248</ArticleId><ArticleId IdType="pmc">8385321</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoni A, Canducci F, Rossi A et al (2017) Revealing enterovirus infection in chronic human disorders: an integrated diagnostic approach. Sci Rep 7(1):5013. https://doi.org/10.1038/s41598-017-04993-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04993-y</ArticleId><ArticleId IdType="pubmed">28694527</ArticleId><ArticleId IdType="pmc">5504018</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwet KL (2010) Handbook of inter-rater reliability. the definitive guide to measuring the extent of agreement among raters. Advanced Analytics, LLC, Gaithersburg, MD 20886-2696</Citation></Reference><Reference><Citation>Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159&#x2013;174. https://doi.org/10.2307/2529310</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529310</ArticleId><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne JL, Richardson SJ, Atkinson MA et al (2019) Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 62(5):744&#x2013;753. https://doi.org/10.1007/s00125-019-4811-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-4811-7</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId><ArticleId IdType="pmc">6450860</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner CL, Luo YX, Isaacs S, Rawlinson WD, Craig ME, Kim KW (2021) The virome in early life and childhood and development of islet autoimmunity and type 1 diabetes: A systematic review and meta-analysis of observational studies. Rev Med Virol 31(5):1&#x2013;14. https://doi.org/10.1002/rmv.2209</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2209</ArticleId><ArticleId IdType="pubmed">33378601</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Mynarek IM, Ponzi E et al (2023) Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nat Med 29(11):2902&#x2013;2908. https://doi.org/10.1038/s41591-023-02576-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02576-1</ArticleId><ArticleId IdType="pubmed">37789144</ArticleId><ArticleId IdType="pmc">10667091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JW, Austin M, Onodera T, Notkins AL (1979) Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300(21):1173&#x2013;1179. https://doi.org/10.1056/NEJM197905243002102</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197905243002102</ArticleId><ArticleId IdType="pubmed">219345</ArticleId></ArticleIdList></Reference><Reference><Citation>Skog O, Klingel K, Roivainen M, Korsgren O (2019) Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Diabetologia 62(6):1097&#x2013;1099. https://doi.org/10.1007/s00125-019-4841-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-4841-1</ArticleId><ArticleId IdType="pubmed">30810767</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T et al (2014) Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57(4):841&#x2013;843. https://doi.org/10.1007/s00125-013-3155-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3155-y</ArticleId><ArticleId IdType="pubmed">24429579</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Genoni A, Puggioni A et al (2022) Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia 65(12):2108&#x2013;2120. https://doi.org/10.1007/s00125-022-05779-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05779-2</ArticleId><ArticleId IdType="pubmed">35953727</ArticleId><ArticleId IdType="pmc">9630231</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Krogvold L, Edwin B et al (2021) Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64(11):2491&#x2013;2501. https://doi.org/10.1007/s00125-021-05525-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05525-0</ArticleId><ArticleId IdType="pubmed">34390364</ArticleId><ArticleId IdType="pmc">8494699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifie E, Russell MA, Dhayal S et al (2018) Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia 61(11):2344&#x2013;2355. https://doi.org/10.1007/s00125-018-4704-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4704-1</ArticleId><ArticleId IdType="pubmed">30074059</ArticleId><ArticleId IdType="pmc">6182664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS, Drescher KM, Oka K, Tracy S (2008) 5&#x2019; terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 375(2):480&#x2013;491. https://doi.org/10.1016/j.virol.2008.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.02.030</ArticleId><ArticleId IdType="pubmed">18378272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S, Smithee S, Alhazmi A, Chapman N (2015) Coxsackievirus can persist in murine pancreas by deletion of 5&#x2019; terminal genomic sequences. J Med Virol 87(2):240&#x2013;247. https://doi.org/10.1002/jmv.24039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24039</ArticleId><ArticleId IdType="pubmed">25111164</ArticleId></ArticleIdList></Reference><Reference><Citation>Knebel UE, Peleg S, Dai C et al (2024) Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes. Cell Metab 36(1):48-61.e46. https://doi.org/10.1016/j.cmet.2023.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2023.11.011</ArticleId><ArticleId IdType="pubmed">38128529</ArticleId></ArticleIdList></Reference><Reference><Citation>Manduchi E, Descamps HC, Schug J et al (2024) No evidence for persistent enteroviral B infection of pancreatic islets in patients with type 1 diabetes and prediabetes from RNA sequencing data. Diabetes 73(10):1697&#x2013;1704. https://doi.org/10.2337/db24-0076</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db24-0076</ArticleId><ArticleId IdType="pubmed">39083653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hy&#xf6;ty H, K&#xe4;&#xe4;ri&#xe4;inen S, Laiho JE et al (2024) Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial. Diabetologia 67(5):811&#x2013;821. https://doi.org/10.1007/s00125-024-06092-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06092-w</ArticleId><ArticleId IdType="pubmed">38369573</ArticleId><ArticleId IdType="pmc">10954874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40085113</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Revising US MMR Vaccine Recommendations Amid Changing Domestic Risks.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2025.3867</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rader</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Computational Epidemiology Lab, Boston Children's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walensky</LastName><ForeName>Rochelle P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Bayer Fellow in Health &amp; Biotech, American Academy in Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Public Leadership, Belfer Center for Science and International Affairs, Women and Public Policy Program, Harvard Kennedy School, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Wesley S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Immunology, Department of Medicine, New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brownstein</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Computational Epidemiology Lab, Boston Children's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint discusses updating the existing recommendation for an additional early MMR dose to infants aged 6 to 11 months traveling to any region with increased probability of measles exposure.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40085113</ArticleId><ArticleId IdType="doi">10.1001/jama.2025.3867</ArticleId><ArticleId IdType="pii">2831828</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40082952</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases.</ArticleTitle><Pagination><StartPage>158</StartPage><MedlinePgn>158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-025-03975-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer (CC), primarily caused by human papillomavirus (HPV) infection, remains a significant global health concern. We aimed to comprehensively investigate the epidemiological status of HPV in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from 2,728,321 women undergoing routine cervical examinations at 2127 medical institutions nationwide from January 2017 to June 2023 were analyzed. HPV genotype testing was conducted using HPV DNA typing kits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall HPV prevalence was 17.70%, with 13.12% classified as high-risk HPV (HR-HPV) and 4.58% as low-risk HPV (LR-HPV). Notably, HPV52 emerged as the most common carcinogenic type, followed by HPV58 and HPV16. Age-specific prevalence revealed a bimodal distribution, with peaks observed in women under 21 and over 61&#xa0;years of age. Geographically, the south (19.48%) exhibited the highest infection rate, while the northwest (12.36%) had the lowest. Furthermore, HPV infection rates were higher during winter and spring. Although HPV infection rates have remained stable overall over the past 7&#xa0;years, the infection rate in 2023 (14.76%) has declined relative to 2017 (16.17%) (P&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides comprehensive insight into HPV epidemiology in China and guidance for future vaccine development and cervical cancer prevention strategies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Han</LastName><ForeName>Sirui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lin</LastName><ForeName>Mengyue</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Mengyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd., Shantou University Medical College, Shantou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shiwan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Pi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jiubiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Medical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Longxu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Papillomavirus Molecular Diagnostic Engineering Technology Research Center, Chaozhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Aijuan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Life Sciences, Henan Normal University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yingmu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Joint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd., Shantou University Medical College, Shantou, Guangdong, China. yingmucai@hybribio.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China. yingmucai@hybribio.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yequn</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, China. gdcycyq@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, China. gdcycyq@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Phenome Institute of Shantou University Medical College, Guangdong Engineering Research Center of Human Phenome, Chemistry and Chemical Engineering Guangdong Laboratory, Shantou, Guangdong, China. gdcycyq@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 82073659</GrantID><Agency>The National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2022-124-6</GrantID><Agency>Guangdong Province Science and Technology Special Fund</Agency><Country/></Grant><Grant><GrantID>2024KCXTD019</GrantID><Agency>Guangdong Provincial Innovation Team</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="Y">Papillomaviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">Genotype distribution</Keyword><Keyword MajorTopicYN="N">HPV prevalence</Keyword><Keyword MajorTopicYN="N">Human papillomavirus</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of The First Affiliated Hospital of Shantou University Medical College (Approval No. B-2024-113). The study adheres to the ethical principles outlined in the Declaration of Helsinki, the International Ethical Guidelines for Health-related Research Involving Humans (CIOMS), and other relevant regulations. Consent for publication: All authors have read and agreed to the published version of the manuscript. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>14</Day><Hour>0</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40082952</ArticleId><ArticleId IdType="pmc">PMC11907810</ArticleId><ArticleId IdType="doi">10.1186/s12916-025-03975-6</ArticleId><ArticleId IdType="pii">10.1186/s12916-025-03975-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029&#x2013;30. 10.1002/cncr.33587.</Citation><ArticleIdList><ArticleId IdType="pubmed">34086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197&#x2013;206. 10.1016/S2214-109X(22)00501-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9848409</ArticleId><ArticleId IdType="pubmed">36528031</ArticleId></ArticleIdList></Reference><Reference><Citation>Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Mu&#xf1;oz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10451482</ArticleId></ArticleIdList></Reference><Reference><Citation>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781057</ArticleId><ArticleId IdType="pubmed">18354839</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of mRNA tests for human papillomavirus (HPV). 2nd ed. Geneva: World Health Organization; 2021. PMID: 35044737</Citation><ArticleIdList><ArticleId IdType="pubmed">35044737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16(2):83&#x2013;97. 10.1002/rmv.488.</Citation><ArticleIdList><ArticleId IdType="pubmed">16287204</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95&#x2013;108. 10.1038/s41579-021-00617-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34522050</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241&#x2013;68.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pubmed">28530369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman M, Doorbar J, Wentzensen N, de Sanjos&#xe9; S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086. 10.1038/nrdp.2016.86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27905473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni L, Diaz M, Castellsagu&#xe9; X, Ferrer E, Bosch FX, de Sanjos&#xe9; S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789&#x2013;99. 10.1086/657321.</Citation><ArticleIdList><ArticleId IdType="pubmed">21067372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, Gao C, Ma D, Liao S. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88&#x2013;102. 10.1016/j.canlet.2019.11.039.</Citation><ArticleIdList><ArticleId IdType="pubmed">31812696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, Zhang X, Belinson JL, Sellors JW, Smith JS, Qiao YL, Franceschi S. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131(12):2929&#x2013;38. 10.1002/ijc.27571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3435460</ArticleId><ArticleId IdType="pubmed">22488743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191791. 10.1542/peds.2019-1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935554</ArticleId><ArticleId IdType="pubmed">31740500</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannone G, Giuliano AR, Bandini M, Marandino L, Raggi D, Earle W, Ayres B, Pettaway CA, McNeish IA, Spiess PE, Necchi A. HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Cancer Treat Rev. 2022;111:102467. 10.1016/j.ctrv.2022.102467.</Citation><ArticleIdList><ArticleId IdType="pubmed">36265336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Jiang Y, Wang Q, Lai Y, Holloway A. The status and challenges of HPV vaccine programme in China: an exploration of the related policy obstacles. BMJ Glob Health. 2023;8(8):e012554. 10.1136/bmjgh-2023-012554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10432676</ArticleId><ArticleId IdType="pubmed">37586782</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, Yu H, Piao H. The prevalence, trends, and geographical distribution of human papillomavirus infection in China: the pooled analysis of 1.7 million women. Cancer Med. 2019;8(11):5373&#x2013;85. 10.1002/cam4.2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718589</ArticleId><ArticleId IdType="pubmed">31350872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Wang Z, Geng J, Tan X. Comparative study on detection and typing of human papillomavirus (HPV) Infection with microarray using paraffin-embedded specimens from squamous cell carcinoma and cervical precursor lesions. J Nanosci Nanotechnol. 2017;17(2):990&#x2013;7. 10.1166/jnn.2017.12769.</Citation><ArticleIdList><ArticleId IdType="pubmed">29671971</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz LE, Unger ER. Human papillomavirus vaccination. N Engl J Med. 2023;388(19):1790&#x2013;8. 10.1056/NEJMcp2108502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11567082</ArticleId><ArticleId IdType="pubmed">37163625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, Andrae B, Elfstr&#xf6;m KM, Dillner J, Spar&#xe9;n P, Sundstr&#xf6;m K. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med. 2018;15(10):e1002666. 10.1371/journal.pmed.1002666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166926</ArticleId><ArticleId IdType="pubmed">30273338</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Men&#xe9;ndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, And&#xfa;jar M, Castellsagu&#xe9; X, S&#xe1;nchez GI, Nowakowski AM, Bornstein J, Mu&#xf1;oz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048&#x2013;56. 10.1016/S1470-2045(10)70230-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumban E. A current update on human papillomavirus-associated head and neck cancers. Viruses. 2019;11(10):922. 10.3390/v11100922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6833051</ArticleId><ArticleId IdType="pubmed">31600915</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Arch Gynecol Obstet. 2020;302(6):1329&#x2013;37. 10.1007/s00404-020-05787-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584548</ArticleId><ArticleId IdType="pubmed">32914222</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine and Immunization Branch, Chinese Preventive Medicine Association. [Expert consensus on immunological prevention of human papillomavirus-related diseases]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019;53(8):761&#x2013;803. 10.3760/cma.j.issn.0253-9624.2019.08.001. Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">31378039</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni L, Albero G, Serrano B, Mena M, Collado JJ, G&#xf3;mez D, Mu&#xf1;oz J, Bosch FX, de Sanjos&#xe9; S.&#xa0;ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary report. 2023.</Citation></Reference><Reference><Citation>Yang X, Li Y, Tang Y, Li Z, Wang S, Luo X, He T, Yin A, Luo M. Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. Emerg Microbes Infect. 2023;12(1):e2176009. 10.1080/22221751.2023.2176009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9936994</ArticleId><ArticleId IdType="pubmed">36744409</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanshan C, Jing C, Tao X. HPV infection status among women of all ages in Jinshan District, Shanghai. J Int Med Res. 2024;52(11):3000605241291754. 10.1177/03000605241291754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11549702</ArticleId><ArticleId IdType="pubmed">39520119</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Hu Z, Yan J, Shen X, Meng Q, Wu H, Xiang Y, Yao C, Du K. Epidemiological study of human papillomavirus infection in 105,679 women in Wuhan, China. BMC Infect Dis. 2024;24(1):1111. 10.1186/s12879-024-10011-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11457396</ArticleId><ArticleId IdType="pubmed">39375610</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37(6 Suppl):S3-9. 10.1016/j.jadohealth.2005.09.011.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310138</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 2021;11(8):1896&#x2013;912. 10.1158/2159-8290.CD-20-1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8338882</ArticleId><ArticleId IdType="pubmed">33990345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang Z, Ren Z, Li Z, Ma W, Gao X, Zhang R, Qiao Y, Li J. HPV vaccine acceptability and willingness-related factors among Chinese adolescents: a nation-wide study. Hum Vaccin Immunother. 2021;17(4):1025&#x2013;32. 10.1080/21645515.2020.1812314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018488</ArticleId><ArticleId IdType="pubmed">33121330</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontillo A, Bricher P, Leal VN, Lima S, Souza PR, Crovella S. Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer development. J Med Virol. 2016;88(9):1646&#x2013;51. 10.1002/jmv.24514.</Citation><ArticleIdList><ArticleId IdType="pubmed">26945813</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisman DN. Seasonality of infectious diseases. Annu Rev Public Health. 2007;28:127&#x2013;43. 10.1146/annurev.publhealth.28.021406.144128.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40076777</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms26052145</ELocationID><Abstract><AbstractText>Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to "overcome the heterogeneity of cancer antigens". For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. Although ROBO1 and GPC3 are often expressed in cytoplasm, there are also cases in which they are expressed on the cell membrane depending on the type of cancer. On the other hand, it has been revealed that three antigens-EphB4, CLDN1, and LAT1-are frequently expressed only on the cell membrane of cancer cells in various solid cancers, suggesting that they may be ideal targets for CAR-T cell therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakatsura</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3918-2385</Identifier><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takenouchi</LastName><ForeName>Kazumasa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Sae</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnuki</LastName><ForeName>Kazunobu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Nobuo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0679-1371</Identifier><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP23fk0210093, JP24fk0210152, JP24ck0106919, and JP24bm1123042.</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>2022-A-9</GrantID><Agency>the National Cancer Center Research and Development Fund</Agency><Country/></Grant><Grant><GrantID>JPMJST2211</GrantID><Agency>JST START Project Promotion Type (Commercialization Support)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="Y">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAR-T cell therapy</Keyword><Keyword MajorTopicYN="N">CLDN1</Keyword><Keyword MajorTopicYN="N">EphB4</Keyword><Keyword MajorTopicYN="N">LAT1</Keyword><Keyword MajorTopicYN="N">ROBO1</Keyword><Keyword MajorTopicYN="N">cocktail CAR-T</Keyword><Keyword MajorTopicYN="N">common cancer antigens</Keyword><Keyword MajorTopicYN="N">glypican-3</Keyword><Keyword MajorTopicYN="N">membrane protein</Keyword><Keyword MajorTopicYN="N">solid cancer</Keyword></KeywordList><CoiStatement>Author Tetsuya Nakatsura (T.N.) has received research grants from BrightPath Biotherapeutics Co., Ltd., Thyas Co., Ltd., ONO PHARMACEUTICAL Co., Ltd., Resonac Corporation, MEDINET Co., Ltd., NapaJen Pharma Inc., Heartseed Inc., Takara BIO Inc., DAICEL CORPORATION, NA Vaccine Institute Co., Ltd., Logomix Inc., Optieum Biotechnologies Inc., and MaxCyte, Inc. T.N. hold stock ownership, stock options, or profits from Noile-Immune Biotech Inc., Logomix Inc., and Optieum Biotechnologies Inc. T.N. have royalties from OncoTherapyScience, Inc. The remaining authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>13</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40076777</ArticleId><ArticleId IdType="pmc">PMC11900252</ArticleId><ArticleId IdType="doi">10.3390/ijms26052145</ArticleId><ArticleId IdType="pii">ijms26052145</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sawada Y., Yoshikawa T., Nobuoka D., Shirakawa H., Kuronuma T., Motomura Y., Mizuno S., Ishii H., Nakachi K., Konishi M., et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 2012;18:3686&#x2013;3696. doi: 10.1158/1078-0432.CCR-11-3044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-11-3044</ArticleId><ArticleId IdType="pubmed">22577059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y., Yoshikawa T., Ofuji K., Yoshimura M., Tsuchiya N., Takahashi M., Nobuoka D., Gotohda N., Takahashi S., Kato Y., et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. doi: 10.1080/2162402X.2015.1129483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1129483</ArticleId><ArticleId IdType="pmc">PMC4910752</ArticleId><ArticleId IdType="pubmed">27467945</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S., Sakata J., Utsumi F., Sekiya R., Kajiyama H., Shibata K., Kikkawa F., Nakatsura T. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology. 2016;5:e1238542. doi: 10.1080/2162402X.2016.1238542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2016.1238542</ArticleId><ArticleId IdType="pmc">PMC5139642</ArticleId><ArticleId IdType="pubmed">27999758</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi M., Mizuno S., Yoshikawa T., Fujinami N., Sugimoto M., Kobayashi S., Takahashi S., Konishi M., Gotohda N., Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747&#x2013;2759. doi: 10.1111/cas.14497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14497</ArticleId><ArticleId IdType="pmc">PMC7419030</ArticleId><ArticleId IdType="pubmed">32449239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya N., Hosono A., Yoshikawa T., Shoda K., Nosaka K., Shimomura M., Hara J., Nitani C., Manabe A., Yoshihara H., et al. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. Oncoimmunology. 2017;7:e1377872. doi: 10.1080/2162402X.2017.1377872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1377872</ArticleId><ArticleId IdType="pmc">PMC5739579</ArticleId><ArticleId IdType="pubmed">29296538</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509&#x2013;1518. doi: 10.1056/NEJMoa1215134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215134</ArticleId><ArticleId IdType="pmc">PMC4058440</ArticleId><ArticleId IdType="pubmed">23527958</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011;365:725&#x2013;733. doi: 10.1056/NEJMoa1103849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1103849</ArticleId><ArticleId IdType="pmc">PMC3387277</ArticleId><ArticleId IdType="pubmed">21830940</ArticleId></ArticleIdList></Reference><Reference><Citation>Raje N., Berdeja J., Lin Y., Siegel D., Jagannath S., Madduri D., Liedtke M., Rosenblatt J., Maus M.V., Turka A., et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2019;380:1726&#x2013;1737. doi: 10.1056/NEJMoa1817226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1817226</ArticleId><ArticleId IdType="pmc">PMC8202968</ArticleId><ArticleId IdType="pubmed">31042825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde M., Joseph S.K., Pashankar F., DeRenzo C., Sanber K., Navai S., Byrd T.T., Hicks J., Xu M.L., Gerken C., et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat. Commun. 2020;11:3549. doi: 10.1038/s41467-020-17175-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17175-8</ArticleId><ArticleId IdType="pmc">PMC7363864</ArticleId><ArticleId IdType="pubmed">32669548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Wang M., Chen Y., Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24:133. doi: 10.1186/s12935-024-03315-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-024-03315-3</ArticleId><ArticleId IdType="pmc">PMC11017638</ArticleId><ArticleId IdType="pubmed">38622705</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.H., Sharma S., Heczey A.A., Woods M.L., Steffin D.H.M., Louis C.U., Grilley B.J., Thakkar S.G., Wu M., Wang T., et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat. Med. 2025 doi: 10.1038/s41591-025-03513-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-025-03513-0</ArticleId><ArticleId IdType="pubmed">39962287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai X., Mao L., Wu M., Liu J., Yu S. Challenges of Anti-Mesothelin CAR-T-Cell Therapy. Cancers. 2023;15:1357. doi: 10.3390/cancers15051357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15051357</ArticleId><ArticleId IdType="pmc">PMC10000068</ArticleId><ArticleId IdType="pubmed">36900151</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi C., Liu C., Gong J., Liu D., Wang X., Zhang P., Qin Y., Ge S., Zhang M., Peng Z., et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results. Nat. Med. 2024;30:2224&#x2013;2234. doi: 10.1038/s41591-024-03037-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03037-z</ArticleId><ArticleId IdType="pubmed">38830992</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D., Shi Y., Kaseb A.O., Qi X., Zhang Y., Chi J., Lu Q., Gao H., Jiang H., Wang H., et al. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin. Cancer Res. 2020;26:3979&#x2013;3989. doi: 10.1158/1078-0432.CCR-19-3259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-3259</ArticleId><ArticleId IdType="pubmed">32371538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chokshi C.R., Shaikh M.V., Brakel B., Rossotti M.A., Tieu D., Maich W., Anand A., Chafe S.C., Zhai K., Suk Y., et al. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells. Nat. Med. 2024;30:2936&#x2013;2946. doi: 10.1038/s41591-024-03138-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03138-9</ArticleId><ArticleId IdType="pubmed">39095594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Funahashi S., Yamauchi N., Shibahara J., Midorikawa Y., Kawai S., Kinoshita Y., Watanabe A., Hippo Y., Ohtomo T., et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin. Cancer Res. 2006;12:3257&#x2013;3264. doi: 10.1158/1078-0432.CCR-05-2787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-05-2787</ArticleId><ArticleId IdType="pubmed">16740745</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki M., Watanabe A., Enomoto S., Kawamura T., Ito H., Kodama T., Hamakubo T., Aburatani H. Human ROBO1 is cleaved by metalloproteinases and gamma-secretase and migrates to the nucleus in cancer cells. FEBS Lett. 2010;584:2909&#x2013;2915. doi: 10.1016/j.febslet.2010.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.05.009</ArticleId><ArticleId IdType="pubmed">20471383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo H., Yagyu S., Nakamura K., Yamashima K., Tomida A., Kikuchi K., Iehara T., Nakazawa Y., Hosoi H. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol. Ther. Oncolytics. 2021;20:646&#x2013;658. doi: 10.1016/j.omto.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7985479</ArticleId><ArticleId IdType="pubmed">33816783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S.R., Scehnet J.S., Ley E.J., Singh J., Krasnoperov V., Liu R., Manchanda P.K., Ladner R.D., Hawes D., Weaver F.A., et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009;69:3736&#x2013;3745. doi: 10.1158/0008-5472.CAN-08-3232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3232</ArticleId><ArticleId IdType="pubmed">19366806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S.R., Singh J., Xia G., Krasnoperov V., Hassanieh L., Ley E.J., Scehnet J., Kumar N.G., Hawes D., Press M.F., et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am. J. Pathol. 2006;169:279&#x2013;293. doi: 10.2353/ajpath.2006.050889.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.050889</ArticleId><ArticleId IdType="pmc">PMC1698769</ArticleId><ArticleId IdType="pubmed">16816380</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Li D., Park R., Liu R., Xia Z., Guo J., Krasnoperov V., Gill P.S., Li Z., Shan H., et al. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J. Nucl. Med. 2013;54:1094&#x2013;1100. doi: 10.2967/jnumed.112.116822.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.116822</ArticleId><ArticleId IdType="pubmed">23667241</ArticleId></ArticleIdList></Reference><Reference><Citation>Masood R., Kumar S.R., Sinha U.K., Crowe D.L., Krasnoperov V., Reddy R.K., Zozulya S., Singh J., Xia G., Broek D., et al. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int. J. Cancer. 2006;119:1236&#x2013;1248. doi: 10.1002/ijc.21926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.21926</ArticleId><ArticleId IdType="pubmed">16615113</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagyu S., Mochizuki H., Yamashima K., Kubo H., Saito S., Tanaka M., Sakamoto K., Shimoi A., Nakazawa Y. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. Clin. Transl. Immunol. 2021;10:e1291. doi: 10.1002/cti2.1291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1291</ArticleId><ArticleId IdType="pmc">PMC8175993</ArticleId><ArticleId IdType="pubmed">34123382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., Neff J., Washington M.K., Beauchamp R.D. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Investig. 2005;115:1765&#x2013;1776. doi: 10.1172/JCI24543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI24543</ArticleId><ArticleId IdType="pmc">PMC1150288</ArticleId><ArticleId IdType="pubmed">15965503</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku N., Sasabe E., Ueta E., Yamamoto T., Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 2006;66:5251&#x2013;5257. doi: 10.1158/0008-5472.CAN-05-4478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-4478</ArticleId><ArticleId IdType="pubmed">16707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Visco Z.R., Sfakianos G., Grenier C., Boudreau M.H., Simpson S., Rodriguez I., Whitaker R., Yao D.Y., Berchuck A., Murphy S.K., et al. Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance. Front. Oncol. 2021;11:620873. doi: 10.3389/fonc.2021.620873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.620873</ArticleId><ArticleId IdType="pmc">PMC8019902</ArticleId><ArticleId IdType="pubmed">33828978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Li J., Jiang Y., Xu W., Li X., Jing W. CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation. Med. Sci. Monit. 2017;23:2906&#x2013;2916. doi: 10.12659/MSM.904177.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.904177</ArticleId><ArticleId IdType="pmc">PMC5479443</ArticleId><ArticleId IdType="pubmed">28614291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol. Ther. 2022;230:107964. doi: 10.1016/j.pharmthera.2021.107964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2021.107964</ArticleId><ArticleId IdType="pubmed">34390745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki S., Nakatani Y., Mawatari A., Hume W.E., Wada Y., Ishii A., Tanaka M., Tsuyuguchi N., Doi H., Watanabe Y. First-in-human assessment of the novel LAT1 targeting PET probe (18)F-FIMP. Biochem. Biophys. Res. Commun. 2022;596:83&#x2013;87. doi: 10.1016/j.bbrc.2022.01.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.01.099</ArticleId><ArticleId IdType="pubmed">35121373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno Y., Suda K., Masuko K., Yagi H., Hashimoto Y., Masuko T. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. Cancer Sci. 2008;99:1000&#x2013;1007. doi: 10.1111/j.1349-7006.2008.00770.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2008.00770.x</ArticleId><ArticleId IdType="pmc">PMC11160021</ArticleId><ArticleId IdType="pubmed">18294274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Holst J. L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia. Am. J. Cancer Res. 2015;5:1281&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473310</ArticleId><ArticleId IdType="pubmed">26101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner R., Wu D., Cherian S., Fang M., Hanafi L.A., Finney O., Smithers H., Jensen M.C., Riddell S.R., Maloney D.G., et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406&#x2013;2410. doi: 10.1182/blood-2015-08-665547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-08-665547</ArticleId><ArticleId IdType="pmc">PMC4874221</ArticleId><ArticleId IdType="pubmed">26907630</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulery R., Guiraud V., Choquet S., Thieblemont C., Bachy E., Barete S., Todesco &#xc8;., Arnulf B., Boissel N., Baruchel A., et al. T cell malignancies after CAR T&#x2009;cell therapy in the DESCAR-T registry. Nat. Med. 2025 doi: 10.1038/s41591-024-03458-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03458-w</ArticleId><ArticleId IdType="pubmed">39779930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko S. Successful organoid-mediated generation of iPSC-derived CAR-T cells. Cell Stem Cell. 2022;29:493&#x2013;495. doi: 10.1016/j.stem.2022.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.03.005</ArticleId><ArticleId IdType="pubmed">35395182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomida A., Yagyu S., Nakamura K., Kubo H., Yamashima K., Nakazawa Y., Hosoi H., Iehara T. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci. 2021;112:4026&#x2013;4036. doi: 10.1111/cas.15074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.15074</ArticleId><ArticleId IdType="pmc">PMC8486218</ArticleId><ArticleId IdType="pubmed">34382720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40071971</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Exploring the standardization of human nasal antibody measurements.</ArticleTitle><Pagination><StartPage>2475822</StartPage><MedlinePgn>2475822</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2475822</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2025.2475822</ELocationID><Abstract><AbstractText>Mucosal immunity is crucial for preventing the infection and transmission of respiratory viruses. Nasal antibody is inversely correlated with a lower risk of infection with respiratory viruses. However, the current reference standard for nasal antibody assessment is serum-based, mainly consisting of monomeric IgG and IgA. The applicability of serum-derived standards for assessing nasal antibodies, consisting mostly of dimeric or polymeric secretory IgA (sIgA), remains unvalidated. Herein, we first proved that the sera-derived standard was not applicable for assessing nasal antibodies. Using a non-homologous standard as a calibrator introduced systematic error up to 10 times, which did not benefit the understanding of mucosal antibody response. Therefore, we attempted to develop two candidate standards (CS1, CS2) using nasal mucosal lining fluids (NMLFs) collected from SARS-CoV-2 Omicron convalescents or intranasal vaccine recipients, and CS3 using a sIgA monoclonal antibody. CS2 exhibited broad-spectrum binding activity against 12 SARS-CoV-2 strains, including all tested Omicron subvariants. A collaborative study conducted by seven laboratories demonstrated that CS2 improved the harmonization of inter-laboratory variability (pre-standardization geometric coefficients of variance, 14-314%; post-standardization, 3-35%). Using CS2 ensured an accurate assessment of nasal antibodies. Thus, CS2 was established as a national standard for evaluating nasal SARS-CoV-2-specific antibodies (Lot: 300052-202401, 1000 U/mL). Our work provides a benchmark for evaluating mucosal vaccines for SARS-CoV-2 and inspires new avenues for developing new reference standards for other mucosal vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuanxuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yulong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Si</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Drug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guanxing</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd., Changchun, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Drug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhongfang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Drug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Drug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Institute of Infectious Disease, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007071">Immunoglobulin A, Secretory</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009297" MajorTopicYN="Y">Nasal Mucosa</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007071" MajorTopicYN="N">Immunoglobulin A, Secretory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">binding activity</Keyword><Keyword MajorTopicYN="N">commutability</Keyword><Keyword MajorTopicYN="N">nasal antibody</Keyword><Keyword MajorTopicYN="N">national standard</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>17</Day><Hour>15</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40071971</ArticleId><ArticleId IdType="pmc">PMC11915745</ArticleId><ArticleId IdType="doi">10.1080/22221751.2025.2475822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 dashboard . Available from: https://data.who.int/dashboards/covid19/cases?n&#x2009;=&#x2009;c</Citation></Reference><Reference><Citation>COVID-19 vaccination, World data. Available from: https://data.who.int/dashboards/covid19/vaccines?n=c</Citation></Reference><Reference><Citation>Regev-Yochay G, Gonen T, Gilboa M, et al. . Efficacy of a fourth dose of COVID-19 mRNA vaccine against Omicron. N Engl J Med. 2022 Apr 7;386 (14):1377&#x2013;1380. doi:10.1056/NEJMc2202542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202542</ArticleId><ArticleId IdType="pmc">PMC9006792</ArticleId><ArticleId IdType="pubmed">35297591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleier BS, Ramanathan M Jr., Lane AP.. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol Head Neck Surg. 2021 Feb;164 (2):305&#x2013;307. doi:10.1177/0194599820982633</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820982633</ArticleId><ArticleId IdType="pubmed">33320052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Zeng C, Cox TM, et al. . Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022 Oct 28;7 (76):eadd4853. doi:10.1126/sciimmunol.add4853</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add4853</ArticleId><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody [EB/OL]. (2020 Nov 08) [cited 2024 Nov 24]. Available from: https://www.who.int/publications/m/item/WHO-BS-2020.2403.</Citation></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27 (7):1205&#x2013;1211. doi:10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpp LN, Hyrien O, Fong Y, et al. . Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial. Nat Commun. 2024 Nov 12;15 (1):9785. doi:10.1038/s41467-024-53727-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-53727-y</ArticleId><ArticleId IdType="pmc">PMC11557889</ArticleId><ArticleId IdType="pubmed">39532861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, et al. . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608 (7923):593&#x2013;602. doi:10.1038/s41586-022-04980-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, et al. . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602 (7898):657&#x2013;663. doi:10.1038/s41586-021-04385-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilapitiya D, Wheatley AK, Tan HX.. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine. 2023 Jun;92:104585. doi:10.1016/j.ebiom.2023.104585</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104585</ArticleId><ArticleId IdType="pmc">PMC10154910</ArticleId><ArticleId IdType="pubmed">37146404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Jiang Y, He J, et al. . Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat Commun. 2023 Jul 11;14 (1):4117. doi:10.1038/s41467-023-39560-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39560-9</ArticleId><ArticleId IdType="pmc">PMC10336035</ArticleId><ArticleId IdType="pubmed">37433761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Yang C, Yin L, et al. . Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. Signal Transduct Target Ther. 2023 Apr 17;8 (1):167. doi:10.1038/s41392-023-01423-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01423-6</ArticleId><ArticleId IdType="pmc">PMC10106878</ArticleId><ArticleId IdType="pubmed">37069171</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U, Bladh O, Havervall S, et al. . 7-month duration of SARS-CoV-2 mucosal immunoglobulin &#x2013; a responses and protection. Lancet Infect Dis. 2023 Feb;23 (2):150&#x2013;152. doi:10.1016/S1473-3099(22)00834-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00834-9</ArticleId><ArticleId IdType="pmc">PMC9833832</ArticleId><ArticleId IdType="pubmed">36640796</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang Z, Wang Q, et al. . Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion. hLife. 2024;2 (9):488&#x2013;491. doi:10.1016/j.hlife.2024.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlife.2024.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang Z, Wang Q, et al. . Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies. Signal Transduct Target Ther. 2024 Jul 22;9 (1):190. doi:10.1038/s41392-024-01906-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01906-0</ArticleId><ArticleId IdType="pmc">PMC11263566</ArticleId><ArticleId IdType="pubmed">39039046</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV) [EB/OL] (2018 Oct 2) [cited 2024 June 16]. Available from: https://cdn.who.int/media/docs/default-source/biologicals/bs-documents-(ecbs)/2019-documents/bs.2018.2338_sipv_is_collaborative_study_report_version.pdf?sfvrsn&#x2009;=&#x2009;9b150f78_5&amp;download&#x2009;=&#x2009;true.</Citation></Reference><Reference><Citation>Guan L, Mao Q, Tan D, et al. . Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: the first National Standard calibration traceability to the WHO International Standard. Front Immunol. 2023;14:1107639. doi:10.3389/fimmu.2023.1107639</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1107639</ArticleId><ArticleId IdType="pmc">PMC9971588</ArticleId><ArticleId IdType="pubmed">36865542</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern [EB/OL]. (2022 July 19) [cited 2024 Feb 24]. Available from: https://www.who.int/publications/m/item/who-bs-2022.2427</Citation></Reference><Reference><Citation>Young IS. The enduring importance and challenge of commutability. Clin Chem. 2018 Mar;64 (3):421&#x2013;423. doi:10.1373/clinchem.2017.284216</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.284216</ArticleId><ArticleId IdType="pubmed">29352042</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO manual for the preparation of reference materials for use as secondary standards in antibody testing, TRS 1043, Annex 2 [EB/OL] (2022 May 11) [cited 2024 June 15]. https://www.who.int/publications/m/item/who-manual-for-reference-material-for-antibody-testing-annex-2.</Citation></Reference><Reference><Citation>CLSI . Characterisation and quantification of commutable reference materials for laboratory medicine; approved guideline. CLSI document EP30-A (ISBN 1-5628-726-X).</Citation></Reference><Reference><Citation>Nelson BC, Pfeiffer CM, Zhang M, et al. . Commutability of NIST SRM 1955 homocysteine and folate in frozen human serum with selected total homocysteine immunoassays and enzymatic assays. Clin Chim Acta. 2008 Sep;395 (1&#x2013;2):99&#x2013;105. doi:10.1016/j.cca.2008.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2008.05.016</ArticleId><ArticleId IdType="pubmed">18565331</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga F, Infusino I, Frusciante E, et al. . Trueness evaluation and verification of interassay agreement of 11 serum IgA measuring systems: implications for medical decisions. Clin Chem. 2019 Mar;65 (3):473&#x2013;483. doi:10.1373/clinchem.2018.297655</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2018.297655</ArticleId><ArticleId IdType="pubmed">30626632</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JU, Rigsby P, Dougall T, et al. . Establishment of the first WHO International Standard for antiserum to respiratory syncytial virus: report of an international collaborative study. Vaccine. 2018 Nov 29;36 (50):7641&#x2013;7649. doi:10.1016/j.vaccine.2018.10.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.10.087</ArticleId><ArticleId IdType="pmc">PMC6838659</ArticleId><ArticleId IdType="pubmed">30389194</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettelman RC, Allen EK, Thomas PG.. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity. 2022 May 10;55 (5):749&#x2013;780. doi:10.1016/j.immuni.2022.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9087965</ArticleId><ArticleId IdType="pubmed">35545027</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Marking U, Svensson J, et al. . Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N Engl J Med. 2022 Oct 6;387 (14):1333&#x2013;1336. doi:10.1056/NEJMc2209651</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId><ArticleId IdType="pmc">PMC9511632</ArticleId><ArticleId IdType="pubmed">36103621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F, Marcotte H, Hammarstrom L, et al. . Mucosal IgA against SARS-CoV-2 Omicron infection. N Engl J Med. 2022 Nov 24;387 (21):e55.</Citation><ArticleIdList><ArticleId IdType="pubmed">36416778</ArticleId></ArticleIdList></Reference><Reference><Citation>Declercq J, Gerlo S, Van Nevel S, et al. . Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa. Sci Transl Med. 2024 Oct 23;16 (770):eadn2364. doi:10.1126/scitranslmed.adn2364</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adn2364</ArticleId><ArticleId IdType="pubmed">39441904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Rowe M, McMahan K, et al. . SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci Transl Med. 2024 Oct 23;16 (770):eadp8920. doi:10.1126/scitranslmed.adp8920</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adp8920</ArticleId><ArticleId IdType="pmc">PMC11542980</ArticleId><ArticleId IdType="pubmed">39441905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Sun J.. From blood to mucosa. Sci Transl Med. 2024 Oct 23;16 (770):eads6271. doi:10.1126/scitranslmed.ads6271</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.ads6271</ArticleId><ArticleId IdType="pubmed">39441906</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. In search of COVID-19 vaccines that elicit mucosal immunity and stop transmission. JAMA. 2025;333 (3):187&#x2013;189. doi:10.1001/jama.2024.23627</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.23627</ArticleId><ArticleId IdType="pubmed">39705023</ArticleId></ArticleIdList></Reference><Reference><Citation>Strugnell RA, Wijburg OL.. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010 Sep;8 (9):656&#x2013;667. doi:10.1038/nrmicro2384</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2384</ArticleId><ArticleId IdType="pubmed">20694027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Guan L, Li N, et al. . Establishment of the first national standard for neutralizing antibodies against SARS-CoV-2 XBB variants. Viruses. 2024 Apr 1;16 (4):554. doi:10.3390/v16040554</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16040554</ArticleId><ArticleId IdType="pmc">PMC11053542</ArticleId><ArticleId IdType="pubmed">38675896</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WG, Schimmel H, Rej R, et al. . IFCC working group recommendations for assessing commutability part 1: general experimental design. Clin Chem. 2018 Mar;64 (3):447&#x2013;454. doi:10.1373/clinchem.2017.277525</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2017.277525</ArticleId><ArticleId IdType="pmc">PMC5832613</ArticleId><ArticleId IdType="pubmed">29348163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y, Zhang Z, Liu M, et al. . Integrated large-scale metagenome assembly and multi-kingdom network analyses identify sex differences in the human nasal microbiome. Genome Biol. 2024 Oct 8;25 (1):257. doi:10.1186/s13059-024-03389-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-024-03389-2</ArticleId><ArticleId IdType="pmc">PMC11463039</ArticleId><ArticleId IdType="pubmed">39380016</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Establishment of the first WHO International Standard and Reference Panel for anti-Lassa Fever virus antibody WHO/BS/2021.2406 [EB/OL] (2021 Oct 21) [cited 2024 Nov 22]. Available from: https://www.who.int/publications/m/item/who-manual-for-reference-material-for-antibody-testing-annex-2.</Citation></Reference><Reference><Citation>Kirkeby L, Rasmussen TT, Reinholdt J, et al. . Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria. Clin Diagn Lab Immunol. 2000 Jan;7 (1):31&#x2013;39. doi:10.1128/CDLI.7.1.31-39.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.7.1.31-39.2000</ArticleId><ArticleId IdType="pmc">PMC95818</ArticleId><ArticleId IdType="pubmed">10618273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40066621</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.</ArticleTitle><Pagination><StartPage>2477384</StartPage><MedlinePgn>2477384</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2477384</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2025.2477384</ELocationID><Abstract><AbstractText>The World Health Organization (WHO) has recently declared another global health emergency due to the rapidly spreading monkeypox (Mpox) outbreak in numerous African countries. To address the unmet need to contain the outbreak using the existing vaccines, this study developed a lyophilization process for an effective, scalable and affordable Mpox mRNA-LNP vaccine candidate to address the global health crisis. A comprehensive evaluation and optimization of the vaccine formulation (the type/concentration of cryoprotectants, the type/concentration of buffer system, as well as the mRNA concentration and reconstitution solvent) and the freeze-drying process parameters (freezing method, temperature, cooling rate and primary/secondary drying conditions) were conducted. The freeze-dried product exhibits a uniform appearance and a moisture content of less than 1%. Reconstitution of the lyophilized mRNA-LNP resulted in equivalent particle size/polydispersity index, encapsulation efficiency and mRNA integrity compared to that of freshly prepared mRNA-LNP. Furthermore, the lyophilization process can be scaled up 100-fold to 2000 vials/batch. Notably, the lyophilized mRNA-LNP demonstrated a storage stability of at least 12&#x2009;months at 4&#xb0;C, and at ambient temperature for a minimum of 8&#xa0;h post-reconstitution, exhibiting minimal deterioration in product quality. The in vitro biological activity and in vivo immunogenicity of the lyophilized mRNA-LNP was comparable to that of the freshly prepared mRNA-LNP. These results provide a compelling rationale for the utilization of lyophilization technology in enhancing the accessibility of the Mpox mRNA vaccine in developing countries, a strategy that is crucial for containing the global epidemic of Mpox infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Quanyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Caixia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Man</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Yingchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhihua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yelin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhilei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Yither Biotech Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097007">Nanovaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005612" MajorTopicYN="Y">Freeze Drying</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008993" MajorTopicYN="N">Monkeypox virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097007" MajorTopicYN="N">Nanovaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Monkeypox</Keyword><Keyword MajorTopicYN="N">batch consistency</Keyword><Keyword MajorTopicYN="N">long-term stability</Keyword><Keyword MajorTopicYN="N">lyophilized mRNA vaccines</Keyword><Keyword MajorTopicYN="N">scalability</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>11</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40066621</ArticleId><ArticleId IdType="pmc">PMC11901372</ArticleId><ArticleId IdType="doi">10.1080/21645515.2025.2477384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saied AA, Metwally P, Metwally AA, Choudhary OP.. Monkeypox: an extra burden on global health. Int J Surg. 2022;104:106745. doi: 10.1016/j.ijsu.2022.106745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106745</ArticleId><ArticleId IdType="pmc">PMC9238059</ArticleId><ArticleId IdType="pubmed">35777695</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Choudhary OP, Choudhary OP.. Emergence of monkeypox: risk assessment and containment measures. Travel Med Infect Dis. 2022;49:102392. doi: 10.1016/j.tmaid.2022.102392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2022.102392</ArticleId><ArticleId IdType="pmc">PMC9217686</ArticleId><ArticleId IdType="pubmed">35752293</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrni ML, Sharma P, Sharma A, Choudhary OP. Monkeypox: prioritizing public health through early intervention and treatment. Int J Surg. 2022;104:106774. doi: 10.1016/j.ijsu.2022.106774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106774</ArticleId><ArticleId IdType="pmc">PMC9293389</ArticleId><ArticleId IdType="pubmed">35863624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Fahrni P, Fahrni ML, Choudhary OP. Monkeypox outbreak: new zoonotic alert after the COVID-19 pandemic. Int J Surg. 2022;104:106812. doi: 10.1016/j.ijsu.2022.106812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106812</ArticleId><ArticleId IdType="pmc">PMC9356763</ArticleId><ArticleId IdType="pubmed">35944803</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary OP, Chopra P, Chopra H, Shafaati M, Dhawan M, Metwally AA, Saied AA, Rabaan AA, Alhumaid S, Al Mutair A, et al. Reverse zoonosis and its relevance to the monkeypox outbreak 2022. New Microbes New Infect. 2022;49-50:49. doi: 10.1016/j.nmni.2022.101049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmni.2022.101049</ArticleId><ArticleId IdType="pmc">PMC9663440</ArticleId><ArticleId IdType="pubmed">36407851</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary P, Shafaati M, Salah MAHA, Chopra H, Choudhary OP, Silva-Cajaleon K, Bonilla-Aldana DK, Rodriguez-Morales AJ. Zoonotic diseases in a changing climate scenario: revisiting the interplay between environmental variables and infectious disease dynamics. Travel Med And Infect Disease. 2024;58:102694. doi: 10.1016/j.tmaid.2024.102694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2024.102694</ArticleId><ArticleId IdType="pubmed">38336336</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary OP, Infant SS, Vickram A, Chopra H, Manuta N. Exploring the potential and limitations of artificial intelligence in animal anatomy. Ann Anat. 2024;258:152366. doi: 10.1016/j.aanat.2024.152366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aanat.2024.152366</ArticleId><ArticleId IdType="pubmed">39631569</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO Director-General declares mpox outbreak a public health emergency of international concern. 2024. https://www.who.int/news.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11376700</ArticleId><ArticleId IdType="pubmed">39218470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah M, Li Y, Munib K, Zhang Z. Epidemiology, host range, and associated risk factors of monkeypox: an emerging global public health threat. Front Microbiol. 2023;14:1160984. doi: 10.3389/fmicb.2023.1160984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1160984</ArticleId><ArticleId IdType="pmc">PMC10196482</ArticleId><ArticleId IdType="pubmed">37213509</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary OP, Fahrni P, Fahrni ML, Saied AA, Chopra H. Ring vaccination for monkeypox containment: strategic implementation and challenges. Int J Surg. 2022;105:106873. doi: 10.1016/j.ijsu.2022.106873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106873</ArticleId><ArticleId IdType="pmc">PMC9424115</ArticleId><ArticleId IdType="pubmed">36055631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra P, Chopra H, Choudhary OP. mRNA vaccines as an armor to combat the infectious diseases. Travel Med And Infect Disease. 2023;52:102550. doi: 10.1016/j.tmaid.2023.102550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2023.102550</ArticleId><ArticleId IdType="pubmed">36754340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abusalah P, Abusalah H, Chopra H, Sharma SA, Mustafa SA, Choudhary OP, Sharma M, Dhawan M, Khosla R, Loshali A, et al. Nanovaccines: a game changing approach in the fight against infectious diseases. Biomed Pharmacother. 2023;167:115597. doi: 10.1016/j.biopha.2023.115597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.115597</ArticleId><ArticleId IdType="pubmed">37783148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. doi: 10.1016/j.ijpharm.2021.120586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120586</ArticleId><ArticleId IdType="pmc">PMC8032477</ArticleId><ArticleId IdType="pubmed">33839230</ArticleId></ArticleIdList></Reference><Reference><Citation>Su C, Li S, Wen Y, Geng X, Yin Q, Wang Y, Xiong Y, Liu Z. A quadrivalent mRNA immunization elicits potent immune responses against multiple orthopoxviral antigens and neutralization of monkeypox virus in rodent models. Vaccines. 2024;12(4):385. doi: 10.3390/vaccines12040385.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12040385</ArticleId><ArticleId IdType="pmc">PMC11053415</ArticleId><ArticleId IdType="pubmed">38675767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H, Long J, Cao Y, Mai J, Miao Y, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Sig Transduct Target Ther. 2023;8(1):172. doi: 10.1038/s41392-023-01432-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01432-5</ArticleId><ArticleId IdType="pmc">PMC10144886</ArticleId><ArticleId IdType="pubmed">37117161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou F, Zhang Y, Liu X, Murad YM, Xu J, Yu Z, Hua X, Song Y, Ding J, Huang H, et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. Nat Commun. 2023;14(1):5925. doi: 10.1038/s41467-023-41628-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41628-5</ArticleId><ArticleId IdType="pmc">PMC10516993</ArticleId><ArticleId IdType="pubmed">37739969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu Y, Palowitch GM, Dokic A, Sanchez-Velazquez R, Schlatterer K, Sarkar S, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024;187(6):1363&#x2013;1373.e12. doi: 10.1016/j.cell.2024.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2024.01.017</ArticleId><ArticleId IdType="pubmed">38366591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Li M, Yang Y, Li C, Peng Y, Yang H, Zhao M, Wu P, Ruan S, Huang Y, et al. An MPXV mRNA-lnp vaccine candidate elicits protective immune responses against monkeypox virus. Chin Chem Lett. 2024;35(8):109270. doi: 10.1016/j.cclet.2023.109270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cclet.2023.109270</ArticleId></ArticleIdList></Reference><Reference><Citation>Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110(3):997&#x2013;15. doi: 10.1016/j.xphs.2020.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.12.006</ArticleId><ArticleId IdType="pmc">PMC7834447</ArticleId><ArticleId IdType="pubmed">33321139</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, Xiao H, Liang X-J, Huang Y. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534. doi: 10.1016/j.biotechadv.2020.107534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2020.107534</ArticleId><ArticleId IdType="pubmed">32088327</ArticleId></ArticleIdList></Reference><Reference><Citation>AboulFotouh K, Southard B, Dao HM, Xu H, Moon C, Williams RO, Cui Z. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying. Int J Pharm. 2024;650:123688. doi: 10.1016/j.ijpharm.2023.123688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2023.123688</ArticleId><ArticleId IdType="pubmed">38070660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Yu T, Li W, Liu Q, Sung T-C, Higuchi A. Design and lyophilization of mRNA-encapsulating lipid nanoparticles. Int J Pharm. 2024;662:124514. doi: 10.1016/j.ijpharm.2024.124514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2024.124514</ArticleId><ArticleId IdType="pubmed">39067550</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark B, Pabst G, Prassl R. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure. Eur J Pharm Sci. 2010;41(3&#x2013;4):546&#x2013;555. doi: 10.1016/j.ejps.2010.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2010.08.010</ArticleId><ArticleId IdType="pubmed">20800680</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu H, Lam K, Bajusz C, Laczk&#xf3; D, Karik&#xf3; K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941&#x2013;1951. doi: 10.1016/j.ymthe.2022.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.001</ArticleId><ArticleId IdType="pmc">PMC8815268</ArticleId><ArticleId IdType="pubmed">35131437</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulewaeter S, Nuytten G, Cheng MH, De Smedt SC, Cullis PR, De Beer T, Lentacker I, Verbeke R. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J Control Release. 2023;357:149&#x2013;160. doi: 10.1016/j.jconrel.2023.03.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.03.039</ArticleId><ArticleId IdType="pmc">PMC10062427</ArticleId><ArticleId IdType="pubmed">36958400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Hou X, Yan J, Du S, Xue Y, Li W, Xiang G, Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020;5(2):358&#x2013;363. doi: 10.1016/j.bioactmat.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7078456</ArticleId><ArticleId IdType="pubmed">32206737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, Han J, Wang W, Wu J, Xu P, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9. doi: 10.1038/s41421-022-00517-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00517-9</ArticleId><ArticleId IdType="pmc">PMC9868121</ArticleId><ArticleId IdType="pubmed">36683074</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y, Miyazaki T, Muto H, Kubara K, Mukai Y, Watari R, Sato S, Kondo K, Tsukumo S-I, Yasutomo K, et al. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Mol Ther - Nucleic Acids. 2022;30:226&#x2013;240. doi: 10.1016/j.omtn.2022.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.09.017</ArticleId><ArticleId IdType="pmc">PMC9508692</ArticleId><ArticleId IdType="pubmed">36187052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamoot A, Lammens J, De Lombaerde E, Zhong Z, Gontsarik M, Chen Y, De Beer TRM, De Geest BG. Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids. Biomater Sci. 2023;11(12):4327&#x2013;4334. doi: 10.1039/D2BM02031A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM02031A</ArticleId><ArticleId IdType="pubmed">37073472</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacela C, Hincha DK. Low amounts of sucrose are sufficient to depress the phase transition temperature of dry phosphatidylcholine, but not for lyoprotection of liposomes. Biophys J. 2006;90(8):2831&#x2013;2842. doi: 10.1529/biophysj.105.074427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.105.074427</ArticleId><ArticleId IdType="pmc">PMC1414563</ArticleId><ArticleId IdType="pubmed">16443655</ArticleId></ArticleIdList></Reference><Reference><Citation>Koster KL, Webb MS, Bryant G, Lynch DV. Interactions between soluble sugars and POPC (1-palmitoyl-2-oleoylphosphatidylcholine) during dehydration: vitrification of sugars alters the phase behavior of the phospholipid. BBA-Biomembranes. 1994;1193(1):143&#x2013;150. doi: 10.1016/0005-2736(94)90343-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2736(94)90343-3</ArticleId><ArticleId IdType="pubmed">8038184</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyajima K. Role of saccharides for the freeze-thawing and freeze drying of liposome. Adv Drug Del Rev. 1997;24(2&#x2013;3):151&#x2013;159. doi: 10.1016/S0169-409X(96)00454-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(96)00454-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister E, Gieseler H. A significant comparison between collapse and glass transition temperatures. Eur Pharm Rev. 2008;13:73&#x2013;79.</Citation></Reference><Reference><Citation>Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21(2):191&#x2013;200. doi: 10.1023/B:PHAM.0000016234.73023.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:PHAM.0000016234.73023.75</ArticleId><ArticleId IdType="pubmed">15032301</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkenschuh E, Friess W. Freeze-drying of nanoparticles: how to overcome colloidal instability by formulation and process optimization. Eur J Pharm Biopharm. 2021;165:345&#x2013;360. doi: 10.1016/j.ejpb.2021.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2021.05.024</ArticleId><ArticleId IdType="pubmed">34052428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolhe P, Amend E, Singh S. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol Progr. 2010;26(3):727&#x2013;733. doi: 10.1002/btpr.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.377</ArticleId><ArticleId IdType="pubmed">20039442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam K, Schreiner P, Leung A, Stainton P, Reid S, Yaworski E, Lutwyche P, Heyes J. Optimizing lipid nanoparticles for delivery in primates. Adv Mater. 2023;35(26):2211420. doi: 10.1002/adma.202211420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202211420</ArticleId><ArticleId IdType="pubmed">36972555</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz&#xe9; S, Selmin F, Samaritani E, Minghetti P, Cilurzo F. Lyophilization of liposomal formulations: still necessary, still challenging. Pharmaceut. 2018;10(3):139. doi: 10.3390/pharmaceutics10030139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics10030139</ArticleId><ArticleId IdType="pmc">PMC6161153</ArticleId><ArticleId IdType="pubmed">30154315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Liu X. Control of ice nucleation: freezing and antifreeze strategies. Chem Soc Rev. 2018;47(18):7116&#x2013;7139. doi: 10.1039/C8CS00626A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8CS00626A</ArticleId><ArticleId IdType="pubmed">30137078</ArticleId></ArticleIdList></Reference><Reference><Citation>Izutsu K-I, Yomota C, Kawanishi T. Stabilization of liposomes in frozen solutions through control of osmotic flow and internal solution freezing by trehalose. J Pharm Sci. 2011;100(7):2935&#x2013;2944. doi: 10.1002/jps.22518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.22518</ArticleId><ArticleId IdType="pubmed">21328583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingvarsson PT, Yang M, Nielsen HM, Rantanen J, Foged C. Stabilization of liposomes during drying. Expert Opin Drug Delivery. 2011;8(3):375&#x2013;388. doi: 10.1517/17425247.2011.553219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2011.553219</ArticleId><ArticleId IdType="pubmed">21294603</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina M, Armstrong TK, Zhang Y, Patel MM, Lentz YK, Anchordoquy TJ. The stability of lyophilized lipid/DNA complexes during prolonged storage. J Pharm Sci. 2004;93(9):2259&#x2013;2273. doi: 10.1002/jps.20138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20138</ArticleId><ArticleId IdType="pubmed">15295787</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Pozo-Rodr&#xed;guez A, Solin&#xed;s M, Gasc&#xf3;n A, Pedraz J. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm. 2009;71(2):181&#x2013;189. doi: 10.1016/j.ejpb.2008.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2008.09.015</ArticleId><ArticleId IdType="pubmed">18940256</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SM, Nail SL, Pikal MJ, Geidobler R, Winter G, Hawe A, Davagnino J, Rambhatla Gupta S. Lyophilized drug product cake appearance: what is acceptable? J Pharm Sci. 2017;106(7):1706&#x2013;1721. doi: 10.1016/j.xphs.2017.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2017.03.014</ArticleId><ArticleId IdType="pubmed">28341598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinugawa K, Kinuhata M, Kagotani R, Imanaka H, Ishida N, Kitamatsu M, Nakanishi K, Imamura K. Inhibitory effects of additives and heat treatment on the crystallization of freeze-dried sugar. J Food Eng. 2015;155:37&#x2013;44. doi: 10.1016/j.jfoodeng.2015.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfoodeng.2015.01.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen JB. A perspective on bleb and empty LNP structures. J Control Release. 2024;373:952&#x2013;961. doi: 10.1016/j.jconrel.2024.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2024.07.046</ArticleId><ArticleId IdType="pubmed">39067793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40064458</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3185</ISSN><JournalIssue CitedMedium="Internet"><Volume>514</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Toxicology</Title><ISOAbbreviation>Toxicology</ISOAbbreviation></Journal><ArticleTitle>Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.</ArticleTitle><Pagination><StartPage>154107</StartPage><MedlinePgn>154107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2025.154107</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0300-483X(25)00063-0</ELocationID><Abstract><AbstractText>mRNA-based technology has been evaluated in clinical trials for rapid control and prevention of emergencies and diseases. HC009, a mRNA vaccine encoding the full-length SARS-CoV-2 spike protein delivered via the QTsome platform, was tested in rats for immunogenicity, toxicity, and biodistribution. For immunogenicity and toxicity, rats received three intramuscular injections of HC009 at 3-week intervals followed by a 4-week observation period. In the biodistribution study, rats received a single intramuscular injection, with mRNA levels measured in organs at various time points. Results showed that HC009 elicited effective, long-lasting humoral immunity and Th1-biased cellular responses. The mRNA primarily localized to the injection site and spleen, with no observed vaccine-related toxicological reactions. These findings support HC009's potential for inducing an effective immune response with a favorable safety profile, warranting further clinical investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: liuj@zhejianghaichang.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xicheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chuanqian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Fengyang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Huafeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yongsheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: yongsheng.yang@thewogroup.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Toxicology</MedlineTA><NlmUniqueID>0361055</NlmUniqueID><ISSNLinking>0300-483X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biodistribution</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Spike protein</Keyword><Keyword MajorTopicYN="N">Toxicity</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40064458</ArticleId><ArticleId IdType="doi">10.1016/j.tox.2025.154107</ArticleId><ArticleId IdType="pii">S0300-483X(25)00063-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40062160</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Toxic Shock Syndrome Caused by Streptococcus dysgalactiae Subspecies equisimilis: A Report of a Rare Pediatric Case.</ArticleTitle><Pagination><StartPage>e78573</StartPage><MedlinePgn>e78573</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e78573</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.78573</ELocationID><Abstract><AbstractText>Streptococcal toxic shock syndrome (STSS) is a severe invasive infection that has a high mortality rate. It is mainly caused by <i>Streptococcus pyogenes</i>. Nevertheless, STSS is also known to be caused by a group G <i>Streptococcus</i> identified as <i>Streptococcus dysgalactiae</i> subsp. <i>equisimilis</i> (SDSE). Invasive SDSE infection predominantly occurs in elderly individuals but is extremely rare in children. Furthermore, reports on STSS caused by SDSE are limited; hence, the clinical aspects and type of invasive mature M protein (<i>emm</i>) gene involved are unknown. A five-year-old girl with Down syndrome, tracheomalacia, and laryngomalacia presented to the emergency department with generalized edema of her face and upper body. She had undergone a tracheostomy and was receiving home ventilation. On admission, she showed hypotension (64/22 mmHg) with impaired consciousness. Blood testing showed elevated levels of inflammatory markers. Blood culture revealed the presence of SDSE and she was consequently diagnosed with STSS. The patient responded well to treatment and was discharged three weeks after admission. The <i>emm</i> subtype of the isolated SDSE strain was <i>stC1400,</i> with mutations in <i>csrS</i> and streptolysin S regulatory RNA in group G <i>Streptococcus</i> (<i>srrG</i>) genes. In this article, we report a case of STSS in a child caused by the <i>stC1400</i>strainof SDSE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Koizumi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Nao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infection and Immunology, Kanagawa Children's Medical Center, Yokohama, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shikama</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Infection and Immunology, Kanagawa Children's Medical Center, Yokohama, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikebe</LastName><ForeName>Tadayoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bacteriology, National Institute of Infectious Diseases, Tokyo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagafuchi</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Kanagawa Children's Medical Center, Yokohama, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imagawa</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infection and Immunology, Kanagawa Children's Medical Center, Yokohama, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">child case</Keyword><Keyword MajorTopicYN="N">japan</Keyword><Keyword MajorTopicYN="N">stc1400</Keyword><Keyword MajorTopicYN="N">streptococcal toxic shock syndrome</Keyword><Keyword MajorTopicYN="N">streptococcus dysgalactiae subsp. equisimilis</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Kanagawa Children's Medical Center issued approval 166-1. This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kanagawa Children's Medical Center (Approval No.: 166-1). The parents of the patient were given oral explanations and gave consent in advance regarding the purpose, method, safety considerations, and risks of the experiment. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: The emm sequencing was performed as described at https://www.cdc.gov/streplab/groupa-strep/resources.html. Primers emm-1 (5&#x2032;-TATT(C/G)GCTTAGAAAATTAA-3&#x2032;) and emm-2 (5&#x2032;-GCAAGTTCTTCAGCTTGTTT-3&#x2032;) were used to amplify the 5&#x2032;-region of emm with TaKaRa PCR Thermal Cycler Dice Touch (Takara Bio, Shiga, Japan). Purified polymerase chain reaction products were sequenced using the emmseq2 primer (5&#x2032;-TAATCGCTTAGAAAATTAAAAACAGG-3&#x2032;) with the Applied Biosystems 3130xl Genetic Analyzer (Applied Biosystems, Tokyo, Japan). The first 180 bases at the 5&#x2032;-end of emm were compared with those in the CDC emm sequence database (https://www2.cdc.gov/vaccines/biotech/strepblast.asp). These experiments were performed at the National Institute of Infectious Diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>17</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40062160</ArticleId><ArticleId IdType="pmc">PMC11888792</ArticleId><ArticleId IdType="doi">10.7759/cureus.78573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Increase in group G streptococcal infections in a community hospital, New York, USA. Wong SS, Lin YS, Mathew L, Rajagopal L, Sepkowitz D. Emerg Infect Dis. 2009;15:991&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727315</ArticleId><ArticleId IdType="pubmed">19523319</ArticleId></ArticleIdList></Reference><Reference><Citation>Invasive group A streptococcal infections in children and adolescents in Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, population-based cohort study. Nygaard U, Hartling UB, Munkstrup C, et al.  https://pubmed.ncbi.nlm.nih.gov/38103567/ Lancet Child Adolesc Health. 2024;8:112&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">38103567</ArticleId></ArticleIdList></Reference><Reference><Citation>Streptococcus dysgalactiae bloodstream infections, Norway, 1999-2021. Oppegaard O, Glambek M, Skutlaberg DH, Skrede S, Sivertsen A, Kittang BR. Emerg Infect Dis. 2023;29:260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9881787</ArticleId><ArticleId IdType="pubmed">36692331</ArticleId></ArticleIdList></Reference><Reference><Citation>Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes. Jensen A, Kilian M. J Clin Microbiol. 2012;50:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256718</ArticleId><ArticleId IdType="pubmed">22075580</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical aspects of invasive infections with Streptococcus dysgalactiae ssp. equisimilis in Japan: differences with respect to Streptococcus pyogenes and Streptococcus agalactiae infections. Takahashi T, Sunaoshi K, Sunakawa K, Fujishima S, Watanabe H, Ubukata K. https://pubmed.ncbi.nlm.nih.gov/19732082/ Clin Microbiol Infect. 2010;16:1097&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19732082</ArticleId></ArticleIdList></Reference><Reference><Citation>Septic arthritis due to Streptococcus dysgalactiae subspecies equisimilis in a healthy school child. Nakano S, Matsuoka N, Yamamoto M, Matsumura Y, Nagao M, Takikawa K, Ichiyama S. Pediatr Infect Dis J. 2017;36:621&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">28505017</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Centers for Disease Control and Prevention. Clinical guidance for streptococcal toxic shock syndrome.  [
Jun;
2024 
]. 2024. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/streptococcal-toxic-shock-syndrome.html https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/streptococcal-toxic-shock-syndrome.html</Citation></Reference><Reference><Citation>Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges. Abo YN, Oliver J, McMinn A, et al. Lancet Reg Health West Pac. 2023;41:100873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10786649</ArticleId><ArticleId IdType="pubmed">38223399</ArticleId></ArticleIdList></Reference><Reference><Citation>Paediatric group A streptococcal disease in England from October to December, 2022. Ladhani SN, Guy R, Bhopal SS, Brown CS, Lamagni T, Sharp A. Lancet Child Adolesc Health. 2023;7:0&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">36566755</ArticleId></ArticleIdList></Reference><Reference><Citation>Rise in group A streptococcal infections in England. Venkatesan P. Lancet Respir Med. 2023;11:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">36549319</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Nelson GE, Pondo T, Toews KA, et al. Clin Infect Dis. 2016;63:478&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776658</ArticleId><ArticleId IdType="pubmed">27105747</ArticleId></ArticleIdList></Reference><Reference><Citation>Streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis from retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: a case report. Fujimoto S, Eriguchi Y, Nakamura R, et al. Mod Rheumatol Case Rep. 2024;8:255&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">38217091</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Infectious Diseases (NIID). Streptococcal toxic shock syndrome. (Article in Japanese)  [
Dec;
2024 
]. 2024. https://www.niid.go.jp/niid/ja/tsls-m/2655-cepr/12718-stss-2024-06.html https://www.niid.go.jp/niid/ja/tsls-m/2655-cepr/12718-stss-2024-06.html</Citation></Reference><Reference><Citation>Invasive infections caused by Lancefield groups C/G and A Streptococcus, Western Australia, Australia, 2000-2018. Wright CM, Moorin R, Pearson G, Dyer J, Carapetis J, Manning L. Emerg Infect Dis. 2022;28:2190&#x2013;2197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622247</ArticleId><ArticleId IdType="pubmed">36285885</ArticleId></ArticleIdList></Reference><Reference><Citation>Neonatal streptococcal toxic shock syndrome caused by Streptococcus dysgalactiae subsp. equisimilis. Yamaoka S, Ogihara T, Yasui M, et al. Pediatr Infect Dis J. 2010;29:979&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879096</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxic shock syndrome caused by Streptococcus dysgalactiae subsp. equisimilis in a Mexican preschool patient. Rodr&#xed;guez-Mu&#xf1;oz L, Garc&#xed;a-Galv&#xe1;n &#xd3;, Gonz&#xe1;lez-Soto M&#xc1;, Ech&#xe1;niz-Avil&#xe9;s G, Sol&#xf3;rzano-Santos F. Bol Med Hosp Infant Mex. 2019;76:237&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">31536040</ArticleId></ArticleIdList></Reference><Reference><Citation>Natural mutation in the regulatory gene (srrG) influences virulence-associated genes and enhances invasiveness in Streptococcus dysgalactiae subsp. equisimilis strains isolated from cases of streptococcal toxic shock syndrome. Ikebe T, Otsuka H, Chiba K, et al. EBioMedicine. 2022;81:104133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9244731</ArticleId><ArticleId IdType="pubmed">35779495</ArticleId></ArticleIdList></Reference><Reference><Citation>Streptococcus dysgalactiae subsp. equisimilis from invasive and non-invasive infections in Spain: combining epidemiology, molecular characterization, and genetic diversity. Rojo-Bezares B, Toca L, Azcona-Guti&#xe9;rrez JM, Ortega-Unanue N, Toledano P, S&#xe1;enz Y. Eur J Clin Microbiol Infect Dis. 2021;40:1013&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33392783</ArticleId></ArticleIdList></Reference><Reference><Citation>Genotyping of erythromycin resistant group C &amp; G streptococci isolated in Chennai, south India. Prabu D, Menon T. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657882/ Indian J Med Res. 2013;137:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657882</ArticleId><ArticleId IdType="pubmed">23481067</ArticleId></ArticleIdList></Reference><Reference><Citation>Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate. Cort&#xe9;s-Penfield N, Ryder JH. Clin Infect Dis. 2023;76:346&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">36056891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40061912</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-6065</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet regional health. Western Pacific</Title><ISOAbbreviation>Lancet Reg Health West Pac</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.</ArticleTitle><Pagination><StartPage>101499</StartPage><MedlinePgn>101499</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101499</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanwpc.2025.101499</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Several domestically-manufactured nonavalent HPV vaccine candidates are in phase III clinical trials and their future availability may address the current dilemma of insufficient supply and high price of the overseas-manufactured nonavalent HPV vaccine in China. We compare the population-level effectiveness and cost-effectiveness of switching to nonavalent HPV vaccination in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used a previously validated transmission model to project the lifetime costs and effectiveness of five same-vaccine and two mixed-vaccine strategies. Nonavalent HPV vaccines were assumed to be available and meet the production requirements for national vaccination between 2030 and 2050. All women living or projected to be born in China during 2023-2100 were considered. We adopted a societal perspective and determined optimal strategies using cost-effectiveness efficiency frontiers.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Under our pricing assumptions, switching to nonavalent vaccination was always cost-saving compared with maintaining the current bivalent vaccination programme, irrespective of the screening scenarios and the year when nonavalent vaccine was assumed to become available (status quo screening: net cost saving $2589-5211 million; improved screening: net cost saving $1852-3789 million). In the same-vaccine strategies, the optimal strategy changed from "routine nonavalent HPV vaccination with catch-up to age 18" to "switching from bivalent to nonavalent HPV vaccination" if nonavalent vaccination is available after 2035. Compared with the optimal same-vaccine strategy, adopting mixed schedules with bivalent and nonavalent vaccines would further save $1336-4280 million net costs and gain 87,000-833,000 QALYs, depending on the screening scenario and the year when nonavalent vaccine becomes available.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Switching from bivalent to nonavalent HPV vaccination is likely to be cost-saving and have a significant impact on reducing the cervical cancer burden in China.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Bill &amp; Melinda Gates Foundation (INV-031449 and INV-003174) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-004).</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shangying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xuelian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Scientific Research Center, China-Japan Friendship Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Youlin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jit</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Fanghui</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health West Pac</MedlineTA><NlmUniqueID>101774968</NlmUniqueID><ISSNLinking>2666-6065</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cost-effectiveness</Keyword><Keyword MajorTopicYN="N">Elimination</Keyword><Keyword MajorTopicYN="N">Human papillomavirus vaccination</Keyword><Keyword MajorTopicYN="N">Mixed schedule</Keyword><Keyword MajorTopicYN="N">Nonavalent</Keyword></KeywordList><CoiStatement>YQ and FZ report grants from GlaxoSmithKline Biologicals, Merck &amp; Co, and Xiamen Innovax Biotech to their institution, to undertake clinical trials on the human papillomavirus (HPV) vaccine. MJ has previously received research grants (unrelated to this paper) from the National Institute for Health Research, Research Councils UK, Gavi, the Vaccine Alliance, the European Commission, and Wellcome Trust. MJ and YL have received research grants (related to this paper) from the Bill &amp; Melinda Gates Foundation. Other co-authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40061912</ArticleId><ArticleId IdType="pmc">PMC11889945</ArticleId><ArticleId IdType="doi">10.1016/j.lanwpc.2025.101499</ArticleId><ArticleId IdType="pii">S2666-6065(25)00036-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Agency for Research on Cancer  Cancer today. 2022. http://gco.iarc.fr/today/home</Citation></Reference><Reference><Citation>Han B., Zheng R., Zeng H., et al. Cancer incidence and mortality in China, 2022. J&#xa0;Natl Cancer Cent. 2024;4(1):47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11256708</ArticleId><ArticleId IdType="pubmed">39036382</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People's Republic of China  Notice on the issuance of the action plan to accelerate the elimination of cervical cancer (2023-2030) 2023. https://www.gov.cn/zhengce/zhengceku/2023-01/21/content_5738364.htm</Citation></Reference><Reference><Citation>Zhao X.L., Hu S.Y., Hu J.W., et al. Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward. Infect Dis Poverty. 2023;12(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10512493</ArticleId><ArticleId IdType="pubmed">37735709</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Vaccination schedule for Human papilloma virus. 2023. https://immunizationdata.who.int/pages/schedule-by-disease/hpv.html?ISO_3_CODE=&amp;TARGETPOP_GENERAL=</Citation></Reference><Reference><Citation>Mennini F.S., Bonanni P., Bianic F., et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504713</ArticleId><ArticleId IdType="pubmed">28701899</ArticleId></ArticleIdList></Reference><Reference><Citation>Drolet M., Laprise J.F., Boily M.C., Franco E.L., Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pubmed">24174175</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisson M., Laprise J.F., Chesson H.W., et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J&#xa0;Natl Cancer Inst. 2016;108(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745694</ArticleId><ArticleId IdType="pubmed">26438574</ArticleId></ArticleIdList></Reference><Reference><Citation>Boiron L., Joura E., Largeron N., Prager B., Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16:153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833954</ArticleId><ArticleId IdType="pubmed">27084683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X., Gai Tobe R., Wang L., et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17(1):502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516327</ArticleId><ArticleId IdType="pubmed">28720082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Gu B., Wang J., Liu G., Zhang X. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model. BMC Public Health. 2022;22(1):777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014632</ArticleId><ArticleId IdType="pubmed">35436877</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Ni W., Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. BMJ Open. 2019;9(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886925</ArticleId><ArticleId IdType="pubmed">31767588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Su Z., Chen F., et al. Chinese mothers' intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province. Hum Vaccines Immunother. 2021;17(1):304&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7872083</ArticleId><ArticleId IdType="pubmed">32401617</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyette A., Yen G.P., Racovitan V., Bhangu P., Kothari S., Franco E.L. Evolution of public health human papillomavirus immunization programs in Canada. Curr Oncol. 2021;28(1):991&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985769</ArticleId><ArticleId IdType="pubmed">33617515</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C., Xu X., Zhao X., et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021;19(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927373</ArticleId><ArticleId IdType="pubmed">33653331</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K., Kim J.J., Kulasingam S., et al. vol. 8. Papillomavirus research; Amsterdam, Netherlands: 2019. (HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6804684</ArticleId><ArticleId IdType="pubmed">31505258</ArticleId></ArticleIdList></Reference><Reference><Citation>Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(6):1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">35474251</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov  Evaluate the efficacy, immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females. 2022. https://clinicaltrials.gov/study/NCT04422366</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Efficacy, immunogenicity and safty study of recombinant human papillomavirus vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) 2023. https://clinicaltrials.gov/study/NCT04537156</Citation></Reference><Reference><Citation>Bao H., Zhang L., Wang L., et al. Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset. Cancer Med. 2018;7(5):2089&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943548</ArticleId><ArticleId IdType="pubmed">29573569</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . 2nd ed. 2021. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.https://www.who.int/publications/i/item/9789240040434</Citation><ArticleIdList><ArticleId IdType="pubmed">34314129</ArticleId></ArticleIdList></Reference><Reference><Citation>Branch of Cancer Prevention and Control, Chinese Preventive Medicine Association, Chinese Obstetrics and Gynecology Association Colposcopy and Cervical Neoplasia Committee Chinese society of colposcopy and cervical pathology of China health birth science association, Beijing medical doctor (technician) society of laboratory medicine. Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening (2022) Natl Med J China (Peking) 2023;103(16):1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">37062594</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger E.A., Smith M.A., Killen J., et al. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020;5(4):e213&#x2013;e222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715100</ArticleId><ArticleId IdType="pubmed">32057315</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Prevalence of cervical cancer screening among women aged 30-49 years (%) 2022. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-cervical-cancer-screening-among-women-aged-30-49-years-%28-%29</Citation></Reference><Reference><Citation>Basu P., Malvi S.G., Joshi S., et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;23(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8560643</ArticleId><ArticleId IdType="pubmed">34634254</ArticleId></ArticleIdList></Reference><Reference><Citation>PAHO  PAHO revolving fund vaccine prices for 2022. 2022. https://www.paho.org/en/documents/paho-revolving-fund-vaccine-prices-2022</Citation></Reference><Reference><Citation>World Bank  World Bank Country and lending groups. 2022. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</Citation></Reference><Reference><Citation>Yu W., Lu M., Wang H., et al. Routine immunization services costs and financing in China, 2015. Vaccine. 2018;36(21):3041&#x2013;3047.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Zhao X., Hu S., et al. Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: a nationwide multicenter cross-sectional study. Chin J Cancer Res. 2023;35(6):675&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10774142</ArticleId><ArticleId IdType="pubmed">38204443</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://www.who.int/publications/i/item/9789240014107</Citation></Reference><Reference><Citation>WHO . 2nd ed. 2019. WHO guide for standardization of economic evaluations of immunization programmes.</Citation></Reference><Reference><Citation>Ochalek J., Lomas J., Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231096</ArticleId><ArticleId IdType="pubmed">30483412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomas J., Claxton K., Ochalek J. Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. Health Pol Plann. 2022;37(1):45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757497</ArticleId><ArticleId IdType="pubmed">34410385</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichon-Riviere A., Drummond M., Palacios A., Garcia-Marti S., Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Global Health. 2023;11(6):e833&#x2013;e842.</Citation><ArticleIdList><ArticleId IdType="pubmed">37202020</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of China  Statistical communiqu&#xe9; of the People's Republic of China on the 2022 national economic and social development. 2023. http://www.stats.gov.cn/english/PressRelease/202302/t20230227_1918979.html</Citation></Reference><Reference><Citation>Bruni L., Saura-L&#xe1;zaro A., Montoliu A., et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144</Citation><ArticleIdList><ArticleId IdType="pubmed">33388322</ArticleId></ArticleIdList></Reference><Reference><Citation>Canfell K., Kim J.J., Brisson M., et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet (London, England) 2020;395(10224):591&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043006</ArticleId><ArticleId IdType="pubmed">32007142</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaeli D.T., Stoycheva S., Marcus S.M., Zhang W., Michaeli J.C., Michaeli T. Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa. Clin Drug Invest. 2022;42(4):333&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989937</ArticleId><ArticleId IdType="pubmed">35294726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S., Tuffaha H. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India. Asia Pac J Clin Oncol. 2024;20(1):55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">37132538</ArticleId></ArticleIdList></Reference><Reference><Citation>Termrungruanglert W., Khemapech N., Vasuratna A., Havanond P., Tantitamit T. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. J&#xa0;Gynecol Oncol. 2024;35(6):e85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11543265</ArticleId><ArticleId IdType="pubmed">38670561</ArticleId></ArticleIdList></Reference><Reference><Citation>Portnoy A., Pedersen K., Trogstad L., et al. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: a model-based analysis. Prev Med. 2021;144</Citation><ArticleIdList><ArticleId IdType="pubmed">33678239</ArticleId></ArticleIdList></Reference><Reference><Citation>Phua L.C., Choi H.C.W., Wu J., et al. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine. 2021;39(16):2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">33744050</ArticleId></ArticleIdList></Reference><Reference><Citation>Government Procurement Center of GuangDong  Announcement of the results of the procurement project of human papillomavirus (HPV) vaccine for girls of school age in Guangdong Province in 2023. 2023. https://gdgpo.czt.gd.gov.cn/freecms/site/gd/ggxx/info/2023/8a7e543c894100c0018972b9b9b65e3b.html</Citation></Reference><Reference><Citation>Center for Drug Evaluation of National Medical Products Administration  Technical guidelines for clinical trials of human papillomavirus vaccines (for trial implementation) 2023. https://www.cde.org.cn/main/news/viewInfoCommon/f1623a35ec967425dd37b2bb8bcac3b5</Citation></Reference><Reference><Citation>Chen W., Zhang X., Molijn A., et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20(9):1705&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">19705288</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland S.M., Cheung T.H., McNeill S., et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855&#x2013;6864.</Citation><ArticleIdList><ArticleId IdType="pubmed">26411885</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilca V., Sauvageau C., Boulianne N., et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccines Immunother. 2015;11(3):732&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514370</ArticleId><ArticleId IdType="pubmed">25714044</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh Z.Q., Russell F.M., Reyburn R., et al. Sustained antibody responses 6 Years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clin Infect Dis. 2017;64(7):852&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">28034886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilca V., Sauvageau C., Panicker G., De Serres G., Ouakki M., Unger E.R. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - a randomized clinical trial. Vaccine. 2018;36(46):7017&#x2013;7024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497054</ArticleId><ArticleId IdType="pubmed">30314913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilca V., Sauvageau C., Panicker G., De Serres G., Ouakki M., Unger E.R. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study. Hum Vaccines Immunother. 2019;15(2):503&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422519</ArticleId><ArticleId IdType="pubmed">30252583</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnabas R.V., Brown E.R., Onono M.A., et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023;29(12):3224&#x2013;3232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10719107</ArticleId><ArticleId IdType="pubmed">38049621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreimer A.R., Sampson J.N., Porras C., et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J&#xa0;Natl Cancer Inst. 2020;112(10):1038&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566548</ArticleId><ArticleId IdType="pubmed">32091594</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Human papillomavirus vaccines: WHO position paper (2022 update) 2022. https://www.who.int/publications/i/item/who-wer9750-645-672</Citation></Reference><Reference><Citation>WHO Meeting of the strategic advisory group of experts on immunization, October 2019: conclusions and recommendations. Wkly Epidemiol Rec. 2019;94(47):541&#x2013;559.</Citation></Reference><Reference><Citation>Wantai BioPharm  Announcement of Beijing Wantai Biological Pharmacy Enterpriseco., Ltd. on the un-blinding results of the phase III clinical trial of 9-valent HPV vaccine. 2024. https://download.wezhan.cn/contents/sitefiles2038/10193563/files/802628.pdf?response-content-disposition=inline%3Bfilename%3D%25e4%25b8%2587%25e6%25b3%25b0%25e7%2594%259f%25e7%2589%25a9%25e5%2585%25b3%25e4%25ba%258e%25e5%2585%25ac%25e5%258f%25b8%25e4%25b9%259d%25e4%25bb%25b7HPV%25e7%2596%25ab%25e8%258b%2597III%25e6%259c%259f%25e4%25b8%25b4%25e5%25ba%258a%25e8%25af%2595%25e9%25aa%258c%25e6%258f%25ad%25e7%259b%25b2%25e7%25bb%2593%25e6%259e%259c%25e7%259a%2584%25e5%2585%25ac%25e5%2591%258a.pdf&amp;response-content-type=application%2Fpdf&amp;auth_key=1723512276-ece40cdc43cf432984fde4d5b7ffb057-0-90a14d0af5c328986431d2dd0bbb4d14</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40058986</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>354</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Corrigendum to "Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-&#x3ba;B pathway" [Virus Research 228 (2017) 102-108].</ArticleTitle><Pagination><StartPage>199553</StartPage><MedlinePgn>199553</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2025.199553</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(25)00030-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yabin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Zhiheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Yansheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Health Science Center, Hebei University, No. 342 Yuhuadonglu, Baoding 071000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chenyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Heqiu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Bio-diagnosis, Institute of Basic Medical Sciences, 27, Taiping Road, Beijing 100850, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Youchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China. Electronic address: wangyc@nifdc.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Virus Res. 2017 Jan 15;228:102-108. doi: 10.1016/j.virusres.2016.11.027.</RefSource><PMID Version="1">27899274</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>8</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>10</Day><Hour>7</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>22</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40058986</ArticleId><ArticleId IdType="pmc">PMC11963192</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2025.199553</ArticleId><ArticleId IdType="pii">S0168-1702(25)00030-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40056795</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-376X</ISSN><JournalIssue CitedMedium="Internet"><Volume>1256</Volume><PubDate><Year>2025</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</Title><ISOAbbreviation>J Chromatogr B Analyt Technol Biomed Life Sci</ISOAbbreviation></Journal><ArticleTitle>Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.</ArticleTitle><Pagination><StartPage>124539</StartPage><MedlinePgn>124539</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchromb.2025.124539</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1570-0232(25)00091-1</ELocationID><Abstract><AbstractText>Residual host cell chromatin imposes numerous challenges on purifying HIV-derived enveloped virus-like particles (VLPs) using anion-exchange chromatography (AEX). According to FDA guidelines, DNA must be reduced to less than 10&#xa0;ng per dose at a fragment size of less than 200&#xa0;bp. To prove the fulfillment of these quality criteria, methods for the qualitative and quantitative analysis of DNA fragments must be applied and adapted to chromatin. DNA and chromatin impede the purification of HIV VLPs with AEX, co-eluting in the same fractions as the VLPs. Although nuclease treatments can be employed, the chromatin structure can shield DNA from nuclease activity. To address these challenges, we adjusted our analytical focus on characterizing the chromatin in our clarified HIV VLP supernatant. We identified two DNA subpopulations: a main large fragment population and a minor population consisting of short fragments below 200&#xa0;bp. Our findings demonstrated that the larger DNA fragments are the primary issue in our process, as they co-elute with the desired VLPs. To remove the long DNA fragment population, we optimized the nuclease treatment using a Design of Experiment approach to digest the DNA despite the tight chromatin structure. The nucleases Benzonase, Denarase, and M-SAN efficiently digested the DNA removing over 90&#xa0;% of the DNA. By shredding the long DNA fragments before the AEX step, we successfully separated the HIV VLPs from the remaining short DNA fragments. Combined with nuclease treatment, AEX membrane chromatography offers an efficient single-step purification platform for HIV VLP-based vaccines and other therapeutics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Elling-Tammen</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Research Group Medical Biotechnology &amp; Bioengineering, Faculty of Applied Natural Sciences, TH K&#xf6;ln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany; Sartorius Stedim Biotech GmbH, August-Spindler-Stra&#xdf;e 11, 37079 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taft</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sartorius Stedim Biotech GmbH, August-Spindler-Stra&#xdf;e 11, 37079 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thom</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sartorius Stedim Biotech GmbH, August-Spindler-Stra&#xdf;e 11, 37079 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stitz</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Group Medical Biotechnology &amp; Bioengineering, Faculty of Applied Natural Sciences, TH K&#xf6;ln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbe</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Group Medical Biotechnology &amp; Bioengineering, Faculty of Applied Natural Sciences, TH K&#xf6;ln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany. Electronic address: stephan.barbe@th-koeln.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sartorius Stedim Biotech GmbH, August-Spindler-Stra&#xdf;e 11, 37079 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Chromatogr B Analyt Technol Biomed Life Sci</MedlineTA><NlmUniqueID>101139554</NlmUniqueID><ISSNLinking>1570-0232</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anion-exchange chromatography</Keyword><Keyword MajorTopicYN="N">Design of Experiment</Keyword><Keyword MajorTopicYN="N">Enveloped virus-like particles</Keyword><Keyword MajorTopicYN="N">Nuclease treatment</Keyword><Keyword MajorTopicYN="N">Residual chromatin</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stitz reports financial support was provided by German Federal Ministry of Education and Research. Stitz has patent #10973907 issued to Janssen Vaccines &amp; Prevention B.V. Stitz has patent #11896663 issued to Janssen Vaccines &amp; Prevention B.V. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>8</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40056795</ArticleId><ArticleId IdType="doi">10.1016/j.jchromb.2025.124539</ArticleId><ArticleId IdType="pii">S1570-0232(25)00091-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40056779</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-3171</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Poultry science</Title><ISOAbbreviation>Poult Sci</ISOAbbreviation></Journal><ArticleTitle>Immunogenic cross-reactivity between different serotypes novel duck reoviruses: Evaluation of cross-protection provided by mono or bivalent vaccine.</ArticleTitle><Pagination><StartPage>104900</StartPage><MedlinePgn>104900</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104900</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psj.2025.104900</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0032-5791(25)00139-7</ELocationID><Abstract><AbstractText>To investigate the immunogenic cross-reactivity among different novel duck reovirus isolates, animals immunized with monovalent inactivated duck reovirus were challenged with homologous and heterologous viruses, and serum samples were collected after immunization for cross-neutralization test. The results showed that the virus neutralizing titer against homologous virus was significantly higher than that against heterologous virus(p &lt; 0.000001), which indicated that there was an important difference in antigenicity between DE13 and WL01 strains, which affected the specificity of protective virus neutralizing antibodies induced. This was further confirmed by cross-protection studies in ducks immunized at 2 d of age with whole-virus inactivated oil emulsion vaccines containing DE13 strain or WL01 strain as monovalent vaccine or both strains as bivalent vaccine. Protection against clinical disease with the monovalent vaccine was fully effective against homologous virus challenge at 2 weeks after vaccination, whereas protection against heterologous virus challenge was significantly lower (p &lt; 0.001). Only the bivalent inactivated vaccine containing both strains protected birds against the two novel duck reovirus that cause disease in ducks. The results showed that vaccination of the inactivated vaccine at 2 day of age induced rapid immunity (within 2 weeks after vaccination) with complete clinical protection in ducks, the high level of neutralizing antibody could be maintained until 60 days-old. Pre-laying ducks immunization with two doses of bivalent inactivated vaccine could induce passive immunity in offspring ducks, and 100 % protection could be obtained through maternal antibody, which could be maintained until 21 days of age.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, 730070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, 730070, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruizhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Qingdao Vland Biotech INC., Qingdao, 266102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Qingdao Vland Biotech INC., Qingdao, 266102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shilei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Shijun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, 730070, China. Electronic address: bsjdy@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Poult Sci</MedlineTA><NlmUniqueID>0401150</NlmUniqueID><ISSNLinking>0032-5791</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bivalent vaccine</Keyword><Keyword MajorTopicYN="N">Cross-protection</Keyword><Keyword MajorTopicYN="N">Novel duck reovirus</Keyword><Keyword MajorTopicYN="N">Serotype</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>8</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40056779</ArticleId><ArticleId IdType="pmc">PMC11930141</ArticleId><ArticleId IdType="doi">10.1016/j.psj.2025.104900</ArticleId><ArticleId IdType="pii">S0032-5791(25)00139-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bi Z., Zhu Y., Chen Z., Li C., Wang Y., Wang G., Liu G. Induction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C protein. Sci. Rep. 2016;6:39092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5156932</ArticleId><ArticleId IdType="pubmed">27974824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.L., Chen S.Y., Cheng X.X., Lin F.Q., Jiang B., Wang S., Zhu X.L., Zhang S.Z., Li Z.L. The study on the pathogenicity of new type duck reovirus. J. Northwest A&amp;F Univer.(Nat. Sci. Ed.), 2010;38:14&#x2013;18.</Citation></Reference><Reference><Citation>Chen S.L., Xiao S.F., Cheng X.X., Lin F.Q., Wang S., Wang J.X., Zhu X.L., Chen S.Y. Efficacy evaluation of a concentrated inactivated vaccine against novel duckling reovirus infection. Fujian J. Agric. Sci. 2017;32:1189&#x2013;1192.</Citation></Reference><Reference><Citation>Chen Y., Yan Z., Liao C., Song Y., Zhou Q., Shen H., Chen F. Recombinant linear multiple epitopes of &#x3c3;b protein protect Muscovy ducks against novel duck reovirus infection. Front. Vet. Sci. 2024;11:1360246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11129634</ArticleId><ArticleId IdType="pubmed">38803800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhu Y., Li C., Liu G. Outbreak-associated novel duck reovirus, China, 2011. Emerg. Infect. Dis. 2012;18:1209&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376814</ArticleId><ArticleId IdType="pubmed">22709408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z.Y., Z Y.Q., Wang S.C., Li C.F., Li L., Wang F.B., Fu Y.Z., Gao J.P., Wang C., Liu G.Q. Isolation and characterization of a new type of duck reovirus. Chinese J. Animal Infect. Diseases. 2012;20:10&#x2013;15.</Citation></Reference><Reference><Citation>Farkas S.L., Varga-Kugler R., Marton S., Lengyel G., Palya V., B&#xe1;nyai K. Genomic sequence and phylogenetic analyses of two novel orthoreovirus strains isolated from Pekin ducks in 2014 in Germany. Virus Res. 2018;257:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">30194945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J., Shao G., Zhang Y., Wang J., Xie Z., Feng K., Zhang X., Xie Q. Molecular characterization, complete genome sequencing, and pathogenicity of Novel Duck Reovirus from South Coastal Area in China. Poult. Sci. 2023;102:102776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10276289</ArticleId><ArticleId IdType="pubmed">37302330</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. Shandong Agricultural University; Taian: 2020. Master.</Citation></Reference><Reference><Citation>Li N., Hong T., Wang Y., Wang Y., Yu K., Cai Y., Liu S., Wei L., Chai T. The pathogenicity of novel duck reovirus in Cherry Valley ducks. Vet. Microbiol. 2016;192:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">27527781</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D., Liu R., Gao Y.L., Li K., Liu C.J., Qi X.L., Cui H.Y., Zhang Y.P., Pan Q., Gao L., Wang X.M. Establishment of the novel duck reovirus animal infection model. Chinese J. Prev. Vet. Med. 2022;44:382&#x2013;387. +422.</Citation></Reference><Reference><Citation>Luo D., Liu R., Weng L., Li K., Qi X., Gao Y., Liu C., Zhang Y., Cui H., Pan Q., Gao L., Wang X. Genomic sequences and pathogenic characteristics of two variant duck reoviruses associated with spleen necrosis. Infect. Genet. Evol. 2021;92:104847.</Citation><ArticleIdList><ArticleId IdType="pubmed">33823307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, F. Y., Cong, Y. F., Yu, C. M., Huang, D., Wang, R. Z., Jiang, H. J., Qu, X. Q., Zhao, Y. H., Wang, W. B., Cui, J. X., &amp; Jiang, Y. H. (2022). Research progress on novel duck reovirusis disease 44, 92-100.</Citation></Reference><Reference><Citation>Ma Q., Xu M.Q., Wang J.H., Zhao J., Zhang Z.B., Shi Y.H., Li Y.F., Zhang X.M. Identification and pathogenic analysis of a novel duck eovirus isolated from Shandong Province. Chinese J. Vet. Med. 2021;57:44&#x2013;47. +55.</Citation></Reference><Reference><Citation>Peng Z., Zhang H., Zhang X., Wang H., Liu Z., Qiao H., Lv Y., Bian C. Identification and molecular characterization of novel duck reoviruses in Henan Province, China. Front. Vet. Sci. 2023;10:1137967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10098080</ArticleId><ArticleId IdType="pubmed">37065255</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao G., Chen T., Feng K., Zhao Q., Zhang X., Li H., Lin W., Xie Q. Efficacy of commercial polyvalent avian infectious bronchitis vaccines against Chinese QX-like and TW-like strain via different vaccination strategies. Poult. Sci. 2020;99:4786&#x2013;4794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7380215</ArticleId><ArticleId IdType="pubmed">32988513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Gao B., Chen H., Diao Y., Tang Y. Isolation and characterization of a variant duck orthoreovirus causing spleen necrosis in Peking ducks, China. Transbound Emerg. Dis. 2019;66:2033&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pubmed">31131546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Wang Y., Gao B., Zhang S., Diao Y., Tang Y. Evidence of vertical transmission of novel duck orthoreovirus in ducks. Vet. Microbiol. 2020;251</Citation><ArticleIdList><ArticleId IdType="pubmed">33059276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Lin F., Cheng X., Wang J., Zhu X., Xiao S., Zheng M., Huang M., Chen S., Chen S. The genomic constellation of a novel duck reovirus strain associated with hemorrhagic necrotizing hepatitis and splenitis in Muscovy ducklings in Fujian, China. Mol. Cell. Probes. 2020;53</Citation><ArticleIdList><ArticleId IdType="pubmed">32502523</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H., Xu G., Zhu Y., Xie Z., Zhang R., Jiang S. Isolation and characterization of a naturally attenuated novel duck reovirus strain as a live vaccine candidate. Vet. Microbiol. 2021;261</Citation><ArticleIdList><ArticleId IdType="pubmed">34461358</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Zhang W., Wang M., Yuan S., Zhang X., Wen F., Guo J., Mei K., Huang S., Li Z. Characterization and pathogenicity evaluation of recombinant novel duck reovirus isolated from Southeast China. Front. Vet. Sci. 2023;10:1124999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10043381</ArticleId><ArticleId IdType="pubmed">36998638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K., Li Y., Han H., Song M., Ma X., Liu C., Huang B., Li F. Complete genome sequence of an avian reovirus isolated from wild mallard ducks in china. Genome Announc. 2014;2:e00813&#x2013;e00814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172264</ArticleId><ArticleId IdType="pubmed">25237015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K., Ti J., Lu X., Pan L., Liu L., Gao Y., Guo X., Hu F., Liu C., Ma X., Li Y., Huang B., Song M. Novel duck reovirus exhibits pathogenicity to specific pathogen-free chickens by the subcutaneous route. Sci. Rep. 2021;11:11769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8175558</ArticleId><ArticleId IdType="pubmed">34083583</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K.X., Lu X., Liu C.X., Gao Y.H., Qi L.H., Song L.L., Li Y.F., Song M.X. Pathogenic characteristics and variation analysis of novel duck reovirus isolated from Shandong Province. Chinese J. Animal Inf. Diseases. 2018;26:24&#x2013;28.</Citation></Reference><Reference><Citation>Yun T., Yu B., Ni Z., Ye W., Chen L., Hua J., Zhang C. Genomic characteristics of a novel reovirus from Muscovy duckling in China. Vet. Microbiol. 2014;168:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Wang X., Jiang W., Fan X., Liu N., Miao R., Zhai X., Wei L., Jiao P., Jiang S. Research note: genetic characterization of novel duck reoviruses from Shandong Province, China in 2022. Poult. Sci. 2023;102:102969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10440558</ArticleId><ArticleId IdType="pubmed">37566967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.L., Shao J.W., Li X.W., Mei M.M., Guo J.Y., Li W.F., Huang W.J., Chi S.H., Yuan S., Li Z.L., Huang S.J. Molecular characterization of two novel reoviruses isolated from Muscovy ducklings in Guangdong, China. BMC Vet Res. 2019;15:143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511161</ArticleId><ArticleId IdType="pubmed">31077188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D., Sun R., Wang M., Jia R., Chen S., Liu M., Zhao X., Yang Q., Wu Y., Zhang S., Huang J., Ou X., Mao S., Gao Q., Sun D., Tian B., Cheng A. First isolation and genomic characterization of avian reovirus from black swans (Cygnus atratus) in China. Poult. Sci. 2023;102:102947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458333</ArticleId><ArticleId IdType="pubmed">37598551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Li C., Bi Z., Chen Z., Meng C., Wang G.J., Ding C., Liu G. Protective immune responses in ducklings induced by a suicidal DNA vaccine of the sigma C gene of novel duck reovirus. Vet. Immunol. Immunopathol. 2015;165:88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25863968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40054503</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>237</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>CVA16 infection causes neurological injury by engaging TLR2/MYD88/TNF-&#x3b1;/CXCL1 signalling pathway in hSCARB2 knock-in mice.</ArticleTitle><Pagination><StartPage>106133</StartPage><MedlinePgn>106133</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2025.106133</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(25)00059-2</ELocationID><Abstract><AbstractText>Coxsackievirus A16 (CVA16), a major pathogen responsible for hand-foot-and-mouth disease (HFMD) in children, has frequently replaced Enterovirus A71 as the predominant causative agent in China and other Asia-Pacific regions. The lack effective drugs and vaccines against this virus exacerbates the concerns on its outbreaks. Clinical reports and laboratory studies indicate that CVA16 infection may lead to neurological injury, but the precise mechanisms remain elusive. In this study, we meticulously established a CVA16 murine disease model using 3-week-old hSCARB2 knock-in mice through intracranial inoculation. Within 4-7 days post-infection, the infected mice exhibited severe neurological symptoms featured as limb paralysis, hind limb weakness and ataxia. Furthermore, high viral loads were detected in the brain, spleen, skeletal muscle tissues, indicating a systemic infection. A robust cytokine response was observed, characterized with the elevation of TNF-&#x3b1;, IL-12 (p40), IL-10 and MIP-1&#x3b2;. Histological and immunofluorescence staining revealed extensive inflammation, marked by the concentrated infiltration of astrocytes cells, as well as severe neurological injury, which included hypertrophic and extended pseudopodia microglia, increased astrocytes with long and stretched protuberances, markedly decreased neuronal cell bodies and nerve fibers in brain. No visible pathological changes were observed in spinal cord tissues. RNA sequencing and immunofluorescence staining of brain tissue verification assays indicated that the neurological injury may engage in TLR2/MYD88/TNF-&#x3b1;/CXCL1 signal pathway. Over all, this work addressed the gap in the availability of CVA16 disease rodent model for vaccine development and provided novel insights into the mechanisms underlying neurological injury caused by enteroviruses and other neurotropic viruses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yanwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Biological Products Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Susu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weijia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zhongyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Biological Products Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. Electronic address: huzhy@nifdc.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Changfa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, China. Electronic address: fancf@nifdc.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">Nerve injury</Keyword><Keyword MajorTopicYN="N">TLR2/MYD88/TNF-&#x3b1;/Cxcl1 signaling pathway</Keyword><Keyword MajorTopicYN="N">hSCARB2 mice</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40054503</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2025.106133</ArticleId><ArticleId IdType="pii">S0166-3542(25)00059-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40050434</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1827</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>British journal of cancer</Title><ISOAbbreviation>Br J Cancer</ISOAbbreviation></Journal><ArticleTitle>Hypoxic tumor cell line lysate-pulsed dendritic cell vaccine exhibits better therapeutic effects on hepatocellular carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41416-025-02975-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dendritic cell (DC) vaccine is a promising immunotherapy for hepatocellular carcinoma (HCC) via triggering antigen-specific anti-tumor immunity. Hypoxia contributes to higher level and broader spectrum of antigen expression in tumor cells.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study aims to compare immunological activity and therapeutic efficacy between hypoxic and normoxic HCC cell line lysate-pulsed DC vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results showed that hypoxic HCC cell line lysate-pulsed DC vaccines exhibited a stronger activity in producing interleukin-12 and promoting T cell proliferation and cytotoxicity in vitro. In HCC mice, hypoxic HCC cell line lysate-pulsed DC vaccines displayed a better efficacy in improving survival time and tumor volume and inducing intratumoral cytotoxic T cell infiltration and activation as well as tumor cell apoptosis. Adenylate kinase 4-derived antigens were important for hypoxic HCC cell line lysate-pulsed DC vaccine-elicited T cell killing.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, this study demonstrated hypoxic HCC cell line lysate-pulsed DC vaccine as a potential therapeutic strategy for HCC.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeng</LastName><ForeName>Long-Bin</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Therapy Center, China Medical University Hospital, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, China Medical University, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Fu-Ying</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Ph.D. Program for Biotech Pharmaceutical Industry, China Medical University, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yu-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shyu</LastName><ForeName>Woei-Cherng</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Medicine Research Center, China Medical University Hospital, Taichung, 404, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, China Medical University Hospital, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Occupational Therapy, Asia University, Taichung, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Chiao-Fang</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-5218-0571</Identifier><AffiliationInfo><Affiliation>Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan, ROC. chiaofangteng@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, ROC. chiaofangteng@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Master Program for Cancer Biology and Drug Discovery, China Medical University, Taichung, Taiwan, ROC. chiaofangteng@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DMR-113-028</GrantID><Agency>China Medical University Hospital (CMUH)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Cancer</MedlineTA><NlmUniqueID>0370635</NlmUniqueID><ISSNLinking>0007-0920</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Ethics approval and consent to participate: All mouse experiments were performed under the approval of the Institutional Animal Care and Use Committee of China Medical University (Protocol No: CMUIACUC-2020-022) in accordance with the guidelines and regulations of the Animal Protection Act of the Council of Agriculture, Executive Yuan, Taiwan. No human experiments were conducted in this study. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>6</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40050434</ArticleId><ArticleId IdType="doi">10.1038/s41416-025-02975-w</ArticleId><ArticleId IdType="pii">10.1038/s41416-025-02975-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477&#x2013;91.e471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.08.065</ArticleId><ArticleId IdType="pubmed">30367835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. Biomedicine. 2016;6:16.</Citation><ArticleIdList><ArticleId IdType="doi">10.7603/s40681-016-0016-2</ArticleId><ArticleId IdType="pubmed">27518399</ArticleId><ArticleId IdType="pmc">4996334</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2019.11.017</ArticleId><ArticleId IdType="pubmed">31954491</ArticleId></ArticleIdList></Reference><Reference><Citation>Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: outcomes and future horizons. World J Gastroenterol. 2021;27:7462&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i43.7462</ArticleId><ArticleId IdType="pubmed">34887643</ArticleId><ArticleId IdType="pmc">8613749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, et al. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends. 2022;16:31&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2022.01044</ArticleId><ArticleId IdType="pubmed">35173139</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00264-x</ArticleId><ArticleId IdType="pubmed">32782275</ArticleId><ArticleId IdType="pmc">7419547</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.09.040191.001415</ArticleId><ArticleId IdType="pubmed">1910679</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.18.1.767</ArticleId><ArticleId IdType="pubmed">10837075</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2009.00879.x</ArticleId><ArticleId IdType="pubmed">20193011</ArticleId></ArticleIdList></Reference><Reference><Citation>Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3258</ArticleId><ArticleId IdType="pubmed">22437871</ArticleId><ArticleId IdType="pmc">3433802</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N, Figini M, Shangguan J, Wang B, Sun C, Pan L, et al. Dendritic cell-based immunotherapy. Am J Cancer Res. 2017;7:2091&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">29119057</ArticleId><ArticleId IdType="pmc">5665855</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantino J, Gomes C, Falcao A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65:798&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-017-8931-1</ArticleId><ArticleId IdType="pubmed">28660480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurje I, Hammerich L, Tacke F. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer. Int J Mol Sci. 2020;21:7378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197378</ArticleId><ArticleId IdType="pubmed">33036244</ArticleId><ArticleId IdType="pmc">7583774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, et al. Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy. Life. 2021;11:1355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11121355</ArticleId><ArticleId IdType="pubmed">34947886</ArticleId><ArticleId IdType="pmc">8704694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeng LB, Liao LY, Shih FY, Teng CF. Dendritic-cell-vaccine-based immunotherapy for hepatocellular carcinoma: clinical trials and recent preclinical studies. Cancers. 2022;14:4380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14184380</ArticleId><ArticleId IdType="pubmed">36139542</ArticleId><ArticleId IdType="pmc">9497058</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl). 2007;85:1301&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-007-0281-3</ArticleId><ArticleId IdType="pubmed">18026916</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5378</ArticleId><ArticleId IdType="pubmed">24512032</ArticleId><ArticleId IdType="pmc">4159937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebestyen A, Kopper L, Danko T, Timar J. Hypoxia signaling in cancer: from basics to clinical practice. Pathol Oncol Res. 2021;27:1609802.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/pore.2021.1609802</ArticleId><ArticleId IdType="pubmed">34257622</ArticleId><ArticleId IdType="pmc">8262153</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2012.01.005</ArticleId><ArticleId IdType="pubmed">22398146</ArticleId><ArticleId IdType="pmc">3437546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirpe AA, Gulei D, Ciortea SM, Crivii C &amp; Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF Genes. Int J Mol Sci. 20 (2019).</Citation></Reference><Reference><Citation>Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Investig. 2022;132:e159839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI159839</ArticleId><ArticleId IdType="pubmed">35642641</ArticleId><ArticleId IdType="pmc">9151701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L, Cornforth AN, Hoa NT, Delgado C, Chiou SK, Zhou YH, et al. Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia. PLoS One. 2012;7:e42661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042661</ArticleId><ArticleId IdType="pubmed">22957023</ArticleId><ArticleId IdType="pmc">3434178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiwara T, Tanaka T, Kukita K, Kutomi G, Saito K, Okuya K, et al. Hypoxia augments MHC class I antigen presentation via facilitation of ERO1-alpha-mediated oxidative folding in murine tumor cells. Eur J Immunol. 2016;46:2842&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646525</ArticleId><ArticleId IdType="pubmed">27667124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36:439&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2016.225</ArticleId><ArticleId IdType="pubmed">27345407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci. 2021;286:120057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.120057</ArticleId><ArticleId IdType="pubmed">34662552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, et al. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 2021;59:100787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drup.2021.100787</ArticleId><ArticleId IdType="pubmed">34840068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8:e2836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.67</ArticleId><ArticleId IdType="pubmed">28569770</ArticleId><ArticleId IdType="pmc">5520949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay ZLZ, Slansky JE. Granzymes: the molecular executors of immune-mediated cytotoxicity. Int J Mol Sci. 2022;23:1833.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031833</ArticleId><ArticleId IdType="pubmed">35163755</ArticleId><ArticleId IdType="pmc">8836949</ArticleId></ArticleIdList></Reference><Reference><Citation>Li E, Lin L, Chen CW, Ou DL. Mouse models for immunotherapy in hepatocellular carcinoma. Cancers. 2019;11:1800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11111800</ArticleId><ArticleId IdType="pubmed">31731753</ArticleId><ArticleId IdType="pmc">6896030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bour G, Martel F, Goffin L, Bayle B, Gangloff J, Aprahamian M, et al. Design and development of a robotized system coupled to microCT imaging for intratumoral drug evaluation in a HCC mouse model. PLoS One. 2014;9:e106675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106675</ArticleId><ArticleId IdType="pubmed">25203629</ArticleId><ArticleId IdType="pmc">4159281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress S, Konig J, Schweizer J, Lohrke H, Bauer-Hofmann R, Schwarz M. p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol Carcinog. 1992;6:148&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.2940060210</ArticleId><ArticleId IdType="pubmed">1382443</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan Q, Sanchez R, Delgado C, Wepsic HT, Morgan K, Chen Y, et al. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor. Mol Ther. 2001;4:427&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mthe.2001.0477</ArticleId><ArticleId IdType="pubmed">11708879</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/20459</ArticleId><ArticleId IdType="pubmed">10353251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation. Science. 2001;292:468&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1059796</ArticleId><ArticleId IdType="pubmed">11292861</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 2005;1:409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2005.05.002</ArticleId><ArticleId IdType="pubmed">16054090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethumadhavan S, Silva M, Philbrook P, Nguyen T, Hatfield SM, Ohta A, et al. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells. PLoS One. 2017;12:e0187314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0187314</ArticleId><ArticleId IdType="pubmed">29155844</ArticleId><ArticleId IdType="pmc">5695785</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao TT, Chen YH, Li ZY, Hsiao AC, Huang YL, Hao RX, et al. Hypoxia-induced long noncoding RNA HIF1A-AS2 regulates stability of MHC class I protein in head and neck cancer. Cancer Immunol Res. 2024;12:1468&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-23-0622</ArticleId><ArticleId IdType="pubmed">38920249</ArticleId><ArticleId IdType="pmc">11443317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Cai M, Yang F, Huang L, Ling Y, Zhang Y, et al. Hypoxia-induced autophagy in pancreatic cancer counteracts the cytotoxicity of CD8(+) T cells by inhibiting the expression of MHC-I. Genes Immun. 2024. https://doi.org/10.1038/s41435-024-00315-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41435-024-00315-1</ArticleId><ArticleId IdType="pubmed">39715814</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy A, Gerber SA, Koch CJ, Lord EM. Intratumoral hypoxia reduces IFN-gamma-mediated immunity and MHC class I induction in a preclinical tumor model. Immunohorizons. 2019;3:149&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.1900017</ArticleId><ArticleId IdType="pubmed">31356176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40048881</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2542</ISSN><JournalIssue CitedMedium="Internet"><Volume>303</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Veterinary microbiology</Title><ISOAbbreviation>Vet Microbiol</ISOAbbreviation></Journal><ArticleTitle>Constructions and immunogenicity evaluations of two porcine epdemic diarrhea virus-like particle vaccines.</ArticleTitle><Pagination><StartPage>110451</StartPage><MedlinePgn>110451</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vetmic.2025.110451</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1135(25)00086-0</ELocationID><Abstract><AbstractText>Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus, causing acute diarrhea, dehydration, and up to 100&#x202f;% mortality in neonatal suckling piglets, leading to huge economic losses in the global swine industry. Vaccination remains the most promising and effective way to prevent and control PEDV. In this study, we produced PEDV virus-like particles (VLPs) composed of S, M, and E proteins with a baculovirus expression system and a mammalian expression system. The S, M, and E proteins were effectively expressed and successfully assembled into VLPs. Subsequently, S subunits and commercially inactivated vaccines were selected and compared with two VLPs vaccines for immune efficacy through mouse immunization. The results showed that both VLPs induced higher levels of IgG, IgA, and neutralizing antibody titers, lymphocyte proliferation indexes and T, B cell ratios. Compared with the baculovirus VLPs, the mammalian VLPs exhibited better effects in inducing neutralizing antibodies, lymphocyte proliferations, and IFN-&#x3b3;. These data indicated that the PEDV VLPs vaccine constructed using the mammalian expression system has better immune efficacy and has the potential to serve as a novel PEDV vaccine.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China; College of Veterinary Medicine, Hebei Agricultural University, Baoding 071000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mengdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shiyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Fangyuan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Vazyme Biotech Co., Ltd, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>YuPeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yunchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chuanhong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jiali</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yongxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China; College of Veterinary Medicine, Hebei Agricultural University, Baoding 071000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Rongli</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jinzhu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Baochao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; School of Life Sciences, Jiangsu University, Zhenjiang 212013, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China; GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou 225300, China. Electronic address: fanbaochao.0405@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing 210014, China; College of Veterinary Medicine, Hebei Agricultural University, Baoding 071000, China; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China; GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou 225300, China. Electronic address: libinana@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vet Microbiol</MedlineTA><NlmUniqueID>7705469</NlmUniqueID><ISSNLinking>0378-1135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053485" MajorTopicYN="Y">Porcine epidemic diarrhea virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="Y">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013553" MajorTopicYN="Y">Swine Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Porcine epidemic diarrhea virus</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Virus-like particles</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>16</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>6</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40048881</ArticleId><ArticleId IdType="doi">10.1016/j.vetmic.2025.110451</ArticleId><ArticleId IdType="pii">S0378-1135(25)00086-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40032214</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9649</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><PubDate><Year>2025</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Ageing research reviews</Title><ISOAbbreviation>Ageing Res Rev</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles and bioactive peptides for regenerative medicine in cosmetology.</ArticleTitle><Pagination><StartPage>102712</StartPage><MedlinePgn>102712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arr.2025.102712</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-1637(25)00058-3</ELocationID><Abstract><AbstractText>As life quality improves and the life pressure increases, people's awareness of maintaining healthy skin and hair grows. However, the use of bioactive peptides in regenerative medical aesthetics is often constrained by the high molecular weight, which impedes skin penetration. In contrast, extracellular vesicles not only possess regenerative properties but also serve as effective carriers for bioactive peptides. Given their anti-inflammatory and bactericidal properties, capacity to promote angiogenesis, optimize collagen alignment, facilitate re-epithelialization and stimulate hair growth, extracellular vesicles become an emerging and promising solution for skin regeneration treatments. The combination of peptides and extracellular vesicles enhances therapeutic efficacy and improves the bioavailability of bioactive peptides. In this review, we summarize the functions of bioactive peptides and plant- and animal-derived extracellular vesicles in regenerative medicine with cosmetology, along with examples of their combined applications. Additionally, we provide an overview of peptides and extracellular vesicles currently available on the market and in clinical practice, discussing the challenges and solutions associated with their use.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yize</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Kailu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Peifen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yinan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Wenlin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Vaccine &amp; Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China. Electronic address: anwenlin@sinopharm.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yiyang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: yydong@mail.buct.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ageing Res Rev</MedlineTA><NlmUniqueID>101128963</NlmUniqueID><ISSNLinking>1568-1637</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cosmetology</Keyword><Keyword MajorTopicYN="N">extracellular vesicles</Keyword><Keyword MajorTopicYN="N">peptides</Keyword><Keyword MajorTopicYN="N">regeneration</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40032214</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2025.102712</ArticleId><ArticleId IdType="pii">S1568-1637(25)00058-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40029331</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>222</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20241432</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20241432</ELocationID><Abstract><AbstractText>Ataxia telangiectasia and Rad3-related (ATR) kinase and its interacting protein ATRIP orchestrate the replication stress response. Homozygous splice variants in the ATRIP gene, resulting in ATRIP deficiency, were identified in two patients of independent ancestry with microcephaly, primordial dwarfism, and recurrent infections. The c.829+5G&gt;T patient exhibited lymphopenia, poor vaccine responses, autoimmune features with hemolytic anemia, and neutropenia. Immunophenotyping revealed reduced CD16+/CD56dim NK cells and absent na&#xef;ve T cells, MAIT cells, and iNKT cells. Lymphocytic defects were characterized by TCR oligoclonality, abnormal class switch recombination, and impaired T cell proliferation. ATRIP deficiency resulted in low-grade ATR activation but impaired CHK1 phosphorylation under genotoxic stress. ATRIP-deficient cells inadequately regulated DNA replication, leading to chromosomal instability, compromised cell cycle control, and impaired cell viability. CRISPR-SelectTIME confirmed reduced cell fitness for both variants. This study establishes ATRIP deficiency as a monogenic cause of microcephalic primordial dwarfism, highlights ATRIP's critical role in protecting immune cells from replication stress, and offers new insights into its canonical functions.</AbstractText><CopyrightInformation>&#xa9; 2025 Duthoo et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Duthoo</LastName><ForeName>Evi</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9680-1341</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Structure and Repair, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Beyls</LastName><ForeName>Elien</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1392-569X</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Structure and Repair, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Backers</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3587-3955</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Genetics, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudj&#xf3;nsson</LastName><ForeName>Thorkell</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5230-4263</Identifier><AffiliationInfo><Affiliation>Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation><Identifier Source="ROR">https://ror.org/035b05819</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Peiquan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation><Identifier Source="ROR">https://ror.org/035b05819</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonckheere</LastName><ForeName>Leander</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1606-495X</Identifier><AffiliationInfo><Affiliation>Respiratory Infection and Defense Lab (RIDL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riemann</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1184-7234</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parton</LastName><ForeName>Bram</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-0879-5915</Identifier><AffiliationInfo><Affiliation>Center for Medical Genetics, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Likun</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8448-2187</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation><Identifier Source="ROR">https://ror.org/056d84691</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debacker</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6525-9422</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bruyne</LastName><ForeName>Marieke</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6636-5537</Identifier><AffiliationInfo><Affiliation>Center for Medical Genetics, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoste</LastName><ForeName>Levi</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9733-1049</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeyens</LastName><ForeName>Ans</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2578-7917</Identifier><AffiliationInfo><Affiliation>Radiobiology Lab, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vral</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7879-6561</Identifier><AffiliationInfo><Affiliation>Radiobiology Lab, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Braeckel</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7242-0747</Identifier><AffiliationInfo><Affiliation>Respiratory Infection and Defense Lab (RIDL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staal</LastName><ForeName>Jens</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2664-3357</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Molecular Signal Transduction in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/04q4ydz28</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortier</LastName><ForeName>Geert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9871-4578</Identifier><AffiliationInfo><Affiliation>Center for Human Genetics, University Hospitals Leuven , Leuven, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/0424bsv16</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerre</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2114-2844</Identifier><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan-Hammarstr&#xf6;m</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-1990-8804</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.</Affiliation><Identifier Source="ROR">https://ror.org/056d84691</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Claus S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0001-6022-9710</Identifier><AffiliationInfo><Affiliation>Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation><Identifier Source="ROR">https://ror.org/035b05819</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Haerynck</LastName><ForeName>Filomeen</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9161-7361</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatric Respiratory and Infectious Medicine, Ghent University Hospital, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Claes</LastName><ForeName>Kathleen B M</ForeName><Initials>KBM</Initials><Identifier Source="ORCID">0000-0003-0841-7372</Identifier><AffiliationInfo><Affiliation>Center for Medical Genetics, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tavernier</LastName><ForeName>Simon J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-2514-5655</Identifier><AffiliationInfo><Affiliation>Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, ERN-RITA Reference Center, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Genetics, Ghent University Hospital , Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00xmkp704</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/00cv9y106</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Molecular Signal Transduction in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium.</Affiliation><Identifier Source="ROR">https://ror.org/04q4ydz28</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Reference Network for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases Network</Agency><Country/></Grant><Grant><GrantID>FWOTBM2018000102</GrantID><Agency>Research Foundation Flanders</Agency><Country/></Grant><Grant><Agency>Vlaams Instituut voor Biotechnologie</Agency><Country/></Grant><Grant><GrantID>BOF23/DOC/013</GrantID><Agency>Ghent University</Agency><Country/></Grant><Grant><Agency>Jeffrey Modell Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004261" MajorTopicYN="Y">DNA Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008831" MajorTopicYN="Y">Microcephaly</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004392" MajorTopicYN="N">Dwarfism</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064007" MajorTopicYN="N">Ataxia Telangiectasia Mutated Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005317" MajorTopicYN="N">Fetal Growth Retardation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: S. Riemann reported grants from Ghent University (predoctoral mandate BOF23/DOC/013), non-financial support from AstraZeneca, and non-financial support from GSK outside the submitted work. L. Jonckheere reported a grant from the Research Foundation&#x2014;Flanders (FWO) (predoctoral mandate 11J2525N). C.S. S&#xf8;rensen reported a patent to the European Patent Office, application no. 21816113.1 on CRISPR-Select pending. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40029331</ArticleId><ArticleId IdType="pmc">PMC11874998</ArticleId><ArticleId IdType="doi">10.1084/jem.20241432</ArticleId><ArticleId IdType="pii">277299</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold, S.R., Spicer D., Kouseff B., Lacson A., and Gilbert-Barness E.. 1999. Seckel-like syndrome in three siblings. Pediatr. Dev. Pathol. 2:180&#x2013;187. 10.1007/s100249900107</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s100249900107</ArticleId><ArticleId IdType="pubmed">9949225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball, H.L., Myers J.S., and Cortez D.. 2005. ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation. Mol. Biol. Cell. 16:2372&#x2013;2381. 10.1091/mbc.e04-11-1006</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e04-11-1006</ArticleId><ArticleId IdType="pmc">PMC1087242</ArticleId><ArticleId IdType="pubmed">15743907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass, T.E., Luzwick J.W., Kavanaugh G., Carroll C., Dungrawala H., Glick G.G., Feldkamp M.D., Putney R., Chazin W.J., and Cortez D.. 2016. ETAA1 acts at stalled replication forks to maintain genome integrity. Nat. Cell Biol. 18:1185&#x2013;1195. 10.1038/ncb3415</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3415</ArticleId><ArticleId IdType="pmc">PMC5245861</ArticleId><ArticleId IdType="pubmed">27723720</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyls, E., Baeyens A., and Vral A.. 2021. The cytokinesis-block micronucleus assay for cryopreserved whole blood. Int. J. Radiat. Biol. 97:1252&#x2013;1260. 10.1080/09553002.2021.1941378</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09553002.2021.1941378</ArticleId><ArticleId IdType="pubmed">34138661</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackford, A.N., and Jackson S.P.. 2017. ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response. Mol. Cell. 66:801&#x2013;817. 10.1016/j.molcel.2017.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.05.015</ArticleId><ArticleId IdType="pubmed">28622525</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, E.J., and Baltimore D.. 2000. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14:397&#x2013;402. 10.1101/gad.14.4.397</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.14.4.397</ArticleId><ArticleId IdType="pmc">PMC316378</ArticleId><ArticleId IdType="pubmed">10691732</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, M.G., Hall B.D., Maclean R.N., Lozzio C.B., Opitz J.M., and Reynolds J.F.. 1987. Do some patients with Seckel syndrome have hematological problems and/or chromosome breakage? Am. J. Med. Genet. 27:645&#x2013;649. 10.1002/ajmg.1320270318</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320270318</ArticleId><ArticleId IdType="pmc">PMC5494982</ArticleId><ArticleId IdType="pubmed">3115102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccia, A., and Elledge S.J.. 2010. The DNA damage response: Making it safe to play with knives. Mol. Cell. 40:179&#x2013;204. 10.1016/j.molcel.2010.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2010.09.019</ArticleId><ArticleId IdType="pmc">PMC2988877</ArticleId><ArticleId IdType="pubmed">20965415</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimprich, K.A., and Cortez D.. 2008. ATR: An essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9:616&#x2013;627. 10.1038/nrm2450</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2450</ArticleId><ArticleId IdType="pmc">PMC2663384</ArticleId><ArticleId IdType="pubmed">18594563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cliby, W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., Schreiber S.L., and Friend S.H.. 1998. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17:159&#x2013;169. 10.1093/emboj/17.1.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/17.1.159</ArticleId><ArticleId IdType="pmc">PMC1170367</ArticleId><ArticleId IdType="pubmed">9427750</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde, C.D., Petronczki &#xd6;.Y., Baris S., Willmann K.L., Girardi E., Salzer E., Weitzer S., Ardy R.C., Krolo A., Ijspeert H., et al. . 2019. Polymerase &#x3b4; deficiency causes syndromic immunodeficiency with replicative stress. J. Clin. Invest. 129:4194&#x2013;4206. 10.1172/JCI128903</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI128903</ArticleId><ArticleId IdType="pmc">PMC6763221</ArticleId><ArticleId IdType="pubmed">31449058</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte, M.I., Poli M.C., Taglialatela A., Leuzzi G., Chinn I.K., Salinas S.A., Rey-Jurado E., Olivares N., Veramendi-Espinoza L., Ciccia A., et al. . 2022. Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia. JCI Insight. 7:e154948. 10.1172/jci.insight.154948</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.154948</ArticleId><ArticleId IdType="pmc">PMC9675456</ArticleId><ArticleId IdType="pubmed">36345943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez, D., Guntuku S., Qin J., and Elledge S.J.. 2001. ATR and ATRIP: Partners in checkpoint signaling. Science. 294:1713&#x2013;1716. 10.1126/science.1065521</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1065521</ArticleId><ArticleId IdType="pubmed">11721054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottineau, J., Kottemann M.C., Lach F.P., Kang Y.H., V&#xe9;ly F., Deenick E.K., Lazarov T., Gineau L., Wang Y., Farina A., et al. . 2017. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J. Clin. Invest. 127:1991&#x2013;2006. 10.1172/JCI90727</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90727</ArticleId><ArticleId IdType="pmc">PMC5409070</ArticleId><ArticleId IdType="pubmed">28414293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, Y., Keles S., Charbonnier L.M., Jul&#xe9; A.M., Henderson L., Celik S.C., Reisli I., Shen C., Xie W.J., Schmitz-Abe K., et al. . 2020. Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1. J. Allergy Clin. Immunol. 145:391&#x2013;401.e8. 10.1016/j.jaci.2019.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2019.10.004</ArticleId><ArticleId IdType="pmc">PMC6961977</ArticleId><ArticleId IdType="pubmed">31629014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cybulski, C., Zamani N., Klu&#x17a;niak W., Milano L., Woko&#x142;orczyk D., Stempa K., Rudnicka H., Zhang S., Zadeh M., Huzarski T., et al. . 2023. Variants in ATRIP are associated with breast cancer susceptibility in the Polish population and UK Biobank. Am. J. Hum. Genet. 110:648&#x2013;662. 10.1016/j.ajhg.2023.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10119148</ArticleId><ArticleId IdType="pubmed">36977412</ArticleId></ArticleIdList></Reference><Reference><Citation>de Klein, A., Muijtjens M., van Os R., Verhoeven Y., Smit B., Carr A.M., Lehmann A.R., and Hoeijmakers J.H.J.. 2000. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10:479&#x2013;482. 10.1016/S0960-9822(00)00447-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(00)00447-4</ArticleId><ArticleId IdType="pubmed">10801416</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacroix, S., Wagner J.M., Kobayashi M., Yamamoto K., and Karnitz L.M.. 2007. The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev. 21:1472&#x2013;1477. 10.1101/gad.1547007</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1547007</ArticleId><ArticleId IdType="pmc">PMC1891424</ArticleId><ArticleId IdType="pubmed">17575048</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande, I., Seeber A., Shimada K., Keusch J.J., Gut H., and Gasser S.M.. 2017. Structural basis of mec1-Ddc2-RPA assembly and activation on single-stranded DNA at sites of damage. Mol. Cell. 68:431&#x2013;445.e5. 10.1016/j.molcel.2017.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.019</ArticleId><ArticleId IdType="pubmed">29033322</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, L., Oksenych V., Wan H., Ye X., Dong J., Ye A.Y., Abolhassani H., Vlachiotis S., Zhang X., de la Rosa K., et al. . 2024. Orientation regulation of class-switch recombination in human B cells. J. Immunol. 213:1093&#x2013;1104. 10.4049/jimmunol.2300842</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2300842</ArticleId><ArticleId IdType="pmc">PMC11457721</ArticleId><ArticleId IdType="pubmed">39248600</ArticleId></ArticleIdList></Reference><Reference><Citation>Duthoo, E., Vral A., and Baeyens A.. 2022. An updated view into the cell cycle kinetics of human T lymphocytes and the impact of irradiation. Sci. Rep. 12:7687. 10.1038/s41598-022-11364-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11364-9</ArticleId><ArticleId IdType="pmc">PMC9090834</ArticleId><ArticleId IdType="pubmed">35538107</ArticleId></ArticleIdList></Reference><Reference><Citation>Eklund, H., Uhlin U., F&#xe4;rneg&#xe5;rdh M., Logan D.T., and Nordlund P.. 2001. Structure and function of the radical enzyme ribonucleotide reductase. Prog. Biophys. Mol. Biol. 77:177&#x2013;268. 10.1016/S0079-6107(01)00014-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6107(01)00014-1</ArticleId><ArticleId IdType="pubmed">11796141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenech, M. 2007. Cytokinesis-block micronucleus cytome assay. Nat. Protoc. 2:1084&#x2013;1104. 10.1038/nprot.2007.77</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.77</ArticleId><ArticleId IdType="pubmed">17546000</ArticleId></ArticleIdList></Reference><Reference><Citation>Foth, S., V&#xf6;lkel S., Bauersachs D., Zemlin M., and Skevaki C.. 2021. T cell repertoire during ontogeny and characteristics in inflammatory disorders in adults and childhood. Front. Immunol. 11:611573. 10.3389/fimmu.2020.611573</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.611573</ArticleId><ArticleId IdType="pmc">PMC7899981</ArticleId><ArticleId IdType="pubmed">33633732</ArticleId></ArticleIdList></Reference><Reference><Citation>Francies, F.Z., Wainwright R., Poole J., De Leeneer K., Coene I., Wieme G., Poirel H.A., Brichard B., Vermeulen S., Vral A., et al. . 2018. Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. DNA Repair (Amst.). 61:17&#x2013;24. 10.1016/j.dnarep.2017.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2017.11.001</ArticleId><ArticleId IdType="pubmed">29154021</ArticleId></ArticleIdList></Reference><Reference><Citation>Frugoni, F., Dobbs K., Felgentreff K., Aldhekri H., Al Saud B.K., Arnaout R., Ali A.A., Abhyankar A., Alroqi F., Giliani S., et al. . 2016. A novel mutation in the POLE2 gene causing combined immunodeficiency. J. Allergy Clin. Immunol. 137:635&#x2013;638.e1. 10.1016/j.jaci.2015.06.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.06.049</ArticleId><ArticleId IdType="pmc">PMC4747780</ArticleId><ArticleId IdType="pubmed">26365386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gineau, L., Cognet C., Kara N., Lach F.P., Dunne J., Veturi U., Picard C., Trouillet C., Eidenschenk C., Aoufouchi S., et al. . 2012. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122:821&#x2013;832. 10.1172/JCI61014</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI61014</ArticleId><ArticleId IdType="pmc">PMC3287233</ArticleId><ArticleId IdType="pubmed">22354167</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodship, J., Gill H., Carter J., Jackson A., Splitt M., and Wright M.. 2000. Autozygosity mapping of a seckel syndrome locus to chromosome 3q22. 1-q24. Am. J. Hum. Genet. 67:498&#x2013;503. 10.1086/303023</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/303023</ArticleId><ArticleId IdType="pmc">PMC1287195</ArticleId><ArticleId IdType="pubmed">10889046</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, C., Nakazawa Y., Woodbine L., Bj&#xf6;rkman A., Shimada M., Fawcett H., Jia N., Ohyama K., Li T.S., Nagayama Y., et al. . 2015. XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency. J. Allergy Clin. Immunol. 136:1007&#x2013;1017. 10.1016/j.jaci.2015.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.06.007</ArticleId><ArticleId IdType="pubmed">26255102</ArticleId></ArticleIdList></Reference><Reference><Citation>Haahr, P., Hoffmann S., Tollenaere M.A.X., Ho T., Toledo L.I., Mann M., Bekker-Jensen S., R&#xe4;schle M., and Mailand N.. 2016. Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat. Cell Biol. 18:1196&#x2013;1207. 10.1038/ncb3422</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3422</ArticleId><ArticleId IdType="pubmed">27723717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanasoge, S., and Ljungman M.. 2007. H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase. Carcinogenesis. 28:2298&#x2013;2304. 10.1093/carcin/bgm157</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgm157</ArticleId><ArticleId IdType="pubmed">17615256</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley, M.E., Murina O., Leitch A., Higgs M.R., Bicknell L.S., Yigit G., Blackford A.N., Zlatanou A., Mackenzie K.J., Reddy K., et al. . 2016. TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism. Nat. Genet. 48:36&#x2013;43. 10.1038/ng.3451</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3451</ArticleId><ArticleId IdType="pmc">PMC4697364</ArticleId><ArticleId IdType="pubmed">26595769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayani, A., Suarez C.R., Molnar Z., LeBeau M., and Godwin J.. 1994. Acute myeloid leukaemia in a patient with Seckel syndrome. J. Med. Genet. 31:148&#x2013;149. 10.1136/jmg.31.2.148</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.31.2.148</ArticleId><ArticleId IdType="pmc">PMC1049679</ArticleId><ArticleId IdType="pubmed">8182723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, J., Meyers R.M., Dong J., Panchakshari R.A., Alt F.W., and Frock R.L.. 2016. Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing. Nat. Protoc. 11:853&#x2013;871. 10.1038/nprot.2016.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.043</ArticleId><ArticleId IdType="pmc">PMC4895203</ArticleId><ArticleId IdType="pubmed">27031497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, C.R., Guasti L., Meimaridou E., Chuang C.H., Schimenti J.C., King P.J., Costigan C., Clark A.J.L., and Metherell L.A.. 2012. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 122:814&#x2013;820. 10.1172/JCI60224</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60224</ArticleId><ArticleId IdType="pmc">PMC3287227</ArticleId><ArticleId IdType="pubmed">22354170</ArticleId></ArticleIdList></Reference><Reference><Citation>Itakura, E., Takai K.K., Umeda K., Kimura M., Ohsumi M., Tamai K., and Matsuura A.. 2004. Amino-terminal domain of ATRIP contributes to intranuclear relocation of the ATR-ATRIP complex following DNA damage. FEBS Lett. 577:289&#x2013;293. 10.1016/j.febslet.2004.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2004.10.026</ArticleId><ArticleId IdType="pubmed">15527801</ArticleId></ArticleIdList></Reference><Reference><Citation>Jazayeri, A., Falck J., Lukas C., Bartek J., Smith G.C.M., Lukas J., and Jackson S.P.. 2006. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8:37&#x2013;45. 10.1038/ncb1337</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1337</ArticleId><ArticleId IdType="pubmed">16327781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon, Y., Ko E., Lee K.Y., Ko M.J., Park S.Y., Kang J., Jeon C.H., Lee H., and Hwang D.S.. 2011. TopBP1 deficiency causes an early embryonic lethality and induces cellular senescence in primary cells. J. Biol. Chem. 286:5414&#x2013;5422. 10.1074/jbc.M110.189704</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.189704</ArticleId><ArticleId IdType="pmc">PMC3037654</ArticleId><ArticleId IdType="pubmed">21149450</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetarpal, P., Das S., Panigrahi I., and Munshi A.. 2016. Primordial dwarfism: Overview of clinical and genetic aspects. Mol. Genet. Genomics. 291:1&#x2013;15. 10.1007/s00438-015-1110-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00438-015-1110-y</ArticleId><ArticleId IdType="pubmed">26323792</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingseisen, A., and Jackson A.P.. 2011. Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev. 25:2011&#x2013;2024. 10.1101/gad.169037</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.169037</ArticleId><ArticleId IdType="pmc">PMC3197200</ArticleId><ArticleId IdType="pubmed">21979914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, F.C. 2022. The DNA damage response - from cell biology to human disease. J. Transl. Genet. Genom. 6:204&#x2013;222. 10.20517/jtgg.2021.61</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/jtgg.2021.61</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y.N., Frugoni F., Dobbs K., Tirosh I., Du L., Ververs F.A., Ru H., Ott de Bruin L., Adeli M., Bleesing J.H., et al. . 2016. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Sci. Immunol. 1:eaah6109. 10.1126/sciimmunol.aah6109</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aah6109</ArticleId><ArticleId IdType="pmc">PMC5586490</ArticleId><ArticleId IdType="pubmed">28783691</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., et al. . 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14:1448&#x2013;1459. 10.1101/gad.14.12.1448</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.14.12.1448</ArticleId><ArticleId IdType="pmc">PMC316686</ArticleId><ArticleId IdType="pubmed">10859164</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S., Shiotani B., Lahiri M., Mar&#xe9;chal A., Tse A., Leung C.C.Y., Glover J.N.M., Yang X.H., and Zou L.. 2011. ATR autophosphorylation as a molecular switch for checkpoint activation. Mol. Cell. 43:192&#x2013;202. 10.1016/j.molcel.2011.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2011.06.019</ArticleId><ArticleId IdType="pmc">PMC3155885</ArticleId><ArticleId IdType="pubmed">21777809</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Agost, M., Luessing J., van Beneden A., Eykelenboom J., O&#x2019;Reilly D., Bicknell L.S., Reynolds J.J., van Koegelenberg M., Hurles M.E., Brady A.F., et al. . 2018. Analysis of novel missense ATR mutations reveals new splicing defects underlying Seckel syndrome. Hum. Mutat. 39:1847&#x2013;1853. 10.1002/humu.23648</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23648</ArticleId><ArticleId IdType="pmc">PMC7615757</ArticleId><ArticleId IdType="pubmed">30199583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossaint, G., Horvat A., Gire V., Ba&#x10d;evi&#x107; K., Mrouj K., Charrier-Savournin F., Georget V., Fisher D., and Duli&#x107; V.. 2022. Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest. J. Cell Sci. 135:jcs259114. 10.1242/jcs.259114</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.259114</ArticleId><ArticleId IdType="pubmed">35343565</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewski, F., Goecke T., and Opitz J.M.. 1982. Studies of microcephalic primordial dwarfism I: Approach to a delineation of the seckel syndrome. Am. J. Med. Genet. 12:7&#x2013;21. 10.1002/ajmg.1320120103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320120103</ArticleId><ArticleId IdType="pubmed">7046443</ArticleId></ArticleIdList></Reference><Reference><Citation>Masih, S., Moirangthem A., Shambhavi A., Rai A., Mandal K., Saxena D., Nilay M., Agrawal N., Srivastava S., Sait H., and Phadke S.R.. 2022. Deciphering the molecular landscape of microcephaly in 87 Indian families by exome sequencing. Eur. J. Med. Genet. 65:104520. 10.1016/j.ejmg.2022.104520</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2022.104520</ArticleId><ArticleId IdType="pubmed">35568357</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos-Rodrigues, G.E., Grigaravicius P., Lopez B.S., Hofmann T.G., Frappart P.O., and Martins R.A.P.. 2020. ATRIP protects progenitor cells against DNA damage in vivo. Cell Death Dis. 11:923. 10.1038/s41419-020-03090-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03090-9</ArticleId><ArticleId IdType="pmc">PMC7591577</ArticleId><ArticleId IdType="pubmed">33110058</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka, S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., et al. . 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 316:1160&#x2013;1166. 10.1126/science.1140321</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1140321</ArticleId><ArticleId IdType="pubmed">17525332</ArticleId></ArticleIdList></Reference><Reference><Citation>Menolfi, D., Jiang W., Lee B.J., Moiseeva T., Shao Z., Estes V., Frattini M.G., Bakkenist C.J., and Zha S.. 2018. Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA. Nat. Commun. 9:5351. 10.1038/s41467-018-07798-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07798-3</ArticleId><ArticleId IdType="pmc">PMC6297235</ArticleId><ArticleId IdType="pubmed">30559436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokrani-Benhelli, H., Gaillard L., Biasutto P., Le Guen T., Touzot F., Vasquez N., Komatsu J., Conseiller E., P&#xef;card C., Gluckman E., et al. . 2013. Primary microcephaly, impaired DNA replication, and genomic instability caused by compound heterozygous ATR mutations. Hum. Mutat. 34:374&#x2013;384. 10.1002/humu.22245</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22245</ArticleId><ArticleId IdType="pubmed">23111928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes, D.A., Glick G.G., Zhao R., and Cortez D.. 2008. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev. 22:1478&#x2013;1489. 10.1101/gad.1666208</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1666208</ArticleId><ArticleId IdType="pmc">PMC2418584</ArticleId><ArticleId IdType="pubmed">18519640</ArticleId></ArticleIdList></Reference><Reference><Citation>Murga, M., Bunting S., Monta&#xf1;a M.F., Soria R., Mulero F., Ca&#xf1;amero M., Lee Y., McKinnon P.J., Nussenzweig A., and Fernandez-Capetillo O.. 2009. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 41:891&#x2013;898. 10.1038/ng.420</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.420</ArticleId><ArticleId IdType="pmc">PMC2902278</ArticleId><ArticleId IdType="pubmed">19620979</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam, E.A., Zhao R., and Cortez D.. 2011a. Analysis of mutations that dissociate G(2) and essential S phase functions of human ataxia telangiectasia-mutated and Rad3-related (ATR) protein kinase. J. Biol. Chem. 286:37320&#x2013;37327. 10.1074/jbc.M111.276113</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.276113</ArticleId><ArticleId IdType="pmc">PMC3199479</ArticleId><ArticleId IdType="pubmed">21908846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam, E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., and Cortez D.. 2011b. Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase. J. Biol. Chem. 286:28707&#x2013;28714. 10.1074/jbc.M111.248914</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.248914</ArticleId><ArticleId IdType="pmc">PMC3190678</ArticleId><ArticleId IdType="pubmed">21705319</ArticleId></ArticleIdList></Reference><Reference><Citation>Namiki, Y., and Zou L.. 2006. ATRIP associates with replication protein A-coated ssDNA through multiple interactions. Proc. Natl. Acad. Sci. USA. 103:580&#x2013;585. 10.1073/pnas.0510223103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0510223103</ArticleId><ArticleId IdType="pmc">PMC1334680</ArticleId><ArticleId IdType="pubmed">16407120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols-Vinueza, D.X., Delmonte O.M., Bundy V., Bosticardo M., Zimmermann M.T., Dsouza N.R., Pala F., Dobbs K., Stoddard J., Niemela J.E., et al. . 2021. POLD1 deficiency reveals a role for POLD1 in DNA repair and T and B cell development. J. Clin. Immunol. 41:270&#x2013;273. 10.1007/s10875-020-00903-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00903-6</ArticleId><ArticleId IdType="pmc">PMC8319811</ArticleId><ArticleId IdType="pubmed">33140240</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu, Y., Ferreira Azevedo C.A., Li X., Kamali E., Haagen Nielsen O., Storgaard S&#xf8;rensen C., and Fr&#xf6;din M.. 2022. Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. Nat. Genet. 54:1983&#x2013;1993. 10.1038/s41588-022-01224-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01224-7</ArticleId><ArticleId IdType="pmc">PMC9729100</ArticleId><ArticleId IdType="pubmed">36471068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykamp, K., Anderson M., Powers M., Garcia J., Herrera B., Ho Y.Y., Kobayashi Y., Patil N., Thusberg J., Westbrook M., et al. . 2017. Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. Genet. Med. 19:1105&#x2013;1117. 10.1038/gim.2017.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.37</ArticleId><ArticleId IdType="pmc">PMC5632818</ArticleId><ArticleId IdType="pubmed">28492532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogi, T., Walker S., Stiff T., Hobson E., Limsirichaikul S., Carpenter G., Prescott K., Suri M., Byrd P.J., Matsuse M., et al. . 2012. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome. PLoS Genet. 8:e1002945. 10.1371/journal.pgen.1002945</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002945</ArticleId><ArticleId IdType="pmc">PMC3493446</ArticleId><ArticleId IdType="pubmed">23144622</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Driscoll, M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., and Goodship J.A.. 2003. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33:497&#x2013;501. 10.1038/ng1129</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1129</ArticleId><ArticleId IdType="pubmed">12640452</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachlopnik Schmid, J., Lemoine R., Nehme N., Cormier-Daire V., Revy P., Debeurme F., Debr&#xe9; M., Nitschke P., Bole-Feysot C., Legeai-Mallet L., et al. . 2012. Polymerase &#x3b5;1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature (&#x201c;FILS syndrome&#x201d;). J. Exp. Med. 209:2323&#x2013;2330. 10.1084/jem.20121303</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121303</ArticleId><ArticleId IdType="pmc">PMC3526359</ArticleId><ArticleId IdType="pubmed">23230001</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan-Hammarstr&#xf6;m, Q., L&#xe4;hdesm&#xe4;ki A., Zhao Y., Du L., Zhao Z., Wen S., Ruiz-Perez V.L., Dunn-Walters D.K., Goodship J.A., and Hammarstr&#xf6;m L.. 2006. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. J. Exp. Med. 203:99&#x2013;110. 10.1084/jem.20050595</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050595</ArticleId><ArticleId IdType="pmc">PMC2118080</ArticleId><ArticleId IdType="pubmed">16390936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, Q., Liu M., Tian Y., Wu Z., Hao Y., Song L., Qin Z., Ding C., Wang H.W., Wang J., and Xu Y.. 2018. Cryo-EM structure of human ATR-ATRIP complex. Cell Res. 28:143&#x2013;156. 10.1038/cr.2017.158</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2017.158</ArticleId><ArticleId IdType="pmc">PMC5799817</ArticleId><ArticleId IdType="pubmed">29271416</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds, J.J., Bicknell L.S., Carroll P., Higgs M.R., Shaheen R., Murray J.E., Papadopoulos D.K., Leitch A., Murina O., Tarnauskait&#x117; &#x17d;., et al. . 2017. Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism. Nat. Genet. 49:537&#x2013;549. 10.1038/ng.3790</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3790</ArticleId><ArticleId IdType="pmc">PMC5450907</ArticleId><ArticleId IdType="pubmed">28191891</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds, J.A., Briggs T.A., Rice G.I., Darmalinggam S., Bondet V., Bruce E., Khan M., Haque S., Chinoy H., Herrick A.L., et al. . 2019. Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res. Ther. 21:147. 10.1186/s13075-019-1929-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1929-4</ArticleId><ArticleId IdType="pmc">PMC6567906</ArticleId><ArticleId IdType="pubmed">31200750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice, G.I., Forte G.M.A., Szynkiewicz M., Chase D.S., Aeby A., Abdel-Hamid M.S., Ackroyd S., Allcock R., Bailey K.M., Balottin U., et al. . 2013. Assessment of interferon-related biomarkers in Aicardi-Gouti&#xe8;res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: A case-control study. Lancet Neurol. 12:1159&#x2013;1169. 10.1016/S1474-4422(13)70258-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70258-8</ArticleId><ArticleId IdType="pmc">PMC4349523</ArticleId><ArticleId IdType="pubmed">24183309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzankina, Y., Pinzon-Guzman C., Asare A., Ong T., Pontano L., Cotsarelis G., Zediak V.P., Velez M., Bhandoola A., and Brown E.J.. 2007. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 1:113&#x2013;126. 10.1016/j.stem.2007.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2920603</ArticleId><ArticleId IdType="pubmed">18371340</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha, J., Wang S.Y., and Davis A.J.. 2017. Examining DNA double-strand break repair in a cell cycle dependent manner. Methods Enzymol. 591:97&#x2013;118. 10.1016/bs.mie.2017.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mie.2017.03.012</ArticleId><ArticleId IdType="pmc">PMC5580029</ArticleId><ArticleId IdType="pubmed">28645381</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldivar, J.C., Cortez D., and Cimprich K.A.. 2017. The essential kinase ATR: Ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18:622&#x2013;636. 10.1038/nrm.2017.67</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.67</ArticleId><ArticleId IdType="pmc">PMC5796526</ArticleId><ArticleId IdType="pubmed">28811666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeler, K., Jakic B., Heppke J., Soratroi C., Aufschnaiter A., Hermann-Kleiter N., Villunger A., and Labi V.. 2019. CHK1 dosage in germinal center B cells controls humoral immunity. Cell Death Differ. 26:2551&#x2013;2567. 10.1038/s41418-019-0318-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0318-5</ArticleId><ArticleId IdType="pmc">PMC7224292</ArticleId><ArticleId IdType="pubmed">30894677</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler, F., Weiss J.G., Lindner S.E., Lohm&#xfc;ller M., Herzog S., Spiegl S.F., Menke P., Geley S., Labi V., and Villunger A.. 2017. Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis. Nat. Commun. 8:1697. 10.1038/s41467-017-01850-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01850-4</ArticleId><ArticleId IdType="pmc">PMC5700047</ArticleId><ArticleId IdType="pubmed">29167438</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, U., Nakhro K., Oh C.K., Carrington B., Song H., Varshney G.K., Kim Y., Song H., Jeon S., Robbins G., et al. . 2021. Large-scale generation and phenotypic characterization of zebrafish CRISPR mutants of DNA repair genes. DNA Repair (Amst.). 107:103173. 10.1016/j.dnarep.2021.103173</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2021.103173</ArticleId><ArticleId IdType="pubmed">34390914</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiff, T., Walker S.A., Cerosaletti K., Goodarzi A.A., Petermann E., Concannon P., O&#x2019;Driscoll M., and Jeggo P.A.. 2006. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J. 25:5775&#x2013;5782. 10.1038/sj.emboj.7601446</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601446</ArticleId><ArticleId IdType="pmc">PMC1698893</ArticleId><ArticleId IdType="pubmed">17124492</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, X., Liu M., Bai J., Xu J., Zhu C., Dong J., and Chen C.. 2021. ATR kinase activity promotes antibody class switch recombination in B cells through cell cycle regulation without suppressing DSB resection and microhomology usage. J. Leukoc. Biol. 110:1101&#x2013;1112. 10.1002/JLB.2MA0321-064R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.2MA0321-064R</ArticleId><ArticleId IdType="pubmed">33884660</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada, S., Weitering T.J., van Os N.J.H., Du L., Pico-Knijnenburg I., Kuipers T.B., Mei H., Salzer E., Willemsen M.A.A.P., Weemaes C.M.R., et al. . 2024. Causative mechanisms and clinical impact of immunoglobulin deficiencies in ataxia telangiectasia. J. Allergy Clin. Immunol. 153:1392&#x2013;1405. 10.1016/j.jaci.2023.12.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2023.12.029</ArticleId><ArticleId IdType="pubmed">38280573</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, E., and Pembrey M.. 1985. Seckel syndrome: An overdiagnosed syndrome. J. Med. Genet. 22:192&#x2013;201. 10.1136/jmg.22.3.192</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.22.3.192</ArticleId><ArticleId IdType="pmc">PMC1049424</ArticleId><ArticleId IdType="pubmed">4040172</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo, L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., and Lukas J.. 2013. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 155:1088&#x2013;1103. 10.1016/j.cell.2013.10.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.10.043</ArticleId><ArticleId IdType="pubmed">24267891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X., Ran T., Zhang X., Xin J., Zhang Z., Wu T., Wang W., and Cai G.. 2017. 3.9 &#xc5; structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP. Science. 358:1206&#x2013;1209. 10.1126/science.aan8414</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan8414</ArticleId><ArticleId IdType="pubmed">29191911</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemsen, M., Staels F., Gerbaux M., Neumann J., Schrijvers R., Meyts I., Humblet-Baron S., and Liston A.. 2023. DNA replication-associated inborn errors of immunity. J. Allergy Clin. Immunol. 151:345&#x2013;360. 10.1016/j.jaci.2022.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.11.003</ArticleId><ArticleId IdType="pubmed">36395985</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods, C.G., Leversha M., and Rogers J.G.. 1995. Severe intrauterine growth retardation with increased mitomycin C sensitivity: A further chromosome breakage syndrome. J. Med. Genet. 32:301&#x2013;305. 10.1136/jmg.32.4.301</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.32.4.301</ArticleId><ArticleId IdType="pmc">PMC1050381</ArticleId><ArticleId IdType="pubmed">7643362</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Z.W., Liu C., Li T.L., Bruhn C., Krueger A., Min W., Wang Z.Q., and Carr A.M.. 2013. An essential function for the ATR-activation-domain (AAD) of TopBP1 in mouse development and cellular senescence. PLoS Genet. 9:e1003702. 10.1371/journal.pgen.1003702</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003702</ArticleId><ArticleId IdType="pmc">PMC3738440</ArticleId><ArticleId IdType="pubmed">23950734</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, L., and Elledge S.J.. 2003. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 300:1542&#x2013;1548. 10.1126/science.1083430</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1083430</ArticleId><ArticleId IdType="pubmed">12791985</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40028694</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Accuracy of Liferiver HarmoniaHPV and VenusHPV Assays on Urine and Vaginal Self-Samples.</ArticleTitle><Pagination><StartPage>e70273</StartPage><MedlinePgn>e70273</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70273</ELocationID><Abstract><AbstractText>In this report, the clinical performance of Liferiver HarmoniaHPV and Liferiver VenusHPV was evaluated under the VALHUDES framework. Five hundred and twenty-three&#xa0;women collected first-void urine (FVU) with Colli-Pee and vaginal samples with Evalyn Brush or Qvintip. Cervical samples were taken with the Cervex Brush by a clinician. Both vaginal and cervical samples were resuspended in 20&#x2009;mL ThinPrep. Triplet samples from 499 women were tested with HarmoniaHPV and VenusHPV tests. The clinical accuracy of HarmoniaHPV did not differ in FVU and vaginal self-samples versus cervical samples. The relative sensitivity for CIN2+ on FVU and vaginal samples was 0.95 [95% CI 0.89-1.02] and 0.95 [95% CI 0.88-1.02], respectively. Relative specificity for &lt;&#x2009;CIN2 was 0.95 [0.86-1.04] on FVU and 0.93 [0.86-1.01] on vaginal samples. VenusHPV demonstrated lower sensitivity on both self-sample types, whereas the specificity was similar to cervical samples. Post-hoc adjustment of the VenusHPV C<sub>t</sub>-values improved sensitivity (ratio FVU/cervical&#x2009;=&#x2009;0.94 [95% CI 0.88-1.00]; ratio vaginal/cervical&#x2009;=&#x2009;0.96 [95% CI 0.92-1.01]) without compromising specificity (ratio FVU/cervical&#x2009;=&#x2009;1.00 [0.92-1.09]; ratio vaginal/cervical&#x2009;=&#x2009;0.95 [95% CI 0.88-1.02]) on both self-samples. In conclusion, HarmoniaHPV and VenusHPV tests demonstrated similar clinical accuracy on FVU and vaginal self- versus cervical samples, although VenusHPV test required cut-off optimization.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Latsuzbaia</LastName><ForeName>Ardashel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Keer</LastName><ForeName>Severien</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1842-7478</Identifier><AffiliationInfo><Affiliation>Centre for the Evaluation of Vaccination (CEV), Vaccine &amp; Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Edegem, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broeck</LastName><ForeName>Davy Vanden</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathology, AML Sonic Healthcare, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Reference Centre for HPV, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AMBIOR, Laboratory for Cell Biology &amp; Histology, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Centre for Reproductive Health, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyers</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donders</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology of the General Regional Hospital Heilig Hart, Tienen, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Femicare vzw, Clinical Research for Women, Tienen.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology University Hospital Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Sutter</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department Gynaecology-Oncology, UZ Brussel-VUB, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjalma</LastName><ForeName>Wiebren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Multidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Antwerp University Hospital (UZA), Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyen</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department Gynaecology-Obstetrics, University Hospital Li&#xe8;ge, Li&#xe8;ge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorsters</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>International Centre for Reproductive Health, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbyn</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7807-5908</Identifier><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>M.A. and A.L. were supported by the RISCC Network [grant no. 8478459] funded by the Horizon 2020 Program for Research and Innovation of the European Commission (Brussels, Belgium). M.A. was supported by the EU Joint Action EUCanScreen (Grant No. 101162959). S.V.K. was supported by a junior postdoctoral fellowship of the Research Foundation - Flanders (1240220N).</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="Y">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030361" MajorTopicYN="Y">Papillomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014621" MajorTopicYN="Y">Vagina</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027383" MajorTopicYN="N">Papillomaviridae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014556" MajorTopicYN="N">Urine</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013048" MajorTopicYN="N">Specimen Handling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002578" MajorTopicYN="N">Uterine Cervical Dysplasia</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HPV</Keyword><Keyword MajorTopicYN="N">VALHUDES</Keyword><Keyword MajorTopicYN="N">cervical cancer screening</Keyword><Keyword MajorTopicYN="N">diagnostic test accuracy</Keyword><Keyword MajorTopicYN="N">self&#x2010;sampling</Keyword></KeywordList><CoiStatement>The VALHUDES project is a researcher&#x2010;induced study, designed by Sciensano (Principal Investigator; Brussels, Belgium), CEV (University of Antwerp, Antwerp, Belgium), and AML (Antwerp, Belgium). Manufacturers of HPV assays and devices can participate in the VALHUDES framework contributing equipment for laboratory testing and financial support for statistical analysis under the condition of accepting independent publication of results. This research was supported by Liferiver Bio&#x2010;Tech (San Diego, Ca), Novosanis NV (Wijnegem, Belgium), and University of Antwerp (Antwerp, Belgium). The study group received sample collection devices from Rovers Medical Devices B.V. (Oss, The Netherlands) and Aprovix AB (Uppsala, Sweden). The funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. A.&#xa0;Vorsters is cofounder and former board member of Novosanis (Belgium), a spin&#x2010;off company of the University of Antwerp, and was minority shareholder until January 2019. The University of Antwerp received payment for participation of S. Van Keer in an Advisory Board of Novosanis (subsidiary of OraSure Technologies Inc, Pennsylvania, USA). All funds are handled and managed by the University of Antwerp. D.&#xa0;Vanden Broeck is employed by AML (Antwerp, Belgium), part of the National Reference Centre HPV, a private lab performing routine cervical cytology and HPV testing.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40028694</ArticleId><ArticleId IdType="pmc">PMC11874160</ArticleId><ArticleId IdType="doi">10.1002/jmv.70273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arbyn M., Weiderpass E., Bruni L., et al., &#x201c;Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis,&#x201d; Lancet Global Health 8, no. 2 (2020): e191&#x2013;e203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025157</ArticleId><ArticleId IdType="pubmed">31812369</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliopoulos G., Nyaga V. N., Santesso N., et al., &#x201c;Cytology Versus HPV Testing for Cervical Cancer Screening in the General Population,&#x201d; Cochrane Database of Systematic Reviews 8, no. 8 (2017): Cd008587, 10.1002/14651858.CD008587.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008587.pub2</ArticleId><ArticleId IdType="pmc">PMC6483676</ArticleId><ArticleId IdType="pubmed">28796882</ArticleId></ArticleIdList></Reference><Reference><Citation>Maver P. J. and Poljak M., &#x201c;Primary HPV&#x2010;Based Cervical Cancer Screening in Europe: Implementation Status, Challenges, and Future Plans,&#x201d; Clinical Microbiology and Infection 26, no. 5 (2020): 579&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">31539637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni L., Serrano B., Roura E., et al., &#x201c;Cervical Cancer Screening Programmes and Age&#x2010;Specific Coverage Estimates for 202 Countries and Territories Worldwide: A Review and Synthetic Analysis,&#x201d; Lancet Global Health 10, no. 8 (2022): e1115&#x2013;e1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9296658</ArticleId><ArticleId IdType="pubmed">35839811</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Smith S. B., Temin S., Sultana F., and Castle P., &#x201c;Detecting Cervical Precancer and Reaching Underscreened Women by Using HPV Testing on Self Samples: Updated Meta&#x2010;Analyses,&#x201d; BMJ 363 (2018): k4823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278587</ArticleId><ArticleId IdType="pubmed">30518635</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdoodt F., Jentschke M., Hillemanns P., Racey C. S., Snijders P. J. F., and Arbyn M., &#x201c;Reaching Women Who Do Not Participate in the Regular Cervical Cancer Screening Programme by Offering Self&#x2010;Sampling Kits: A Systematic Review and Meta&#x2010;Analysis of Randomised Trials,&#x201d; European Journal of Cancer 51, no. 16 (2015): 2375&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296294</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano B., Ib&#xe1;&#xf1;ez R., Robles C., Peremiquel&#x2010;Trillas P., de Sanjos&#xe9; S., and Bruni L., &#x201c;Worldwide Use of HPV Self&#x2010;Sampling for Cervical Cancer Screening,&#x201d; Preventive Medicine 154 (2022): 106900.</Citation><ArticleIdList><ArticleId IdType="pubmed">34861338</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Verdoodt F., Snijders P. J. F., et al., &#x201c;Accuracy of Human Papillomavirus Testing on Self&#x2010;Collected Versus Clinician&#x2010;Collected Samples: A Meta&#x2010;Analysis,&#x201d; Lancet Oncology 15, no. 2 (2014): 172&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433684</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Peeters E., Benoy I., et al., &#x201c;VALHUDES: A Protocol for Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self&#x2010;Samples and Urine Samples,&#x201d; Journal of Clinical Virology 107 (2018): 52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30195193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia R., Boada E. A., Bonde J., et al., &#x201c;Evaluation of Harmoniahpv Test for Detection of Clinically Significant Human Papillomavirus Infection Using the VALGENT Framework,&#x201d; Journal of Virological Methods 294 (2021): 114161.</Citation><ArticleIdList><ArticleId IdType="pubmed">33895238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. F., Korevaar D. A., Altman D. G., et al., &#x201c;STARD 2015 Guidelines for Reporting Diagnostic Accuracy Studies: Explanation and Elaboration,&#x201d; BMJ Open 6, no. 11 (2016): e012799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5128957</ArticleId><ArticleId IdType="pubmed">28137831</ArticleId></ArticleIdList></Reference><Reference><Citation>Latsuzbaia A., Vanden Broeck D., Van Keer S., et al., &#x201c;Clinical Performance of the Realtime High Risk HPV Assay on Self&#x2010;Collected Vaginal Samples Within the VALHUDES Framework,&#x201d; Microbiology Spectrum 10, no. 5 (2022): e0163122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9602690</ArticleId><ArticleId IdType="pubmed">36047900</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Keer S., Peeters E., Vanden Broeck D., et al., &#x201c;Clinical and Analytical Evaluation of the RealTime High Risk HPV Assay in Colli&#x2010;Pee Collected First&#x2010;Void Urine Using the VALHUDES Protocol,&#x201d; Gynecologic Oncology 162, no. 3 (2021): 575&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">34172287</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Depuydt C., Benoy I., et al., &#x201c;VALGENT: A Protocol for Clinical Validation of Human Papillomavirus Assays,&#x201d; supplement, Journal of Clinical Virology 76, no. S1 (2016): S14&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26522865</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Simon M., Peeters E., et al., &#x201c;2020 List of Human Papillomavirus Assays Suitable for Primary Cervical Cancer Screening,&#x201d; Clinical Microbiology and Infection 27, no. 8 (2021): 1083&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">33975008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei F., Georges D., Man I., Baussano I., and Clifford G. M., &#x201c;Causal Attribution of Human Papillomavirus Genotypes to Invasive Cervical Cancer Worldwide: A Systematic Analysis of the Global Literature,&#x201d; Lancet 404, no. 10451 (2024): 435&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">39097395</ArticleId></ArticleIdList></Reference><Reference><Citation>Latsuzbaia A., Martinelli M., Giubbi C., et al., &#x201c;Clinical Accuracy of Oncopredict HPV Quantitative Typing (QT) Assay on Self&#x2010;Samples,&#x201d; Journal of Clinical Virology 175 (2024): 105737.</Citation><ArticleIdList><ArticleId IdType="pubmed">39486311</ArticleId></ArticleIdList></Reference><Reference><Citation>Giubbi C., Martinelli M., Latsuzbaia A., et al., &#x201c;Clinical Performance of Oncopredict HPV Screening Assay on Self&#x2010;Collected Vaginal and Urine Specimens Within the VALHUDES Framework,&#x201d; Journal of Medical Virology 96, no. 11 (2024): e70079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11590042</ArticleId><ArticleId IdType="pubmed">39588720</ArticleId></ArticleIdList></Reference><Reference><Citation>Latsuzbaia A., Vanden Broeck D., Van Keer S., et al., &#x201c;Comparison of the Clinical Accuracy of Xpert HPV Assay on Vaginal Self&#x2010;Samples and Cervical Clinician&#x2010;Taken Samples Within the VALHUDES Framework,&#x201d; Journal of Molecular Diagnostics 25, no. 9 (2023): 702&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">37354994</ArticleId></ArticleIdList></Reference><Reference><Citation>Latsuzbaia A., Van Keer S., Vanden Broeck D., et al., &#x201c;Clinical Accuracy of Alinity m HR HPV Assay on Self&#x2010; Versus Clinician&#x2010;Taken Samples Using the VALHUDES Protocol,&#x201d; Journal of Molecular Diagnostics 25, no. 12 (2023): 957&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">37865293</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Keer S., Latsuzbaia A., Vanden Broeck D., et al., &#x201c;Analytical and Clinical Performance of Extended HPV Genotyping With BD Onclarity HPV Assay in Home&#x2010;Collected First&#x2010;Void Urine: A Diagnostic Test Accuracy Study,&#x201d; Journal of Clinical Virology 155 (2022): 105271.</Citation><ArticleIdList><ArticleId IdType="pubmed">36049283</ArticleId></ArticleIdList></Reference><Reference><Citation>Latsuzbaia A., Vanden Broeck D., Van Keer S., et al., &#x201c;Validation of BD Onclarity HPV Assay on Vaginal Self&#x2010;Samples Versus Cervical Samples Using the VALHUDES Protocol,&#x201d; Cancer Epidemiology, Biomarkers &amp; Prevention 31, no. 12 (2022): 2177&#x2013;2184.</Citation><ArticleIdList><ArticleId IdType="pubmed">36099441</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbyn M., Latsuzbaia A., Castle P. E., Sahasrabuddhe V. V., and Broeck D. V., &#x201c;HPV Testing of Self&#x2010;Samples: Influence of Collection and Sample Handling Procedures on Clinical Accuracy to Detect Cervical Precancer,&#x201d; Lancet Regional Health&#x2014;Europe 14 (2022): 100332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857649</ArticleId><ArticleId IdType="pubmed">35243475</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor L., Elasifer H., Sargent A., Bhatia R., Graham C., and Cuschieri K., &#x201c;Influence of Resuspension Volume on Dry Sampling Devices Taken for Human Papillomavirus Testing: Implications for Self&#x2010;Sampling,&#x201d; Biotechniques 74, no. 2 (2023): 77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">36655599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordaens S., Zwaenepoel K., Tjalma W., et al., &#x201c;Urine Biomarkers in Cancer Detection: A Systematic Review of Preanalytical Parameters and Applied Methods,&#x201d; International Journal of Cancer 152, no. 10 (2023): 2186&#x2013;2205.</Citation><ArticleIdList><ArticleId IdType="pubmed">36647333</ArticleId></ArticleIdList></Reference><Reference><Citation>
Arbyn M., Dhillon S., and Poljak M., Validated HPV Tests Usable in Cervical Cancer Screening on Clinician&#x2010;Collected Cervical Specimens, www.HPVWorld.com (HPV World, 2024), 270, https://www.hpvworld.com/articles/validated-hpv-screening-tests:-the-importance-of-validation/.</Citation></Reference><Reference><Citation>Martinelli M., Latsuzbaia A., Bonde J., et al., &#x201c;Performance of BD Onclarity HPV Assay on FLOQSwabs Vaginal Self&#x2010;Samples,&#x201d; Microbiology Spectrum 12 (2024): e0287223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10913526</ArticleId><ArticleId IdType="pubmed">38323823</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinson J. L., Hu S., Niyazi M., et al., &#x201c;Prevalence of Type&#x2010;Specific Human Papillomavirus in Endocervical, Upper and Lower Vaginal, Perineal and Vaginal Self&#x2010;Collected Specimens: Implications for Vaginal Self&#x2010;Collection,&#x201d; International Journal of Cancer 127, no. 5 (2010): 1151&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">20039323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fobian S. F., Mei X., Crezee J., et al., &#x201c;Increased Human Papillomavirus Viral Load Is Correlated to Higher Severity of Cervical Disease and Poorer Clinical Outcome: A Systematic Review,&#x201d; Journal of Medical Virology 96, no. 6 (2024): e29741.</Citation><ArticleIdList><ArticleId IdType="pubmed">38922964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Du H., Xiao A., et al., &#x201c;Verification of the Association of the Cycle Threshold (Ct) Values From HPV Testing on Cobas4800 With the Histologic Grades of Cervical Lesions Using Data From Two Population&#x2010;Based Cervical Cancer Screening Trials,&#x201d; Infectious Agents and Cancer 17, no. 1 (2022): 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9188717</ArticleId><ArticleId IdType="pubmed">35690793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40024263</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Zika virus: advancing a priority research agenda for preparedness and response.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(24)00794-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(24)00794-1</ELocationID><Abstract><AbstractText>The 2015-16 Zika virus epidemic emerged in the Americas and rapidly spread throughout the region and beyond, showing the epidemic potential of this mosquito-borne Orthoflavivirus and its capacity to cause severe congenital malformations and neurological sequelae. WHO declared the Zika virus epidemic a public health emergency of international concern in 2016. Despite this declaration, there are no licensed Zika virus vaccines, therapeutics, or diagnostic tests appropriate for routine antenatal screening. To address this absence of essential tools to detect and mitigate the threat of future Zika virus outbreaks, a group of global experts developed a priority agenda for Zika virus research and development. This Series paper summarises crucial challenges and knowledge gaps and outlines a comprehensive strategy to advance research, surveillance, global capacity, policy, and investment for Zika virus preparedness and response.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lackritz</LastName><ForeName>Eve M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA. Electronic address: lackritz@umn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Lee-Ching</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>National Environment Agency, Environmental Health Institute, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Ernesto T A</ForeName><Initials>ETA</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Department of Virology and Experimental Therapeutics, Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabe</LastName><ForeName>Ingrid B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourne</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staples</LastName><ForeName>J Erin</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-Rico</LastName><ForeName>Jairo A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Pan American Health Organization, WHO Region of the Americas, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brault</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Albert I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; Ministry of Health, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>David W C</ForeName><Initials>DWC</Initials><AffiliationInfo><Affiliation>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leighton</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilder-Smith</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrowsky</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehr</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Angela K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velayudhan</LastName><ForeName>Raman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golding</LastName><ForeName>Josephine P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fay</LastName><ForeName>Petra C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cehovin</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moua</LastName><ForeName>Nicolina M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Kristine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterholm</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Alan D T</ForeName><Initials>ADT</Initials><AffiliationInfo><Affiliation>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Zika Expert Workgroup</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests This project was supported by the Wellcome Trust, grant #226438/Z/22/Z, awarded to the Center for Infectious Disease Research and Policy at the University of Minnesota. ADTB and DWCB declare a subcontract from Hawaii Biotech related to testing of West Nile virus vaccine candidates in small animal models. EH declares grant U01 AI153416 from the National Institutes of Health (NIH). L-CN was the Chair of the Global Arbovirus Initiative Technical Advisory Group Meetings with WHO (2022&#x2013;23). AIK declares a research grant from Takeda on Zika vaccine evaluation for which he is the principal investigator. IBR is a consultant to WHO (from June, 2018, to present). Wellcome programme staff served as members of the Zika Steering Group and participated in the project design, meetings, and reviews of manuscripts for publication. Wellcome Trust provided travel support to the December, 2023, meeting on Zika and arboviruses for EML, ADTB, DWCB, NB, EH, L-CN, TL, JES, JAM-R, ACB, AIK, JTO, AJM, AKU, and MTO. All other authors declare no competing interests. No authors were paid by a pharmaceutical company to write this Series paper. The authors alone are responsible for the views expressed in this Series paper and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Mention of trade names is for information only and does not imply endorsement.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adams Waldorf</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Barrett</LastName><ForeName>Alan D T</ForeName><Initials>ADT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Beasley</LastName><ForeName>David W C</ForeName><Initials>DWC</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bennie</LastName><ForeName>Joseph Y B</ForeName><Initials>JYB</Initials><AffiliationInfo><Affiliation>Ghana.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bourne</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Brault</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Cehovin</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Coelho</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brazil.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Diamond</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Emperador</LastName><ForeName>Devy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Switzerland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Faria</LastName><ForeName>Nuno R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fay</LastName><ForeName>Petra C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Golding</LastName><ForeName>Josephine P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hasanin</LastName><ForeName>Nagwa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denmark.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Jaenisch</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Albert I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lackritz</LastName><ForeName>Eve M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Leighton</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Leo</LastName><ForeName>Yee-Sin</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Singapore.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mehr</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Memish</LastName><ForeName>Ziad A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Saudi Arabia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>M&#xe9;ndez-Rico</LastName><ForeName>Jairo A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Kristine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mura</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>Lee-Ching</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Singapore.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Osterholm</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ostrowsky</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Peeling</LastName><ForeName>Rosanna W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Rabe</LastName><ForeName>Ingrid B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Switzerland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salje</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Staples</LastName><ForeName>J Erin</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Angela K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vanhomwegen</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Wongsawat</LastName><ForeName>Jurai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Thailand.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>2</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40024263</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00794-1</ArticleId><ArticleId IdType="pii">S1473-3099(24)00794-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40024262</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(24)00750-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(24)00750-3</ELocationID><Abstract><AbstractText>The 2015-16 Zika virus epidemic in the Americas drew global attention to Zika virus infection as a cause of microcephaly and Guillain-Barr&#xe9; syndrome. The epidemic highlighted the urgent need for preventive measures, including vaccines and monoclonal antibodies (mAbs). However, nearly 9 years later, no licensed Zika virus vaccines or mAbs are available, leaving the world's populations unprotected from ongoing disease transmission and future epidemics. The current low Zika virus incidence and unpredictability of future outbreaks complicates prospects for evaluation, licensure, and commercial viability of Zika virus vaccines and mAbs. We conducted an extensive review of Zika virus vaccines and mAbs in development, identifying 16 vaccines in phase 1 or phase 2 trials and three mAbs in phase 1 trials, and convened a 2-day meeting of 130 global Zika virus experts to discuss research priorities to advance their development. This Series paper summarises a priority research agenda to address key knowledge gaps and accelerate the licensure of Zika virus vaccines and mAbs for global use.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostrowsky</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzelnick</LastName><ForeName>Leah C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourne</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Alan D T</ForeName><Initials>ADT</Initials><AffiliationInfo><Affiliation>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA; Institute for Global Health and Translational Sciences, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology and Center for Genome Sciences, Lab and Genomic Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>David W C</ForeName><Initials>DWC</Initials><AffiliationInfo><Affiliation>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Vaccinology, School of Public Health, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilder-Smith</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leighton</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehr</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moua</LastName><ForeName>Nicolina M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Angela K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cehovin</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fay</LastName><ForeName>Petra C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golding</LastName><ForeName>Josephine P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Infectious Disease Strategic Programme, Wellcome Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Kristine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterholm</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lackritz</LastName><ForeName>Eve M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN, USA. Electronic address: lackritz@umn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Zika Expert Workgroup</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests This project was funded by the Wellcome Trust, grant 226438/Z/22/Z awarded to the Center for Infectious Disease Research and Policy at the University of Minnesota. LCK is supported by the US National Institutes of Health (NIH). ADTB and DWCB declare a subcontract from Hawaii Biotech related to testing of West Nile virus vaccine candidates in small animal models. EH declares grant U01 AI153416 from the NIH. SJT declares a previous grant from NIH National Institute of Allergy and Infectious Disease on dengue (which included Zika epidemiology) and a previous contract with Moderna as a Data and Safety Monitory Board member for a Zika vaccine trial (activities completed), contracts for dengue committee memberships, and a patent and royalties related to his role as inventor of a Zika vaccine candidate, ZPIV (patent awarded by the US Patent and Trademark Office), and all rights assigned to the US Army. MSD declares grants from Moderna, Vir Biotechnology, Bavarian Nordic, and IntegerBio; royalties or licenses from Ocugen, AstraZeneca, and BharatBiotech; consulting fees from Moderna, InBios, GlaxoSmithKline, Merck, IntegerBio, Vir Biotechnology, and Akagera Medicines; and stock or stock options from IntegerBio and Vir Biotechnology. Wellcome Trust provided travel support to the December, 2023, meeting on Zika and arboviruses for JTO, EH, EML, ADTB, DWCB, NB, TL, AJM, AKU, MTO, and SJT. All other authors declare no competing interests. No authors were paid by a pharmaceutical company to write this Series paper. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Mention of trade names is for information only and does not imply endorsement.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adams Waldorf</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Barrett</LastName><ForeName>Alan D T</ForeName><Initials>ADT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Beasley</LastName><ForeName>David W C</ForeName><Initials>DWC</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bennie</LastName><ForeName>Joseph Y B</ForeName><Initials>JYB</Initials><AffiliationInfo><Affiliation>Ghana.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bourne</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Brault</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Cehovin</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Coelho</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Brazil.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Diamond</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Emperador</LastName><ForeName>Devy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Switzerland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Faria</LastName><ForeName>Nuno R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fay</LastName><ForeName>Petra C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Golding</LastName><ForeName>Josephine P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hasanin</LastName><ForeName>Nagwa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denmark.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Jaenisch</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Albert I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lackritz</LastName><ForeName>Eve M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Leighton</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Leo</LastName><ForeName>Yee-Sin</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Singapore.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mehr</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Memish</LastName><ForeName>Ziad A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Saudi Arabia.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>M&#xe9;ndez-Rico</LastName><ForeName>Jairo A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Kristine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mura</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Netherlands.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>Lee-Ching</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Singapore.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Osterholm</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ostrowsky</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Peeling</LastName><ForeName>Rosanna W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Rabe</LastName><ForeName>Ingrid B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Switzerland.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salje</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UK.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Staples</LastName><ForeName>J Erin</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Angela K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>USA.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Vanhomwegen</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Wongsawat</LastName><ForeName>Jurai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Thailand.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>2</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40024262</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00750-3</ArticleId><ArticleId IdType="pii">S1473-3099(24)00750-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40015292</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(24)00804-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(24)00804-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sipavibart is an anti-spike monoclonal antibody that neutralises SARS-CoV-2 with exceptions, including Phe456Leu-containing variants (eg, KP.2* and KP.3*). This trial assessed sipavibart efficacy and safety for prevention of symptomatic COVID-19 in participants who are immunocompromised.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this ongoing, double-blind, international, phase 3 trial, we enrolled participants who were immunocompromised and aged 12 years or older at 197 hospitals, university health centres, and clinical trial units in 18 countries. Participants were randomly allocated 1:1 to a sipavibart group (intramuscular sipavibart 300 mg on days 1 and 181) or a comparator group (tixagevimab 300 mg-cilgavimab 300 mg on day 1 and placebo on day 181 or placebo on days 1 and 181), stratified by previous COVID-19 vaccination and infection status and use of tixagevimab-cilgavimab. The primary efficacy outcomes were symptomatic COVID-19 caused by any variant or symptomatic COVID-19 caused by non-Phe456Leu-containing variants within 181 days of dosing, assessed in the SARS-CoV-2-negative set, comprising all participants without a positive RT-PCR test for SARS-CoV-2 at baseline and who received at least one trial intervention dose. Safety outcomes for adverse events were assessed 90 days following the first dose and for serious adverse events throughout the study in the safety analysis set (ie, all participants who received at least one injection of sipavibart or comparator). This study is registered with ClinicalTrials.gov, NCT05648110.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Participants were screened from March 31 to Oct 27, 2023; 3349 participants (56&#xb7;8% female) were randomly assigned: 1674 to the sipavibart group (five no first dose; 1669 sipavibart) and 1675 to the comparator group (nine no first dose; 1105 tixagevimab-cilgavimab and 561 placebo). Within 181 days of dosing, 122 (7&#xb7;4%) of 1649 participants in the sipavibart group and 178 (10&#xb7;9%) of 1631 participants in the comparator group had symptomatic COVID-19 due to any variant (relative risk reduction [RRR] 34&#xb7;9% [97&#xb7;5% CI 15&#xb7;0 to 50&#xb7;1]; p=0&#xb7;0006), 54 (3&#xb7;3%) participants in the sipavibart group and 90 (5&#xb7;5%) participants in the comparator group had symptomatic COVID-19 due to non-Phe456Leu-containing variants (RRR 42&#xb7;9% [95% CI 19&#xb7;9 to 59&#xb7;3]; p=0&#xb7;0012), and 47 (2&#xb7;9%) participants in the sipavibart group and 64 (3&#xb7;9%) participants in the comparator group had symptomatic COVID-19 due to Phe456Leu-containing variants (30&#xb7;4% [-1&#xb7;8 to 52&#xb7;5]). Adverse events occurred in 833 (49&#xb7;9%) of 1671 participants in the sipavibart group and 857 (51&#xb7;5%) of 1663 participants in the comparator group within 3 months of the first dose. One COVID-19-related death occurred in the comparator group. Serious adverse events considered related to trial intervention occurred in two (0&#xb7;1%) of 1671 participants in the sipavibart group and seven (0&#xb7;4%) of 1663 participants in the comparator group (none fatal). No serious cardiovascular or thrombotic events were considered to be related to sipavibart.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The primary analysis showed efficacy and safety of sipavibart in preventing symptomatic COVID-19 in participants who are immunocompromised when susceptible (ie, non-Phe456Leu-containing) variants dominated, although no efficacy was shown against resistant (ie, Phe456Leu-containing) variants that dominate as of November, 2024.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">AstraZeneca.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haidar</LastName><ForeName>Ghady</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: haidarg@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biometrics, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses et Tropicales, CHU N&#xee;mes Car&#xe9;meau, Universit&#xe9; de Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Ross I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, WA, Australia; Clinical Research Unit, Perth Blood Institute, Perth, WA, Australia; Hollywood Hospital Haemophilia Centre, Haematology Academic Unit, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonyaratanakornkit</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiertiburanakul</LastName><ForeName>Sasisopin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Alfred H J</ForeName><Initials>AHJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longbrake</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University of Paris Cit&#xe9;, INSERM U944, H&#xf4;pital Saint-Louis, Lariboisi&#xe8;re Hospitals, Assistance Publique Hopitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Infectious Diseases and IrsiCaixa, University Hospital Germans Trias i Pujol, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Haematology Research Department, Haematology Clinic, Royal Cornwall Hospital NHS Trust, Truro, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uriel</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital (Manchester University NHS Foundation Trust), Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinmann-Menke</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>First Department of Medicine and Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksyuk</LastName><ForeName>Anastasia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clegg</LastName><ForeName>Lindsay E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Currie</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flyrin</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shroff</LastName><ForeName>Manish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Patient Safety, Chief Medical Office, Research &amp; Development, AstraZeneca, Waltham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Lee-Jah</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Taylor S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Vaccines &amp; Immune Therapies, BioPharmaceuticals Research &amp; Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SUPERNOVA study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05648110</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests GH reports receiving research grants from Allovir Pharmaceuticals, AstraZeneca, Karius, the Cystic Fibrosis Foundation, and Regeneron Pharmaceuticals, and serves on the scientific advisory boards of Karius, AstraZeneca, SNIPR BIOME, Pfizer, and RedQueen. PL reports receiving honoraria for lectures and presentations, and is an advisor or consultant for AstraZeneca, GSK, Janssen, Merck Sharp &amp; Dohme, Pfizer, and Sanofi. RIB reports receiving research grants from Bayer, Takeda, Pfizer, Daiichi Sankyo, CSL Behring, Roche, Amgen, Celgene, Rigel Pharmaceuticals, Ionis Pharmaceuticals, AbbVie, Sanofi, MorphoSys, Acerta Pharma, Janssen-Cilag, Bristol Myers Squibb, Boehringer Ingelheim, and AstraZeneca, and honoraria for speaking at educational meetings from Bayer, Bristol Myers Squibb, Cardinal Health, and AstraZeneca; he provided expert testimony for Sandoz and participated on data safety monitoring or advisory boards for Roche, Janssen-Cilag, CSL Behring, Pharmaxis, and the George Institute. TB reports receiving grants from Novo Nordisk Foundation, Lundbeck Foundation, Simonsen Foundation, GSK, Pfizer, and Gilead, and personal fees from GSK, Pfizer, Bavarian Nordic, Boehringer Ingelheim, Gilead, Merck Sharp &amp; Dohme, Janssen, Moderna, and AstraZeneca (outside the submitted work). JB reports receiving grants or research support from IgM Biosciences and consulting for Third Rock Ventures and Shionogi. SK reports receiving grants or research support from Pfizer, AstraZeneca, Merck Sharp &amp; Dohme, Sanofi, and Gilead, and honoraria from Pfizer, AstraZeneca, Merck Sharp &amp; Dohme, Sanofi, and GSK. AHJK reports receiving grants or research support from AstraZeneca, GSK, Novartis, National Institutes of Health (NIH), and Bristol Myers Squibb; consultancy fees for Amgen, ANI Pharmaceuticals, Atara Bio, Aurinia Pharmaceuticals, Cargo Tx, Exagen Diagnostics, GSK, Kypha, Miltenyi Biotech, Pfizer, Synthekine, and Technotic Tx; speaker fees from Exagen, GSK, and The Rheumatology Education Group; intellectual property or patents from Kypha; participation on a data safety monitoring board for NIH and National Institute of Arthritis and Musculoskeletal and Skin Diseases; and Board of Directors role for the Rheumatology Research Foundation. EEL reports receiving grants or research support from Biogen, Genentech, NIH, National MS Society, and Department of Defense; is an advisor or consultant for Genentech; and reports participation on a data safety monitoring board or advisory board for Novartis, Genentech, Bristol Myers Squibb, EMD Serono, and TG Therapeutics. J-MM reports receiving advisory board fees from Gilead Sciences, Merck, and ViiV Healthcare. RP reports research grants from Merck Sharp &amp; Dohme, ViiV Healthcare, Gilead Sciences, and PharmaMar; consultancy fees for Gilead Sciences, Pfizer, Roche Therapeutics, AstraZeneca, Merck Sharp &amp; Dohme, GSK, ViiV Healthcare, Eli Lilly and Company, and PharmaMar; and honoraria from Gilead Sciences, Pfizer, AstraZeneca, Merck Sharp &amp; Dohme, and PharmaMar. DT served on advisory boards for Regeneron Pharmaceuticals and BeiGene; received speaker fees from AbbVie and BeiGene; and received reimbursement of travel costs from AbbVie and BeiGene. JW-M received speaker fees and travel support from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, and grant support from Miltenyi Biotech and Diamed. ST was an employee of AstraZeneca at the time of this analysis. AC, AAA, LEC, HY, KF, MG, MS, JLP, L-JC, and TSC are employees of, and might hold stock or stock options in, AstraZeneca. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Griffin</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrissey</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yong</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Ross</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sasadeusz</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bollen</LastName><ForeName>Hilde</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orban</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremblay</LastName><ForeName>Cecile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiese</LastName><ForeName>Lothar</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breinholt Staerke</LastName><ForeName>Nina</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johansen</LastName><ForeName>Isik</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimard</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maakaroun Vermesse</LastName><ForeName>Zoha</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>Maeva</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deplanque</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben Ghezala</LastName><ForeName>In&#xe8;s</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagneux Brunon</LastName><ForeName>Amandine</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nassim</LastName><ForeName>Kamar</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benotmane</LastName><ForeName>Illies</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Systchenko</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wassenberg</LastName><ForeName>Siegrfried</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Everding</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malin</LastName><ForeName>Jakob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinmann-Menke</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witzke</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucker</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dargan</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koch</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rampling</LastName><ForeName>Thomas William</ForeName><Initials>TW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Protheroe</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whittington</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uriel</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munir</LastName><ForeName>Talha</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regev</LastName><ForeName>Gili</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eliakim Raz</LastName><ForeName>Noa</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>Hock Hin</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ang</LastName><ForeName>Peng Peng</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ali</LastName><ForeName>Adli</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Syed Omar</LastName><ForeName>Sharifah Faridah</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Chieh Lee</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korkosz</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwiatek</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choe</LastName><ForeName>Pyoeng Gyun</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Eu Suk</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung-Han</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Sung Yong</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chai</LastName><ForeName>Louis Yi Ann</ForeName><Initials>LYA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chia</LastName><ForeName>Po Ying</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Yvonne Fu Zi</ForeName><Initials>YFZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Echave-Sustaeta</LastName><ForeName>Jose Mar&#xed;a</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ignacio Garcia</LastName><ForeName>Jose Maria</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez Fernandez</LastName><ForeName>Antonio Manuel</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estrada Perez</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salcedo Leal</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tejerina Picado</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Contreras Gonzalez</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aldea Novo</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Campo Perez</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moza Mori&#xf1;igo</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez Gomez</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castrodeza Sanz</LastName><ForeName>Jos&#xe9; Javier</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez Rivas</LastName><ForeName>Jose Angel</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Min-Chi</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Feng-Yee</ForeName><Initials>FY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mootsikapun</LastName><ForeName>Piroon</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chayakulkeeree</LastName><ForeName>Methee</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiertiburanakul</LastName><ForeName>Sasisopin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaiwarith</LastName><ForeName>Romanee</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudjaritruk</LastName><ForeName>Tavitiya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manosuthi</LastName><ForeName>Weerawat</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reinfeld</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pickrell</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amin</LastName><ForeName>Faisal</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fanning</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kutner</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moy</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denenberg</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Manish</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rensoli Velazquez</LastName><ForeName>Marimer</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venereo</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakor</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murillo</LastName><ForeName>Abel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rose</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhat</LastName><ForeName>Jodumutt</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haidar</LastName><ForeName>Ghady</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levinson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Edouard</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vishnepolsky</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yanez</LastName><ForeName>Giralt</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palma</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Anup</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boonyaratanakornkit</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Alfred</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vutikullird</LastName><ForeName>Apinya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rose</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>German</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waller</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colander</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avery</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Cameron</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madan</LastName><ForeName>Arvind</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chuang</LastName><ForeName>Peale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Towner</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yanuck</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koff</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanbang</LastName><ForeName>Antony Nguyen</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Jaswinder</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balani</LastName><ForeName>Bindu</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mustafa</LastName><ForeName>Syed</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fadda</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrak</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstock-Guttman</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pippas</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedd</LastName><ForeName>Khan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raasch</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamat</LastName><ForeName>Sona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>Bobby</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upadhyay</LastName><ForeName>Hiten</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peaz</LastName><ForeName>Armando</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mooney</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koo</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ylisastigui</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julien</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frome</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedd</LastName><ForeName>Khan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Standaert</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slenker</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>Belkis</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longbrake</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anand</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koren</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramesh</LastName><ForeName>Mayur</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kivitz</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huaman</LastName><ForeName>Moises</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farmakiotis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qiao</LastName><ForeName>Xian</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saba</LastName><ForeName>Fadi</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sachdeva</LastName><ForeName>Yessica</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sajid</LastName><ForeName>Saleha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Enrique</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tebas-Medrano</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majjhoo</LastName><ForeName>Amar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igbinadolor</LastName><ForeName>Awawu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandkovsky</LastName><ForeName>Uriel</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Studdard</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noveck</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohli</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Jayant</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabbaa</LastName><ForeName>Mousab</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sisay</LastName><ForeName>Moges</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amin</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Adnan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dela Llana</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kniery</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fogarty</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singhal</LastName><ForeName>Atul</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazar</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>Binh Quang</ForeName><Initials>BQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chu</LastName><ForeName>Hanh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdalla</LastName><ForeName>Jehad</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Kaabi</LastName><ForeName>Nawal</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>28</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>28</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40015292</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00804-1</ArticleId><ArticleId IdType="pii">S1473-3099(24)00804-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40014791</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>90</EndPage><MedlinePgn>83-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7406a2</ELocationID><Abstract><AbstractText>Annual influenza vaccination is recommended for all persons aged &#x2265;6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged &lt;18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged &#x2265;18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged &#x2265;6 months as long as influenza viruses continue to circulate locally.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frutos</LastName><ForeName>Aaron M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Cleary</LastName><ForeName>Seana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Emily L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Haris M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Ashley M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Self</LastName><ForeName>Wesley H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuwei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Safdar</LastName><ForeName>Basmah</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Peltan</LastName><ForeName>Ithan D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Exline</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Lauring</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>DeSilva</LastName><ForeName>Malini</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tartof</LastName><ForeName>Sara Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Dascomb</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Vaughn</LastName><ForeName>Ivana A</ForeName><Initials>IA</Initials></Author><Author ValidYN="Y"><LastName>House</LastName><ForeName>Stacey L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Faryar</LastName><ForeName>Kiran A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Nowalk</LastName><ForeName>Mary Patricia</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Gaglani</LastName><ForeName>Manjusha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wernli</LastName><ForeName>Karen J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Murugan</LastName><ForeName>Vel</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Olivia L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Selvarangan</LastName><ForeName>Rangaraj</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Staat</LastName><ForeName>Mary A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Halasa</LastName><ForeName>Natasha B</ForeName><Initials>NB</Initials></Author><Author ValidYN="Y"><LastName>Sahni</LastName><ForeName>Leila C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Michaels</LastName><ForeName>Marian G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Marie K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Surie</LastName><ForeName>Diya</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dawood</LastName><ForeName>Fatimah S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Clopper</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Moline</LastName><ForeName>Heidi L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Link-Gelles</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Harker</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wielgosz</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Duck-Hye</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Nathaniel M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>DeCuir</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Samantha M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jessie R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Grohskopf</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Carrie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Shikha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ellington</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><CollectiveName>CDC Influenza Vaccine Effectiveness Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 IP001189</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 IP001158</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 IP001191</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 IP001157</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 IP001194</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Basmah Safdar reports travel support from Novo Nordisk and Danish Heart Foundation, and membership in Society of Academic Emergency Medicine. Ithan D. Peltan reports institutional support from National Heart, Lung, and Blood Institute, Intermountain Research and Medical Foundation, Bluejay Diagnostics, and Novartis; travel support from Novartis. Kevin W. Gibbs reports grants or contracts from the Department of Defense, Patient-Centered Outcomes Research Institute (PCORI), and the National Institutes of Health; travel support to Critical Care Reviews 24; and participation on the Vanderbilt University Medical Center Data Safety Monitoring Board. Adam S. Lauring reports institutional support from Roche, National Institute of Allergy and Infectious Diseases, Flulab; and consulting fees from Roche. Sarah W. Ball reports institutional support from the University of Utah and Novavax. Sara Y. Tartof reports institutional support from Pfizer including receipt of vaccines for a study. Nicola P. Klein reports institutional support from Sanofi Pasteur, Merck, Pfizer, Seqirus, and GSK; membership on an expert panel for a planned hepatitis E Phase II vaccine clinical trial among pregnant women in Pakistan; membership in Western States COVID-19 Scientific Safety Review Workgroup, Board on Population Health and Public Health Practice, National Academies of Science, Engineering and Medicine, and National Vaccine Advisory Committee Safety Subcommittee. Toan C. Ong reports receipt of travel support to attend the PCORI Annual Meeting in 2023 in Washington D.C. and the OHIE 23 meeting in Malawi. Stacey L. House reports institutional support from Seegene, Inc., Abbot, Healgen, Roche, CorDx, Hologic, Cepheid, Janssen, and Wondfo Biotech. Kiran A. Faryar reports institutional support from Gilead Sciences. Mary Patricia Nowalk reports institutional support from Sanofi Pasteur and Icosavax/AstraZeneca; consulting fees from GSK, Merck, Sharpe, and Dohme; Stock from Eli Lilly and Abbot Labs; and receipt of equipment from Sequiris and Sanofi. Manjusha Gaglani reports receipt of honorarium for educational webinar presentation on respiratory viruses from the Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics, and serving as co-chair of the Infectious Diseases and Immunization Committee and Chair of the Texas Respiratory Syncytial Virus Taskforce, Texas Pediatric Society. Rangaraj Selvarangan reports honoraria from BioM&#xe9;rieux and GSK. Geoffrey A. Weinberg reports institutional support from the New York State Department of Health; consulting fees from Inhalon Biopharma, New York State Department of Health, and ReViral; participation on a Scientific Advisory Board for Emory University; and honoraria from Merck. Mary A. Staat reports institutional support from the National Institutes of Health, Pfizer, and Cepheic; royalties from Up-to-Date; and consulting fees from Merck. Natasha B. Halasa reports institutional support from Merck; consulting fees from CSL Seqirus; and participation on an advisory Board for Emory University. Leila C. Sahni reports travel support from the Bill and Melinda Gates Foundation. Marian G. Michaels reports institutional support from the National Institutes of Health; Merck and complimentary meeting attendance for presentation at the American Transplant Congress on respiratory viruses; and participation on a Data Safety Monitoring Board for National Institute on Allergy and Infectious Diseases. Janet A. Englund reports institutional support from AstraZeneca, GSK, Pfizer, and Moderna; consulting fees from Abbvie, AstraZeneca, GSK, Merck, Meissa Vaccines, Moderna, Pfizer, Shionogi, and Cidarra; and honoraria from Pfizer. Zachary A. Weber reports institutional support from Novavax. Samantha M. Olson reports travel support from the Gates Foundation. No other potential conflicts of interest were disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Busse</LastName><ForeName>Laurence W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Emory University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Columbus</LastName><ForeName>Cristie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Baylor University Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Duggal</LastName><ForeName>Abhijit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cleveland Clinic.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ginde</LastName><ForeName>Adit A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>University of Colorado.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Gong</LastName><ForeName>Michelle N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Montefiore Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hager</LastName><ForeName>David N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Johns Hopkins University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Estelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Utah.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>University of Washington.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>Akram</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oregon Health &amp; Science University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jennie H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Washington University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mallow</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Miami.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mohr</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>University of Iowa.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mosier</LastName><ForeName>Jarrod M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University of Arizona.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Prekker</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Hennepin County Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Qadir</LastName><ForeName>Nida</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Ratcliff</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Nathan I</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Steingrub</LastName><ForeName>Jay S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Baystate Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Jennifer G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Stanford University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Akinsete</LastName><ForeName>Omobosola</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>HealthPartners Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Barron</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bride</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Intermountain Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Duszynski</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Indiana University.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Grannis</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regenstrief Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Northern California.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Koppolu</LastName><ForeName>Padma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Charlene</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HealthPartners Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Center for Health Research.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Salas</LastName><ForeName>S Bianca</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Southern California.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Intermountain Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Sy</LastName><ForeName>Lina S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Southern California.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Ousseny</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Northern California.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Boom</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine and Texas Children's Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Eileen J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Seattle Children's Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Moffatt</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Piedra</LastName><ForeName>Pedro A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine and Texas Children's Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Schlaudecker</LastName><ForeName>Elizabeth P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Schuster</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Laura S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Szilagyi</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine and Dentistry and UCLA Mattel Children's Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>John V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, and University of Wisconsin School of Medicine and Public Health.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Zerr</LastName><ForeName>Danielle M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Seattle Children's Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Balasubramani</LastName><ForeName>G K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bontrager</LastName><ForeName>Natalie A B</ForeName><Initials>NAB</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Curley</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Donskey</LastName><ForeName>Curtis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Louis Stokes Cleveland Veterans Administration Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>DaSilva</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fairall</LastName><ForeName>Britan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Geffel</LastName><ForeName>Krissy Moehling</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hoyen</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Cleveland Hospitals Rainbow Babies &amp; Children's Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Keong</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kiniry</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Leis</LastName><ForeName>Aleda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of Michigan.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Emily T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>University of Michigan.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Nordstrom</LastName><ForeName>Lora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Valleywise Health Medical Center.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Odame-Bamfo</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>C Hallie</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Emmanuel B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Yeager</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Phoenix Children's Hospital.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40014791</ArticleId><ArticleId IdType="pmc">PMC11867582</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7406a2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices&#x2014;United States, 2024&#x2013;25 influenza season. MMWR Recomm Rep 2024;73:1&#x2013;25. 10.15585/mmwr.rr7305a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.rr7305a1</ArticleId><ArticleId IdType="pmc">PMC11501009</ArticleId><ArticleId IdType="pubmed">39197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll MK, Pettigrew SM, Ma J, Verma A. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. Clin Infect Dis 2022;75:e564&#x2013;71. 10.1093/cid/ciac234</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac234</ArticleId><ArticleId IdType="pmc">PMC9129127</ArticleId><ArticleId IdType="pubmed">35325923</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. Clin Infect Dis 2019;69:1817&#x2013;23. 10.1093/cid/ciz411</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz411</ArticleId><ArticleId IdType="pubmed">31102401</ArticleId></ArticleIdList></Reference><Reference><Citation>Frutos AM, Price AM, Harker E, et al.; CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2023&#x2013;24 seasonal influenza vaccine effectiveness&#x2014;United States. MMWR Morb Mortal Wkly Rep 2024;73:168&#x2013;74. 10.15585/mmwr.mm7308a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7308a3</ArticleId><ArticleId IdType="pmc">PMC10907036</ArticleId><ArticleId IdType="pubmed">38421935</ArticleId></ArticleIdList></Reference><Reference><Citation>Separovic L, Zhan Y, Kaweski SE, et al. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill 2025;30. 10.2807/1560-7917.ES.2025.30.4.2500059</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2025.30.4.2500059</ArticleId><ArticleId IdType="pmc">PMC11920781</ArticleId><ArticleId IdType="pubmed">39885824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeno EE, Nogareda F, Regan A, et al.; REVELAC-i Network. Interim effectiveness estimates of 2024 southern hemisphere influenza vaccines in preventing influenza-associated hospitalization&#x2014;REVELAC-i network, five South American countries, March&#x2013;July 2024. MMWR Morb Mortal Wkly Rep 2024;73:861&#x2013;8. 10.15585/mmwr.mm7339a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7339a1</ArticleId><ArticleId IdType="pmc">PMC11449270</ArticleId><ArticleId IdType="pubmed">39361525</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung JR, Price AM, Zimmerman RK, et al.; US Flu VE Network Investigators. Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023&#x2013;24 season. Clin Infect Dis 2025;ciae658. 10.1093/cid/ciae658</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae658</ArticleId><ArticleId IdType="pubmed">39761230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose AM, Lucaccioni&#xa0;H, Marsh&#xa0;K, et al.; European IVE group. Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025 Euro Surveill 2025;30.10.1093/cid/ciae658</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae658</ArticleId><ArticleId IdType="pmc">PMC11843620</ArticleId><ArticleId IdType="pubmed">39980423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40013818</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>RNA vaccines: The dawn of a new age for tuberculosis?</ArticleTitle><Pagination><StartPage>2469333</StartPage><MedlinePgn>2469333</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2469333</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2025.2469333</ELocationID><Abstract><AbstractText>Since 2019, there has been a growing focus on mRNA vaccines for infectious disease prevention, particularly following the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). mRNA vaccines offer advantages such as rapid production and the ability to induce robust cellular and antibody responses, which are essential for combating infections that require cell-mediated immunity, including Tuberculosis (TB). This review explores recent progress in TB mRNA vaccines and addresses several key areas: (1) the urgent need for new TB vaccines; (2) current advancements in TB vaccine development, and the advantages and challenges of mRNA technology; (3) the design and characteristics of TB mRNA vaccines; (4) the immunological mechanisms of TB mRNA vaccines; (5) manufacturing processes for TB mRNA vaccines; and (6) safety and regulatory considerations. This interdisciplinary review aims to provide insights for researchers working to address critical questions in TB mRNA vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Junli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Graduate School of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaochi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jiazheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Weixin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Aihua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D032581">Tuberculosis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032581" MajorTopicYN="Y">Tuberculosis Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="Y">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="Y">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mycobacterium tuberculosis</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword><Keyword MajorTopicYN="N">immunological mechanisms</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword><Keyword MajorTopicYN="N">manufacture and quality control</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40013818</ArticleId><ArticleId IdType="pmc">PMC11869779</ArticleId><ArticleId IdType="doi">10.1080/21645515.2025.2469333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global tuberculosis report . World Health Organization; 2024.</Citation></Reference><Reference><Citation>Parveen U, Sultana S, Heba SF, Rafi R, Begum A, Fatima N.. Pretomanid: a novel therapeutic paradigm for treatment of drug resistant tuberculosis. Indian J Tuberc. 2021;68(1):106&#x2013;17. doi:10.1016/j.ijtb.2020.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.09.005</ArticleId><ArticleId IdType="pubmed">33641829</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldar R, Narayanan SJ. A novel ensemble based recommendation approach using network based analysis for identification of effective drugs for tuberculosis. Math Biosci Eng. 2022;19(1):873&#x2013;891. doi:10.3934/mbe.2022040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2022040</ArticleId><ArticleId IdType="pubmed">34903017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Nandi S, Saxena AK. An updated patent review on drugs for the treatment of tuberculosis (2018-present). Expert Opin Ther Pat. 2022;32(3):243&#x2013;260. doi:10.1080/13543776.2022.2012151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2022.2012151</ArticleId><ArticleId IdType="pubmed">34846976</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida D, Converse PJ, Li SY, Upton AM, Fotouhi N, Nuermberger EL. Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2021;65(12):e0141221. doi:10.1128/AAC.01412-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01412-21</ArticleId><ArticleId IdType="pmc">PMC8597756</ArticleId><ArticleId IdType="pubmed">34570644</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkins-Ford J, Greenstein T, Van N, Degefu YN, Olson MC, Sokolov A, Aldridge BB. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 2021;12(11):1046&#x2013;63.e7. doi:10.1016/j.cels.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8617591</ArticleId><ArticleId IdType="pubmed">34469743</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben R, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin H-H, Wu C-Y, Mandal S, Pandey S, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4(11):e806&#x2013;e15. doi:10.1016/S2214-109X(16)30199-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(16)30199-1</ArticleId><ArticleId IdType="pmc">PMC6375908</ArticleId><ArticleId IdType="pubmed">27720688</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health. 2016;4(11):e816&#x2013;e26. doi:10.1016/S2214-109X(16)30265-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(16)30265-0</ArticleId><ArticleId IdType="pmc">PMC5527122</ArticleId><ArticleId IdType="pubmed">27720689</ArticleId></ArticleIdList></Reference><Reference><Citation>Global tuberculosis report . World Health Organization; 2018.</Citation></Reference><Reference><Citation>Global tuberculosis report . World Health Organization; 2019.</Citation></Reference><Reference><Citation>Global tuberculosis report . World Health Organization; 2020.</Citation></Reference><Reference><Citation>Arregui S, Iglesias MJ, Samper S, Marinova D, Martin C, Sanz J, Moreno Y. Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures. Proc Natl Acad Sci USA. 2018;115(14):E3238&#x2013;e45. doi:10.1073/pnas.1720606115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1720606115</ArticleId><ArticleId IdType="pmc">PMC5889657</ArticleId><ArticleId IdType="pubmed">29563223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83&#x2013;112. doi:10.1016/j.addr.2020.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.12.014</ArticleId><ArticleId IdType="pmc">PMC7837307</ArticleId><ArticleId IdType="pubmed">33400957</ArticleId></ArticleIdList></Reference><Reference><Citation>Handbook for good clinical research practice (GCP): Guidance for implementation . World Health Organization; 2005.</Citation></Reference><Reference><Citation>Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40(40):5798&#x2013;5805. doi:10.1016/j.vaccine.2022.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.036</ArticleId><ArticleId IdType="pmc">PMC9428332</ArticleId><ArticleId IdType="pubmed">36055877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Letter to the editor. Vaccine. 2023; doi:10.1016/j.vaccine.2023.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.06.035</ArticleId><ArticleId IdType="pmc">PMC10272990</ArticleId><ArticleId IdType="pubmed">37331839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537&#x2013;544. doi:10.1038/31159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31159</ArticleId><ArticleId IdType="pubmed">9634230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis. 2007;7(5):328&#x2013;337. doi:10.1016/S1473-3099(07)70108-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(07)70108-1</ArticleId><ArticleId IdType="pubmed">17448936</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H, Dill-Mcfarland KA, Benson B, Simmons JD, Peterson GJ, Benchek P, Stein CM, Boom WH, Mayanja-Kizza H, Hawn TR. Mycobacterium tuberculosis -induced monocyte transcriptional responses associated with resistance to tuberculin skin test/interferon-&#x3b3; release assay conversion in people with HIV. Aids. 2023;37(15):2287&#x2013;2296. doi:10.1097/QAD.0000000000003716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003716</ArticleId><ArticleId IdType="pmc">PMC10873024</ArticleId><ArticleId IdType="pubmed">37696247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek CC, Harris SA, O&#x2019;Shea MK, Wright D, Wittenberg R, et al. The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Res. 2021;10:257. doi:10.12688/f1000research.51640.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.51640.1</ArticleId><ArticleId IdType="pmc">PMC8097740</ArticleId><ArticleId IdType="pubmed">33976866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovar M, Moreno Y, Sanz J. Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines. Nat Commun. 2023;14(1):5312. doi:10.1038/s41467-023-40976-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40976-6</ArticleId><ArticleId IdType="pmc">PMC10474143</ArticleId><ArticleId IdType="pubmed">37658078</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell DG. Tuberculosis progression does not necessarily equate with a failure of immune control. Microorganisms. 2019;7(7):185. doi:10.3390/microorganisms7070185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms7070185</ArticleId><ArticleId IdType="pmc">PMC6680517</ArticleId><ArticleId IdType="pubmed">31252553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisu D, Johnston L, Mattila JT, Russell DG. The frequency of CD38(+) alveolar macrophages correlates with early control of M. tuberculosis in the murine lung. Nat Commun. 2024;15(1):8522. doi:10.1038/s41467-024-52846-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-52846-w</ArticleId><ArticleId IdType="pmc">PMC11447019</ArticleId><ArticleId IdType="pubmed">39358361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Zhang D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Front Immunol. 2023;14:1238649. doi:10.3389/fimmu.2023.1238649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1238649</ArticleId><ArticleId IdType="pmc">PMC10652786</ArticleId><ArticleId IdType="pubmed">38022657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chugh S, Bahal RK, Dhiman R, Singh R. Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development. NPJ Vaccines. 2024;9(1):57. doi:10.1038/s41541-024-00834-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00834-y</ArticleId><ArticleId IdType="pmc">PMC10924964</ArticleId><ArticleId IdType="pubmed">38461350</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Krammer F. mRNA vaccines for infectious diseases &#x2014; advances, challenges and opportunities. Nat Rev Drug Discov. 2024;23(11):838&#x2013;861. doi:10.1038/s41573-024-01042-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-024-01042-y</ArticleId><ArticleId IdType="pubmed">39367276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLOS ONE. 2017;12(4):e0176784. doi:10.1371/journal.pone.0176784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0176784</ArticleId><ArticleId IdType="pmc">PMC5409163</ArticleId><ArticleId IdType="pubmed">28453555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, Fitilev SB, Maksimov SL, Smolyarchuk EA, Manuylov VA, et al. Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines (Basel). 2020;8(4):652. doi:10.3390/vaccines8040652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040652</ArticleId><ArticleId IdType="pmc">PMC7712213</ArticleId><ArticleId IdType="pubmed">33153191</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun. 2004;72(11):6622&#x2013;6632. doi:10.1128/IAI.72.11.6622-6632.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.11.6622-6632.2004</ArticleId><ArticleId IdType="pmc">PMC523007</ArticleId><ArticleId IdType="pubmed">15501795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortier MC, Jongert E, Mettens P, Ruelle JL. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens. BMC Immunol. 2015;16(1):63. doi:10.1186/s12865-015-0119-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-015-0119-7</ArticleId><ArticleId IdType="pmc">PMC4619029</ArticleId><ArticleId IdType="pubmed">26493839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Lu J, Li J, Du W, Shen X, Su C, Wu Y, Zhao A, Xu M. The subunit AEC/BC02 vaccine combined with antibiotics provides protection in Mycobacterium tuberculosis-infected Guinea pigs. Vaccines (Basel). 2022;10(12):2164. doi:10.3390/vaccines10122164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122164</ArticleId><ArticleId IdType="pmc">PMC9781032</ArticleId><ArticleId IdType="pubmed">36560574</ArticleId></ArticleIdList></Reference><Reference><Citation>Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018;3(1):34. doi:10.1038/s41541-018-0057-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-018-0057-5</ArticleId><ArticleId IdType="pmc">PMC6123489</ArticleId><ArticleId IdType="pubmed">30210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZRM, Wright D, Stockdale L, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime &#x2013; MVA85A boost in healthy UK adults. Vaccine. 2020;38(4):779&#x2013;789. doi:10.1016/j.vaccine.2019.10.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.10.102</ArticleId><ArticleId IdType="pmc">PMC6985898</ArticleId><ArticleId IdType="pubmed">31735500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeeva M, Romanovskaya-Romanko E, Zabolotnyh N, Pulkina A, Vasilyev K, Shurigina AP, Buzitskaya J, Zabrodskaya Y, Fadeev A, Vasin A, et al. Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against mycobacterium tuberculosis in mice and Guinea pigs. Vaccines (Basel). 2021;9(4):394. doi:10.3390/vaccines9040394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9040394</ArticleId><ArticleId IdType="pmc">PMC8073308</ArticleId><ArticleId IdType="pubmed">33923548</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkman K, Lindenstr&#xf8;m T, Rosenkrands I, S&#xf8;e R, Woodworth JS, Lindestam Arlehamn CS, Mortensen R. A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. NPJ Vaccines. 2023;8(1):66. doi:10.1038/s41541-023-00666-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00666-2</ArticleId><ArticleId IdType="pmc">PMC10169149</ArticleId><ArticleId IdType="pubmed">37160970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-Cell epitope prediction. J Immunol Res. 2017;2017:1&#x2013;14. doi:10.1155/2017/2680160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2680160</ArticleId><ArticleId IdType="pmc">PMC5763123</ArticleId><ArticleId IdType="pubmed">29445754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahlwes KC, Dias BRS, Campos PC, Alvarez-Arguedas S, Shiloh MU. Pathogenicity and virulence of Mycobacterium tuberculosis. Virulence. 2023;14(1):2150449. doi:10.1080/21505594.2022.2150449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2022.2150449</ArticleId><ArticleId IdType="pmc">PMC9817126</ArticleId><ArticleId IdType="pubmed">36419223</ArticleId></ArticleIdList></Reference><Reference><Citation>Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front Immunol. 2014;5:180. doi:10.3389/fimmu.2014.00180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00180</ArticleId><ArticleId IdType="pmc">PMC4001014</ArticleId><ArticleId IdType="pubmed">24795723</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt KD. Role of MHC class I pathways in Mycobacterium tuberculosis antigen presentation. Front Cell Infect Microbiol. 2023;13:1107884. doi:10.3389/fcimb.2023.1107884.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1107884</ArticleId><ArticleId IdType="pmc">PMC10050577</ArticleId><ArticleId IdType="pubmed">37009503</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Li X, Wan K, Zhao X, Deng Y, Chen Z, Luan X, Lu S, Liu H. Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis. Vaccine. 2021;39(47):6860&#x2013;6865. doi:10.1016/j.vaccine.2021.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.10.034</ArticleId><ArticleId IdType="pubmed">34702619</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao TY, Liu HC, Li XQ, Huang MX, Li GL, Li N, Yan YH, Luo Q, Wang XZ, Li MC, et al. Immunological evaluation of a novel Mycobacterium tuberculosis antigen Rv0674. Biomed Environ Sci. 2019;32(6):427&#x2013;437. doi:10.3967/bes2019.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3967/bes2019.056</ArticleId><ArticleId IdType="pubmed">31262388</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan X, Fan X, Li G, Li M, Li N, Yan Y, Zhao X, Liu H, Wan K. Exploring the immunogenicity of Rv2201-519: a T-cell epitope-based antigen derived from Mycobacterium tuberculosis AsnB with implications for tuberculosis infection detection and vaccine development. Int Immunopharmacol. 2024;129:111542. doi:10.1016/j.intimp.2024.111542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2024.111542</ArticleId><ArticleId IdType="pubmed">38342063</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda S, Morgan J, Cheng C, Saito M, Gilman RH, Ciobanu N, Crudu V, Catanzaro DG, Catanzaro A, Rodwell T, et al. Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection. Nat Commun. 2024;15(1):765. doi:10.1038/s41467-024-45058-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45058-9</ArticleId><ArticleId IdType="pmc">PMC10817963</ArticleId><ArticleId IdType="pubmed">38278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaiah A, Nayak S, Rakshit S, Manson AL, Abeel T, Shanmugam S, Sahoo PN, John AJUK, Sundaramurthi JC, Narayanan S, et al. Evidence for highly variable, region-specific patterns of T-Cell epitope mutations accumulating in Mycobacterium tuberculosis strains. Front Immunol. 2019;10:195. doi:10.3389/fimmu.2019.00195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00195</ArticleId><ArticleId IdType="pmc">PMC6381025</ArticleId><ArticleId IdType="pubmed">30814998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Chen X, Wang J, Wu F, Zhang J, Dong J, Zhang H, Liu X, Hu N, Wu J, et al. Prediction and identification of CD4+ T cell epitope for the protective antigens of Mycobacterium tuberculosis. Medicine (Baltim). 2021;100(6):e24619. doi:10.1097/MD.0000000000024619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024619</ArticleId><ArticleId IdType="pmc">PMC7886468</ArticleId><ArticleId IdType="pubmed">33578573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yari S, Afrough P, Yari F, Ghazanfari Jajin M, Fateh A, Hadizadeh Tasbiti A. A potent subset of Mycobacterium tuberculosis glycoproteins as relevant candidates for vaccine and therapeutic target. Sci Rep. 2023;13(1):22194. doi:10.1038/s41598-023-49665-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-49665-2</ArticleId><ArticleId IdType="pmc">PMC10719292</ArticleId><ArticleId IdType="pubmed">38092899</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2022;35(6):947&#x2013;951. doi:10.1177/08971900211009650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08971900211009650</ArticleId><ArticleId IdType="pubmed">33840294</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, T&#xfc;reci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009&#x2013;4017. doi:10.1182/blood-2006-04-015024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-04-015024</ArticleId><ArticleId IdType="pubmed">16940422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallie DR. The cap and poly(a) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991;5(11):2108&#x2013;2116. doi:10.1101/gad.5.11.2108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.5.11.2108</ArticleId><ArticleId IdType="pubmed">1682219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002;48(10):1647&#x2013;1653. doi:10.1093/clinchem/48.10.1647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/48.10.1647</ArticleId><ArticleId IdType="pubmed">12324479</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuichi Y, LaFiandra A, Shatkin AJ. 5&#x2032;-terminal structure and mRNA stability. Nature. 1977;266(5599):235&#x2013;239. doi:10.1038/266235a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/266235a0</ArticleId><ArticleId IdType="pubmed">557727</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S, Jacob F, Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature. 1961;190(4776):576&#x2013;581. doi:10.1038/190576a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/190576a0</ArticleId><ArticleId IdType="pubmed">20446365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullenger BA, Nair S. From the RNA world to the clinic. Science. 2016;352(6292):1417&#x2013;1420. doi:10.1126/science.aad8709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8709</ArticleId><ArticleId IdType="pmc">PMC6035743</ArticleId><ArticleId IdType="pubmed">27313039</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F, Lindgren G, Lin A, Thompson EA, Ols S, R&#xf6;hss J, John S, Hassett K, Yuzhakov O, Bahl K, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635&#x2013;2647. doi:10.1016/j.ymthe.2017.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.006</ArticleId><ArticleId IdType="pmc">PMC5768558</ArticleId><ArticleId IdType="pubmed">28958578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering BM, Willis AE. The implications of structured 5&#x2032; untranslated regions on translation and disease. Semin Cell Dev Biol. 2005;16(1):39&#x2013;47. doi:10.1016/j.semcdb.2004.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2004.11.006</ArticleId><ArticleId IdType="pubmed">15659338</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Pal JK. Role of 5&#x2032;- and 3&#x2032;-untranslated regions of mRNAs in human diseases. Biol Cell. 2009;101(5):251&#x2013;262. doi:10.1042/BC20080104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BC20080104</ArticleId><ArticleId IdType="pubmed">19275763</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Schnierle BS. Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development. Pathogens. 2023. Jan 13. 12(1):138. doi:10.3390/pathogens12010138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12010138</ArticleId><ArticleId IdType="pmc">PMC9863218</ArticleId><ArticleId IdType="pubmed">36678486</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen SE, Erasmus JH, Reese VA, Pecor T, Archer J, Kandahar A, Hsu F-C, Nicholes K, Reed SG, Baldwin SL, et al. An RNA-Based vaccine platform for use against Mycobacterium tuberculosis. Vaccines. 2023;11(1):130. doi:10.3390/vaccines11010130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010130</ArticleId><ArticleId IdType="pmc">PMC9862644</ArticleId><ArticleId IdType="pubmed">36679975</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tte B, Liu L, McInerney GM. The enigmatic alphavirus non-structural protein 3 (nsP3) revealing its secrets at last. Viruses. 2018;10(3):105. doi:10.3390/v10030105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10030105</ArticleId><ArticleId IdType="pmc">PMC5869498</ArticleId><ArticleId IdType="pubmed">29495654</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietil&#xe4; MK, Hellstr&#xf6;m K, Ahola T. Alphavirus polymerase and RNA replication. Virus Res. 2017;234:44&#x2013;57. doi:10.1016/j.virusres.2017.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.01.007</ArticleId><ArticleId IdType="pubmed">28104453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fros JJ, Pijlman GP. Alphavirus infection: host cell shut-off and inhibition of antiviral responses. Viruses. 2016;8(6):166. doi:10.3390/v8060166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8060166</ArticleId><ArticleId IdType="pmc">PMC4926186</ArticleId><ArticleId IdType="pubmed">27294951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, Debasitis JC, Maruggi G, Otten GR, Geall AJ, et al. Induction of an IFN-Mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol. 2017;198(10):4012&#x2013;4024. doi:10.4049/jimmunol.1601877.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601877</ArticleId><ArticleId IdType="pmc">PMC5421303</ArticleId><ArticleId IdType="pubmed">28416600</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney AK, McKay PF, Shattock RJ. Structural components for amplification of positive and negative strand VEEV splitzicons. Front Mol Biosci. 2018;5:71. doi:10.3389/fmolb.2018.00071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00071</ArticleId><ArticleId IdType="pmc">PMC6070733</ArticleId><ArticleId IdType="pubmed">30094239</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel). 2021;9(2):97. doi:10.3390/vaccines9020097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020097</ArticleId><ArticleId IdType="pmc">PMC7911542</ArticleId><ArticleId IdType="pubmed">33525396</ArticleId></ArticleIdList></Reference><Reference><Citation>Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, T&#xfc;reci &#xd6;, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 2020;28(1):119&#x2013;128. doi:10.1016/j.ymthe.2019.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.09.009</ArticleId><ArticleId IdType="pmc">PMC6953774</ArticleId><ArticleId IdType="pubmed">31624015</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343&#x2013;353. doi:10.1038/ni.3123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3123</ArticleId><ArticleId IdType="pmc">PMC4507498</ArticleId><ArticleId IdType="pubmed">25789684</ArticleId></ArticleIdList></Reference><Reference><Citation>The Working Group on New TB Vaccines . [accessed 2024 Aug
8]. https://newtbvaccines.org.</Citation></Reference><Reference><Citation>Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science. 1995;268(5209):415&#x2013;417. doi:10.1126/science.7536344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7536344</ArticleId><ArticleId IdType="pubmed">7536344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangus DA, Evans MC, Jacobson A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 2003;4(7):223. doi:10.1186/gb-2003-4-7-223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2003-4-7-223</ArticleId><ArticleId IdType="pmc">PMC193625</ArticleId><ArticleId IdType="pubmed">12844354</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010;11(2):113&#x2013;127. doi:10.1038/nrm2838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2838</ArticleId><ArticleId IdType="pmc">PMC4461372</ArticleId><ArticleId IdType="pubmed">20094052</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkovic S, M&#xfc;ller S. RNA circularization strategies in vivo and in vitro. Nucleic Acids Res. 2015;43(4):2454&#x2013;2465. doi:10.1093/nar/gkv045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv045</ArticleId><ArticleId IdType="pmc">PMC4344496</ArticleId><ArticleId IdType="pubmed">25662225</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdt LM, Kohlmaier A, Teupser D. Circular RNAs as therapeutic agents and targets. Front Physiol. 2018;9:1262. doi:10.3389/fphys.2018.01262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.01262</ArticleId><ArticleId IdType="pmc">PMC6189416</ArticleId><ArticleId IdType="pubmed">30356745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315&#x2013;328. doi:10.1038/cr.2017.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2017.15</ArticleId><ArticleId IdType="pmc">PMC5339834</ArticleId><ArticleId IdType="pubmed">28106072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, Jin Y, Yang Y, Chen L-L, Wang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626&#x2013;641. doi:10.1038/cr.2017.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2017.31</ArticleId><ArticleId IdType="pmc">PMC5520850</ArticleId><ArticleId IdType="pubmed">28281539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Guo H, Wang L, Yang L, Shao Z, Zhang W. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer. Mol Ther Nucleic Acids. 2022;27:947&#x2013;955. doi:10.1016/j.omtn.2022.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.01.013</ArticleId><ArticleId IdType="pmc">PMC8829442</ArticleId><ArticleId IdType="pubmed">35211355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicens Q, Paukstelis PJ, Westhof E, Lambowitz AM, Cech TR. Toward predicting self-splicing and protein-facilitated splicing of group I introns. Rna. 2008;14(10):2013&#x2013;2029. doi:10.1261/rna.1027208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.1027208</ArticleId><ArticleId IdType="pmc">PMC2553746</ArticleId><ArticleId IdType="pubmed">18768647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wei H, Zhang K, Li Z, Wei T, Tang C, Yang Y, Wang Z. A flexible, efficient, and scalable platform to produce circular RNAs as new therapeutics. bioRxiv. 2022;2022:05.31.494115.</Citation></Reference><Reference><Citation>Cheng F, Li J, Hu C, Bai Y, Liu J, Liu D, He Q, Jin Q, Mao Q, Liang Z, et al. Study on the characterization and degradation pattern of circular RNA vaccines using an HPLC method. Chemosensors. 2024;12(7):120. doi:10.3390/chemosensors12070120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/chemosensors12070120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang HJ, Kim YK. Molecular mechanisms of circular RNA translation. Exp Mol Med. 2024. June. 56(6):1272&#x2013;1280. doi:10.1038/s12276-024-01220-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-024-01220-3</ArticleId><ArticleId IdType="pmc">PMC11263353</ArticleId><ArticleId IdType="pubmed">38871818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonez C, Vandenbranden M, Ruysschaert JM. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev. 2012;64(15):1749&#x2013;1758. doi:10.1016/j.addr.2012.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2012.05.009</ArticleId><ArticleId IdType="pubmed">22634161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang W-J, Gao P, Zhou C, Zhang R-R, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271&#x2013;83.e16. doi:10.1016/j.cell.2020.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7377714</ArticleId><ArticleId IdType="pubmed">32795413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102. doi:10.3390/pharmaceutics12020102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12020102</ArticleId><ArticleId IdType="pmc">PMC7076378</ArticleId><ArticleId IdType="pubmed">32013049</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84&#x2013;94. doi:10.1016/j.jconrel.2022.05.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.05.043</ArticleId><ArticleId IdType="pmc">PMC9644292</ArticleId><ArticleId IdType="pubmed">35649485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9(1):2629. doi:10.1038/s41467-018-05096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05096-6</ArticleId><ArticleId IdType="pmc">PMC6035260</ArticleId><ArticleId IdType="pubmed">29980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Liu D, He Q, Liu J, Mao Q, Liang Z. Research progress on circular RNA vaccines. Front Immunol. 2022;13:1091797. doi:10.3389/fimmu.2022.1091797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1091797</ArticleId><ArticleId IdType="pmc">PMC9878156</ArticleId><ArticleId IdType="pubmed">36713460</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728&#x2013;44.e16. doi:10.1016/j.cell.2022.03.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId><ArticleId IdType="pmc">PMC8971115</ArticleId><ArticleId IdType="pubmed">35460644</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, Zeng X, Wang J, Yang B, Zhang Y, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2024;625(7995):593&#x2013;602. doi:10.1038/s41586-023-06834-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06834-7</ArticleId><ArticleId IdType="pubmed">38093017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Ye T, Yang Y, Li E, Zhang K, Wang Y, Chen S, Hu J, Zhang K, Liu F, et al. Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice. Mol Ther. 2024;32(6):1779&#x2013;1789. doi:10.1016/j.ymthe.2024.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2024.04.028</ArticleId><ArticleId IdType="pmc">PMC11184329</ArticleId><ArticleId IdType="pubmed">38659224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949):1465&#x2013;1468. doi:10.1126/science.1690918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1690918</ArticleId><ArticleId IdType="pubmed">1690918</ArticleId></ArticleIdList></Reference><Reference><Citation>Johanning FW, Conry RM, LoBuglio AF, Wright M, Sumerel LA, Pike MJ, Curiel DT. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res. 1995;23(9):1495&#x2013;1501. doi:10.1093/nar/23.9.1495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/23.9.1495</ArticleId><ArticleId IdType="pmc">PMC306888</ArticleId><ArticleId IdType="pubmed">7784202</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggott JM, Sheahan BJ, Soden DM, O&#x2019;Sullivan GC, Atkins GJ. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol Med Rep. 2009;2(5):753&#x2013;756. doi:10.3892/mmr_00000168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr_00000168</ArticleId><ArticleId IdType="pubmed">21475897</ArticleId></ArticleIdList></Reference><Reference><Citation>Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA. 2012;109(36):14604&#x2013;14609. doi:10.1073/pnas.1209367109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1209367109</ArticleId><ArticleId IdType="pmc">PMC3437863</ArticleId><ArticleId IdType="pubmed">22908294</ArticleId></ArticleIdList></Reference><Reference><Citation>Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55(7):1397&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">7882341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay KE, Bhosle SM, Zurla C, Beyersdorf J, Rogers KA, Vanover D, Xiao P, Ara&#xed;nga M, Shirreff LM, Pitard B, et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET&#x2013;CT and near-infrared imaging. Nat Biomed Eng. 2019;3(5):371&#x2013;380. doi:10.1038/s41551-019-0378-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-019-0378-3</ArticleId><ArticleId IdType="pubmed">30936432</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines &#x2014; a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261&#x2013;279. doi:10.1038/nrd.2017.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511&#x2013;1520. doi:10.1016/S0140-6736(17)31665-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31665-3</ArticleId><ArticleId IdType="pubmed">28754494</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney AK, McKay PF, Ibarzo Yus B, Hunter JE, Dex EA, Shattock RJ. The skin you are In: design-of-experiments optimization of lipid nanoparticle self-amplifying RNA formulations in human skin explants. ACS Nano. 2019. May 28;13(5):5920&#x2013;5930. doi:10.1021/acsnano.9b01774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.9b01774</ArticleId><ArticleId IdType="pmc">PMC7007275</ArticleId><ArticleId IdType="pubmed">31046232</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22(12):2118&#x2013;2129. doi:10.1038/mt.2014.133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.133</ArticleId><ArticleId IdType="pmc">PMC4429691</ArticleId><ArticleId IdType="pubmed">25027661</ArticleId></ArticleIdList></Reference><Reference><Citation>Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25(2):152&#x2013;159. doi:10.1016/j.smim.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2013.05.001</ArticleId><ArticleId IdType="pubmed">23735226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs AL, Neu A, Sprangers R. A general method for rapid and cost-efficient large-scale production of 5&#x2032; capped RNA. Rna. 2016;22(9):1454&#x2013;1466. doi:10.1261/rna.056614.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.056614.116</ArticleId><ArticleId IdType="pmc">PMC4986899</ArticleId><ArticleId IdType="pubmed">27368341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wochner A, Roos T, Ketterer T, editors. Methods and means for enhancing RNA production. Application Number: 20210040526 17/071279 Document ID: / Family ID: 1000005170142. 2021. February 11.</Citation></Reference><Reference><Citation>Pascolo S. The messenger&#x2019;s great message for vaccination. Expert Rev Vaccines. 2015;14(2):153&#x2013;156. doi:10.1586/14760584.2015.1000871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.1000871</ArticleId><ArticleId IdType="pubmed">25586101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, Puglisi JD. Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides. Rna. 2004;10(5):889&#x2013;893. doi:10.1261/rna.5264804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.5264804</ArticleId><ArticleId IdType="pmc">PMC1370578</ArticleId><ArticleId IdType="pubmed">15100443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther. 2004;4(8):1285&#x2013;1294. doi:10.1517/14712598.4.8.1285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.4.8.1285</ArticleId><ArticleId IdType="pubmed">15268662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim I, McKenna SA, Viani Puglisi E, Puglisi JD. Rapid purification of RNAs using fast performance liquid chromatography (FPLC). Rna. 2007;13(2):289&#x2013;294. doi:10.1261/rna.342607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.342607</ArticleId><ArticleId IdType="pmc">PMC1781364</ArticleId><ArticleId IdType="pubmed">17179067</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna SA, Kim I, Puglisi EV, Lindhout DA, Aitken CE, Marshall RA, Puglisi JD. Purification and characterization of transcribed RNAs using gel filtration chromatography. Nat Protoc. 2007;2(12):3270&#x2013;3277. doi:10.1038/nprot.2007.480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.480</ArticleId><ArticleId IdType="pubmed">18079727</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007;14(15):1175&#x2013;1180. doi:10.1038/sj.gt.3302964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302964</ArticleId><ArticleId IdType="pubmed">17476302</ArticleId></ArticleIdList></Reference><Reference><Citation>Karik&#xf3; K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. doi:10.1093/nar/gkr695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr695</ArticleId><ArticleId IdType="pmc">PMC3241667</ArticleId><ArticleId IdType="pubmed">21890902</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman D, Pardi N, Muramatsu H, Karik&#xf3; K. HPLC purification of in vitro transcribed long RNA. Methods Mol Biol. 2013;969:43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23296926</ArticleId></ArticleIdList></Reference><Reference><Citation>Easton LE, Shibata Y, Lukavsky PJ. Rapid, nondenaturing RNA purification using weak anion-exchange fast performance liquid chromatography. Rna. 2010;16(3):647&#x2013;653. doi:10.1261/rna.1862210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.1862210</ArticleId><ArticleId IdType="pmc">PMC2822929</ArticleId><ArticleId IdType="pubmed">20100812</ArticleId></ArticleIdList></Reference><Reference><Citation>Technical guidelines for pharmaceutical research of novel coronavirus preventive vaccine (Draft edition). Beijing, China: Center for Drug Evaluation of China; 2022.</Citation></Reference><Reference><Citation>Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations. Geneva, Switzerland: WHO; 2021.</Citation></Reference><Reference><Citation>ICH . Q8&#xff08;R2&#xff09;pharmaceutical development. 2009.</Citation></Reference><Reference><Citation>Technical guidelines for pharmaceutical research and evaluation of in vitro gene modification systems (Draft edition). Beijing, China: Center for Drug Evaluation of China; 2022.</Citation></Reference><Reference><Citation>WHO: Situational assessment checklist to guide . Geneva, Switzerland: World Health Organization; 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40006663</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines13020116</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">An assay for protein content is essential but insufficient for quality control of acellular pertussis vaccines, which might consist of up to five components, each needing individual quantification. Generally, purified pertussis antigens such as pertussis toxin (PTx), filamentous haemagglutinin (FHA), and pertactin (PRN) should be detoxified or stabilized chemically before being formulated into vaccine bulk. The use of chemical agents like formaldehyde and glutaraldehyde can alter the immunological reactivity of these antigens, rendering direct assays by methods such as ELISA ineffective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, a simple method based on single radial diffusion (SRD) using low concentrations of polyclonal antisera against PT toxoid (PTd), FHA, and PRN was developed. By adding a detergent, diffusible subunits are produced regardless of the original physical state of the antigens, making it suitable for quantifying these antigens after chemical treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The assay has shown good specificity, accuracy, and precision. Furthermore, it can differentiate between preparations with the same protein concentration but different antigenic contents. A significant positive correlation between the antigen content and the in vivo immunogenicity has also been demonstrated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An assay for quality control and consistency monitoring of combined vaccines containing acellular pertussis antigen components has been established.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chongyang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xinshuo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wenming</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-8395-3496</Identifier><AffiliationInfo><Affiliation>Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuntao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China National Biotec Group Co., Ltd., Beijing 100024, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KTZC1200006B</GrantID><Agency>China National Biotech Group Co.,LTD</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acellular pertussis vaccine components</Keyword><Keyword MajorTopicYN="N">analytical methods validation</Keyword><Keyword MajorTopicYN="N">antigen content quantification</Keyword><Keyword MajorTopicYN="N">quality control</Keyword><Keyword MajorTopicYN="N">single radial immunodiffusion</Keyword></KeywordList><CoiStatement>The authors Chongyang Wu, Xi Wang, Yu Zhou, Xinshuo Zhu, Yu Ma, and Wenming Wei are employed by Beijing Institute of Biological Products Co., Ltd. The author Yuntao Zhang is employed by China National Biotech Group Co., Ltd (CNBG). Additionally, Yuntao Zhang has received funding support from CNBG.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>26</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40006663</ArticleId><ArticleId IdType="pmc">PMC11860560</ArticleId><ArticleId IdType="doi">10.3390/vaccines13020116</ArticleId><ArticleId IdType="pii">vaccines13020116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Locht C. Live pertussis vaccines: Will they protect against carriage and spread of pertussis? Clin. Microbiol. Infect. 2016;22:S96&#x2013;S102. doi: 10.1016/j.cmi.2016.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.05.029</ArticleId><ArticleId IdType="pubmed">28341014</ArticleId></ArticleIdList></Reference><Reference><Citation>Smout E., Mellon D., Rae M. Whooping cough rises sharply in UK and Europe. BMJ. 2024;385:q736. doi: 10.1136/bmj.q736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.q736</ArticleId><ArticleId IdType="pubmed">38565246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung K.H.T., Duclos P., Nelson E.A.S., Hutubessy R.C.W. An update of the global burden of pertussis in children younger than 5 years: A modelling study. Lancet Infect. Dis. 2017;17:974&#x2013;980. doi: 10.1016/S1473-3099(17)30390-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30390-0</ArticleId><ArticleId IdType="pubmed">28623146</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N.P., Bartlett J., Fireman B., Rowhani-Rahbar A., Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131:e1716&#x2013;e1722. doi: 10.1542/peds.2012-3836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2012-3836</ArticleId><ArticleId IdType="pubmed">23690518</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfel J.M., Edwards K.M. Pertussis vaccines and the challenge of inducing durable immunity. Curr. Opin. Immunol. 2015;35:48&#x2013;54. doi: 10.1016/j.coi.2015.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2015.05.008</ArticleId><ArticleId IdType="pubmed">26091979</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med. 2012;367:1012&#x2013;1019. doi: 10.1056/NEJMoa1200850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1200850</ArticleId><ArticleId IdType="pubmed">22970945</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N.P., Bartlett J., Fireman B., Baxter R. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016;137:e20153326. doi: 10.1542/peds.2015-3326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2015-3326</ArticleId><ArticleId IdType="pubmed">26908667</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S., Orenstein W., Offit P.A. Plotkin&#x2019;s Vaccines. Elsevier; Amsterdam, The Netherlands: 2018.</Citation></Reference><Reference><Citation>Yuen C.-T., Asokanathan C., Cook S., Lin N., Xing D. Effect of different detoxification procedures on the residual pertussis toxin activities in vaccines. Vaccine. 2016;34:2129&#x2013;2134. doi: 10.1016/j.vaccine.2016.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.03.007</ArticleId><ArticleId IdType="pubmed">26973066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler S., Xing D.K.-L., Bolgiano B., Yuen C.-T., Corbel M.J. Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: Effects on toxicity and immunogenicity. Vaccine. 2003;21:2329&#x2013;2337. doi: 10.1016/S0264-410X(03)00104-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(03)00104-X</ArticleId><ArticleId IdType="pubmed">12744863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland J.N., Chang C., Yoder S.M., Rock M.T., Maynard J.A. Antibodies Recognizing Protective Pertussis Toxin Epitopes Are Preferentially Elicited by Natural Infection versus Acellular Immunization. Clin. Vaccine Immunol. 2011;18:954&#x2013;962. doi: 10.1128/CVI.00561-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00561-10</ArticleId><ArticleId IdType="pmc">PMC3122608</ArticleId><ArticleId IdType="pubmed">21508166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibsen P.H. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine. 1996;14:359&#x2013;368. doi: 10.1016/0264-410X(95)00230-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)00230-X</ArticleId><ArticleId IdType="pubmed">8735545</ArticleId></ArticleIdList></Reference><Reference><Citation>Recommendations to Assure the Quality, Safety and Efficacy of Acellular Pertussis Vaccines, Annex 4, TRS No 979. World Health Organization; Geneva, Switzerland: 2014.</Citation></Reference><Reference><Citation>Schild G.C., Wood J.M., Newman R.W. A single radial immunodiffusion technique for the assay of influenza hae-mag-glutinin antigen: Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull WHO. 1975;52:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366365</ArticleId><ArticleId IdType="pubmed">816480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood J., Schild G., Newman R., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 1977;5:237&#x2013;247. doi: 10.1016/S0092-1157(77)80008-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-1157(77)80008-5</ArticleId><ArticleId IdType="pubmed">408355</ArticleId></ArticleIdList></Reference><Reference><Citation>Winsnes R., Sesardic D., Daas A., Terao E., Behr-Gross M.E. Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines. Pharmeur. Bio Sci. Notes. 2009;1:27&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20144450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Guo Y., Dong Y., Liu Y., Zhao Y., Yu S., Li S., Wu C., Yang B., Li W., et al. Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models. Hum. Vaccines Immunother. 2022;18:2160158. doi: 10.1080/21645515.2022.2160158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2160158</ArticleId><ArticleId IdType="pmc">PMC9891680</ArticleId><ArticleId IdType="pubmed">36576263</ArticleId></ArticleIdList></Reference><Reference><Citation>de Cell&#xe8;s M.D., Rohani P. Pertussis vaccines, epidemiology and evolution. Nat. Rev. Microbiol. 2024;22:722&#x2013;735. doi: 10.1038/s41579-024-01064-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-024-01064-8</ArticleId><ArticleId IdType="pubmed">38907021</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S., Stefanelli P., Fry N.K., Fedele G., He Q., Paterson P., Tan T., Knuf M., Rodrigo C., Olivier C.W., et al. Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Front. Immunol. 2019;10:1344. doi: 10.3389/fimmu.2019.01344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01344</ArticleId><ArticleId IdType="pmc">PMC6616129</ArticleId><ArticleId IdType="pubmed">31333640</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfel J.M., Zimmerman L.I., Merkel T.J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl. Acad. Sci. USA. 2014;111:787&#x2013;792. doi: 10.1073/pnas.1314688110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1314688110</ArticleId><ArticleId IdType="pmc">PMC3896208</ArticleId><ArticleId IdType="pubmed">24277828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland J.N., Maynard J.A. Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7. Biochemistry. 2009;48:11982&#x2013;11993. doi: 10.1021/bi901532z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi901532z</ArticleId><ArticleId IdType="pmc">PMC2794999</ArticleId><ArticleId IdType="pubmed">19899804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H., Sato Y., Ohishi I. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect. Immun. 1991;59:3832&#x2013;3835. doi: 10.1128/iai.59.10.3832-3835.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.59.10.3832-3835.1991</ArticleId><ArticleId IdType="pmc">PMC258960</ArticleId><ArticleId IdType="pubmed">1894382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing D.K., Canthaboo C., Corbel M.J., Schild G.C. Single radial immunodiffusion as a method for the assay of the acellular pertussis vaccine components, pertussis toxoid, filamentous haemagglutinin and pertactin. Biologicals. 1998;26:217&#x2013;224. doi: 10.1006/biol.1998.0145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/biol.1998.0145</ArticleId><ArticleId IdType="pubmed">10208723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39999432</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle><i>Streptococcus pneumoniae</i> serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?</ArticleTitle><Pagination><StartPage>2461844</StartPage><MedlinePgn>2461844</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2461844</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2025.2461844</ELocationID><Abstract><AbstractText><i>S. pneumoniae</i> serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhawale</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Global Business Development, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sanket</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Strategic Medical Affairs, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Kaushal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Strategic Projects, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikriwal</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research and Development, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Varnik</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Research and Development, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagawati</LastName><ForeName>Arnabjyoti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research and Development, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhar</LastName><ForeName>Sakshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research and Development, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Pratiksha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Regulatory Affairs, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Syed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Business Development and Strategy, Techinvention Lifecare Private Limited, Mumbai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="Y">Pneumococcal Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="Y">Streptococcus pneumoniae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="Y">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095143" MajorTopicYN="N" Type="Geographic">Asia, Southern</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">South Asia</Keyword><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword><Keyword MajorTopicYN="N">antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">invasive pneumococcal disease</Keyword><Keyword MajorTopicYN="N">pneumococcal vaccines</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>25</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>25</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>25</Day><Hour>16</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39999432</ArticleId><ArticleId IdType="pmc">PMC11864319</ArticleId><ArticleId IdType="doi">10.1080/21645515.2025.2461844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leonard A, M&#xf6;hlis K, Schl&#xfc;ter R, Taylor E, Lalk M, Methling K.. Exploring metabolic adaptation of Streptococcus pneumoniae to antibiotics. J Antibiot (Tokyo). 2020;73(7):441&#x2013;25. doi:10.1038/s41429-020-0296-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41429-020-0296-3</ArticleId><ArticleId IdType="pmc">PMC7292801</ArticleId><ArticleId IdType="pubmed">32210362</ArticleId></ArticleIdList></Reference><Reference><Citation>Plainvert C, Varon E, Viriot D, Kempf M, Plainvert C, Alauzet C, Auger G, Batah J, Brieu N, Cattoir V, et al. Invasive pneumococcal infections in France: changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network. Infect Dis Now. 2023;53(1):104632. doi:10.1016/j.idnow.2022.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2022.11.001</ArticleId><ArticleId IdType="pubmed">36375765</ArticleId></ArticleIdList></Reference><Reference><Citation>Deloria Knoll M, Bennett J, Garcia Quesada M, Kagucia E, Peterson M, Feikin D, Cohen A, Hetrich M, Yang Y, Sinkevitch J, et al. Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project. Microorganisms. 2021;9(4):742. doi:10.3390/microorganisms9040742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9040742</ArticleId><ArticleId IdType="pmc">PMC8066045</ArticleId><ArticleId IdType="pubmed">33918127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui YA, Patel H, Wm O, Li S, Saddier P. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccines Immunother. 2017;13(6):1229&#x2013;1241. doi:10.1080/21645515.2016.1277300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1277300</ArticleId><ArticleId IdType="pmc">PMC5489298</ArticleId><ArticleId IdType="pubmed">28125317</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira R, Kossyvaki V, Galvez P, M&#xe9;ndez C. Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review. Microorganisms. 2023;11(6):1376. doi:10.3390/microorganisms11061376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11061376</ArticleId><ArticleId IdType="pmc">PMC10303156</ArticleId><ArticleId IdType="pubmed">37374878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Chung DR, Song J-H, Baek JY, Thamlikitkul V, Wang H, Carlos C, Ahmad N, Arushothy R, Tan SH, et al. Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes. Vaccine. 2020;38(38):6065&#x2013;6073. doi:10.1016/j.vaccine.2019.09.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.065</ArticleId><ArticleId IdType="pubmed">31590932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumococcal Disease Surveillance and Trends. [accessed 2024 Jul
3]. https://www.cdc.gov/pneumococcal/php/surveillance/index.html.</Citation></Reference><Reference><Citation>Cill&#xf3;niz C, Garcia-Vidal C, Ceccato A, Torres A. Antimicrobial resistance among Streptococcus pneumoniae. In: Fong I; Shlaes DDrlica K, editors. Antimicrobial Resistance in the 21st Century. Cham: Springer International Publishing; 2018. p. 13&#x2013;38.</Citation></Reference><Reference><Citation>Li S, Liang H, Zhao S-H, Yang X-Y, Guo Z. Recent progress in pneumococcal protein vaccines. Front Immunol. 2023;14:1278346. doi:10.3389/fimmu.2023.1278346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1278346</ArticleId><ArticleId IdType="pmc">PMC10560988</ArticleId><ArticleId IdType="pubmed">37818378</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva PH, V&#xe1;zquez Y, Campusano C, Retamal-D&#xed;az A, Lay MK, Mu&#xf1;oz CA, Gonz&#xe1;lez PA, Kalergis AM, Bueno SM. Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection. Front Cell Infect Microbiol. 2022;12:949469. doi:10.3389/fcimb.2022.949469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.949469</ArticleId><ArticleId IdType="pmc">PMC9548657</ArticleId><ArticleId IdType="pubmed">36225231</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355&#x2013;367. doi:10.1038/s41579-018-0001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0001-8</ArticleId><ArticleId IdType="pmc">PMC5949087</ArticleId><ArticleId IdType="pubmed">29599457</ArticleId></ArticleIdList></Reference><Reference><Citation>Micoli F, Romano MR, Carboni F, Adamo R, Berti F. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023;40(2):135&#x2013;148. doi:10.1007/s10719-023-10100-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10719-023-10100-3</ArticleId><ArticleId IdType="pmc">PMC10027807</ArticleId><ArticleId IdType="pubmed">36652051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers GL, Whitney CG, Klugman KP. Triumph of pneumococcal conjugate vaccines: overcoming a common foe. J Infect Dis. 2021;224(Supplement_4):S352&#x2013;9. doi:10.1093/infdis/jiaa535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa535</ArticleId><ArticleId IdType="pmc">PMC8482025</ArticleId><ArticleId IdType="pubmed">34590137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartasasmita CB, Rezeki Hadinegoro S, Kurniati N, Triasih R, Halim C, Gamil G. Triumph of pneumococcal conjugate vaccines: overcoming a common foe. Infect Dis Ther. 2020;9(4):723&#x2013;736. doi:10.1007/s40121-020-00330-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00330-5</ArticleId><ArticleId IdType="pmc">PMC7680475</ArticleId><ArticleId IdType="pubmed">32864725</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf8;chen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10(1):18977. doi:10.1038/s41598-020-75691-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75691-5</ArticleId><ArticleId IdType="pmc">PMC7643077</ArticleId><ArticleId IdType="pubmed">33149149</ArticleId></ArticleIdList></Reference><Reference><Citation>Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013;28(1):4. doi:10.3346/jkms.2013.28.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2013.28.1.4</ArticleId><ArticleId IdType="pmc">PMC3546102</ArticleId><ArticleId IdType="pubmed">23341706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattal C, Goel N, Byotra SP. pneumococcal serotypes in adults &#x2265;50 years of age. Indian J Med Microbiol. 2017;35(1):95&#x2013;100. doi:10.4103/ijmm.IJMM_16_132.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_16_132</ArticleId><ArticleId IdType="pubmed">28303826</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Q, Shi W, Yu D, Yao K. Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines. Hum Vaccines Immunother. 2024;17(12):5628&#x2013;5637. doi:10.1080/21645515.2021.1985353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1985353</ArticleId><ArticleId IdType="pmc">PMC8903918</ArticleId><ArticleId IdType="pubmed">34726580</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert R-R, Jodar L, Gessner BD. Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023;76(3):e1062&#x2013;70. doi:10.1093/cid/ciac475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac475</ArticleId><ArticleId IdType="pmc">PMC9907512</ArticleId><ArticleId IdType="pubmed">35789262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister AJJ, Le CF, Cheah ESG, Desa MNM, Cleary DW, Clarke SC. Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis. Pneumonia. 2021;13(1):9. doi:10.1186/s41479-021-00086-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41479-021-00086-7</ArticleId><ArticleId IdType="pmc">PMC8147341</ArticleId><ArticleId IdType="pubmed">34030731</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Beleidy A, El-Saied M, Fasseeh N, El Saie RZ, Haridy H. A Systematic review of pneumococcal carriage, disease, antimicrobial resistance, and vaccination in Egyptian children aged 18 years and younger. Infect Dis Ther. 2021;10(4):2119&#x2013;2155. doi:10.1007/s40121-021-00523-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00523-6</ArticleId><ArticleId IdType="pmc">PMC8408359</ArticleId><ArticleId IdType="pubmed">34468962</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebaw T-A, Aregay WK, Ashami MT. Risk factors for childhood pneumonia at Adama Hospital Medical College, Adama, Ethiopia: a case-control study. Pneumonia Nathan Qld. 2022;14(1):9. doi:10.1186/s41479-022-00102-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41479-022-00102-4</ArticleId><ArticleId IdType="pmc">PMC9721024</ArticleId><ArticleId IdType="pubmed">36471452</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal N, Singh M, Thumburu KK, Bharti B, Agarwal A, Kumar A, Kaur H, Chadha N. Burden of invasive pneumococcal disease in children aged 1 month to 12 years living in South Asia: A Systematic Review. PLOS ONE. 2014;9(5):e96282. doi:10.1371/journal.pone.0096282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096282</ArticleId><ArticleId IdType="pmc">PMC4010478</ArticleId><ArticleId IdType="pubmed">24798424</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman MD, Perdrizet J, Grant L, Hayford K, Singh S, Saharia P, Horn EK, Farkouh RA. Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age. Infect Dis Ther. 2021;10(4):2701&#x2013;2720. doi:10.1007/s40121-021-00544-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00544-1</ArticleId><ArticleId IdType="pmc">PMC8503717</ArticleId><ArticleId IdType="pubmed">34633639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J, Lai JY, Von Mollendorf C, Blyth C, Dance DAB, Datta S, Dunne EM, Ford R, Fox K, Hinds J, et al. Determining the pneumococcal conjugate vaccine coverage required for indirect protection within Asia and the Pacific: a prospective observational study. Lancet Glob Health. 2019;7:S15. doi:10.1016/S2214-109X(19)30100-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30100-7</ArticleId></ArticleIdList></Reference><Reference><Citation>View-hub Report: Global Vaccine Introduction and Implementation. [accessed 2025 Jan
18]. https://view-hub.org/sites/default/files/2024-09/VIEW-hub_Report_August2024.pdf.</Citation></Reference><Reference><Citation>Syeed MS, Ghule P, Le LM, Veettil SK, Horn EK, Perdrizet J, Wasserman M, Thakkinstian A, Chaiyakunapruk N. Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies. Value Health. 2023;26(4):598&#x2013;611. doi:10.1016/j.jval.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2022.10.006</ArticleId><ArticleId IdType="pubmed">36328324</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J, Nguyen CD, Dunne EM, Kim Mulholland E, Mungun T, Pomat WS, Rafai E, Satzke C, Weinberger DM, Russell FM. Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. Vaccine. 2019;37(43):6299&#x2013;6309. doi:10.1016/j.vaccine.2019.08.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.073</ArticleId><ArticleId IdType="pubmed">31500968</ArticleId></ArticleIdList></Reference><Reference><Citation>Masomian M, Ahmad Z, Ti Gew L, Poh CL. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines. 2020;8(1):132. doi:10.3390/vaccines8010132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8010132</ArticleId><ArticleId IdType="pmc">PMC7157650</ArticleId><ArticleId IdType="pubmed">32192117</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Tonder AJ, Gladstone RA, Lo SW, Nahm MH, du Plessis M, Cornick J, Kwambana-Adams B, Madhi SA, Hawkins PA, Benisty R, et al. Putative novel cps loci in a large global collection of pneumococci. Microb Genomics. 2019;5(7). doi:10.1099/mgen.0.000274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000274</ArticleId><ArticleId IdType="pmc">PMC6700660</ArticleId><ArticleId IdType="pubmed">31184299</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzanal A, Vicente D, Alonso M, Azkue N, Ercibengoa M, Marim&#xf3;n JM. Impact of the progressive uptake of pneumococcal conjugate vaccines on the epidemiology and antimicrobial resistance of invasive pneumococcal disease in Gipuzkoa, northern Spain, 1998&#x2013;2022. Front Public Health. 2023;11:1238502. doi:10.3389/fpubh.2023.1238502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1238502</ArticleId><ArticleId IdType="pmc">PMC10501722</ArticleId><ArticleId IdType="pubmed">37719737</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger DM, Warren JL, Dalby T, Shapiro ED, Valentiner-Branth P, Slotved H-C, Harboe ZB. Differences in the impact of pneumococcal serotype replacement in individuals with and pneumococcal serotype replacement in individuals with and without underlying medical conditions.Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(1):100&#x2013;106. doi:10.1093/cid/ciy875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy875</ArticleId><ArticleId IdType="pmc">PMC6579958</ArticleId><ArticleId IdType="pubmed">30321313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. Lancet Infect Dis. 2019;19(6):e213&#x2013;20. doi:10.1016/S1473-3099(18)30660-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30660-1</ArticleId><ArticleId IdType="pubmed">30709666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambugu P, Shah M-M, Nguyen H-A, Le K-A, Le H-H, Vo H-M, Toizumi M, Bui M-X, Dang D-A, Yoshida L-M. Molecular epidemiology of streptococcus pneumoniae detected in hospitalized pediatric acute respiratory infection cases in Central Vietnam. Pathogens. 2023;12(7):943. doi:10.3390/pathogens12070943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12070943</ArticleId><ArticleId IdType="pmc">PMC10385502</ArticleId><ArticleId IdType="pubmed">37513790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbar H, Mahraoui C, Bast&#xec;as Garci&#xe0; M, Jroundi I. Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: let&#x2019;s recap! Vaccine X. 2022;11:100170. doi:10.1016/j.jvacx.2022.100170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2022.100170</ArticleId><ArticleId IdType="pmc">PMC9127579</ArticleId><ArticleId IdType="pubmed">35620569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo SW, Gladstone RA, Van Tonder AJ, Lees JA, du Plessis M, Benisty R, Givon-Lavi N, Hawkins PA, Cornick JE, Kwambana-Adams B, et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019;19(7):759&#x2013;769. doi:10.1016/S1473-3099(19)30297-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30297-X</ArticleId><ArticleId IdType="pmc">PMC7641901</ArticleId><ArticleId IdType="pubmed">31196809</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsells E, Guillot L, Nair H, Kyaw MH, Borrow R. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-pcv era: a systematic review and meta-analysis. PLOS ONE. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177113</ArticleId><ArticleId IdType="pmc">PMC5423631</ArticleId><ArticleId IdType="pubmed">28486544</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott NR, Mann B, Tuomanen EI, Orihuela CJ. Multi-valent protein hybrid pneumococcal vaccines: a strategy for the next. Vaccines. 2021;9(3):209. doi:10.3390/vaccines9030209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030209</ArticleId><ArticleId IdType="pmc">PMC8002124</ArticleId><ArticleId IdType="pubmed">33801372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabihullah R, Dhoubhadel BG, Rauf FA, Shafiq SA, Suzuki M, Watanabe K, Yoshida LM, Yasunami M, Zabihullah S, Parry CM, et al. Risk for death among children with pneumonia, Afghanistan. Emerg Infect Dis. 2017;23(8):1404&#x2013;1408. doi:10.3201/eid2308.151550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2308.151550</ArticleId><ArticleId IdType="pmc">PMC5547795</ArticleId><ArticleId IdType="pubmed">28726625</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichichero M, Malley R, Kaur R, Zagursky R, Anderson P. Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines. Expert Rev Vaccines. 2023;22(1):118&#x2013;138. doi:10.1080/14760584.2023.2162506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2162506</ArticleId><ArticleId IdType="pubmed">36565291</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaker R, Saha S, Hanif M, Ahmed A, Saha S, Hasanuzzaman M, Khondakar T, Islam M, Baqui AH, Santosham M, et al. Invasive pneumococcal infections in children with nephrotic syndrome in Bangladesh. Pediatr Infect Dis J. 2019;38(8):798&#x2013;803. doi:10.1097/INF.0000000000002386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002386</ArticleId><ArticleId IdType="pubmed">31220048</ArticleId></ArticleIdList></Reference><Reference><Citation>Baqui AH, McCollum ED, Mahmud A, Roy A, Chowdhury NH, Rafiqullah I, Rizvi SJR, Begum N, Mitra DK, Khanam R, et al. Population-based incidence and serotype distribution of invasive pneumococcal disease prior to introduction of conjugate pneumococcal vaccine in Bangladesh. PLOS ONE. 2020;15(2):e0228799. doi:10.1371/journal.pone.0228799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228799</ArticleId><ArticleId IdType="pmc">PMC7018078</ArticleId><ArticleId IdType="pubmed">32053640</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha SK, Hossain B, Islam M, Hasanuzzaman M, Saha S, Hasan M, Darmstadt GL, Chowdury M, Arifeen SE, Baqui AH, et al. Epidemiology of invasive pneumococcal disease in Bangladeshi children before introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2016;35(6):655&#x2013;661. doi:10.1097/INF.0000000000001037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001037</ArticleId><ArticleId IdType="pubmed">26658530</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddik AB, Tanvir NA, Bhuyan GS, Alam MS, Islam Z, Bulbul MRH, Moniruzzaman M, Halder CE, Rahman T, Endtz H, et al. Bacterial and viral etiology of acute respiratory infection among the Forcibly Displaced Myanmar Nationals (FDMNs) in fragile settings in Cox&#x2019;s Bazar- a prospective case-control study. PloS Negl Trop Dis. 2023;17(4):e0011189. doi:10.1371/journal.pntd.0011189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011189</ArticleId><ArticleId IdType="pmc">PMC10085056</ArticleId><ArticleId IdType="pubmed">37036845</ArticleId></ArticleIdList></Reference><Reference><Citation>Naziat H, Saha S, Islam M, Saha S, Uddin MJ, Hussain M, Luby SP, Darmstadt GL, Whitney CG, Gessner BD, et al. Epidemiology of Otitis media with Otorrhea among Bangladeshi children: Baseline study for future assessment of pneumococcal conjugate vaccine impact. Pediatr Infect Dis J. 2018;37(7):715&#x2013;721. doi:10.1097/INF.0000000000002077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002077</ArticleId><ArticleId IdType="pubmed">29634626</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte A, Dayma G, Naziat H, Williams L, Sanghavi S, Uddin J, Kawade A, Islam M, Kar S, Li Y, et al. Nasopharyngeal pneumococcal carriage in South Asian infants: results of observational cohort studies in vaccinated and unvaccinated populations. J Glob Health. 2021;11:04054. doi:10.7189/jogh.11.04054.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.11.04054</ArticleId><ArticleId IdType="pmc">PMC8442578</ArticleId><ArticleId IdType="pubmed">34552723</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidanapathirana G, Angulmaduwa S, Munasinghe T, Ekanayake A, Kudagammana T, Dissanayaka N, Liyanapathirana V. Pneumococcal colonization among healthy and hospitalized vaccine-naive Sri Lankan children. Vaccine. 2020;38(46):7308&#x2013;7315. doi:10.1016/j.vaccine.2020.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.09.040</ArticleId><ArticleId IdType="pubmed">32981783</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidanapathirana G, Angulmaduwa ALSK, Munasinghe TS, Ekanayake EWMA, Harasgama P, Kudagammana ST, Dissanayake BN, Liyanapathirana LVC. Comparison of pneumococcal colonization density among healthy children and children with respiratory symptoms using real time PCR (RT-PCR). BMC Microbiol. 2022;22(1):31. doi:10.1186/s12866-022-02442-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-022-02442-z</ArticleId><ArticleId IdType="pmc">PMC8772066</ArticleId><ArticleId IdType="pubmed">35057744</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter MJ, Gurung M, Pokhrel B, Bijukchhe SM, Karmacharya S, Khadka B, Maharjan A, Bhattarai S, Shrestha S, Khadka B, et al. Childhood invasive bacterial disease in Kathmandu, Nepal (2005&#x2013;2013). Pediatr Infect Dis J. 2022;41(3):192&#x2013;198. doi:10.1097/INF.0000000000003421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003421</ArticleId><ArticleId IdType="pubmed">34955523</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha S, Gurung M, Amatya P, Bijukchhe S, Bose AS, Carter MJ, Gautam MC, Gurung S, Hinds J, Kandasamy R, et al. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study. Lancet Glob Health. 2022;10(10):e1494&#x2013;504. doi:10.1016/S2214-109X(22)00281-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00281-9</ArticleId><ArticleId IdType="pubmed">36113533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy R, Gurung M, Thapa A, Ndimah S, Adhikari N, Murdoch DR, Kelly DF, Waldron DE, Gould KA, Thorson S, et al. Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine na&#xef;ve Nepalese children, assessed using molecular serotyping. PLOS ONE. 2015;10(2):e0114286. doi:10.1371/journal.pone.0114286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114286</ArticleId><ArticleId IdType="pmc">PMC4313945</ArticleId><ArticleId IdType="pubmed">25643355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandasamy R, Lo S, Gurung M, Carter MJ, Gladstone R, Lees J, Shrestha S, Thorson S, Bijukchhe S, Gautam MC, et al. Effect of childhood vaccination and antibiotic use on pneumococcal populations and genome-wide associations with disease among children in Nepal: an observational study. The Lancet Microbe. 2022;3(7):e503&#x2013;11. doi:10.1016/S2666-5247(22)00066-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00066-0</ArticleId><ArticleId IdType="pmc">PMC9242864</ArticleId><ArticleId IdType="pubmed">35779566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jullien S, Sharma R, Lhamu Mynak M, Henares D, Mu&#xf1;oz-Almagro C, Bassat Q. Pneumococcal nasopharyngeal carriage among Bhutanese children hospitalized with clinical pneumonia: serotypes and viral co-infection. BMC Infect Dis. 2020;20(1):940. doi:10.1186/s12879-020-05674-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05674-4</ArticleId><ArticleId IdType="pmc">PMC7725031</ArticleId><ArticleId IdType="pubmed">33297987</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid S, Nisar MI, Jehan F, Ahmed S, Kabir F, Hotwani A, Muneer S, Qazi MF, Muhammad S, Ali A, et al. Co-carriage of Staphylococcus aureus and Streptococcus pneumoniae among children younger than 2 years of age in a rural population in Pakistan. Clin Epidemiol Glob Health. 2023;21:101293. doi:10.1016/j.cegh.2023.101293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2023.101293</ArticleId><ArticleId IdType="pmc">PMC10276771</ArticleId><ArticleId IdType="pubmed">37337613</ArticleId></ArticleIdList></Reference><Reference><Citation>Riaz A, Mohiuddin S, Husain S, Yousafzai MT, Sajid M, Kabir F, Rehman NU, Mirza W, Salam B, Nadeem N, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan. Int J Infect Dis. 2019;80:28&#x2013;33. doi:10.1016/j.ijid.2018.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.12.007</ArticleId><ArticleId IdType="pubmed">30576865</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisar MI, Nayani K, Akhund T, Riaz A, Irfan O, Shakoor S, Muneer S, Muslim S, Hotwani A, Kabir F, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in children under 5 years of age before introduction of pneumococcal vaccine (PCV10) in urban and rural districts in Pakistan. BMC Infect Dis. 2018;18(1):672. doi:10.1186/s12879-018-3608-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3608-5</ArticleId><ArticleId IdType="pmc">PMC6299586</ArticleId><ArticleId IdType="pubmed">30563483</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F, Khan MA, Ahmed N, Bashir H, Taahir S, Zafar AU. Molecular Characterization of Pneumococcal Surface Protein A (PspA), Serotype Distribution and Antibiotic Susceptibility of Streptococcus pneumoniae Strains Isolated from Pakistan. Infect Dis Ther. 2018. Jun;7(2):291. doi:10.1007/s40121-018-0199-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-018-0199-9</ArticleId><ArticleId IdType="pmc">PMC5986679</ArticleId><ArticleId IdType="pubmed">29524198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisar MI, Jehan F, Shahid S, Ahmed S, Shakoor S, Kabir F, Hotwani A, Muneer S, Khalid F, Muhammad S, et al. Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan. PLOS ONE. 2022;17(1):e0262466. doi:10.1371/journal.pone.0262466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262466</ArticleId><ArticleId IdType="pmc">PMC8782386</ArticleId><ArticleId IdType="pubmed">35061793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoor S, Kabir F, Khowaja AR, Qureshi SM, Jehan F, Qamar F, Whitney CG, Zaidi AKM. Pneumococcal serotypes and serogroups causing invasive disease in Pakistan, 2005&#x2013;2013. PLOS ONE. 2014;9(6):e98796. doi:10.1371/journal.pone.0098796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098796</ArticleId><ArticleId IdType="pmc">PMC4043782</ArticleId><ArticleId IdType="pubmed">24892937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisar MI, Shahid S, Jehan F, Ahmed S, Shakoor S, Kabir F, Hotwani A, Munir S, Khalid F, Muhammad S, et al. Antimicrobial resistance in pneumococcal carriage isolates from children under 2 years of age in rural Pakistan. Microbiol Spectr. 2021;9(3):e01019&#x2013;21. doi:10.1128/Spectrum.01019-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01019-21</ArticleId><ArticleId IdType="pmc">PMC8693922</ArticleId><ArticleId IdType="pubmed">34935431</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaid N, Lo SW, Nisar MI, Basharat A, Jaleel H, Rasool K, Sultana Q, Kabir F, Hotwani A, Breiman RF, et al. Strain features of pneumococcal isolates in the pre- and post-PCV10 era in Pakistan. Microb Genomics. 2024;10(1). doi:10.1099/mgen.0.001163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.001163</ArticleId><ArticleId IdType="pmc">PMC10868622</ArticleId><ArticleId IdType="pubmed">38270581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid S, Khan A, Nisar MI, Khalid F, Qazi MF, Ahmed S, Kabir F, Hotwani A, Muneer S, Ali SA, et al. Pneumococcal carriage in infants post-PCV10 introduction in Pakistan: results from serial cross-sectional surveys. Vaccines. 2022;10(6):971. doi:10.3390/vaccines10060971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060971</ArticleId><ArticleId IdType="pmc">PMC9230137</ArticleId><ArticleId IdType="pubmed">35746579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisar MI, Ahmed S, Jehan F, Shahid S, Shakoor S, Kabir F, Hotwani A, Munir S, Muhammad S, Khalid F, et al. Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan. Vaccine. 2021;39(8):1319&#x2013;1327. doi:10.1016/j.vaccine.2020.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.12.066</ArticleId><ArticleId IdType="pmc">PMC7910277</ArticleId><ArticleId IdType="pubmed">33422379</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal N, Singh M, Das RR, Jindal I, Agarwal A, Thumburu KK, Kumar A, Chauhan A. Distribution of serotypes, vaccine coverage, and antimicrobial susceptibility pattern of streptococcus pneumoniae in children living in SAARC countries: A systematic review. PLOS ONE. 2014;9(9):e108617. doi:10.1371/journal.pone.0108617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108617</ArticleId><ArticleId IdType="pmc">PMC4182530</ArticleId><ArticleId IdType="pubmed">25268974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dananch&#xe9; C, Paranhos-Baccal&#xe0; G, Messaoudi M, Sylla M, Awasthi S, Bavdekar A, Sanghavi S, Diallo S, Pape JW, Rouzier V, et al. Serotypes of Streptococcus pneumoniae in Children Aged &lt;5 Years Hospitalized With or Without Pneumonia in Developing and Emerging Countries: A Descriptive, Multicenter Study. Clin Infect Dis. 2020;70(5):875&#x2013;883. doi:10.1093/cid/ciz277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz277</ArticleId><ArticleId IdType="pubmed">31556939</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaji V, Jayaraman R, Verghese V, Baliga P, Kurien T. Pneumococcal serotypes associated with invasive disease in under five children in India &amp; implications for vaccine policy. Indian J Med Res. 2015;142(3):286. doi:10.4103/0971-5916.166588.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-5916.166588</ArticleId><ArticleId IdType="pmc">PMC4669863</ArticleId><ArticleId IdType="pubmed">26458344</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavan B, Jayaraman R, John J, Varghese R, Neeravi A, Verghese VP, Thomas K. Customized sequential multiplex PCR for accurate and early determination of invasive pneumococcal serotypes found in India. J Microbiol Methods. 2016;130:133&#x2013;135. doi:10.1016/j.mimet.2016.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mimet.2016.09.007</ArticleId><ArticleId IdType="pubmed">27623479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj S, Kalal BS, Manoharan A, Shet A. Streptococcus pneumoniae serotype prevalence and antibiotic resistance among young children with invasive pneumococcal disease: experience from a tertiary care center in South India. GERMS. 2017;7(2):78&#x2013;85. doi:10.18683/germs.2017.1112.</Citation><ArticleIdList><ArticleId IdType="doi">10.18683/germs.2017.1112</ArticleId><ArticleId IdType="pmc">PMC5466826</ArticleId><ArticleId IdType="pubmed">28626738</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Sundaresan S, Manoharan A, Shet A. Serotype distribution and antimicrobial susceptibility pattern in children &#x2264; 5 years with invasive pneumococcal disease in India &#x2013; a systematic review. Vaccine. 2017;35(35):4501&#x2013;4509. doi:10.1016/j.vaccine.2017.06.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.06.079</ArticleId><ArticleId IdType="pubmed">28711387</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman R, Varghese R, Kumar JL, Neeravi A, Shanmugasundaram D, Ralph R, Thomas K, Veeraraghavan B. Invasive pneumococcal disease in Indian adults: 11 years&#x2019; experience. J Microbiol Immunol Infect. 2019;52(5):736&#x2013;742. doi:10.1016/j.jmii.2018.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2018.03.004</ArticleId><ArticleId IdType="pubmed">29884448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutcliffe CG, Shet A, Varghese R, Veeraraghavan B, Manoharan A, Wahl B, Chandy S, Sternal J, Khan R, Singh RK, et al. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study. BMC Infect Dis. 2019;19(1):605. doi:10.1186/s12879-019-4254-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4254-2</ArticleId><ArticleId IdType="pmc">PMC6621985</ArticleId><ArticleId IdType="pubmed">31291902</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoharan A, Manchanda V, Balasubramanian S, Lalwani S, Modak M, Bai S, Vijayan A, Shet A, Nagaraj S, Karande S, et al. Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study. Lancet Infect Dis. 2017;17(3):305&#x2013;312. doi:10.1016/S1473-3099(16)30466-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30466-2</ArticleId><ArticleId IdType="pubmed">27956163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P, Awasthi S, Gupta U, Verma N, Rastogi T, Pandey AK, Naziat H, Rahman H, Islam M, Saha S. Nasopharyngeal carriage of streptococcus pneumoniae serotypes among healthy children in Northern India. Curr Microbiol. 2023;80(1):41. doi:10.1007/s00284-022-03114-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-022-03114-x</ArticleId><ArticleId IdType="pmc">PMC9763132</ArticleId><ArticleId IdType="pubmed">36534266</ArticleId></ArticleIdList></Reference><Reference><Citation>John J, Varghese R, Lionell J, Neeravi A, Veeraraghavan B. Nonvaccine pneumococcal serotypes among children with invasive pneumococcal disease. Indian Pediatr. 2018;55(10):874&#x2013;876. doi:10.1007/s13312-018-1398-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13312-018-1398-x</ArticleId><ArticleId IdType="pubmed">30426954</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese VP, Veeraraghavan B, Jayaraman R, Varghese R, Neeravi A, Jayaraman Y, Thomas K, Mehendale SM. Increasing incidence of penicillin- and cefotaxime-resistant streptococcus pneumoniae causing meningitis in India: time for revision of treatment guidelines? Indian J Med Microbiol. 2017;35(2):228&#x2013;236. doi:10.4103/ijmm.IJMM_17_124.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_17_124</ArticleId><ArticleId IdType="pubmed">28681811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Sharma M, Ray P, Chakraborti A. Antimicrobial susceptibility pattern and serotype distribution of streptococcus pneumoniae isolates from a hospital-based study in Chandigarh, North India. Cureus. 2022; published online Jan 19. DOI:10.7759/cureus.21437.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.21437</ArticleId><ArticleId IdType="pmc">PMC8860682</ArticleId><ArticleId IdType="pubmed">35223224</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandana G, Feroze AG, Geetha N, Avid H, Ravi Kumar KL. Pan India distribution of pneumococcal serotypes (PIDOPS) causing invasive pneumococcal disease and pneumonia in children between 6 weeks and 5 years and their antimicrobial resistance &#x2013; Phase I. Pediatr Infect Dis. 2016;8(2):47&#x2013;51. doi:10.1016/j.pid.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pid.2016.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian S, Singh P, Dhanalakshmi K, Putlibai S, Varghese R. Clinico-microbiological profile of invasive pneumococcal disease amongst hospitalised children in South India. Indian J Med Microbiol. 2019;37(4):598&#x2013;599. doi:10.4103/ijmm.IJMM_20_135.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_20_135</ArticleId><ArticleId IdType="pubmed">32436889</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman Y, Veeraraghavan B, Girish Kumar CP, Sukumar B, Rajkumar P, Kangusamy B, Verghese VP, Varghese R, Jayaraman R, Kapoor AN, et al. Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India. Vaccine. 2021;39(28):3737&#x2013;3744. doi:10.1016/j.vaccine.2021.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.041</ArticleId><ArticleId IdType="pubmed">34074545</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma N, Gupta P, Pandey AK, Awasthi S. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among sick and healthy children in Northern India: a case-control study. Vaccine. 2023;41(44):6619&#x2013;6624. doi:10.1016/j.vaccine.2023.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.09.029</ArticleId><ArticleId IdType="pmc">PMC10663590</ArticleId><ArticleId IdType="pubmed">37758571</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoharan A, Jayaraman R. Pneumococcal aaccines. Indian J Med Microbiol. 2018;36(4):465&#x2013;474. doi:10.4103/ijmm.IJMM_18_442.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_18_442</ArticleId><ArticleId IdType="pubmed">30880692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumdar D, Sarma A, Medhi D, Dutta R, Kataki M, Baishya L, Dutta BS, Saikia L. Capsular typing of Streptococcus pneumoniae isolated from clinical specimens in Gauhati Medical College and hospital, Assam, India. Indian J Med Microbiol. 2023;44:100350. doi:10.1016/j.ijmmb.2023.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmmb.2023.01.008</ArticleId><ArticleId IdType="pubmed">37356826</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Neeravi A, Subramanian N, Pavithra B, Kavipriya A, Kumar JL, Kumar CPG, Jeyraman Y, Karthik G, Verghese VP, et al. Clonal similarities and sequence-Type diversity of invasive and carriage Streptococcus pneumoniae in India among children under 5 years. Indian J Med Microbiol. 2019;37(3):358&#x2013;361. doi:10.4103/ijmm.IJMM_19_348.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_19_348</ArticleId><ArticleId IdType="pubmed">32003333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj G, Govindan V, Ganaie F, Venkatesha VT, Hawkins PA, Gladstone RA, McGee L, Breiman RF, Bentley SD, Klugman KP, et al. Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microb Genomics. 2021;7(9). doi:10.1099/mgen.0.000645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000645</ArticleId><ArticleId IdType="pmc">PMC8715438</ArticleId><ArticleId IdType="pubmed">34494953</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolean M, Rosemol V, John M, Varghese AM, Periyasamy J, Balaji V, Naina P. Nasopharyngeal colonization of otopathogens in South Indian children with acute otitis media &#x2013; a case control pilot study. J Otol. 2021;16(4):220&#x2013;224. doi:10.1016/j.joto.2021.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joto.2021.02.004</ArticleId><ArticleId IdType="pmc">PMC8438633</ArticleId><ArticleId IdType="pubmed">34548867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Das BK, Mahajan N, Kapil A, Chaudhry R, Sood S, Kabra SK, Dwivedi SN. Molecular capsular typing and multi locus sequence typing of invasive, non-invasive and commensal Streptococcus pneumoniae isolates from North India. Indian J Med Microbiol. 2020;38(1):78&#x2013;86. doi:10.4103/ijmm.IJMM_20_111.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_20_111</ArticleId><ArticleId IdType="pubmed">32719213</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Neeravi A, Jacob JJ, Vasudevan K, Kumar JL, Subramanian N, Veeraraghavan B. Comparative genomics of invasive Streptococcus pneumoniae CC320/271 serotype 19F/19A before the introduction of pneumococcal vaccine in India. Mol Biol Rep. 2021;48(4):3265&#x2013;3276. doi:10.1007/s11033-021-06353-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06353-6</ArticleId><ArticleId IdType="pubmed">33876375</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman Y, Veeraraghavan B, Chethrapilly Purushothaman GK, Sukumar B, Kangusamy B, Nair Kapoor A, Gupta N, Mehendale SM. Burden of bacterial meningitis in India: Preliminary data from a hospital based sentinel surveillance network. PLOS ONE. 2018;13(5):e0197198. doi:10.1371/journal.pone.0197198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197198</ArticleId><ArticleId IdType="pmc">PMC5955554</ArticleId><ArticleId IdType="pubmed">29768458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiqullah IM, Varghese R, Hellmann KT, Velmurugan A, Neeravi A, Kumar Daniel JL, Vidal JE, Kompithra RZ, Verghese VP, Veeraraghavan B, et al. Pneumococcal population genomics changes during the early time period of conjugate vaccine uptake in southern India. Microb Genomics. 2024;10(2). doi:10.1099/mgen.0.001191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.001191</ArticleId><ArticleId IdType="pmc">PMC10926699</ArticleId><ArticleId IdType="pubmed">38315173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Purakayastha DR, Kapil A, Saha S, Dawood FS, Das BK, Amarchand R, Kumar R, Lafond KE, Jain S, et al. Carriage rates and antimicrobial sensitivity of pneumococci in the upper respiratory tract of children less than ten years old, in a North Indian rural community. PLOS ONE. 2021;16(2):e0246522. doi:10.1371/journal.pone.0246522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246522</ArticleId><ArticleId IdType="pmc">PMC7861412</ArticleId><ArticleId IdType="pubmed">33539406</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya BK, Bhattacharya SD, Sutcliffe CG, Ganaie F, Bhaskar A, Bhattacharyya S, Niyogi SK, Moss WJ, Panda S, Ravikumar KL, et al. Nasopharyngeal pneumococcal colonization and impact of a single dose of 13-valent pneumococcal conjugate vaccine in Indian children with HIV and their unvaccinated parents. Pediatr Infect Dis J. 2018;37(5):451&#x2013;458. doi:10.1097/INF.0000000000001800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001800</ArticleId><ArticleId IdType="pubmed">28961675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganaie F, Nagaraj G, Govindan V, Basha R, Hussain M, Ashraf N, Ahmed S, Ravi Kumar KL. Impact of Hajj on the S. pneumoniae carriage among Indian pilgrims during 2016- a longitudinal molecular surveillance study. Travel Med Infect Dis. 2018;23:64&#x2013;71. doi:10.1016/j.tmaid.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2018.04.002</ArticleId><ArticleId IdType="pubmed">29625178</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson D, Rupa V, Veeraraghavan B, Varghese R, Isaac R, J L. Follow up of a birth cohort to identify prevalence and risk factors for otitis media among Indian children in the eighth year of life. Int J Pediatr Otorhinolaryngol. 2020;137:110201. doi:10.1016/j.ijporl.2020.110201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2020.110201</ArticleId><ArticleId IdType="pubmed">32658800</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya BK, Bhattacharya SD, Harigovind G, Das RS, Khan T, Ganaie F, Niyogi SK, Ravikumar KL, Manoharan A, Bhattacharyya S, et al. Streptococcus pneumoniae acquisition and carriage in vaccine Na&#xef;ve Indian children with HIV and their parents: a longitudinal household study. Indian J Pediatr. 2019;86(11):1002&#x2013;1010. doi:10.1007/s12098-019-02995-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-019-02995-4</ArticleId><ArticleId IdType="pubmed">31222554</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavan B, Varghese R, Saigal K, Balasubramanian S, Bai PSP, Lal Y B, Neeravi A, Baskar P, Anandhan K, Kumar CPG, et al. Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. JAC-Antimicrob Resist. 2021;3(2):dlab066. doi:10.1093/jacamr/dlab066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlab066</ArticleId><ArticleId IdType="pmc">PMC8210042</ArticleId><ArticleId IdType="pubmed">34223128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanungo R, Anandhalakshmi S, Sheeladevi C, Sudhagar M, John J, Prashanth K. Fatal infection in adults by pneumolysin &amp; autolysin producing, non-vaccine serotype Streptococcus pneumonia. Indian J Med Res. 2016;143(4):514. doi:10.4103/0971-5916.184307.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0971-5916.184307</ArticleId><ArticleId IdType="pmc">PMC4928560</ArticleId><ArticleId IdType="pubmed">27377510</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Sankar J, Putlibai S, Raghavan V. Demographic profile of healthy children with Nasopharyngeal colonisation of Streptococcus pneumoniae: a research paper. Indian J Med Microbiol. 2017;35(4):607&#x2013;609. doi:10.4103/ijmm.IJMM_15_347.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmm.IJMM_15_347</ArticleId><ArticleId IdType="pubmed">29405160</ArticleId></ArticleIdList></Reference><Reference><Citation>Amritha GN, M N, R APS, Shanmugam P, Jayaraman P. A comparative profile of Oropharyngeal colonization of Streptococcus pneumoniae and Hemophilus influenzae among HealthCare Workers (HCW) in a tertiary care hospital and non-healthcare individuals. J Prev Med Hyg. 2020;61(3):E 379. doi:10.15167/2421-4248/jpmh2020.61.3.1479.</Citation><ArticleIdList><ArticleId IdType="doi">10.15167/2421-4248/jpmh2020.61.3.1479</ArticleId><ArticleId IdType="pmc">PMC7595066</ArticleId><ArticleId IdType="pubmed">33150226</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun R, Ratheesh RS, Mohan V, Uduman S, Jalaludeen S, Prabhakaran A, Sasidharan A, Niyas VKM. Susceptibility and serotypes of Streptococcus pneumoniae isolates in invasive pneumococcal disease: a study from Kerala, South India. Infez Med. 2020;28(4):558&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257631</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Daniel JL, Neeravi A, Baskar P, Manoharan A, Sundaram B, Manchanda V, Saigal K, Yesudhasan BL, Veeraraghavan B. Multicentric analysis of Erythromycin resistance determinants in invasive Streptococcus pneumoniae; associated serotypes and sequence types in India. Curr Microbiol. 2021;78(8):3239&#x2013;3245. doi:10.1007/s00284-021-02594-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-021-02594-7</ArticleId><ArticleId IdType="pubmed">34223923</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Yesudhason BL, Vimala LR, Neeravi A, Anandhan K, Baskar P, Elangovan D, Manesh A, James P, Gupta R, et al. Pneumococcal serotypes causing non-invasive pneumonia in adults from a South Indian tertiary care hospital and the impact of the newer conjugate vaccines. Access Microbiol. 2021;3(12). doi:10.1099/acmi.0.000258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/acmi.0.000258</ArticleId><ArticleId IdType="pmc">PMC8749137</ArticleId><ArticleId IdType="pubmed">35024548</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira GS, Oliveira MLS, Miyaji EN, Rodrigues TC. Pneumococcal vaccines: past findings, present work, and future strategies. Vaccines. 2021;9(11):1338. doi:10.3390/vaccines9111338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111338</ArticleId><ArticleId IdType="pmc">PMC8620834</ArticleId><ArticleId IdType="pubmed">34835269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein&#x2013;polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213&#x2013;220. doi:10.1038/nri2494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2494</ArticleId><ArticleId IdType="pubmed">19214194</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais V, Suarez N. Conjugation mechanism for pneumococcal glycoconjugate vaccines: classic and emerging methods. Bioengineering. 2022;9(12):774. doi:10.3390/bioengineering9120774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering9120774</ArticleId><ArticleId IdType="pmc">PMC9774679</ArticleId><ArticleId IdType="pubmed">36550980</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera SR, Sokaribo AS, White AP. Polysaccharide vaccines: a perspective on non-typhoidal Salmonella. Polysaccharides. 2021;2(3):691&#x2013;714. doi:10.3390/polysaccharides2030042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polysaccharides2030042</ArticleId></ArticleIdList></Reference><Reference><Citation>PNEUMOVAX 23 dosage and administration. [accessed 2024 Aug
7]. https://www.merckvaccines.com/vaxneuvancepneumovax23/p23-dosage-and-administration/.</Citation></Reference><Reference><Citation>Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453&#x2013;1460. doi:10.1056/NEJM199111213252101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199111213252101</ArticleId><ArticleId IdType="pubmed">1944423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18):1747&#x2013;1755. doi:10.1056/NEJMoa022678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa022678</ArticleId><ArticleId IdType="pubmed">12724480</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D&#x2019;Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340(mar08 1):c1004&#x2013;c1004. doi:10.1136/bmj.c1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c1004</ArticleId><ArticleId IdType="pmc">PMC2834887</ArticleId><ArticleId IdType="pubmed">20211953</ArticleId></ArticleIdList></Reference><Reference><Citation>Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. In: Cochrane Acute Respiratory Infections Group, editor. The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. Chichester (UK): John Wiley &amp; Sons, Ltd,; 2008. p. CD000422.</Citation><ArticleIdList><ArticleId IdType="pubmed">18253977</ArticleId></ArticleIdList></Reference><Reference><Citation>See KC. Pneumococcal vaccination in adults: a narrative review of considerations for individualized decision-making. Vaccines. 2023;11(5):908. doi:10.3390/vaccines11050908.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050908</ArticleId><ArticleId IdType="pmc">PMC10223523</ArticleId><ArticleId IdType="pubmed">37243012</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27&#x2013;35. doi:10.5863/1551-6776-21.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.5863/1551-6776-21.1.27</ArticleId><ArticleId IdType="pmc">PMC4778694</ArticleId><ArticleId IdType="pubmed">26997927</ArticleId></ArticleIdList></Reference><Reference><Citation>Micoli F, Stefanetti G, MacLennan CA. Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines. Front Mol Biosci. 2023;10:1201693. doi:10.3389/fmolb.2023.1201693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1201693</ArticleId><ArticleId IdType="pmc">PMC10227950</ArticleId><ArticleId IdType="pubmed">37261327</ArticleId></ArticleIdList></Reference><Reference><Citation>Alicino C, Paganino C, Orsi A, Astengo M, Trucchi C, Icardi G, Ansaldi F. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine. 2017;35(43):5776&#x2013;5785. doi:10.1016/j.vaccine.2017.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.09.005</ArticleId><ArticleId IdType="pubmed">28911902</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyburn R, Tsatsaronis A, Von Mollendorf C, Mulholland K, Russell FM. ARI Review group. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old. J Glob Health. 2023;13:05002 doi:10.7189/jogh.13.05002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.13.05002</ArticleId><ArticleId IdType="pmc">PMC9896304</ArticleId><ArticleId IdType="pubmed">36734192</ArticleId></ArticleIdList></Reference><Reference><Citation>Changes in invasive pneumococcal disease incidence following introduction of PCV10 and 1170 PCV13 in children and adults globally: the pserenade project. [accessed 2024 May
14]. https://cslide.ctimeetingtech.com/isppd22/attendee/eposter/poster/852.</Citation></Reference><Reference><Citation>Weuphoria launching ceremony successfully held. [accessed 2024 May
14]. https://en.walvax.com/news/weuphoria-launching-ceremony-successfully-held-in-thailand.html.</Citation></Reference><Reference><Citation>Tin Tin Htar M, Morato Mart&#xed;nez J, Theilacker C, Schmitt H-J, Swerdlow D. Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD). Expert Rev Vaccines. 2019;18(11):1145&#x2013;1155. doi:10.1080/14760584.2019.1688149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1688149</ArticleId><ArticleId IdType="pubmed">31682762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanquet G, Krizova P, Dalby T, Ladhani SN, Nuorti JP, Danis K, Mereckiene J, Knol MJ, Winje BA, Ciruela P, et al. Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe. Emerg Infect Dis. 2022;28(1):137&#x2013;138. doi:10.3201/eid2801.210734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2801.210734</ArticleId><ArticleId IdType="pmc">PMC8714201</ArticleId><ArticleId IdType="pubmed">34932457</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. FDA Approves Merck&#x2019;s VAXNEUVANCETM (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of invasive pneumococcal disease in infants and children. Merck.com;  [accessed 2024 Aug
8]. https://www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/.</Citation></Reference><Reference><Citation>Prevnar 20 FDA Approval History. Drugs.com. [accessed 2024 Aug
8]. https://www.drugs.com/history/prevnar-20.html.</Citation></Reference><Reference><Citation>VAXNEUVANCE Prescribing Information. [accessed 2024 May
14]. https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf.</Citation></Reference><Reference><Citation>Prevnar 20 . [accessed 2024 May
14]. https://www.prevnar20.com/.</Citation></Reference><Reference><Citation>U.S. FDA approves PREVNAR 20&#xae;, Pfizer&#x2019;s 20-valent Pneumococcal conjugate vaccine for infants and children. [accessed 2024 May
14]. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal.</Citation></Reference><Reference><Citation>U.S. FDA approves PREVNAR 20TM, Pfizer&#x2019;s Pneumococcal 20 valent conjugate vaccine for adults ages 18 years or older. [accessed 2024 May
14]. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent.</Citation></Reference><Reference><Citation>DCGI approves BE&#x2019;s 14-valent pneumococcal conjugate vaccine. [accessed 2024 Aug
8]. https://www.biologicale.com/news.html.</Citation></Reference><Reference><Citation>Tergene Biotech Pvt . Ltd. a Joint Venture company, receives SEC recommendation for pneumococcal 15 valent (PCV15) vaccine. [accessed 2024 Aug
8]. https://nsearchives.nseindia.com/corporate/AUROPHARMA_27122022115948_LtrToSEsPressReleaseTergene27122022.pdf.</Citation></Reference><Reference><Citation>U.S . FDA approves CAPVAXIVETM (Pneumococcal 21-valent Conjugate Vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Merck.com. [accessed 2024 Aug
8]. https://www.merck.com/news/u-s-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/.</Citation></Reference><Reference><Citation>R&amp;D pipeline . [accessed 2024 Aug
8]. https://www.panaceabiotec.com/en/products/pipeline.</Citation></Reference><Reference><Citation>Vaccines . [accessed 2024 Jul
7]. https://techinvention.biz/rnd-vaccines.html.</Citation></Reference><Reference><Citation>SK bioscience-Sanofi announce positive results from phase II study of 21-valent pneumococcal conjugate vaccine candidate. [accessed 2024 Aug
8]. https://www.skbioscience.com/en/news/news_01_01.</Citation></Reference><Reference><Citation>GSK completes acquisition of Affinivax, Inc. [accessed 2024 May
14]. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/.</Citation></Reference><Reference><Citation>Vaxcyte reports positive data from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older and full six-month safety data from adult phase 1/2 and phase 2 studies. [accessed 2024 May
14]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-data-phase-2-study-its-24-valent/.</Citation></Reference><Reference><Citation>Vaxcyte doses first participants in phase 1/2 clinical study evaluating VAX-31 for the prevention of invasive pneumococcal disease in adults. [accessed 2024 May
14]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-doses-first-participants-phase-12-clinical-study-0/.</Citation></Reference><Reference><Citation>Vaxcyte announces FDA clearance of investigational new drug application for VAX-31 for the prevention of invasive pneumococcal disease in adults. [accessed 2024 May
14]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-fda-clearance-investigational-new-drug-1/.</Citation></Reference><Reference><Citation>McGuinness D, Kaufhold RM, McHugh PM, Winters MA, Smith WJ, Giovarelli C, He J, Zhang Y, Musey L, Skinner JM. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine. 2021;39(30):4231&#x2013;4237. doi:10.1016/j.vaccine.2021.04.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.067</ArticleId><ArticleId IdType="pubmed">34074546</ArticleId></ArticleIdList></Reference><Reference><Citation>Inventprise completes vaccination of participants in a phase 2 dose ranging study of its 25 valent pneumococcal vaccine candidate. [accessed 2024 Aug
9]. https://inventprise.com/2024/01/02/inventprise-completes-vaccination-of-participants-in-a-phase-2-dose-ranging-study-of-its-25-valent-pneumococcal-vaccine-candidate/.</Citation></Reference><Reference><Citation>Conjugate vaccine introduction &amp; use. [accessed 2025 Jan
18]. https://view-hub.org/vaccine/pcv.</Citation></Reference><Reference><Citation>Pneumococcal Conjugate Vaccine (PCV) Review of impact evidence (PRIME) summary of findings from systematic review October 2017. [accessed 2025 Jan
18]. https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2017/9_session_PCV/Oct2019_session9_PCV_PRIMEsummary.pdf.</Citation></Reference><Reference><Citation>Duke JA, Avci FY. Emerging vaccine strategies against the incessant pneumococcal disease. NPJ Vaccines. 2023;8(1):122. doi:10.1038/s41541-023-00715-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00715-w</ArticleId><ArticleId IdType="pmc">PMC10435554</ArticleId><ArticleId IdType="pubmed">37591986</ArticleId></ArticleIdList></Reference><Reference><Citation>WALVAX Package Insert . [accessed 2024 May
14]. https://en.walvax.com/media/upload/product/Package%20Insert%20of%20PPSV23.pdf.</Citation></Reference><Reference><Citation>Pneumococcal Conjugate Vaccine (PCV) . [accessed 2024 May
14]. https://view-hub.org/vaccine/pcv/product.</Citation></Reference><Reference><Citation>Rao MIS, Kasi SG, Dhir SK, Wadhwa A, Rajsekhar B, Kumar CM, Lalwani S, Shenoy B, Kesavan TMA, Kalyani S, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2023) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2024;61(2):113&#x2013;125. doi:10.1007/s13312-024-3104-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13312-024-3104-5</ArticleId><ArticleId IdType="pubmed">38243749</ArticleId></ArticleIdList></Reference><Reference><Citation>Affordable Vaccine platform . [accessed 2024 Aug
8]. http://www.tergene.com/news3.html.</Citation></Reference><Reference><Citation>Curry S, Kaufhold RM, Monslow MA, Zhang Y, McGuinness D, Kim E, Nawrocki DK, McHugh PM, Briggs ML, Smith WJ, et al. Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models. Vaccine. 2023;41(4):903&#x2013;913. doi:10.1016/j.vaccine.2022.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.12.017</ArticleId><ArticleId IdType="pubmed">36566163</ArticleId></ArticleIdList></Reference><Reference><Citation>Permission to conduct clinical trial of new drug or investigational new drug. [accessed 2024 Aug
8]. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCTApprovals/39_Panacea%20Biotech%20Pneumococcal.pdf.</Citation></Reference><Reference><Citation>Intellectual property . [accessed 2024 Aug
9]. https://techinvention.biz/intellectual-property.html.</Citation></Reference><Reference><Citation>Composition of multivalent pneumococcal polysacaride-protein conjugate. [accessed 2024 Aug
8]. https://pubchem.ncbi.nlm.nih.gov/patent/BR-112020014978-A2.</Citation></Reference><Reference><Citation>GSK - A phase 2 study to evaluate the safety, tolerability, and immunogenicity of AFX3772 vaccine in healthy infants. [accessed 2024 May
14]. https://www.gsk-studyregister.com/en/trial-details/?id=219651.</Citation></Reference><Reference><Citation>Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, Davey P, Fernsten P, Grainger C, Guo S, et al. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine. 2021;39(23):3197&#x2013;3206. doi:10.1016/j.vaccine.2021.03.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.070</ArticleId><ArticleId IdType="pubmed">33965258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain SS, Singh VK, Kante RK, Jana SK, Patil RH. Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges. Biol J Int Assoc Biol Stand. 2024;87:101784. doi:10.1016/j.biologicals.2024.101784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2024.101784</ArticleId><ArticleId IdType="pubmed">39053122</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Kapre K, Andi-Lolo I, Kapre S. Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production. Hum Vaccines Immunother. 2022;18(4):2117949. doi:10.1080/21645515.2022.2117949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2117949</ArticleId><ArticleId IdType="pmc">PMC9721430</ArticleId><ArticleId IdType="pubmed">36239596</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens C, Fairman J, Agarwal P, Arulkumar S, Barbanel S, Bautista L, Berges A, Burky J, Davey P, Grainger C, et al. 1047. Development of a next generation 30+ valent pneumococcal conjugate vaccine (VAX-XP) using site-specific carrier protein conjugation. Open Forum Infect Dis. 2021;8(Supplement_1):S615&#x2013;S615. doi:10.1093/ofid/ofab466.1241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab466.1241</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumococcal Vaccines . [accessed 2024 Aug
28]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/01-Pneumococcal-Loehr-508.pdf.</Citation></Reference><Reference><Citation>Feemster K, Buchwald UK, Banniettis N, Joyce JG, Velentgas P, Chapman TJ, Yildirim I. Immunogenicity of current and next generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities. Open Forum Infect Dis. 2024;11(5):ofae220. doi:10.1093/ofid/ofae220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae220</ArticleId><ArticleId IdType="pmc">PMC11103622</ArticleId><ArticleId IdType="pubmed">38770212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassil J, Sisti M, Fairman J, Rankin B, Clark J, Bennett S, Johnson D, Migone T-S, Nguyen K, Paschenko A, et al. A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older. Vaccine. 2024;42(25):126124. doi:10.1016/j.vaccine.2024.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.07.025</ArticleId><ArticleId IdType="pubmed">39025698</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigational pneumococcal vaccine broadens coverage without
reducing immunogenicity. [accessed 2024 Dec
13]. https://www.contagionlive.com/view/investigational-pneumococcal-vaccine-broadens-coverage-without-reducing-immunogenicity.</Citation></Reference><Reference><Citation>Akkoyunlu M. State of pneumococcal vaccine immunity. Hum Vaccines Immunother. 2024;20(1):2336358. doi:10.1080/21645515.2024.2336358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2336358</ArticleId><ArticleId IdType="pmc">PMC10993918</ArticleId><ArticleId IdType="pubmed">38567485</ArticleId></ArticleIdList></Reference><Reference><Citation>Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines Replacement of WHO Technical Report Series, No. 927, Annex 2. [accessed 2024 Dec
13]. https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/pneumococcus/trs_977_annex_3.pdf.</Citation></Reference><Reference><Citation>Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, et al. Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011&#x2013;15. J Antimicrob Chemother. 2018;73(suppl_7):vii20&#x2013;31. doi:10.1093/jac/dky157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky157</ArticleId><ArticleId IdType="pubmed">29982573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chochua S, Metcalf BJ, Li Z, Walker H, Tran T, McGee L, Beall B. Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015&#x2013;2016. Emerg Infect Dis. 2017;23(6):922&#x2013;930. doi:10.3201/eid2306.170071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2306.170071</ArticleId><ArticleId IdType="pmc">PMC5443455</ArticleId><ArticleId IdType="pubmed">28516866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagousi T, Basdeki P, Routsias J, Spoulou V. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines. 2019;7(1):9. doi:10.3390/vaccines7010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7010009</ArticleId><ArticleId IdType="pmc">PMC6466302</ArticleId><ArticleId IdType="pubmed">30669439</ArticleId></ArticleIdList></Reference><Reference><Citation>Feemster K, Weaver J, Buchwald U, Banniettis N, Cox KS, McIntosh ED, Spoulou V. Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review. Vaccines. 2023;11(12):1750. doi:10.3390/vaccines11121750.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121750</ArticleId><ArticleId IdType="pmc">PMC10747311</ArticleId><ArticleId IdType="pubmed">38140155</ArticleId></ArticleIdList></Reference><Reference><Citation>Oligbu G, Hsia Y, Folgori L, Collins S, Ladhani S. Pneumococcal conjugate vaccine failure in children: a systematic review of the literature. Vaccine. 2016;34(50):6126&#x2013;6132. doi:10.1016/j.vaccine.2016.10.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.050</ArticleId><ArticleId IdType="pubmed">27838066</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceil J, Avci FY. Pneumococcal surface proteins as virulence factors, immunogens, and conserved vaccine targets. Front Cell Infect Microbiol. 2022;12:832254. doi:10.3389/fcimb.2022.832254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.832254</ArticleId><ArticleId IdType="pmc">PMC9133333</ArticleId><ArticleId IdType="pubmed">35646747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan R, Poolman J, Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513&#x2013;5523. doi:10.1016/j.vaccine.2010.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.06.026</ArticleId><ArticleId IdType="pubmed">20600514</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia. 2022;14(1):5. doi:10.1186/s41479-022-00097-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41479-022-00097-y</ArticleId><ArticleId IdType="pmc">PMC9509586</ArticleId><ArticleId IdType="pubmed">36153636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang A-Y, Ahn KB, Zhi Y, Ji H-J, Zhang J, Han SH, Guo H, Lim S, Song JY, Lim JH, et al. Serotype-independent protection against invasive pneumococcal infections conferred by live Vaccine with lgt deletion. Front Immunol. 2019;10:1212. doi:10.3389/fimmu.2019.01212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01212</ArticleId><ArticleId IdType="pmc">PMC6549034</ArticleId><ArticleId IdType="pubmed">31191555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumraj G, Pathak S, Shah S, Majumder P, Jain J, Bhati D, Hanif S, Mukherjee S, Ahmed S. Capacity building for vaccine manufacturing across developing countries: the way forward. Hum Vaccines Immunother. 2022;18(1):2020529. doi:10.1080/21645515.2021.2020529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2020529</ArticleId><ArticleId IdType="pmc">PMC8986212</ArticleId><ArticleId IdType="pubmed">35086416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto AT, Rosch JW, Tuomanen EI. Pneumolysin: pathogenesis and therapeutic target. Front Microbiol. 2020;11:1543. doi:10.3389/fmicb.2020.01543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01543</ArticleId><ArticleId IdType="pmc">PMC7343714</ArticleId><ArticleId IdType="pubmed">32714314</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JM, Xu S, Leong JM, Sousa S. The Yin and Yang of pneumolysin during pneumococcal infection. Front Immunol. 2022;13:878244. doi:10.3389/fimmu.2022.878244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.878244</ArticleId><ArticleId IdType="pmc">PMC9074694</ArticleId><ArticleId IdType="pubmed">35529870</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo AP, Oliveira MLS, Miyaji EN. Negligible role for pneumococcal surface protein a (PspA) and pneumococcal surface protein C (PspC) in the nasopharyngeal colonization of mice with a serotype 6B pneumococcal strain. Microb Pathog. 2023;185:106391. doi:10.1016/j.micpath.2023.106391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2023.106391</ArticleId><ArticleId IdType="pubmed">37839762</ArticleId></ArticleIdList></Reference><Reference><Citation>Du S, Vilhena C, King S, Sahag&#xfa;n-Ruiz A, Hammerschmidt S, Skerka C, Zipfel PF. Molecular analyses identifies new domains and structural differences among Streptococcus pneumoniae immune evasion proteins PspC and Hic. Sci Rep. 2021;11(1):1701. doi:10.1038/s41598-020-79362-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-79362-3</ArticleId><ArticleId IdType="pmc">PMC7814132</ArticleId><ArticleId IdType="pubmed">33462258</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MN, Sharma SK, Filkins LM, Pichichero ME. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect. 2012;14(12):1102&#x2013;1110. doi:10.1016/j.micinf.2012.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2012.06.007</ArticleId><ArticleId IdType="pmc">PMC3490615</ArticleId><ArticleId IdType="pubmed">22796387</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshar D, Rafiee F, Kheirandish M, Ohadian Moghadam S, Azarsa M. Autolysin (lytA) recombinant protein: a potential target for developing vaccines against pneumococcal infections. Clin Exp Vaccine Res. 2020;9(2):76. doi:10.7774/cevr.2020.9.2.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2020.9.2.76</ArticleId><ArticleId IdType="pmc">PMC7445314</ArticleId><ArticleId IdType="pubmed">32864363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Park N, Seo KS, Park JY, Somarathne RP, Vonkchalee N, Jackson K, Olivier AK, Fitzkee NC, Thornton JA. Pneumococcal surface adhesion a protein (PsaA) interacts with human Annexin A2 on airway epithelial cells. Virulence. 2021;12(1):1947176. doi:10.1080/21505594.2021.1947176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2021.1947176</ArticleId><ArticleId IdType="pmc">PMC8274441</ArticleId><ArticleId IdType="pubmed">34233589</ArticleId></ArticleIdList></Reference><Reference><Citation>Waz NT, Milani B, Assoni L, Coelho GR, Sciani JM, Parisotto T, Ferraz LFC, Hakansson AP, Converso TR, Darrieux M. Pneumococcal surface protein a (PspA) prevents killing of Streptococcus pneumoniae by indolicidin. Sci Rep. 2024;14(1):23517. doi:10.1038/s41598-024-73564-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-73564-9</ArticleId><ArticleId IdType="pmc">PMC11464550</ArticleId><ArticleId IdType="pubmed">39384882</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamou JE, Heinrichs JH, Erwin AL, Walsh W, Gayle T, Dormitzer M, Dagan R, Brewah YA, Barren P, Lathigra R, et al. dentification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun. 2001;69(2):949&#x2013;958. doi:10.1128/IAI.69.2.949-958.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.2.949-958.2001</ArticleId><ArticleId IdType="pmc">PMC97974</ArticleId><ArticleId IdType="pubmed">11159990</ArticleId></ArticleIdList></Reference><Reference><Citation>Melin M, Di Paolo E, Tikkanen L, Jarva H, Neyt C, K&#xe4;yhty H, Meri S, Poolman J, V&#xe4;kev&#xe4;inen M. Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun. 2010;78(5):2089&#x2013;2098. doi:10.1128/IAI.00811-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00811-09</ArticleId><ArticleId IdType="pmc">PMC2863542</ArticleId><ArticleId IdType="pubmed">20194599</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MN, Pichichero ME. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine. 2012;30(18):2900&#x2013;2907. doi:10.1016/j.vaccine.2012.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.02.023</ArticleId><ArticleId IdType="pmc">PMC3490617</ArticleId><ArticleId IdType="pubmed">22349524</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshari E, Ahangari Cohan R, Shams Nosrati MS, Mousavi SF. Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein a in combination with pneumococcal histidine triad protein D. Front Immunol. 2023;14:1187773. doi:10.3389/fimmu.2023.1187773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1187773</ArticleId><ArticleId IdType="pmc">PMC10480505</ArticleId><ArticleId IdType="pubmed">37680628</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Gingerich AD, Royer F, Paschall AV, Pena-Briseno A, Avci FY, Mousa JJ. Broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection. Infect Immun. 2021;89(5):e00747&#x2013;20. doi:10.1128/IAI.00747-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00747-20</ArticleId><ArticleId IdType="pmc">PMC8091081</ArticleId><ArticleId IdType="pubmed">33649050</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijkelkamp BA, Pederick VG, Plumptre CD, Harvey RM, Hughes CE, Paton JC, McDevitt CA. The first histidine triad motif of PhtD is critical for Zinc homeostasis in streptococcus pneumoniae. Infect Immun. 2016;84(2):407&#x2013;415. doi:10.1128/IAI.01082-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.01082-15</ArticleId><ArticleId IdType="pmc">PMC4730578</ArticleId><ArticleId IdType="pubmed">26573735</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai K, Domon H, Maekawa T, Hiyoshi T, Tamura H, Yonezawa D, Habuka R, Saitoh A, Terao Y. Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection. Vaccine. 2019;37(1):160&#x2013;168. doi:10.1016/j.vaccine.2018.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.11.015</ArticleId><ArticleId IdType="pubmed">30442480</ArticleId></ArticleIdList></Reference><Reference><Citation>Salha D, Szeto J, Myers L, Claus C, Sheung A, Tang M, Ljutic B, Hanwell D, Ogilvie K, Ming M, et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun. 2012;80(6):2212&#x2013;2220. doi:10.1128/IAI.06348-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.06348-11</ArticleId><ArticleId IdType="pmc">PMC3370579</ArticleId><ArticleId IdType="pubmed">22473606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Wu K, Xu W, Yuan T, Wang X, Zhang J, Min Y, Yin Y, Zhang X. Engineering detoxified pneumococcal pneumolysin derivative &#x394;A146PLY for self-biomineralization of calcium phosphate: assessment of their protective efficacy in murine infection models. Biomaterials. 2018;155:152&#x2013;164. doi:10.1016/j.biomaterials.2017.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2017.11.018</ArticleId><ArticleId IdType="pubmed">29179131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermand P, Vandercammen A, Mertens E, Di Paolo E, Verlant V, Deno&#xeb;l P, Godfroid F. Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen. Hum Vaccines Immunother. 2017;13(1):220&#x2013;228. doi:10.1080/21645515.2016.1234553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1234553</ArticleId><ArticleId IdType="pmc">PMC5287308</ArticleId><ArticleId IdType="pubmed">27768518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xia L, Wang G, Lu H, Wang H, Luo S, Zhang T, Gao S, Huang J, Min X. Subcutaneous immunization with the fusion protein &#x394;A146Ply-SP0148 confers protection against Streptococcus pneumoniae infection. Microb Pathog. 2022;162:105325. doi:10.1016/j.micpath.2021.105325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.105325</ArticleId><ArticleId IdType="pubmed">34848296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkham L-A, Kerr AR, Douce GR, Paterson GK, Dilts DA, Liu D-F, Mitchell TJ. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun. 2006;74(1):586&#x2013;593. doi:10.1128/IAI.74.1.586-593.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.74.1.586-593.2006</ArticleId><ArticleId IdType="pmc">PMC1346677</ArticleId><ArticleId IdType="pubmed">16369015</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanawastien A, Joyce KE, Cartee RT, Haines LA, Pelton SI, Tweten RK, Killeen KP. Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid. Vaccine. 2021;39(11):1652&#x2013;1660. doi:10.1016/j.vaccine.2020.04.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.04.064</ArticleId><ArticleId IdType="pmc">PMC8237519</ArticleId><ArticleId IdType="pubmed">32532546</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeven D, Perry S, Pichichero ME, Plotkin SA. Contributions to protection from streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge. Clin Vaccine Immunol. 2014;21(8):1037&#x2013;1045. doi:10.1128/CVI.00052-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00052-14</ArticleId><ArticleId IdType="pmc">PMC4135924</ArticleId><ArticleId IdType="pubmed">24850621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann B, Orihuela C, Antikainen J, Gao G, Sublett J, Korhonen TK, Tuomanen E. Multifunctional Role of Choline Binding Protein G in Pneumococcal Pathogenesis. Infect Immun. 2006;74(2):821&#x2013;829. doi:10.1128/IAI.74.2.821-829.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.74.2.821-829.2006</ArticleId><ArticleId IdType="pmc">PMC1360319</ArticleId><ArticleId IdType="pubmed">16428724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemian H, Afshar D, Garcia E, Pourmand MR, Jeddi-Tehrani M, Aminharati F, Shokri F, Yazdi MH. CbpM and CbpG of Streptococcus Pneumoniae elicit a high protection in Mice challenged with a serotype 19F pneumococcus. Iran J Allergy Asthma Immunol. 2018;17:574&#x2013;585. doi:10.18502/ijaai.v17i6.622.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijaai.v17i6.622</ArticleId><ArticleId IdType="pubmed">30644702</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan ZQ, Lv ZY, Gan HQ, Xian M, Zhang KX, Mai JY, Yu XB, Wu ZD. Intranasal immunization with autolysin (LytA) in mice model induced protection against five prevalent Streptococcus pneumoniae serotypes in China. Immunol Res. 2011;51(1):108. doi:10.1007/s12026-011-8234-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-011-8234-x</ArticleId><ArticleId IdType="pubmed">21748446</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsini B, Aguinagalde L, Ruiz S, Domenech M, Antequera ML, Fenoll A, Garc&#xed;a P, Garc&#xed;a E, Yuste J. Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis. Vaccine. 2016;34(50):6148&#x2013;6157. doi:10.1016/j.vaccine.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.11.001</ArticleId><ArticleId IdType="pubmed">27840016</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. Role of pneumococcal surface Protein C in Nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun. 2002;70(5):2526&#x2013;2534. doi:10.1128/IAI.70.5.2526-2534.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.70.5.2526-2534.2002</ArticleId><ArticleId IdType="pmc">PMC127914</ArticleId><ArticleId IdType="pubmed">11953392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC, Tuomanen EI. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun. 2001;69(10):5997&#x2013;6003. doi:10.1128/IAI.69.10.5997-6003.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.10.5997-6003.2001</ArticleId><ArticleId IdType="pmc">PMC98727</ArticleId><ArticleId IdType="pubmed">11553536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Gong Y, Li D, Yin N, Chen T, Xu W, Zhang X, Yin Y. CD4+ T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. Vaccine. 2009;27(21):2838&#x2013;2844. doi:10.1016/j.vaccine.2009.02.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.02.093</ArticleId><ArticleId IdType="pubmed">19366577</ArticleId></ArticleIdList></Reference><Reference><Citation>De L&#xfa;cia Hernani M, Ferreira PCD, Ferreira DM, Miyaji EN, Ho PL, Oliveira MLS. Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol. 2011;62(3):263&#x2013;272. doi:10.1111/j.1574-695X.2011.00809.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.2011.00809.x</ArticleId><ArticleId IdType="pubmed">21492260</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks-Walter A, Briles DE, Hollingshead SK, Fischetti VA. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA 1535 and provides immunity to Pneumococcal Bacteremia. Infect Immun. 1999;67(12):6533&#x2013;6542. doi:10.1128/IAI.67.12.6533-6542.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.67.12.6533-6542.1999</ArticleId><ArticleId IdType="pmc">PMC97064</ArticleId><ArticleId IdType="pubmed">10569772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira DM, Darrieux M, Silva DA, Leite LCC, Ferreira JMC, Ho PL, Miyaji EN, Oliveira MLS. Characterization of protective mucosal and systemic immune responses elicited by Pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in Mice. Clin Vaccine Immunol. 2009;16(5):636&#x2013;645. doi:10.1128/CVI.00395-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00395-08</ArticleId><ArticleId IdType="pmc">PMC2681601</ArticleId><ArticleId IdType="pubmed">19279169</ArticleId></ArticleIdList></Reference><Reference><Citation>Briles DE, Hollingshead SK, King J, Swift A, Braun P, Park M, Ferguson L, Nahm M, Nabors G. Immunization of humans with recombinant Pneumococcal surface protein a (rPspA) elicits antibodies that passively protect Mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis. 2000;182(6):1694&#x2013;1701. doi:10.1086/317602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/317602</ArticleId><ArticleId IdType="pubmed">11069242</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano H, Kawabata M, Sugita G, Tsuruhara A, Ohori J, Jimura T, Miyashita K, Kurono Y, Tomonaga K, Briles DE, et al. Transcutaneous immunization with pneumococcal surface protein A in mice. The Laryngoscope. 2018;128(3). doi:10.1002/lary.26971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.26971</ArticleId><ArticleId IdType="pubmed">29226330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun. 2013;81(5):1625&#x2013;1634. doi:10.1128/IAI.00240-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00240-13</ArticleId><ArticleId IdType="pmc">PMC3647999</ArticleId><ArticleId IdType="pubmed">23460513</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo DBD, Kaneko K, Rodrigues TDC, MacLoughlin R, Miyaji EN, Saleem I, Gon&#xe7;alves VM. Pneumococcal surface protein A-hybrid nanoparticles protect Mice from lethal challenge after mucosal immunization targeting the lungs. Pharmaceutics. 2022;14(6):1238. doi:10.3390/pharmaceutics14061238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14061238</ArticleId><ArticleId IdType="pmc">PMC9230107</ArticleId><ArticleId IdType="pubmed">35745810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Lu J, Yu J, Hou H, Leenhouts K, Van Roosmalen ML, Gu T, Jiang C, Kong W, Wu Y. A Novel PspA protein vaccine intranasal delivered by bacterium-like particles provides broad protection against pneumococcal pneumonia in Mice. Immunol Invest. 2018;47(4):403&#x2013;415. doi:10.1080/08820139.2018.1439505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2018.1439505</ArticleId><ArticleId IdType="pubmed">29498560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Guo J, Wang D, Yu J, Gu T, Jiang C, Kong W, Wu Y. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments. Hum Vaccines Immunother. 2019;15(2):371&#x2013;380. doi:10.1080/21645515.2018.1526556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1526556</ArticleId><ArticleId IdType="pmc">PMC6422497</ArticleId><ArticleId IdType="pubmed">30235046</ArticleId></ArticleIdList></Reference><Reference><Citation>Anish C, Upadhyay AK, Sehgal D, Panda AK. Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein a. Int J Pharm. 2014;466(1&#x2013;2):198&#x2013;210. doi:10.1016/j.ijpharm.2014.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2014.03.025</ArticleId><ArticleId IdType="pubmed">24631054</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TC, Oliveira MLS, Soares-Schanoski A, Chavez-Rico SL, Figueiredo DB, Gon&#xe7;alves VM, Ferreira DM, Kunda NK, Saleem IY, Miyaji EN, et al. Mucosal immunization with PspA (Pneumococcal surface protein a)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS One. 2018;13(1):e0191692. doi:10.1371/journal.pone.0191692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191692</ArticleId><ArticleId IdType="pmc">PMC5779684</ArticleId><ArticleId IdType="pubmed">29360883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y. Nasal vaccination with pneumococcal surface protein a in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Int Immunopharmacol. 2018;61:385&#x2013;393. doi:10.1016/j.intimp.2018.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.06.027</ArticleId><ArticleId IdType="pubmed">29945026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner-Mu&#xf1;iz DA, Haughney SL, Kelly SM, Wannemuehler MJ, Narasimhan B. Room temperature stable PspA-based Nanovaccine induces protective immunity. Front Immunol. 2018;9:325. doi:10.3389/fimmu.2018.00325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00325</ArticleId><ArticleId IdType="pmc">PMC5863507</ArticleId><ArticleId IdType="pubmed">29599766</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama Y, Yuki Y, Katakai Y, Harada N, Takahashi H, Takeda S, Mejima M, Joo S, Kurokawa S, Sawada S, et al. Nanogel-based pneumococcal surface protein a nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques. Mucosal Immunol. 2015;8(5):1144&#x2013;1153. doi:10.1038/mi.2015.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2015.5</ArticleId><ArticleId IdType="pmc">PMC4762909</ArticleId><ArticleId IdType="pubmed">25669148</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo S-U, Kim J-J, Yang H, Kwon H-J, Yang J-Y, Curtiss Iii R, Kweon M-N. Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice. Vaccine. 2012;30(48):6816&#x2013;6823. doi:10.1016/j.vaccine.2012.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.015</ArticleId><ArticleId IdType="pubmed">23000127</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes APY, Ren B, Briles DE, Hollingshead SK, Leite LCC. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun. 2007;75(12):5930&#x2013;5938. doi:10.1128/IAI.00940-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00940-07</ArticleId><ArticleId IdType="pmc">PMC2168346</ArticleId><ArticleId IdType="pubmed">17923518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahashi-Ouchida R, Uchida Y, Yuki Y, Katakai Y, Yamanoue T, Ogawa H, Munesue Y, Nakano N, Hanari K, Miyazaki T, et al. A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci. Vaccine. 2021;39(25):3353&#x2013;3364. doi:10.1016/j.vaccine.2021.04.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.069</ArticleId><ArticleId IdType="pubmed">34016473</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao Z, Akeda Y, Takeuchi D, Ishii KJ, Ubukata K, Briles DE, Tomono K, Oishi K. Protective properties of a fusion pneumococcal surface protein a (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice. Vaccine. 2014;32(43):5607&#x2013;5613. doi:10.1016/j.vaccine.2014.07.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.07.108</ArticleId><ArticleId IdType="pubmed">25132335</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira MLS, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PCD, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, et al. Combination of pneumococcal surface protein a (PspA) with whole cell pertussis vaccine increases protection against Pneumococcal challenge in Mice. PLOS ONE. 2010;5(5):e10863. doi:10.1371/journal.pone.0010863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010863</ArticleId><ArticleId IdType="pmc">PMC2877721</ArticleId><ArticleId IdType="pubmed">20523738</ArticleId></ArticleIdList></Reference><Reference><Citation>Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin a (PsaA). Microb Pathog. 1996;21(1):17&#x2013;22. doi:10.1006/mpat.1996.0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mpat.1996.0038</ArticleId><ArticleId IdType="pubmed">8827703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, Curtiss R. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun. 2010;78(7):3258&#x2013;3271. doi:10.1128/IAI.00176-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00176-10</ArticleId><ArticleId IdType="pmc">PMC2897375</ArticleId><ArticleId IdType="pubmed">20479086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gor DO, Ding X, Li Q, Sultana D, Mambula SS, Bram RJ, Greenspan NS. Enhanced immunogenicity of pneumococcal surface adhesin a (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS). Biol Direct. 2011;6(1):9. doi:10.1186/1745-6150-6-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6150-6-9</ArticleId><ArticleId IdType="pmc">PMC3055212</ArticleId><ArticleId IdType="pubmed">21306646</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X. Intranasal vaccination with Chitosan-DNA nanoparticles expressing Pneumococcal surface antigen a protects Mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol. 2011;18(1):75&#x2013;81. doi:10.1128/CVI.00263-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00263-10</ArticleId><ArticleId IdType="pmc">PMC3019786</ArticleId><ArticleId IdType="pubmed">21047997</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J-H, Dai W-J, Chen B, Fan X-Y. Mucosal immunization with PsaA protein, using Chitosan as a delivery system, increases protection against acute Otitis media and invasive infection by Streptococcus pneumoniae. Scand J Immunol. 2015;81(3):177&#x2013;185. doi:10.1111/sji.12267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12267</ArticleId><ArticleId IdType="pubmed">25565478</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; GO, Borges MT, Assoni L, Ferraz LFC, Sakshi P, Adamson P, Gordon DL, Ogunniyi AD, Venter H, Converso TR, et al. Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis. Vaccine. 2021;39(27):3626&#x2013;3632. doi:10.1016/j.vaccine.2021.04.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.068</ArticleId><ArticleId IdType="pubmed">34045100</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekan M, Siadat SD, Aghasadeghi M, Shahrokhi N, Afrough P, Behrouzi A, Ahmadi K, Mousavi SF. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants. J Med Microbiol. 2020;69(3):465&#x2013;477. doi:10.1099/jmm.0.001103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001103</ArticleId><ArticleId IdType="pubmed">32100705</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MN, Pichichero ME, Camilli A. CD4 T Cell Memory and Antibody Responses Directed against the Pneumococcal Histidine Triad Proteins PhtD and PhtE following Nasopharyngeal colonization and immunization and their role in protection against Pneumococcal colonization in Mice. Infect Immun. 2013;81(10):3781&#x2013;3792. doi:10.1128/IAI.00313-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00313-13</ArticleId><ArticleId IdType="pmc">PMC3811773</ArticleId><ArticleId IdType="pubmed">23897609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D, Brodeur BR. Prevention of Pneumococcal disease in Mice immunized with conserved surface-accessible proteins. Infect Immun. 2004;72(5):2659&#x2013;2670. doi:10.1128/IAI.72.5.2659-2670.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.5.2659-2670.2004</ArticleId><ArticleId IdType="pmc">PMC387903</ArticleId><ArticleId IdType="pubmed">15102774</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose L, Shivshankar P, Hinojosa E, Rodriguez A, Sanchez CJ, Orihuela CJ. Antibodies against PsrP, a Novel Streptococcus pneumoniae Adhesin, block adhesion and protect Mice against Pneumococcal challenge. J Infect Dis. 2008;198(3):375&#x2013;383. doi:10.1086/589775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/589775</ArticleId><ArticleId IdType="pubmed">18507531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C-J, Lock RA, Andrew PW, Mitchell TJ, Hansman D, Paton JC. Protection of infant mice from challenge with Strptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide&#x2014;pneumolysoid conjugate. Vaccine. 1994;12(10):875&#x2013;878. doi:10.1016/0264-410X(94)90028-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(94)90028-0</ArticleId><ArticleId IdType="pubmed">7975828</ArticleId></ArticleIdList></Reference><Reference><Citation>Michon F, Fusco PC, Minetti CASA, Laude-Sharp M, Uitz C, Huang C-H, D&#x2019;Ambra AJ, Moore S, Remeta DP, Heron I, et al. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine. 1998;16(18):1732&#x2013;1741. doi:10.1016/S0264-410X(98)00225-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(98)00225-4</ArticleId><ArticleId IdType="pubmed">9778749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo J, Douglas M, Ree HK, Lindberg AA. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect Immun. 1995;63(7):2706&#x2013;2713. doi:10.1128/iai.63.7.2706-2713.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.63.7.2706-2713.1995</ArticleId><ArticleId IdType="pmc">PMC173362</ArticleId><ArticleId IdType="pubmed">7790088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Guo R, Xu J, Qiu C. Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier. Front Med. 2016;10(4):490&#x2013;498. doi:10.1007/s11684-016-0470-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-016-0470-y</ArticleId><ArticleId IdType="pubmed">27650380</ArticleId></ArticleIdList></Reference><Reference><Citation>Deno&#xeb;l P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine. 2011;29(33):5495&#x2013;5501. doi:10.1016/j.vaccine.2011.05.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.05.051</ArticleId><ArticleId IdType="pmc">PMC5061031</ArticleId><ArticleId IdType="pubmed">21624422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill S, Entwisle C, Pang Y, Joachim M, McIlgorm A, Dalton K, Burbidge P, Colaco C, Brown J, Goldblatt D, et al. Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae. Vaccine. 2018;36(29):4255&#x2013;4264. doi:10.1016/j.vaccine.2018.05.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.122</ArticleId><ArticleId IdType="pubmed">29895498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A, Mann B, Gao G, Heath R, King J, Maissoneuve J, Alderson M, Tate A, Hollingshead SK, Tweten RK, et al. Multivalent Pneumococcal protein vaccines comprising Pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protection. Clin Vaccine Immunol. 2015;22(10):1079&#x2013;1089. doi:10.1128/CVI.00293-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00293-15</ArticleId><ArticleId IdType="pmc">PMC4580740</ArticleId><ArticleId IdType="pubmed">26245351</ArticleId></ArticleIdList></Reference><Reference><Citation>Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, Virolainen A, Swiatlo E, Hollingshead SK. Intranasal immunization of Mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against Nasopharyngeal Carriage of Streptococcus pneumoniae. Infect Immun. 2000;68(2):796&#x2013;800. doi:10.1128/IAI.68.2.796-800.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.68.2.796-800.2000</ArticleId><ArticleId IdType="pmc">PMC97207</ArticleId><ArticleId IdType="pubmed">10639448</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Chen X, Li B, Gu T, Meng X, Kong W, Wu Y. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains. Immunol Res. 2018;66(4):528&#x2013;536. doi:10.1007/s12026-018-9016-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-018-9016-5</ArticleId><ArticleId IdType="pubmed">30128745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zane L, Kraschowetz S, Trentini MM, Alves VDS, Araujo SC, Goulart C, Leite LCDC, Gon&#xe7;alves VM. Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate. Front Bioeng Biotechnol. 2023;11:1108300. doi:10.3389/fbioe.2023.1108300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2023.1108300</ArticleId><ArticleId IdType="pmc">PMC9909212</ArticleId><ArticleId IdType="pubmed">36777254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann B, Thornton J, Heath R, Wade KR, Tweten RK, Gao G, El Kasmi K, Jordan JB, Mitrea DM, Kriwacki R, et al. Broadly protective protein-based Pneumococcal vaccine composed of Pneumolysin Toxoid&#x2013;CbpA peptide recombinant fusion protein. J Infect Dis. 2014;209(7):1116&#x2013;1125. doi:10.1093/infdis/jit502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit502</ArticleId><ArticleId IdType="pmc">PMC3952665</ArticleId><ArticleId IdType="pubmed">24041791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive Pneumococcal disease based on combinations of virulence proteins. Infect Immun. 2007;75(1):350&#x2013;357. doi:10.1128/IAI.01103-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.01103-06</ArticleId><ArticleId IdType="pmc">PMC1828427</ArticleId><ArticleId IdType="pubmed">17088353</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeven D, Xu Q, Pichichero ME. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model. Vaccine. 2014;32(26):3205&#x2013;3210. doi:10.1016/j.vaccine.2014.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.04.004</ArticleId><ArticleId IdType="pubmed">24731814</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Surendran N, Verhoeven D, Klapa J, Ochs M, Pichichero ME. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis. Vaccine. 2015;33(8):993&#x2013;1000. doi:10.1016/j.vaccine.2015.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.01.014</ArticleId><ArticleId IdType="pubmed">25597944</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Pryharski K, Pichichero ME. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model. Vaccine. 2017;35(2):337&#x2013;344. doi:10.1016/j.vaccine.2016.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.11.046</ArticleId><ArticleId IdType="pubmed">27919628</ArticleId></ArticleIdList></Reference><Reference><Citation>Visan L, Rouleau N, Proust E, Peyrot L, Donadieu A, Ochs M. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism. Hum Vaccines Immunother. 2018;14(2):489&#x2013;494. doi:10.1080/21645515.2017.1403698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1403698</ArticleId><ArticleId IdType="pmc">PMC5806646</ArticleId><ArticleId IdType="pubmed">29135332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, Kong FT, Liang C, Gu T, Chen P, et al. Protective immune responses elicited by fusion protein containing PsaA and PspA fragments. Immunol Invest. 2015;44(5):482&#x2013;496. doi:10.3109/08820139.2015.1037956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08820139.2015.1037956</ArticleId><ArticleId IdType="pubmed">26107747</ArticleId></ArticleIdList></Reference><Reference><Citation>Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I, Camilli A. Novel protein-based Pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against Pneumococcal disease in neonatal. Infect Immun. 2012;80(1):461&#x2013;468. doi:10.1128/IAI.05801-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.05801-11</ArticleId><ArticleId IdType="pmc">PMC3255653</ArticleId><ArticleId IdType="pubmed">22025519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jomaa M, Yuste J, Paton JC, Jones C, Dougan G, Brown JS. Antibodies to the iron uptake ABC transporter Lipoproteins PiaA and PiuA promote Opsonophagocytosis of Streptococcus pneumoniae. Infect Immun. 2005;73(10):6852&#x2013;6859. doi:10.1128/IAI.73.10.6852-6859.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.10.6852-6859.2005</ArticleId><ArticleId IdType="pmc">PMC1230898</ArticleId><ArticleId IdType="pubmed">16177364</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC, Tuomanen EI. Immunization with components of two iron uptake ABC transporters protects Mice against systemic Streptococcus pneumoniae infection. Infect Immun. 2001;69(11):6702&#x2013;6706. doi:10.1128/IAI.69.11.6702-6706.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.11.6702-6706.2001</ArticleId><ArticleId IdType="pmc">PMC100046</ArticleId><ArticleId IdType="pubmed">11598041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jomaa M, Terry S, Hale C, Jones C, Dougan G, Brown J. Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae. Vaccine. 2006;24(24):5133&#x2013;5139. doi:10.1016/j.vaccine.2006.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.04.012</ArticleId><ArticleId IdType="pubmed">16707196</ArticleId></ArticleIdList></Reference><Reference><Citation>Malley R, Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated Pneumococci. Infect Immun. 2001;69(8):4870&#x2013;4873. doi:10.1128/IAI.69.8.4870-4873.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.8.4870-4873.2001</ArticleId><ArticleId IdType="pmc">PMC98576</ArticleId><ArticleId IdType="pubmed">11447162</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H, Dunham A, Hansen B, Anderson K, Maisonneuve J-F, Hem SL. Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. J Immune Based Ther Vaccines. 2011;9(1):5. doi:10.1186/1476-8518-9-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-8518-9-5</ArticleId><ArticleId IdType="pmc">PMC3161839</ArticleId><ArticleId IdType="pubmed">21801401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y-J, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, Seid R, Look J, Alderson M, Tate A, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated Pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010;17(6):1005&#x2013;1012. doi:10.1128/CVI.00036-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00036-10</ArticleId><ArticleId IdType="pmc">PMC2884428</ArticleId><ArticleId IdType="pubmed">20427625</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Meng J, Wang Y, Zheng J, Wu K, Zhang X, Yin Y, Zhang Q. Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1. J Microbiol. 2014;52(4):315&#x2013;323. doi:10.1007/s12275-014-3583-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12275-014-3583-5</ArticleId><ArticleId IdType="pubmed">24682994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E-H, Choi S-Y, Kwon M-K, Tran TDH, Park S-S, Lee K-J, Bae S-M, Briles DE, Rhee D-K. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine. 2012;30(11):2008&#x2013;2019. doi:10.1016/j.vaccine.2011.11.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.073</ArticleId><ArticleId IdType="pubmed">22154770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-J, Seon SH, Luong TT, Ghosh P, Pyo S, Rhee D-K. Immunization with attenuated non-transformable pneumococcal pep27 and comD mutant provides serotype-independent protection against pneumococcal infection. Vaccine. 2019;37(1):90&#x2013;98. doi:10.1016/j.vaccine.2018.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.11.027</ArticleId><ArticleId IdType="pubmed">30467061</ArticleId></ArticleIdList></Reference><Reference><Citation>Amonov M, Simbak N, Wan Hassan W, Ismail SA, Rahman NI, Clarke SC, Yeo CC. Disruption of the cpsE and endA genescattenuates Streptococcus pneumoniae virulence: towards the development of a live attenuated vaccine candidate. Vaccines. 2020;8(2):187. doi:10.3390/vaccines8020187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020187</ArticleId><ArticleId IdType="pmc">PMC7349068</ArticleId><ArticleId IdType="pubmed">32326482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Sevillano E, Ercoli G, Guerra-Assun&#xe7;&#xe3;o JA, Felgner P, Ramiro de Assis R, Nakajima R, Goldblatt D, Tetteh KKA, Heyderman RS, Gordon SB, et al. Protective Effect of Nasal Colonisation with &#x2206;cps/piaA and &#x2206;cps/proAbcstreptococcus pneumoniae Strains against Recolonisation and Invasive Infection. Vaccines. 2021;9(3):261. doi:10.3390/vaccines9030261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030261</ArticleId><ArticleId IdType="pmc">PMC8000150</ArticleId><ArticleId IdType="pubmed">33804077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, Corde N, Pouzet C, Zimmermann G, Gurunathan S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013;31(2):327&#x2013;333. doi:10.1016/j.vaccine.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.11.005</ArticleId><ArticleId IdType="pubmed">23153437</ArticleId></ArticleIdList></Reference><Reference><Citation>Entwisle C, Hill S, Pang Y, Joachim M, McIlgorm A, Colaco C, Goldblatt D, De Gorguette D&#x2019;Argoeuves P, Bailey C. Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial. Vaccine. 2017;35(51):7181&#x2013;7186. doi:10.1016/j.vaccine.2017.10.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.10.076</ArticleId><ArticleId IdType="pubmed">29132988</ArticleId></ArticleIdList></Reference><Reference><Citation>Prymula R, Pazdiora P, Traskine M, R&#xfc;ggeberg JU, Borys D. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine. 2014;32(25):3025&#x2013;3034. doi:10.1016/j.vaccine.2014.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.066</ArticleId><ArticleId IdType="pubmed">24699466</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012;30(52):7455&#x2013;7460. doi:10.1016/j.vaccine.2012.10.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.080</ArticleId><ArticleId IdType="pubmed">23131206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein a (PcpA) vaccine and bivalent PcpA&#x2013;pneumococcal histidine triad protein D vaccine. Vaccine. 2012;30(52):7461&#x2013;7468. doi:10.1016/j.vaccine.2012.10.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.076</ArticleId><ArticleId IdType="pubmed">23123106</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks WA, Chang L-J, Sheng X, Hopfer R. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. Vaccine. 2015;33(36):4610&#x2013;4617. doi:10.1016/j.vaccine.2015.06.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.078</ArticleId><ArticleId IdType="pubmed">26143615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines. 2017;16(12):1181&#x2013;1190. doi:10.1080/14760584.2017.1393335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1393335</ArticleId><ArticleId IdType="pmc">PMC6277969</ArticleId><ArticleId IdType="pubmed">29130395</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels I, Devaster J-M, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapeli&#xe8;re P, et al. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials. Vaccine. 2015;33(4):577&#x2013;584. doi:10.1016/j.vaccine.2013.10.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.10.052</ArticleId><ArticleId IdType="pubmed">24176494</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroux-Roels G, Maes C, De Boever F, Traskine M, R&#xfc;ggeberg JU, Borys D. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine. 2014;32(50):6838&#x2013;6846. doi:10.1016/j.vaccine.2014.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.02.052</ArticleId><ArticleId IdType="pubmed">24607003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapeli&#xe8;re PG, Verlant V, Vink PE. Randomized controlled study of the safety and immunogenicity of Pneumococcal vaccine formulations containing PhtD and detoxified Pneumolysin with alum or adjuvant system AS02V in elderly adults. Clin Vaccine Immunol. 2014;21(5):651&#x2013;660. doi:10.1128/CVI.00807-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00807-13</ArticleId><ArticleId IdType="pmc">PMC4018883</ArticleId><ArticleId IdType="pubmed">24599529</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutola A, Ota M, Ogundare E, Antonio M, Owiafe P, Worwui A, Greenwood B, Alderson M, Traskine M, Verlant V, et al. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2&#x2013;4 years: a phase II randomized study. Hum Vaccines Immunother. 2016;12(2):393&#x2013;402. doi:10.1080/21645515.2015.1111496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1111496</ArticleId><ArticleId IdType="pmc">PMC5049746</ArticleId><ArticleId IdType="pubmed">26618243</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study. Vaccine. 2017;35(19):2531&#x2013;2542. doi:10.1016/j.vaccine.2017.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.071</ArticleId><ArticleId IdType="pubmed">28389097</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Owiafe PK, Worwui A, Idoko OT, Owolabi O, Kampmann B, et al. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines &#x2013; a phase II, randomised, observer-blind study in Gambian infants. Vaccine. 2019;37(19):2586&#x2013;2599. doi:10.1016/j.vaccine.2019.03.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.03.033</ArticleId><ArticleId IdType="pubmed">30975570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammitt LL, Campbell JC, Borys D, Weatherholtz RC, Reid R, Goklish N, Moulton LH, Traskine M, Song Y, Swinnen K, et al. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: a phase IIb randomized study. Vaccine. 2019;37(51):7482&#x2013;7492. doi:10.1016/j.vaccine.2019.09.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.076</ArticleId><ArticleId IdType="pubmed">31629570</ArticleId></ArticleIdList></Reference><Reference><Citation>Borys D, Rupp R, Smulders R, Chichili GR, Kovanda LL, Santos V, Malinoski F, Siber G, Malley R, Sebastian S. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: a phase 1 randomized controlled trial. Vaccine. 2024;42(10):2560&#x2013;2571. doi:10.1016/j.vaccine.2024.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.02.001</ArticleId><ArticleId IdType="pubmed">38360475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chichili GR, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, Malinoski F, Sebastian S, Siber G, Malley R. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine. 2022;40(31):4190&#x2013;4198. doi:10.1016/j.vaccine.2022.05.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.079</ArticleId><ArticleId IdType="pubmed">35690500</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaji EN, Oliveira MLS, Carvalho E, Ho PL. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70(18):3303&#x2013;3326. doi:10.1007/s00018-012-1234-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-1234-8</ArticleId><ArticleId IdType="pmc">PMC11113425</ArticleId><ArticleId IdType="pubmed">23269437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G-L, Seon S-H, Rhee D-K. Pneumonia and Streptococcus pneumoniae vaccine. Arch Pharm Res. 2017;40(8):885&#x2013;893. doi:10.1007/s12272-017-0933-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-017-0933-y</ArticleId><ArticleId IdType="pmc">PMC7090487</ArticleId><ArticleId IdType="pubmed">28735461</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo&#xdf; F, Kohler TP, Meyer T, Abdullah MR, van Opzeeland FJ, Saleh M, Michalik S, van Selm S, Schmidt F, de Jonge MI, et al. Intranasal vaccination with lipoproteins confers protection against Pneumococcal colonisation. Front Immunol. 2018;9:2405. doi:10.3389/fimmu.2018.02405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02405</ArticleId><ArticleId IdType="pmc">PMC6202950</ArticleId><ArticleId IdType="pubmed">30405609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler S, Vo&#xdf; F, G&#xf3;mez Mejia A, Brown JS, Hammerschmidt S. Pneumococcal lipoproteins involved in bacterial fitness, virulence, and immune evasion. FEBS Lett. 2016;590(21):3820&#x2013;3839. doi:10.1002/1873-3468.12352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12352</ArticleId><ArticleId IdType="pubmed">27508940</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccines Immunother. 2016;12(2):383&#x2013;392. doi:10.1080/21645515.2015.1087625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1087625</ArticleId><ArticleId IdType="pmc">PMC5049723</ArticleId><ArticleId IdType="pubmed">26535755</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech CA, Morrison R, Anderson P, Tate A, Flores J, Goldblatt D, Briles D, Hural J, Malley R, Alderson MR. A Phase 1 Randomized, Placebo-controlled, Observer-blinded trial to evaluate the safety and immunogenicity of inactivated Streptococcus pneumoniae whole-cell vaccine in adults. Pediatr Infect Dis J. 2020;39(4):345&#x2013;351. doi:10.1097/INF.0000000000002567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002567</ArticleId><ArticleId IdType="pubmed">31895881</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais V, Texeira E, Suarez N. Next-generation whole-cell Pneumococcal vaccine. Vaccines. 2019;7(4):151. doi:10.3390/vaccines7040151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040151</ArticleId><ArticleId IdType="pmc">PMC6963273</ArticleId><ArticleId IdType="pubmed">31623286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dose-Finding Study of S. Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers. [accessed 2024 Dec
13]. https://clinicaltrials.gov/study/NCT02097472.</Citation></Reference><Reference><Citation>A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya. [accessed 2024 Dec
13]. https://clinicaltrials.gov/study/NCT02543892.</Citation></Reference><Reference><Citation>Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults. [accessed 2024 Dec
13]. https://clinicaltrials.gov/study/NCT00896064.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39994387</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography.</ArticleTitle><Pagination><StartPage>6577</StartPage><MedlinePgn>6577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-90730-9</ELocationID><Abstract><AbstractText>Neutralizing antibody titers have been found to be strongly correlated with observed vaccine effectiveness against symptomatic and severe COVID-19. Few non-high complexity assays are currently available to detect the presence of neutralizing antibodies. This retrospective single-center cross-sectional study compared the performance of a lateral flow immunochromatography assay coupled with a spectrophotometric measurement system for detecting SARS-CoV-2 neutralizing antibodies against an enzyme-linked immunosorbent assay (ELISA) neutralization antibody assay in the context of post-vaccination responses. The limit of detection was similar to the ELISA with strong linearity throughout the measuring interval. Repeatability, interfering substances, and cross-reactivity studies were found to be robust. Results for 274 plasma samples on whom SARS-CoV-2 RNA test and vaccination status, including vaccination number and manufacturer, was known showed a positive predictive value (PPV) of 99.0% (CI 96.4-99.7%) and a negative predictive value (NPV) of 91.9% (CI 83.4-96.2%) compared to ELISA. The PPV for all vaccination number and manufacturer subgroups was&#x2009;&gt;&#x2009;95% except for those individuals who had only 1 Pfizer vaccination (PPV of 80%). The NPV for those who were PCR positive with no vaccinations was 100% while only 88.1% for those without a previous positive test or vaccination. The NPV for those with Pfizer vaccinations was 80% in contrast to 100% for those with Moderna vaccinations. Alternative methodologies requiring less sophisticated laboratory support to measure neutralizing antibodies may be useful to measure vaccine responses.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jianqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DiaVac Biotech Company, Doylestown, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaniper</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vabishchevich</LastName><ForeName>Yuliya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyantakyi</LastName><ForeName>Nana</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Dorret</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Hai-Lung</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>DiaVac Biotech Company, Doylestown, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Glenn S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA. gsgerhard@Temple.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>268129</GrantID><Agency>Dia-Vac</Agency><Country/></Grant><Grant><GrantID>G-76756</GrantID><Agency>Genentech Foundation</Agency><Country/></Grant><Grant><GrantID>57279519</GrantID><Agency>Pfizer</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="Y">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013053" MajorTopicYN="N">Spectrophotometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neutralizing antibody</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: H-LD is a stockholder and Chair of the DiaVac Scientific Advisory board. GSG has obtained grant funding from DiaVac, Genentech, and Pfizer. H-LD and GSG are employees of Temple University. H-LD and GSG have conflict of interest mitigation/monitoring plans enforced by Temple University. JM is an employee of DiaVac. None of the other authors (SK, YV, NN, DL, FC) have any competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>25</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>25</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>24</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39994387</ArticleId><ArticleId IdType="pmc">PMC11850742</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-90730-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-90730-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kudlay, D., Svistunov, A. &amp; Satyshev, O. COVID-19 vaccines: An updated overview of different platforms. Bioengineering (Basel)10.3390/bioengineering9110714 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9687223</ArticleId><ArticleId IdType="pubmed">36421115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: A meta-analysis. Nat. Commun.14, 1633. 10.1038/s41467-023-37176-7 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10036966</ArticleId><ArticleId IdType="pubmed">36964146</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccaluga, P. P. et al. COVID-19 vaccine: Between Myth and Truth. Vaccines (Basel)10.3390/vaccines10030349 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950941</ArticleId><ArticleId IdType="pubmed">35334981</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet398, 1407&#x2013;1416. 10.1016/S0140-6736(21)02183-8 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Interim Guidelines for COVID-19 Antibody Testing, &lt;https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html#AntibodyTests&gt; (2023).</Citation></Reference><Reference><Citation>Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis.26, 1478&#x2013;1488. 10.3201/eid2607.200841 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323511</ArticleId><ArticleId IdType="pubmed">32267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C., Wen, T., Shi, F. J., Zeng, X. Y. &amp; Jiao, Y. J. Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay. ACS Omega5, 12550&#x2013;12556. 10.1021/acsomega.0c01554 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241732</ArticleId><ArticleId IdType="pubmed">32542208</ArticleId></ArticleIdList></Reference><Reference><Citation>Markmann, A. J. et al. A semi-quantitative, rapid, point of care SARS-CoV-2 serologic assay predicts neutralizing antibody levels. bioRxiv, 10.1101/2023.05.30.542314 (2023).</Citation></Reference><Reference><Citation>Zhang, Y. et al. Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test. Talanta255, 124200. 10.1016/j.talanta.2022.124200 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767659</ArticleId><ArticleId IdType="pubmed">36565525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabidian, M. et al. Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants. J. Clin. Virol.155, 105268. 10.1016/j.jcv.2022.105268 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383946</ArticleId><ArticleId IdType="pubmed">35998394</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulford, T. S. et al. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine74, 103729. 10.1016/j.ebiom.2021.103729 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641961</ArticleId><ArticleId IdType="pubmed">34871960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake, D. F. et al. Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. J. Clin. Virol.145, 105024. 10.1016/j.jcv.2021.105024 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8567411</ArticleId><ArticleId IdType="pubmed">34781240</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel, O., Rockstroh, A., Borte, S. &amp; Wolf, J. Evaluation of simple lateral flow immunoassays for detection of SARS-CoV-2 neutralizing antibodies. Vaccines (Basel)10.3390/vaccines10030347 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949379</ArticleId><ArticleId IdType="pubmed">35334979</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes, N. et al. Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from Plasma or fingerstick whole-blood of COVID-19 vaccinees. Vaccines (Basel)10.3390/vaccines10081318 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415525</ArticleId><ArticleId IdType="pubmed">36016206</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. In Vitro Diagnostics Emergency Use Authorizations (EUAs) - Serology and Other Adaptive Immune Response Tests for SARS-CoV-2, &lt;https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2&gt; (2023).</Citation></Reference><Reference><Citation>Taylor, S. C. et al. A new SARS-CoV-2 dual-purpose serology test: Highly accurate infection tracing and neutralizing antibody response detection. J. Clin. Microbiol.10.1128/JCM.02438-20 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092720</ArticleId><ArticleId IdType="pubmed">33500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, K. et al. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. J. Clin. Lab. Anal.35, e23921. 10.1002/jcla.23921 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418513</ArticleId><ArticleId IdType="pubmed">34369009</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, J., Rajapakshe, D., Julien, C. &amp; Devaraj, S. Analytical and clinical performance of cPass neutralizing antibodies assay. Clin. Biochem.98, 70&#x2013;73. 10.1016/j.clinbiochem.2021.09.008 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453782</ArticleId><ArticleId IdType="pubmed">34560062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri, M. et al. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies. Arch. Virol.167, 1285&#x2013;1291. 10.1007/s00705-022-05422-w (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977564</ArticleId><ArticleId IdType="pubmed">35377034</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu, W. H. et al. A faster, novel technique to detect COVID-19 neutralizing antibodies. Med. Sci. Monit.28, e935812. 10.12659/MSM.935812 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9344884</ArticleId><ArticleId IdType="pubmed">35340017</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath, J. et al. Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity-lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices. Front. Public Health11, 1245464. 10.3389/fpubh.2023.1245464 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10569692</ArticleId><ArticleId IdType="pubmed">37841735</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, R. L. et al. A lateral flow immunoassay coupled with a spectrum-based reader for SARS-CoV-2 neutralizing antibody detection. Vaccines (Basel)10.3390/vaccines10020271 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877288</ArticleId><ArticleId IdType="pubmed">35214731</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, J. D. et al. Comparison of four systems for SARS-CoV-2 antibody at three time points after SARS-CoV-2 vaccination. Diagnostics (Basel)10.3390/diagnostics12061349 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9222035</ArticleId><ArticleId IdType="pubmed">35741159</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene, S. E. et al. A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination. J. Clin. Virol. Plus3, 100135. 10.1016/j.jcvp.2023.100135 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9831968</ArticleId><ArticleId IdType="pubmed">36644774</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhamid, G., Tombuloglu, H., Rabaan, A. A. &amp; Al-Suhaimi, E. SARS-CoV-2 detection methods: A comprehensive review. Saudi J. Biol. Sci.29, 103465. 10.1016/j.sjbs.2022.103465 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9512523</ArticleId><ArticleId IdType="pubmed">36186678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. et al. Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2. Anal. Biochem.673, 115199. 10.1016/j.ab.2023.115199 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226777</ArticleId><ArticleId IdType="pubmed">37257735</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicuzza, L. et al. An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. AIMS Microbiol.9, 375&#x2013;401. 10.3934/microbiol.2023020 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113162</ArticleId><ArticleId IdType="pubmed">37091823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhani, K. et al. Clinical utility of SARS-CoV-2 serological testing and defining a correlate of protection. Vaccines (Basel)10.3390/vaccines11111644 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10674881</ArticleId><ArticleId IdType="pubmed">38005976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden, M. K. et al. Infectious diseases society of America Guidelines on the diagnosis of COVID-19: Serologic testing. Clin. Infect. Dis.10.1093/cid/ciae121 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38489670</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos, H., Trougakos, I. P., Dimopoulos, M. A. &amp; Terpos, E. Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies. Eur. J. Intern. Med.10.1016/j.ejim.2022.11.009 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647045</ArticleId><ArticleId IdType="pubmed">36379820</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA (2023).</Citation></Reference><Reference><Citation>Lingas, G. et al. Neutralizing antibody levels as a correlate of protection against SARS-CoV-2 infection: A modeling analysis. Clin. Pharmacol. Ther.115, 86&#x2013;94. 10.1002/cpt.3069 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37795693</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, P. et al. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci. Transl. Med.15, eadg2783. 10.1126/scitranslmed.adg2783 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36947596</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med.27, 1205&#x2013;1211. 10.1038/s41591-021-01377-8 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra, A. &amp; Theel, E. S. Immunity to SARS-CoV-2: What do we know and should we be testing for it?. J. Clin. Microbiol.60, e0048221. 10.1128/jcm.00482-21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9199399</ArticleId><ArticleId IdType="pubmed">35249377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen, H. et al. Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2. NPJ Vaccines8, 159. 10.1038/s41541-023-00756-1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10589259</ArticleId><ArticleId IdType="pubmed">37863890</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthar, M. S. Durability of immune responses to SARS-CoV-2 infection and vaccination. Semin. Immunol.73, 101884. 10.1016/j.smim.2024.101884 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11490408</ArticleId><ArticleId IdType="pubmed">38861769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinger, P., Ohradanova-Repic, A. &amp; Valenta, R. Importance, applications and features of assays measuring SARS-CoV-2 neutralizing antibodies. Int. J. Mol. Sci.10.3390/ijms24065352 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048970</ArticleId><ArticleId IdType="pubmed">36982424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39982277</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2673-6284</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Biotech (Basel (Switzerland))</Title><ISOAbbreviation>BioTech (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Live-Cell Imaging-Based Fluorescent SARS-CoV-2 Neutralization Assay by Antibody-Mediated Blockage of Receptor Binding Domain-ACE2 Interaction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biotech14010010</ELocationID><Abstract><AbstractText>Neutralization assays have become an important tool since the beginning of the COVID-19 pandemic for testing vaccine responses and therapeutic antibodies as well as for monitoring humoral immunity to SARS-CoV-2 in epidemiological studies. The spike glycoprotein (S) present on the viral surface contains a receptor binding domain (RBD) that recognizes the angiotensin-converting enzyme 2 receptor (ACE2) in host cells, allowing virus entry. The gold standard for determining SARS-CoV-2 neutralizing antibodies is the plaque reduction neutralization test (PRNT), which relies on live-virus replication performed exclusively in biosafety level 3 (BSL-3) laboratories. Here, we report the development of a surrogate live-cell imaging-based fluorescent SARS-CoV-2 neutralization assay, applicable to BSL-1 or BSL-2 laboratories, by antibody-mediated blockage of the interaction between recombinant RBD with overexpressed ACE2 receptor in a genetically modified HEK 293T stable cell line. Our approach was able to detect neutralizing antibodies both in COVID-19-positive human serum samples and polyclonal equine formulations against SARS-CoV-2. This new cell-based surrogate neutralization assay represents a virus-free fluorescence imaging alternative to the reported approaches, which can be used to detect antibody-neutralizing capabilities toward SARS-CoV-2. This assay could also be extrapolated in the future to other established and emergent viral agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arias-Arias</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-7872-1068</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Enfermedades Tropicales (CIET), Facultad de Microbiolog&#xed;a, Universidad de Costa Rica, San Jos&#xe9; 11501-2060, Costa Rica.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dulbecco Lab Studio, Residencial Lisboa 2G, Alajuela 20102, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monturiol-Gross</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7910-4715</Identifier><AffiliationInfo><Affiliation>Instituto Clodomiro Picado (ICP), Facultad de Microbiolog&#xed;a, Universidad de Costa Rica, San Jos&#xe9; 11501-2060, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrales-Aguilar</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0845-8329</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Enfermedades Tropicales (CIET), Facultad de Microbiolog&#xed;a, Universidad de Costa Rica, San Jos&#xe9; 11501-2060, Costa Rica.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C1509</GrantID><Agency>International Centre for Genetic Engineering and Biotechnology</Agency><Country/></Grant><Grant><GrantID>Fondo de Est&#xed;mulo C1015, Grant UCREA C0344</GrantID><Agency>Universidad de Costa Rica</Agency><Country/></Grant><Grant><GrantID>MICITT grant C2500</GrantID><Agency>National Ministry of Science and Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>BioTech (Basel)</MedlineTA><NlmUniqueID>9918383086206676</NlmUniqueID><ISSNLinking>2673-6284</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cell-based COVID-19 serology</Keyword><Keyword MajorTopicYN="N">fluorescence live-cell imaging</Keyword><Keyword MajorTopicYN="N">surrogate neutralization assay</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39982277</ArticleId><ArticleId IdType="pmc">PMC11843899</ArticleId><ArticleId IdType="doi">10.3390/biotech14010010</ArticleId><ArticleId IdType="pii">biotech14010010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., Haagmans B., Lauber C., Leontovich A.M., Neuman B.W., et al. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M., Khaleeq A., Syeda H. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis. J. Med. Virol. 2020;92:2792&#x2013;2803. doi: 10.1002/jmv.26212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26212</ArticleId><ArticleId IdType="pmc">PMC7362098</ArticleId><ArticleId IdType="pubmed">32573788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215&#x2013;220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Yang C., Xu X., Xu W., Liu S. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 2020;41:1141&#x2013;1149. doi: 10.1038/s41401-020-0485-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Li W., Farzan M., Harrison S.C. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. Science (1979) 2005;309:1864&#x2013;1869. doi: 10.1126/science.1116480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1116480</ArticleId><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221&#x2013;224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W., He L., Zhang X., Pu J., Voronin D., Jiang S., Zhou Y., Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol. 2020;17:613&#x2013;620. doi: 10.1038/s41423-020-0400-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0400-4</ArticleId><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685&#x2013;700. doi: 10.1038/s41579-021-00630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollet J., Chen W.H., Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv. Drug Deliv. Rev. 2021;170:71&#x2013;82. doi: 10.1016/j.addr.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.01.001</ArticleId><ArticleId IdType="pmc">PMC7788321</ArticleId><ArticleId IdType="pubmed">33421475</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcharoen O., Wacharapluesadee S., Chia W.N., Paitoonpong L., Tan C.W., Suwanpimolkul G., Jantarabenjakul W., Ruchisrisarod C., Wanthong P., Sophonphan J., et al. Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE. 2021;16:e0246864. doi: 10.1371/journal.pone.0246864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246864</ArticleId><ArticleId IdType="pmc">PMC7880427</ArticleId><ArticleId IdType="pubmed">33577615</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033&#x2013;1036. doi: 10.1038/s41591-020-0913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0913-5</ArticleId><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Argentinian AntiCovid Consortium Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells. Sci. Rep. 2020;10:21779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732851</ArticleId><ArticleId IdType="pubmed">33311634</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias-Arias J.L., Molina-Castro S.E., Monturiol-Gross L., Lomonte B., Corrales-Aguilar E. Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. Biotechnol. Rep. 2023;37:e00780. doi: 10.1016/j.btre.2022.e00780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.btre.2022.e00780</ArticleId><ArticleId IdType="pmc">PMC9805376</ArticleId><ArticleId IdType="pubmed">36619904</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindha S., Kuroda Y. A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in E. coli Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein. Int. J. Mol. Sci. 2022;23:1703. doi: 10.3390/ijms23031703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031703</ArticleId><ArticleId IdType="pmc">PMC8835783</ArticleId><ArticleId IdType="pubmed">35163624</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig-Beihammer J., Vavra U., Shin Y.J., Veit C., Gr&#xfc;nwald-Gruber C., Gillitschka Y., Huber J., Hofner M., Vierlinger K., Mitteregger D., et al. In Planta Production of the Receptor-Binding Domain From SARS-CoV-2 With Human Blood Group A Glycan Structures. Front. Chem. 2022;9:816544. doi: 10.3389/fchem.2021.816544.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.816544</ArticleId><ArticleId IdType="pmc">PMC8846405</ArticleId><ArticleId IdType="pubmed">35178379</ArticleId></ArticleIdList></Reference><Reference><Citation>Limonta-Fern&#xe1;ndez M., Chinea-Santiago G., Mart&#xed;n-Dunn A.M., Gonzalez-Roche D., Bequet-Romero M., Marquez-Perera G., Gonz&#xe1;lez-Moya I., Canaan-Haden-Ayala C., Cabrales-Rico A., Espinosa-Rodr&#xed;guez L.A., et al. An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen. New Biotechnol. 2022;72:11&#x2013;21. doi: 10.1016/j.nbt.2022.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2022.08.002</ArticleId><ArticleId IdType="pmc">PMC9359770</ArticleId><ArticleId IdType="pubmed">35953030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalvie N.C., Rodriguez-Aponte S.A., Hartwell B.L., Tostanoski L.H., Biedermann A.M., Crowell L.E., Kaur K., Kumru O.S., Carter L., Yu J., et al. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. Proc. Natl. Acad. Sci. USA. 2021;118:e2106845118. doi: 10.1073/pnas.2106845118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2106845118</ArticleId><ArticleId IdType="pmc">PMC8463846</ArticleId><ArticleId IdType="pubmed">34493582</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I.C., Tiu C., Hu Z., Chen V.C.W., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2&#x2013;spike protein&#x2013;protein interaction. Nat. Biotechnol. 2020;38:1073&#x2013;1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan M., Kozhaya L., Placek L., Gunter C., Yigit M., Hardy R., Plassmeyer M., Coatney P., Lillard K., Bukhari Z., et al. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun. Biol. 2021;4:129. doi: 10.1038/s42003-021-01649-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01649-6</ArticleId><ArticleId IdType="pmc">PMC7846565</ArticleId><ArticleId IdType="pubmed">33514825</ArticleId></ArticleIdList></Reference><Reference><Citation>Inchauste L., Nurtop E., Brisbarre N., Ninove L., Gallian P., de Lamballerie X., Priet S. Exploring cell-free assays for COVID-19 serosurvey. Sci. Rep. 2024;14:6096. doi: 10.1038/s41598-024-55852-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55852-6</ArticleId><ArticleId IdType="pmc">PMC10938000</ArticleId><ArticleId IdType="pubmed">38480769</ArticleId></ArticleIdList></Reference><Reference><Citation>Okba N.M., M&#xfc;ller M.A., Li W., Wang C., GeurtsvanKessel C.H., Corman V.M., Lamers M.M., Sikkema R.S., de Bruin E., Chandler F.D., et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg. Infect. Dis. 2020;26:1478&#x2013;1488. doi: 10.3201/eid2607.200841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.200841</ArticleId><ArticleId IdType="pmc">PMC7323511</ArticleId><ArticleId IdType="pubmed">32267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H.S., Racine-Brzostek S.E., Lee W.T., Hunt D., Yee J., Chen Z., Kubiak J., Cantu M., Hatem L., Zhong E., et al. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays. Clin. Chim. Acta. 2020;509:117&#x2013;125. doi: 10.1016/j.cca.2020.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7272145</ArticleId><ArticleId IdType="pubmed">32505774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi-Estopi&#xf1;an F., P&#xe9;rez M.T., Fraga A., Bergado G., D&#xed;az G.D., Orosa I., D&#xed;az M., Soloz&#xe1;bal J.A., Rodr&#xed;guez L.M., Garcia-Rivera D., et al. A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. Vaccine. 2022;40:1958&#x2013;1967. doi: 10.1016/j.vaccine.2022.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.044</ArticleId><ArticleId IdType="pmc">PMC8856731</ArticleId><ArticleId IdType="pubmed">35193792</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D., Yadav A.K., Chaudhary N., Mukherjee M.D., Kumar P., Kumar A., Solanki P.R. Recent Advances in Understanding SARS-CoV-2 Infection and Updates on Potential Diagnostic and Therapeutics for COVID-19. Coronaviruses. 2022;3:14&#x2013;31.</Citation></Reference><Reference><Citation>Yadav A.K., Verma D., Kumar A., Kumar P., Solanki P.R. The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management. Mater. Today Chem. 2021;20:100443. doi: 10.1016/j.mtchem.2021.100443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtchem.2021.100443</ArticleId><ArticleId IdType="pmc">PMC7877231</ArticleId><ArticleId IdType="pubmed">33615086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalandra R., Yadav A.K., Verma D., Dalal N., Sharma M., Singh R., Kumar A., Solanki P.R. Strategies and perspectives to develop SARS-CoV-2 detection methods and diagnostics. Biomed. Pharmacother. 2020;129:110446. doi: 10.1016/j.biopha.2020.110446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110446</ArticleId><ArticleId IdType="pmc">PMC7303646</ArticleId><ArticleId IdType="pubmed">32768943</ArticleId></ArticleIdList></Reference><Reference><Citation>Septisetyani E.P., Prasetyaningrum P.W., Anam K., Santoso A. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. Immune Netw. 2021;21:e39. doi: 10.4110/in.2021.21.e39.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2021.21.e39</ArticleId><ArticleId IdType="pmc">PMC8733193</ArticleId><ArticleId IdType="pubmed">35036026</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.T., Han Y.J., Wu G.H., Huang K.Y.A., Huang P.N. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses. 2022;14:1560. doi: 10.3390/v14071560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071560</ArticleId><ArticleId IdType="pmc">PMC9322699</ArticleId><ArticleId IdType="pubmed">35891540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Huang W., Xiang H., Nie J. SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review. Vaccines. 2024;12:554. doi: 10.3390/vaccines12050554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12050554</ArticleId><ArticleId IdType="pmc">PMC11125816</ArticleId><ArticleId IdType="pubmed">38793805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W.T., Girardin R.C., Dupuis A.P., Kulas K.E., Payne A.F., Wong S.J., Arinsburg S., Nguyen F.T., Mendu D.R., Firpo-Betancourt A., et al. Neutralizing Antibody Responses in COVID-19 Convalescent Sera. J. Infect. Dis. 2021;223:47&#x2013;55. doi: 10.1093/infdis/jiaa673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa673</ArticleId><ArticleId IdType="pmc">PMC7665673</ArticleId><ArticleId IdType="pubmed">33104179</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell P.K., Nisalak A., Sukhavachana P., Vivona S. A Plaque Reduction Test for Dengue Virus Neutralizing Antibodies. J. Immunol. 1967;99:285&#x2013;290. doi: 10.4049/jimmunol.99.2.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.99.2.285</ArticleId><ArticleId IdType="pubmed">6031202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.J., Jung J., Lee J.H., Lee D.G., Kim Y.B., Oh E.J. Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population. Viruses. 2022;14:946. doi: 10.3390/v14050946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050946</ArticleId><ArticleId IdType="pmc">PMC9147836</ArticleId><ArticleId IdType="pubmed">35632688</ArticleId></ArticleIdList></Reference><Reference><Citation>Padoan A., Bonfante F., Pagliari M., Bortolami A., Negrini D., Zuin S., Bozzato D., Cosma C., Sciacovelli L., Plebani M. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine. 2020;62:103101. doi: 10.1016/j.ebiom.2020.103101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103101</ArticleId><ArticleId IdType="pmc">PMC7640894</ArticleId><ArticleId IdType="pubmed">33160207</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruato A.E., Fontes-Garfias C.R., Ren P., Garcia-Blanco M.A., Menachery V.D., Xie X., Shi P.Y. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 2020;11:4059. doi: 10.1038/s41467-020-17892-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17892-0</ArticleId><ArticleId IdType="pmc">PMC7426916</ArticleId><ArticleId IdType="pubmed">32792628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M., et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680&#x2013;686. doi: 10.1080/22221751.2020.1743767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltr&#xe1;n-Pavez C., Riquelme-Barrios S., Oyarz&#xfa;n-Arrau A., Gaete-Argel A., Gonz&#xe1;lez-Stegmaier R., Cereceda-Solis K., Aguirre A., Travisany D., Palma-Vejares R., Barriga G.P., et al. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Sci. Adv. 2021;7:eabe6855. doi: 10.1126/sciadv.abe6855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe6855</ArticleId><ArticleId IdType="pmc">PMC7880587</ArticleId><ArticleId IdType="pubmed">33579701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zettl F., Meister T.L., Vollmer T., Fischer B., Steinmann J., Krawczyk A., V&#x2019;kovski P., Todt D., Steinmann E., Pfaender S., et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines. 2020;8:886. doi: 10.3390/vaccines8030386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030386</ArticleId><ArticleId IdType="pmc">PMC7563800</ArticleId><ArticleId IdType="pubmed">32679691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha V.P.C., Machado B.A.S., Quadros H.C., Fernandes A.M.S., Fiuza B.S.D., Meira C.S., da Silva V.T.B., Evangelista A.F., Fonseca L.M.D.S., Badar&#xf3; R.J.D.S., et al. High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies. Vaccines. 2024;12:236. doi: 10.3390/vaccines12030236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030236</ArticleId><ArticleId IdType="pmc">PMC10974448</ArticleId><ArticleId IdType="pubmed">38543870</ArticleId></ArticleIdList></Reference><Reference><Citation>Heggestad J.T., Britton R.J., Kinnamon D.S., Wall S.A., Joh D.Y., Hucknall A.M., Olson L.B., Anderson J.G., Mazur A., Wolfe C.R., et al. Rapid test to assess the escape of SARS-CoV-2 variants of concern. Sci. Adv. 2021;7:eabl7682. doi: 10.1126/sciadv.abl7682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abl7682</ArticleId><ArticleId IdType="pmc">PMC8641938</ArticleId><ArticleId IdType="pubmed">34860546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kweon O.J., Bae J.Y., Lim Y.K., Choi Y., Lee S., Park M.S., Suh I.B., Kim H., Jee Y.S., Lee M.K. Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2. Sci. Rep. 2023;13:4961. doi: 10.1038/s41598-023-31114-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-31114-9</ArticleId><ArticleId IdType="pmc">PMC10041486</ArticleId><ArticleId IdType="pubmed">36973368</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon G., Herrera M., Vargas M., Arguedas M., Sanchez A., Segura A., Gomez A., Solano G., Corrales-Aguilar E., Risner K., et al. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19. Sci. Rep. 2021;11:9825. doi: 10.1038/s41598-021-89242-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89242-z</ArticleId><ArticleId IdType="pmc">PMC8110969</ArticleId><ArticleId IdType="pubmed">33972631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowarz E., L&#xf6;scher D., Marschalek R. Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. Biotechnol. J. 2015;10:647&#x2013;653. doi: 10.1002/biot.201400821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.201400821</ArticleId><ArticleId IdType="pubmed">25650551</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;t&#xe9;s L., Chuah M.K., Belay E., Jerchow B., Manoj N., Acosta-Sanchez A., Grzela D.P., Schmitt A., Becker K., Matrai J., et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet. 2009;41:753&#x2013;761. doi: 10.1038/ng.343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.343</ArticleId><ArticleId IdType="pubmed">19412179</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage H.R., Santos V.S., Edwards T., Giorgi E., Krishna S., Planche T.D., Staines H.M., Fitchett J.R., Kirwan D.E., Cubas Atienzar A.I., et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis. PLoS Negl. Trop. Dis. 2021;15:e0009551. doi: 10.1371/journal.pntd.0009551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0009551</ArticleId><ArticleId IdType="pmc">PMC8291969</ArticleId><ArticleId IdType="pubmed">34237072</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson R.S., editor. ELISA Methods and Protocols [Internet] 1st ed. Humana Press; New York, NY, USA: 2023.  [(accessed on 1 July 2024)]. pp. 1&#x2013;244. Available online:  http://www.springer.com/series/7651.</Citation></Reference><Reference><Citation>Coutlee F., Viscidi R.P., Yolken R.H., Modlin J.F., Yolken R.H., Bowman M. Comparison of Colorimetric, Fluorescent, and Enzymatic Amplification Substrate Systems in an Enzyme Immunoassay for Detection of DNA-RNA Hybrids. J. Clin. Microbiol. 1989;27:1002&#x2013;1007. doi: 10.1128/jcm.27.5.1002-1007.1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.27.5.1002-1007.1989</ArticleId><ArticleId IdType="pmc">PMC267471</ArticleId><ArticleId IdType="pubmed">2473088</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Hillyer C., Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020;41:355&#x2013;359. doi: 10.1016/j.it.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.03.007</ArticleId><ArticleId IdType="pmc">PMC7129017</ArticleId><ArticleId IdType="pubmed">32249063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhao X., Zhou H., Zhu H., Jiang S., Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 2023;23:189&#x2013;199. doi: 10.1038/s41577-022-00784-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39978867</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2542</ISSN><JournalIssue CitedMedium="Internet"><Volume>302</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Veterinary microbiology</Title><ISOAbbreviation>Vet Microbiol</ISOAbbreviation></Journal><ArticleTitle>Impact of foot-and-mouth disease virus on memory T and B cell populations in swine.</ArticleTitle><Pagination><StartPage>110406</StartPage><MedlinePgn>110406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vetmic.2025.110406</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1135(25)00041-0</ELocationID><Abstract><AbstractText>Foot-and-mouth disease virus (FMDV) is a highly contagious picornavirus that poses a serious threat to the global livestock industry. This study aimed to investigate the impact of FMDV infection on the memory immune response in pigs and to analyze the role of type II interferon (IFN-&#x3b3;) in this process. By comparing pigs artificially infected with FMDV and those vaccinated with inactivated FMDV vaccine, we found that FMDV infection significantly suppressed the development of memory T helper (Th) and B cell populations, affecting the memory immune response. Further experiments showed that pretreatment with IFN-&#x3b3; could counteract the immunosuppression caused by FMDV, and this counteraction was achieved by promoting the expression of three transcription factors: T-bet, Eomes, and Bcl-6. Our findings emphasize the key role of IFN-&#x3b3; in regulating the host's immune response to FMDV infection and provide new scientific evidence for the development of effective FMDV vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Qinghong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Zhonghai Biotech Co., Ltd., Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Hongxu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yueyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing 100081, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dongdong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inner Mongolia Bigvet Biotech Co., Ltd., Inner Mongolia 011500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guohua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Inner Mongolia Bigvet Biotech Co., Ltd., Inner Mongolia 011500, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiangmei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China. Electronic address: zhouxm@cau.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vet Microbiol</MedlineTA><NlmUniqueID>7705469</NlmUniqueID><ISSNLinking>0378-1135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005536" MajorTopicYN="Y">Foot-and-Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029544" MajorTopicYN="Y">Foot-and-Mouth Disease Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013553" MajorTopicYN="Y">Swine Diseases</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="Y">Interferon-gamma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091246" MajorTopicYN="N">Memory T Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bcl-6</Keyword><Keyword MajorTopicYN="N">Eomes</Keyword><Keyword MajorTopicYN="N">Foot-and-mouth disease virus</Keyword><Keyword MajorTopicYN="N">Humoral immune response</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword><Keyword MajorTopicYN="N">Memory immunity</Keyword><Keyword MajorTopicYN="N">Swine</Keyword><Keyword MajorTopicYN="N">T-bet</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39978867</ArticleId><ArticleId IdType="doi">10.1016/j.vetmic.2025.110406</ArticleId><ArticleId IdType="pii">S0378-1135(25)00041-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39971929</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Product and trial design considerations on the path towards a vaccine to combat opioid overdose.</ArticleTitle><Pagination><StartPage>35</StartPage><MedlinePgn>35</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">35</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-025-01083-3</ELocationID><Abstract><AbstractText>Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl vaccination as a complementary strategy for opioid overdose prevention with a focus on vaccine safety, efficacy, and considerations for vaccine development and testing in early phase human clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angelidou</LastName><ForeName>Asimenia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6716-6561</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koster</LastName><ForeName>Jacob A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-4645-6308</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Amy C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6075-3990</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLoughlin</LastName><ForeName>Caitlyn</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0001-6559-8539</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalwani</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Aisling</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Ahsan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEnaney</LastName><ForeName>Kerry</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0378-3456</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baden</LastName><ForeName>Lindsey R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brogna</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Addiction Medicine, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weitzman</LastName><ForeName>Elissa R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Addiction Medicine, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Addiction Medicine, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowling</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-1095-6156</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-5859-1945</Identifier><AffiliationInfo><Affiliation>Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA. ofer.levy@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, MA, USA. ofer.levy@childrens.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT &amp; Harvard, Cambridge, MA, USA. ofer.levy@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>75N93020C00038</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AI168487</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: O.L., S.L., and D.J.D. are inventors on patents held by BCH relating to vaccine adjuvants. O.L. is an advisor to GlaxoSmithKline (GSK) and Hillevax and a co-founder of and advisor to OVAX Inc. O.L's laboratory is supported in part by sponsored research from GSK and Pfizer. D.J.D. has served as a consultant for Merck Research Laboratories/Merck Sharp &amp; Dohme Corp. (a Merck &amp; Co. Inc. subsidiary) and is on EdJen BioTech&#x2019;s scientific advisory board. D.J.D. is a co-founder of OVAX Inc. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39971929</ArticleId><ArticleId IdType="pmc">PMC11840009</ArticleId><ArticleId IdType="doi">10.1038/s41541-025-01083-3</ArticleId><ArticleId IdType="pii">10.1038/s41541-025-01083-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spencer, M. G.; Mini&#xf1;o, A. Drug Overdose Deaths in the United States, 2002-2022. NCHS Data Briefs 2023; Available from: https://www.cdc.gov/nchs/products/databriefs/db491.htm (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36598401</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. NCHS Data Briefs 2024. Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm (2025).</Citation></Reference><Reference><Citation>Hall, O. T. et al. Unintentional Drug Overdose Mortality in Years of Life Lost Among Adolescents and Young People in the US From 2015 to 2019. JAMA Pediatr.176, 415&#x2013;417 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8804970</ArticleId><ArticleId IdType="pubmed">35099529</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, R. G., Koroshetz, W. J. &amp; Volkow, N. D. The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health. JAMA326, 1005&#x2013;1006 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34436519</ArticleId></ArticleIdList></Reference><Reference><Citation>Clotz, M. A. &amp; Nahata, M. C. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin. Pharm.10, 581&#x2013;593 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1834393</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell, J., Gladden. R. M., Mattson, C. L., Hunter, C. T. &amp; Davis, N. L. Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants &#x2014; 24 States and the District of Columbia, January&#x2013;June 2019. MMWR Morb. Mortal Wkly Rep. 69, 1189&#x2013;1197 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470457</ArticleId><ArticleId IdType="pubmed">32881854</ArticleId></ArticleIdList></Reference><Reference><Citation>Counterfeit Pills Fact Sheet. Available from: https://www.dea.gov/sites/default/files/2021-12/DEA-OPCK_FactSheet_December%202021.pdf (2021).</Citation></Reference><Reference><Citation>DEA Issues Public Safety Alert on Sharp Increase in Fake Prescription Pills Containing Fentanyl and Meth (Drug Enforcement Administration, 2021).</Citation></Reference><Reference><Citation>Tanz, L. J. et al. Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021. MMWR Morb. Mortal. Wkly Rep.71, 1576&#x2013;1582 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9762908</ArticleId><ArticleId IdType="pubmed">36520659</ArticleId></ArticleIdList></Reference><Reference><Citation>Comer, S. D. &amp; Cahill, C. M. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci. Biobehav Rev.106, 49&#x2013;57 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233332</ArticleId><ArticleId IdType="pubmed">30528374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanks, K. G. &amp; Behonick, G. S. Detection of Carfentanil by LC-MS-MS and Reports of Associated Fatalities in the USA. J. Anal. Toxicol.41, 466&#x2013;472 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28830120</ArticleId></ArticleIdList></Reference><Reference><Citation>Riches, J. R. et al. Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. J. Anal. Toxicol.36, 647&#x2013;656 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23002178</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein, C. Opioid Receptors. Annu Rev. Med.67, 433&#x2013;451 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26332001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieffer, B. L. Opioids: first lessons from knockout mice. Trends Pharm. Sci.20, 19&#x2013;26 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10101958</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattinson, K. T. Opioids and the control of respiration. Br. J. Anaesth.100, 747&#x2013;758 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18456641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman, M. et al. Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. J. Adolesc. Health67, 778&#x2013;785 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683373</ArticleId><ArticleId IdType="pubmed">32873500</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt, L. et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst. Rev.9, CD012021 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621373</ArticleId><ArticleId IdType="pubmed">28922449</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb. Mortal. Wkly Rep.61, 101&#x2013;105 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378715</ArticleId><ArticleId IdType="pubmed">22337174</ArticleId></ArticleIdList></Reference><Reference><Citation>Razaghizad, A. et al. The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. Am. J. Public Health111, e1&#x2013;e12 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489614</ArticleId><ArticleId IdType="pubmed">34214412</ArticleId></ArticleIdList></Reference><Reference><Citation>Saloner, B. et al. A Public Health Strategy for the Opioid Crisis. Public Health Rep.133, 24S&#x2013;34S (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6243441</ArticleId><ArticleId IdType="pubmed">30426871</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, K. et al. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend.128, 104&#x2013;110 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184803</ArticleId><ArticleId IdType="pubmed">22974490</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolina, K. et al. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study. Subst. Abus.43, 92&#x2013;98 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">32441588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadland, S. E. et al. Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction116, 2790&#x2013;2800 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8429061</ArticleId><ArticleId IdType="pubmed">33739476</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghsoudi, N. et al. Drug checking services for people who use drugs: a systematic review. Addiction117, 532&#x2013;544 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9299873</ArticleId><ArticleId IdType="pubmed">34729849</ArticleId></ArticleIdList></Reference><Reference><Citation>Luba, R. et al. Immunotherapeutic strategies for treating opioid use disorder and overdose. Expert Opin. Investig. Drugs32, 77&#x2013;87 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10035039</ArticleId><ArticleId IdType="pubmed">36696567</ArticleId></ArticleIdList></Reference><Reference><Citation>Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol. Rev.296, 169&#x2013;190 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497245</ArticleId><ArticleId IdType="pubmed">32594569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, B. et al. Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations. Pharmaceutics15, 1766 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10305121</ArticleId><ArticleId IdType="pubmed">37376214</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouse, B. et al. A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models. NPJ Vaccines8, 107 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10366150</ArticleId><ArticleId IdType="pubmed">37488109</ArticleId></ArticleIdList></Reference><Reference><Citation>Natori, Y. et al. A chemically contiguous hapten approach for a heroin-fentanyl vaccine. Beilstein J. Org. Chem.15, 1020&#x2013;1031 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541359</ArticleId><ArticleId IdType="pubmed">31164940</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers, N. et al. Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge. Bioconjug. Chem.34, 1811&#x2013;1821 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10587865</ArticleId><ArticleId IdType="pubmed">37758302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonese, K. F. et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature252, 708&#x2013;710 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4474602</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone, A. E. et al. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. NPJ Vaccines6, 69 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119695</ArticleId><ArticleId IdType="pubmed">33986280</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, S. M. et al. A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. NPJ Vaccines8, 97 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10333387</ArticleId><ArticleId IdType="pubmed">37429853</ArticleId></ArticleIdList></Reference><Reference><Citation>Havlicek, D. F. et al. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose &#x201c;binge&#x201d; cocaine use. PLoS One15, e0239780 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703925</ArticleId><ArticleId IdType="pubmed">33253224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabato, B. et al. Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model. Vaccine41, 2127&#x2013;2136 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36822966</ArticleId></ArticleIdList></Reference><Reference><Citation>Pravetoni, M. &amp; Comer, S. D. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology158, 107662 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919211</ArticleId><ArticleId IdType="pubmed">31173759</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, S. et al. Factors Associated with Opioid Overdose Among Patients Prescribed Opioids: A Scoping Review.</Citation></Reference><Reference><Citation>Patocka, J. et al. Fentanyl and its derivatives: Pain-killers or man-killers? Heliyon10, e28795 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11031787</ArticleId><ArticleId IdType="pubmed">38644874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy, M. C. et al. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study. PLoS Med.19, e1004123 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714711</ArticleId><ArticleId IdType="pubmed">36454732</ArticleId></ArticleIdList></Reference><Reference><Citation>Baehr, C. et al. Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats. ACS Omega7, 16584&#x2013;16592 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9118421</ArticleId><ArticleId IdType="pubmed">35601290</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick, Z. et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature587, 472&#x2013;476 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748383</ArticleId><ArticleId IdType="pubmed">33149302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepworth, M. R., Greenhalgh, A. D. &amp; Cook, P. C. B cells on the brain: meningeal IgA and a novel gut-brain firewall. Immunol. Cell Biol.99, 17&#x2013;20 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33107992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremer, P. T. &amp; Janda, K. D. Conjugate Vaccine Immunotherapy for Substance Use Disorder. Pharm. Rev.69, 298&#x2013;315 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482184</ArticleId><ArticleId IdType="pubmed">28634286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, X. et al. Opioid System Modulates the Immune Function: A Review. Transl. Perioper. Pain. Med.1, 5&#x2013;13 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4790459</ArticleId><ArticleId IdType="pubmed">26985446</ArticleId></ArticleIdList></Reference><Reference><Citation>Plein, L. M. &amp; Rittner, H. L. Opioids and the immune system - friend or foe. Br. J. Pharm.175, 2717&#x2013;2725 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6016673</ArticleId><ArticleId IdType="pubmed">28213891</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzman, E. R. et al. Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making. Clin. Infect. Dis.75, S98&#x2013;S109 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376272</ArticleId><ArticleId IdType="pubmed">35579508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaeta Gazzola, M. et al. A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States. Subst. Abus.44, 62&#x2013;72 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37226909</ArticleId></ArticleIdList></Reference><Reference><Citation>Scendoni, R. et al. Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines&#x2019; immunogenicity. Hum. Vaccin Immunother.18, 2140552 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9746524</ArticleId><ArticleId IdType="pubmed">36351881</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong, T. T. &amp; Kosten, T. R. Current status of vaccines for substance use disorders: A brief review of human studies. J. Neurol. Sci.434, 120098 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34952345</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone, N. C. et al. Mobile health clinics in the United States. Int. J. Equity Health19, 40 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7085168</ArticleId><ArticleId IdType="pubmed">32197637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehagia, E., Papakyriakopoulou, P. &amp; Valsami, G. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization. Vaccine41, 3589&#x2013;3603 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10173027</ArticleId><ArticleId IdType="pubmed">37179163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf, H. &amp; Kett, V. Current prospects and future challenges for nasal vaccine delivery. Hum. Vaccin Immunother.13, 34&#x2013;45 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287317</ArticleId><ArticleId IdType="pubmed">27936348</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites, R. S. et al. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. Nat. Commun.14, 8053 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697962</ArticleId><ArticleId IdType="pubmed">38052824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury, F. et al. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh. Vaccine40, 640&#x2013;649 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34969541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, M. et al. Polyphosphazene: A New Adjuvant Platform for Cocaine Vaccine Development. Mol. Pharmaceutics19, 3358&#x2013;3366 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35984034</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong, V. A., Nguyen, T. T. &amp; Maeng, H. J. Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery. Pharmaceutics15, 207 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9865923</ArticleId><ArticleId IdType="pubmed">36678838</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts, P. J. &amp; Smith, A. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? Drug Discov. Today16, 4&#x2013;7 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21074635</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell, R. E. et al. Characterization of beta-adrenergic receptors in cultured human and bovine endothelial cells. J. Appl. Physiol.65, 1251&#x2013;1257 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2846493</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore, A. P. S. &amp; John, A. L. St Promises and challenges of mucosal COVID-19 vaccines. Vaccine41, 4042&#x2013;4049 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10083204</ArticleId><ArticleId IdType="pubmed">37045682</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, J. R. Jr. et al. The unfulfilled potential of mucosal immunization. J. Allergy Clin. Immunol.150, 1&#x2013;11 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098804</ArticleId><ArticleId IdType="pubmed">35569567</ArticleId></ArticleIdList></Reference><Reference><Citation>Luba, R. &amp; Comer, S. D. Opioid vaccine clinical testing: lessons learned. Curr. Opin. Psychiatry37, 264&#x2013;269 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38726813</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzman, E. R. et al. Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl. Vaccine42, 126082 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11401752</ArticleId><ArticleId IdType="pubmed">38991914</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, L. C. et al. Monoclonal Antibodies for Combating Synthetic Opioid Intoxication. J. Am. Chem. Soc.141, 10489&#x2013;10503 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662938</ArticleId><ArticleId IdType="pubmed">31187995</ArticleId></ArticleIdList></Reference><Reference><Citation>Baehr, C. et al. Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. J. Pharm. Exp. Ther.375, 469&#x2013;477 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7718726</ArticleId><ArticleId IdType="pubmed">32980813</ArticleId></ArticleIdList></Reference><Reference><Citation>Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol.67, 171&#x2013;182 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25900877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39967854</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2162-2531</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecular therapy. Nucleic acids</Title><ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation></Journal><ArticleTitle>COVID-19 mRNA vaccines are effective at stopping a nosy virus.</ArticleTitle><Pagination><StartPage>102458</StartPage><MedlinePgn>102458</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102458</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2025.102458</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beloki</LastName><ForeName>Uxue</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of DNA and RNA Medicine, Cima Universidad de Navarra, Av. P&#xed;o XII 55, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanogrow Biotech, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salaberry</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of DNA and RNA Medicine, Cima Universidad de Navarra, Av. P&#xed;o XII 55, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdISNA) and CCUN, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanogrow Biotech, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortu&#xf1;o-Moya</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of DNA and RNA Medicine, Cima Universidad de Navarra, Av. P&#xed;o XII 55, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdISNA) and CCUN, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Angie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of DNA and RNA Medicine, Cima Universidad de Navarra, Av. P&#xed;o XII 55, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smerdou</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of DNA and RNA Medicine, Cima Universidad de Navarra, Av. P&#xed;o XII 55, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdISNA) and CCUN, Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Nucleic Acids</MedlineTA><NlmUniqueID>101581621</NlmUniqueID><ISSNLinking>2162-2531</ISSNLinking></MedlineJournalInfo><CoiStatement>L.S. is currently an employee of Nanogrow Biotech.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39967854</ArticleId><ArticleId IdType="pmc">PMC11833997</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2025.102458</ArticleId><ArticleId IdType="pii">S2162-2531(25)00012-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fricke C., Ulrich L., Kochmann J., Gergen J., Kovacikova K., Roth N., Beer J., Schnepf D., Mettenleiter T.C., Rauch S., et al. mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice. Mol. Ther. Nucleic Acids. 2024;35:102360. doi: 10.1016/j.omtn.2024.102360.eCollection.2024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2024.102360.eCollection.2024</ArticleId><ArticleId IdType="pmc">PMC11550364</ArticleId><ArticleId IdType="pubmed">39524696</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis S.A., Kakara M., Painter M.M., Goel R.R., Mathew D., Lenzi K., Rezk A., Patterson K.R., Espinoza D.A., Kadri J.C., et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 2021;27:1990&#x2013;2001. doi: 10.1038/s41591-021-01507-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01507-2</ArticleId><ArticleId IdType="pmc">PMC8604727</ArticleId><ArticleId IdType="pubmed">34522051</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli V., Rav&#xe0; M., Marotta D., Di Lucia P., Bono E.B., Giustini L., De Leo F., Casalgrandi M., Monteleone E., Mouro V., et al. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat. Immunol. 2024;25:633&#x2013;643. doi: 10.1038/s41590-024-01787-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01787-z</ArticleId><ArticleId IdType="pmc">PMC11003867</ArticleId><ArticleId IdType="pubmed">38486021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason D.Y., Jones M., Goodnow C.C. Development and follicular localization of tolerant B lymphocytes in lysozyme/anti-lysozyme IgM/IgD transgenic mice. Int. Immunol. 1992;4:163&#x2013;175. doi: 10.1093/intimm/4.2.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/4.2.163</ArticleId><ArticleId IdType="pubmed">1622894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao K.T., Cobos-Uribe C., Knight N., Jonnalagadda R., Robinette C., Jaspers I., Rebuli M.E. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies. J. Allergy Clin. Immunol. Glob. 2023;2:100129. doi: 10.1016/j.jacig.2023.100129.eCollection.2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacig.2023.100129.eCollection.2023</ArticleId><ArticleId IdType="pmc">PMC10290737</ArticleId><ArticleId IdType="pubmed">37781659</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39967209</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-0873</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JACC. CardioOncology</Title><ISOAbbreviation>JACC CardioOncol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>95</EndPage><MedlinePgn>83-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccao.2024.09.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0873(24)00368-5</ELocationID><Abstract><AbstractText>The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial safety evaluation have limitations in their ability to detect signals of cardiovascular risk. Mechanisms to increase power and specificity to clarify cardiovascular safety are required. However, implications include increased costs and slower development. The Cardiovascular Safety Research Consortium facilitated stakeholder discussions with representation from academia, industry, and regulators. A think tank was assembled with the aim of providing recommendations for improved collection and reporting of cardiovascular safety signals in oncology trials. Two working groups were formed. The first focuses on incorporation of consensus definitions of cardiovascular disease into the Common Terminology Criteria for Adverse Events used in oncology trial reporting. The second group considers methods for ascertainment and adjudication of cardiovascular events in cancer trials. The overarching aim of this primer is to improve understanding of the potential cardiovascular toxicities of cancer therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonaca</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>CPC Clinical Research, Cardiology &amp; Vascular medicine, University of Colorado Anschutz Medical School, Aurora, Colorado, USA. Electronic address: marc.bonaca@cpcmed.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Ninian N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom. Electronic address: https://twitter.com/ninianlang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amiri-Kordestani</LastName><ForeName>Laleh</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research (CDER), and Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipka</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Merck &amp; Co, Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwiewka</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paul-Ehrlich-Institut, Bundesinstitut f&#xfc;r Impfstoffe und biomedizinische Arzneimittel, Federal Institute for Vaccines and Biomedicines, Langen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strnadova</LastName><ForeName>Colette</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Canada, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klaar</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NDA Group, Upplands V&#xe4;sby, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dent</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Duke Cancer Institute, Duke University, Durham, North Carolina, USA. Electronic address: https://twitter.com/sdent_cardioonc.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janicijevic</LastName><ForeName>Tijana Krnjeta</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>F. Hoffmann - La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Joerg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/mayocvonc.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barac</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inova Schar Cancer Institute and Inova Heart and Vascular Institute, Annandale, Virginia, USA. Electronic address: https://twitter.com/AnaBaracCardio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Rudolf A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: https://twitter.com/anita_deswal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schou</LastName><ForeName>Morten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Herlev-Gentofte Hospital, University of Copenhagen, Herlev-Gentofte, Denmark. Electronic address: https://twitter.com/mortschou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neilan</LastName><ForeName>Tomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/TomasNeilan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moslehi</LastName><ForeName>Javid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardio-Oncology &amp; Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondapalli</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Colorado, School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ky</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine the University of Pennsylvania, Thalheimer Center for Cardio-Oncology, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Teresa Lopez</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Cardiology Department, Institute for Health Research, La Paz University Hospital, Madrid, Spain; Cardiology Department, Quir&#xf3;n Pozuelo University Hospital, Madrid, Spain. Electronic address: https://twitter.com/TeresaLpezFdez1.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornell</LastName><ForeName>R Frank</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>AbbVie, Inc, North Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaig</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsia</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CPC Clinical Research, Cardiology &amp; Vascular medicine, University of Colorado Anschutz Medical School, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharon</LastName><ForeName>Elad</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address: https://twitter.com/EladSharonMD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Azambuja</LastName><ForeName>Evandro</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute Jules Bordet and l'Universit&#xe9; Libre de Bruxelles (L.U.B), Brussels, Belgium. Electronic address: https://twitter.com/E_de_Azambuja.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seltzer</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sandpiper Research, Narberth, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Januzzi</LastName><ForeName>James L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital, Harvard Medical School; Heart Failure and Biomarker Trials, Baim Institute for Clinical Research, Boston, Massachusetts, USA. Electronic address: https://twitter.com/jjheart_doc.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrie</LastName><ForeName>Mark C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>University of Glasgow, Glasgow, United Kingdom. Electronic address: https://twitter.com/markcpetrie20.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC CardioOncol</MedlineTA><NlmUniqueID>101761697</NlmUniqueID><ISSNLinking>2666-0873</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">cardiotoxicity</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">reporting</Keyword><Keyword MajorTopicYN="N">targeted therapy</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures Dr Bonaca has received support from the American Heart Association SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). Dr Lang is supported by British Heart Foundation Centre of Research Excellence Award RE/18/6/34217. Dr Deswal is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair. Dr Moslehi is supported by National Institutes of Health grants R01HL141466, R01HL155990, R01HL156021, R01HL160688, and R01HL170038. Dr Bonaca is the executive director of CPC Clinical Research, a nonprofit academic research organization affiliated with the University of Colorado; has received research grant/consulting funding between August 2021 and present from: Abbott Laboratories, Agios Pharmaceuticals, Inc, Alexion Pharma, Alnylam Pharmaceuticals, Inc, Amgen Inc, Angionetics, Inc, Anthos Therapeutics, ARCA Biopharma, Inc, Array BioPharma, Inc, AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc, Bayer and Affiliates, Beth Israel Deaconess Medical Center, Better Therapeutics, Inc, Boston Clinical Research Institute, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc, Cardiol Therapeutics Inc, CellResearch Corp, Cleerly Inc, Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc, EP Trading Co Ltd, EPG Communication Holdings Ltd, Epizon Pharma, Inc, Esperion Therapeutics, Inc, Everly Well, Inc, Exicon Consulting Pvt Ltd, Faraday Pharmaceuticals, Inc, Foresee Pharmaceuticals Co Ltd, Fortress Biotech, Inc, HDL Therapeutics Inc, HeartFlow Inc, Hummingbird Bioscience, Insmed Inc, Ionis Pharmaceuticals, IQVIA Inc, Janssen and Affiliates, Kowa Research Institute, Inc, Kyushu University, Lexicon Pharmaceuticals, Inc, Medimmune Ltd, Medpace, Merck &amp; Affiliates, Nectero Medical Inc, Novartis Pharmaceuticals Corp, Novo Nordisk, Inc, Osiris Therapeutics Inc, Pfizer Inc, PhaseBio Pharmaceuticals, Inc, PPD Development, LP, Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc, Regio Biosciences, Inc, Saint Luke&#x2019;s Hospital of Kansas City, Sanifit Therapeutics S.A., Sanofi-Aventis Groupe, Silence Therapeutics PLC, Silence, Smith &amp; Nephew plc, Stanford Center for Clinical Research, Stealth BioTherapeutics Inc, State of Colorado CCPD Grant, The Brigham &amp; Women's Hospital, Inc, The Feinstein Institutes for Medical Research, Thrombosis Research Institute, University of Colorado, University of Pittsburgh, VarmX, Virta Health Corporation, Worldwide Clinical Trials Inc, WraSer, LLC, and Yale Cardiovascular Research Group. Dr Lang has received research grants from Roche Diagnostics, AstraZeneca, and Boehringer Ingelheim; and consultancy/speaker fees from Roche Diagnostics, Myokardia, Pharmacosmos, Akero Therapeutics, CV6 Therapeutics, Jazz Pharma, and Novartis outside the submitted work. Dr Chen reports that the National Cancer Institute has Cooperative Research and Development Agreements with Genentech and AstraZeneca for trials in which she is the principal investigator. Dr Lipka is an employee of Merck &amp; Co; and owns stock in Merck &amp; Co. Dr Janicijevic is employee of F. Hoffmann-La Roche Ltd, Basel, Switzerland; and has nonvoting shares in F. Hoffmann-La Roche. Dr Herrmann has served on advisory boards for AstraZeneca, Astellas, and Pfizer. Dr de Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Novo Nordisk, and Roche; and has had speaker engagements with and/or received fees from Abbott, AstraZeneca, Bristol Myers Squibb, Cardior Pharmaceuticals GmbH, Novartis, and Roche. Dr Deswal has received research support from the NIH and CPRIT; and consultancy fees from Bayer. Dr Ky is the editor-in-chief of JACC: CardioOncology; has received research funding from Pfizer; has received honoraria from UpToDate and Medscape; and has been a consultant to AstraZeneca. Dr Dent has been a consultant to AstraZeneca, Novartis, Pfizer, Race Oncology, Myocardial Solutions, Bristol Myers Squibb, and Gilead Sciences. Dr Fernandez has received honoraria or consultation fees from Philips, Myocardial Solutions, Bayer, Daiichi Sankyo, AstraZeneca, Beigene, Janssen, and Pfizer outside the submitted work. Dr Cornell is employed at AbbVie; and owns stock in AbbVie. Dr Flaig has a leadership role and owns stock in Aurora Oncology; has been a consultant to Seagen and Janssen Oncology; has received research support from Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol Myers Squibb, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, AstraZeneca/MedImmune, Eli Lilly, Astellas Pharma, Agensys, Seagen, La Roche-Posay, Merck, Myovant Sciences, and Criterium; and is the inventor on patents filed by the University of Colorado. Dr de Azambuja has received honoraria from and/or served on advisory boards for Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Pierre Fabre, Eli Lilly, AstraZeneca, MSD, and Gilead Sciences; has received travel grants from Roche/GNE and AstraZeneca; has received institutional research grants from Roche/GNE, AstraZeneca, GSK/Novartis, and Gilead Sciences. Dr Seltzer has served on safety committee for AstraZeneca, Minoryx, Moderna, Vivoryon Therapeutics, Pathalys Pharma, Takeda, and Crinetics. Dr Neilan has been a consultant to and received fees from Parexel Imaging, Bristol Myers Squibb, Roivant, Intrinsic Imaging, H3-Biomedicine, Amgen, Sanofi, Genentech, Roche, and AbbVie; and has received research grant funding from Bristol Myers Squibb, Abbott, and AstraZeneca. Dr Moleshi has served on advisory boards for Bristol Myers Squibb, Takeda, AstraZeneca, Myovant, Kurome Therapeutics, Kiniksa Pharmaceuticals, Daiichi Sankyo, CRC Oncology, BeiGene, Prelude Therapeutics, TransThera Sciences, and Cytokinetics. Dr Januzzi is a trustee of the American College of Cardiology; is a director at Imbria Pharmaceuticals; is an advisor at Jana Care; has received grant support from Abbott, Applied Therapeutics, AstraZeneca, HeartFlow Inc, Innolife, and Roche Diagnostics; has received consulting income from Abbott, Beckman-Coulter, Boehringer Ingelheim, Janssen, Novartis, Merck, Roche Diagnostics, Siemens, Quidel-Ortho; and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer, and Takeda. Dr Petrie has received research funding from Boehringer Ingelheim, Roche, SQ Innovations, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, and Pharmacosmos; and has been a consultant and/or served on trial committees for Akero, Applied Therapeutics, AnaCardio, Biosensors, Boehringer Ingelheim, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Bayer, Takeda, Cardiorentis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, AnaCardio, and Teikuko. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>19</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39967209</ArticleId><ArticleId IdType="pmc">PMC11866450</ArticleId><ArticleId IdType="doi">10.1016/j.jaccao.2024.09.014</ArticleId><ArticleId IdType="pii">S2666-0873(24)00368-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moslehi J.J. Cardiovascular toxic effects of targeted cancer therapies. N&#xa0;Engl J Med. 2016;375:1457&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732808</ArticleId></ArticleIdList></Reference><Reference><Citation>Navi B.B., Reiner A.S., Kamel H., et al. Risk of arterial thromboembolism in patients with cancer. J&#xa0;Am Coll Cardiol. 2017;70:926&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667567</ArticleId><ArticleId IdType="pubmed">28818202</ArticleId></ArticleIdList></Reference><Reference><Citation>Martei Y.M., Afari H.A., Guerra C.E. Diversity in cardio-oncology clinical trials: JACC: CardioOncology how to. JACC CardioOncol. 2024;6:386&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11229538</ArticleId><ArticleId IdType="pubmed">38983389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia M., Onwuanyi A., Agu E., Kpodonu J. Advocating for a path to increase diversity in enrollment in cardiovascular clinical trials. JACC Adv. 2022;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11198180</ArticleId><ArticleId IdType="pubmed">38939463</ArticleId></ArticleIdList></Reference><Reference><Citation>Addison D., Branch M., Baik A.H., et al. Equity in cardio-oncology care and research: a scientific statement from the American Heart Association. Circulation. 2023;148:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">37377045</ArticleId></ArticleIdList></Reference><Reference><Citation>Barac A., Sharon E. From detecting signals to understanding cardiovascular toxicities of cancer therapies: all the light we could see. J&#xa0;Am Coll Cardiol. 2021;78:1814&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pubmed">34711340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonsu J.M., Guha A., Charles L., et al. Reporting of Cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J&#xa0;Am Coll Cardiol. 2020;75:620&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7860639</ArticleId><ArticleId IdType="pubmed">32057377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondapalli L., Bottinor W., Lenneman C. By releasing the brakes with immunotherapy, are we accelerating atherosclerosis? Circulation. 2020;142:2312&#x2013;2315.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315491</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Send&#xf3;n J., &#xc1;lvarez-Ortega C., Zamora Au&#xf1;on P., et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720&#x2013;1729. doi: 10.1093/eurheartj/ehaa006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa006</ArticleId><ArticleId IdType="pubmed">32016393</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi J.J., Salem J.E., Sosman J.A., Lebrun-Vignes B., Johnson D.B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668330</ArticleId><ArticleId IdType="pubmed">29536852</ArticleId></ArticleIdList></Reference><Reference><Citation>Witteles R.M., Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned? J&#xa0;Clin Oncol. 2012;30:1916&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pubmed">22454419</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem J.E., Manouchehri A., Moey M., et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287923</ArticleId><ArticleId IdType="pubmed">30442497</ArticleId></ArticleIdList></Reference><Reference><Citation>IQVIA  Global Oncology Innovation Continues Despite Pandemic; Global R&amp;D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015. Says New Report from the IQVIA Institute for Human Data Science. 2021 https://www.iqvia.com/newsroom/2021/06/global-oncology-innovation-continues-despite-pandemic-global-rd-pipeline-reached-3500-new-drugs-in-2</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  Oncology Regulatory Review. 2022. https://www.fda.gov/about-fda/2022-oce-annual-report/oncology-regulatory-review</Citation></Reference><Reference><Citation>European Medicines Agency  Human Medicines Highlights 2022. 2023. https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2022_en.pdf</Citation></Reference><Reference><Citation>National Cancer Institute  Statistics and Graphs. Office of Cancer Survivorship. 2024. https://cancercontrol.cancer.gov/ocs/statistics#stats</Citation></Reference><Reference><Citation>de Wit S., Glen C., de Boer R.A., Lang N.N. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovasc Res. 2023;118(18):3451&#x2013;3466. doi: 10.1093/cvr/cvac132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac132</ArticleId><ArticleId IdType="pmc">PMC9897696</ArticleId><ArticleId IdType="pubmed">36004495</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann J., Lenihan D., Armenian S., et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803367</ArticleId><ArticleId IdType="pubmed">34904661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiac Safety Research Consortium  Cardiac Safety Research Consortium (CSRC) 2024. https://cardiac-safety.org/</Citation></Reference><Reference><Citation>Turner J.R., Kowey P.R., Rodriguez I., et al. The Cardiac Safety Research Consortium enters its second decade: an invitation to participate. Am Heart J. 2016;177:96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27297854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiac Safety Research Consortium  CSRC Meeting &amp; CSRC Think Tank: Detection, Assessment and Risk Mitigation of Cardiac Safety Signals&#xa0;in. Oncology Drug Development. 2017 https://cardiac-safety.org/our-impact/think-tanks/csrc-meeting-csrc-think-tank-detection-assessment-and-risk-mitigation-of-cardiac-safety-signals-in-oncology-drug-development/</Citation></Reference><Reference><Citation>Seltzer J.H., Gintant G., Amiri-Kordestani L., et al. Assessing cardiac safety in oncology drug development. Am Heart J. 2019;214:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316329</ArticleId><ArticleId IdType="pubmed">31202099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiac Safety Research Consortium  CSRC Think Tank: CV Safety in Oncology Clinical Trials: Providing Clarity for a New Era of Cancer Therapeutics. 2021. https://cardiac-safety.org/our-impact/think-tanks/csrc-think-tank-cv-safety-in-oncology-clinical-trials-providing-clarity-for-a-new-era-of-cancer-therapeutics/</Citation></Reference><Reference><Citation>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use  ICH Guidelines. https://www.ich.org/page/ich-guidelines</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  CBER Biologics Effectiveness and Safety (BEST) System. 2022. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-biologics-effectiveness-and-safety-best-system</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  National Evaluation System for health Technology (NEST) 2019. https://www.fda.gov/about-fda/cdrh-reports/national-evaluation-system-health-technology-nest January 2, 2024.</Citation></Reference><Reference><Citation>European Medicines Agency  EudraVigilance. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance</Citation></Reference><Reference><Citation>Mhaskar R., Woo H., Reljic T., Kumar A., Djulbegovic B. Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on quality of treatment related harms reporting: an analysis of National Cancer Institute's Co-Operative Group phase iii randomized controlled trials. Blood. 2011;118(21):673. doi: 10.1182/blood.V118.21.673.673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V118.21.673.673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavo N., Raderer M., Hulsmann M., et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874&#x2013;1880.</Citation><ArticleIdList><ArticleId IdType="pubmed">26416836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon A.R., Lopez-Fernandez T., Couch L.S., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43:4229&#x2013;4361.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Oren O., Neilan T.G., Fradley M.G., Bhatt D.L. Cardiovascular safety assessment in cancer drug development. J&#xa0;Am Heart Assoc. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9075223</ArticleId><ArticleId IdType="pubmed">34913360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks K.A., Mahaffey K.W., Mehran R., et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">29483172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca M.P., Olenchock B.A., Salem J.E., et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779326</ArticleId><ArticleId IdType="pubmed">31390169</ArticleId></ArticleIdList></Reference><Reference><Citation>Waliany S., Neal J.W., Reddy S., et al. Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 2021;3:137&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009332</ArticleId><ArticleId IdType="pubmed">33796869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pudil R., Mueller C., Celutkiene J., et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart&#xa0;Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">33006257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondapalli L., Hsia J., Miller R., Flaig T.W., Bonaca M.P. Burden of cardiovascular disease in immune checkpoint inhibitor-treated patients: reconciling adjudicated and coded outcomes. JACC CardioOncol. 2022;4:649&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830208</ArticleId><ArticleId IdType="pubmed">36636437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39946236</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Mechanistic insight into the induction of liver tissue-resident memory CD8<sup>+</sup> T&#xa0;cells by glycolipid-peptide vaccination.</ArticleTitle><Pagination><StartPage>115295</StartPage><MedlinePgn>115295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2025.115295</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(25)00066-X</ELocationID><Abstract><AbstractText>We recently demonstrated that vaccines comprising antigenic peptides conjugated to a glycolipid agonist, termed glycolipid-peptide (GLP) vaccines, efficiently generate substantial numbers of long-lived CD8<sup>+</sup> liver-resident memory T (Trm) cells that are crucial for protection against malaria liver-stage infection. To understand the underlying mechanism, we examined the prerequisites for priming, differentiation, and secondary boosting of liver Trm cells using these GLP vaccines. Our study revealed that generation of long-lived liver Trm cells relies on CD8<sup>+</sup> T&#xa0;cell priming by type 1 conventional dendritic (cDC1) cells, followed by post-priming exposure to a combination of vaccine-derived inflammatory and antigenic signals. Boosting of liver Trm cells is feasible using the same GLP vaccine, but a substantial delay is required for optimal responses due to natural killer T (NKT) cell anergy. Overall, our study unveils key requirements for the development of long-lived liver Trm cells, offering valuable insights for future vaccine design.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Yu Cheng</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Shirley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Menezes</LastName><ForeName>Maria N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganley</LastName><ForeName>Mitch</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Zhengyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phabmixay</LastName><ForeName>Taylah</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschmann</LastName><ForeName>Daria</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Sage A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Otago, Dunedin 9016, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Peck Szee</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tullett</LastName><ForeName>Kirsteen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Regan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayasinghe</LastName><ForeName>Dhilshan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozijnsen</LastName><ForeName>Anton</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of BioSciences, The University of Melbourne, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahoud</LastName><ForeName>Mireille H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caminschi</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beattie</LastName><ForeName>Lynette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFadden</LastName><ForeName>Geoffrey I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>School of BioSciences, The University of Melbourne, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Otago, Dunedin 9016, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaisho</LastName><ForeName>Tsuneyasu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia; Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermans</LastName><ForeName>Ian F</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Malaghan Institute of Medical Research, Wellington 6012, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compton</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heath</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Painter</LastName><ForeName>Gavin F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holz</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. Electronic address: lauren.holz@unimelb.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006017">Glycolipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="Y">Liver</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006017" MajorTopicYN="Y">Glycolipids</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="Y">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055611" MajorTopicYN="N">Natural Killer T-Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091246" MajorTopicYN="N">Memory T Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CP: Immunology</Keyword><Keyword MajorTopicYN="N">glycolipid peptide</Keyword><Keyword MajorTopicYN="N">liver</Keyword><Keyword MajorTopicYN="N">tissue-resident memory T&#xa0;cells</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Declaration of interests G.F.P. and I.F.H. have been chief technical officer and chief scientific officer, respectively, of biotech start-up Avalia Immunotherapies Limited, and W.R.H. was a member of its Scientific Advisory Board. Avalia holds exclusive, worldwide license to patents related to aspects of the chemical design reported here. Avalia partially funded the study. W.R.H., I.F.H., L.E.H., B.J.C., and G.F.P. are inventors on patent application (WO2020231274) submitted by Victoria University of Wellington, Malcorp Biodiscoveries Limited, and Victoria Link Limited that covers the production of tissue-resident memory T&#xa0;cells with GLP vaccines. M.H.L., K.M.T., and I.C. are inventors on patents relating to Clec9A antibodies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39946236</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2025.115295</ArticleId><ArticleId IdType="pii">S2211-1247(25)00066-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39938154</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5586</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neoplasia (New York, N.Y.)</Title><ISOAbbreviation>Neoplasia</ISOAbbreviation></Journal><ArticleTitle>Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers.</ArticleTitle><Pagination><StartPage>101135</StartPage><MedlinePgn>101135</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neo.2025.101135</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1476-5586(25)00014-4</ELocationID><Abstract><AbstractText>Targeting cancer antigens expressed in cancer cells is necessary to develop cancer-specific immunotherapy. We have performed immunohistochemical analysis of various solid cancer specimens, adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to the previously studied glypican-3 (GPC3), HSP105&#x3b1;, FOXM1, and SPARC, and found that these 10 common cancer antigens are sufficient to cover most solid cancers. These antigens were frequently expressed in various solid cancers but shown to be rarely ex-pressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In this study, we predicted 72 and 73 peptides that bind to HLA-A24 and -A2 in silico from the full-length amino acid sequences of these 10 common cancer antigens and immunized each HLA transgenic mouse with a cocktail of synthesized peptides together with the poly I:CLC three times weekly to analyze the antigen-specific immune response. As a result, 68 peptide sequences (30 and 38, respectively) were identified that had higher cytotoxic T lymphocyte (CTL) induction ability than GPC3 298-306 and GPC3 144-152 used in the clinical trials. Furthermore, experiments with cocktail peptide vaccines using mouse models expressing subcutaneous tumors of each antigen showed promising results in terms of safety and efficacy. These peptides identified in this study, derived from 10 common cancer antigens covering all solid cancers, are expected to be clinically applicable as cocktail peptide vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Graduate School of Biological Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takenouchi</LastName><ForeName>Kazumasa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukamoto</LastName><ForeName>Nobuo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnuki</LastName><ForeName>Kazunobu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatsura</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Electronic address: tnakatsu@east.ncc.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neoplasia</MedlineTA><NlmUniqueID>100886622</NlmUniqueID><ISSNLinking>1476-5586</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059871">HLA-A24 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="Y">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="Y">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="Y">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015789" MajorTopicYN="Y">HLA-A2 Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059871" MajorTopicYN="Y">HLA-A24 Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019496" MajorTopicYN="N">Cancer Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer-specific antigen</Keyword><Keyword MajorTopicYN="N">Common cancer antigen</Keyword><Keyword MajorTopicYN="N">Cytotoxic T lymphocyte (CTL)</Keyword><Keyword MajorTopicYN="N">HLA-A2</Keyword><Keyword MajorTopicYN="N">HLA-A24</Keyword><Keyword MajorTopicYN="N">Peptide vaccine</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Corresponding author, Tetsuya Nakatsura (TN) received a research grant from BrightPath Biotherapeutics Co., Ltd, Thyas Co., Ltd, ONOPHARMACEUTICAL CO., Ltd, Resonac Corporation, MEDINET Co., Ltd, NapaJen Pharma Inc, Heartseed Inc, Takara BIO Inc, DAICEL CORPORATION, NA Vaccine Institute CO., Ltd, Logomix Inc, Optieum Biotechnologies Inc, and MaxCyte, Inc. TN hold Stock Ownership, Stock Option or Profits from Noile-Immune Biotech Inc., Logomix Inc, and Optieum Biotechnologies Inc, and, TN have royalties from OncoTherapyScience,Inc. All of co-authors, Hiroki Kinoshita (HK), Kazumasa Takenouchi (KT), Nobuo Tsukamoto (NT), Kazunobu Ohnuki (KO), and Toshihiro Suzuki (TS) have no conflict of interest (COI) to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39938154</ArticleId><ArticleId IdType="pmc">PMC11869973</ArticleId><ArticleId IdType="doi">10.1016/j.neo.2025.101135</ArticleId><ArticleId IdType="pii">S1476-5586(25)00014-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taniguchi M., Mizuno S., Yoshikawa T., Fujinami N., Sugimoto M., Kobayashi S., Takahashi S., Konishi M., Gotohda N., Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747&#x2013;2759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419030</ArticleId><ArticleId IdType="pubmed">32449239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya N., Hosono A., Yoshikawa T., Shoda K., Nosaka K., Shimomura M., Hara J., Nitani C., Manabe A., Yoshihara H., Hosoya Y., Kaneda H., Kinoshita Y., Kohashi K., Yoshimura K., Fujinami N., Saito K., Mizuno S., Nakatsura T. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. Oncoimmunology. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5739579</ArticleId><ArticleId IdType="pubmed">29296538</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S., Sakata J., Utsumi F., Sekiya R., Kajiyama H., Shibata K., Kikkawa F., Nakatsura T. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139642</ArticleId><ArticleId IdType="pubmed">27999758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y., Yoshikawa T., Ofuji K., Yoshimura M., Tsuchiya N., Takahashi M., Nobuoka D., Gotohda N., Takahashi S., Kato Y., Konishi M., Kinoshita T., Ikeda M., Nakachi K., Yamazaki N., Mizuno S., Takayama T., Yamao K., Uesaka K., Furuse J., Endo I., Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910752</ArticleId><ArticleId IdType="pubmed">27467945</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S., Shibata K., Kikkawa F., Nakatsura T. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. Hum. Vaccines Immunother. 2014;10:338&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185885</ArticleId><ArticleId IdType="pubmed">24252799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y., Yoshikawa T., Fujii S., Mitsunaga S., Nobuoka D., Mizuno S., Takahashi M., Yamauchi C., Endo I., Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Hum. Vaccines Immunother. 2013;6:228&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901810</ArticleId><ArticleId IdType="pubmed">23466818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y., Yoshikawa T., Nobuoka D., Shirakawa H., Kuronuma T., Motomura Y., Mizuno S., Ishii H., Nakachi K., Konishi M., Nakagohri T., Takahashi S., Gotohda N., Takayama T., Yamao K., Uesaka K., Furuse J., Kinoshita T., Nakatsura T. Phase I trial of a glypican-3&#x2013;derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012;18:3686&#x2013;3696.</Citation><ArticleIdList><ArticleId IdType="pubmed">22577059</ArticleId></ArticleIdList></Reference><Reference><Citation>Komori H., Nakatsura T., Senju S., Yoshitake Y., Motomura Y., Ikuta Y., Fukuma D., Yokomine K., Harao M., Beppu T., Matsui M., Torigoe T., Sato N., Baba H., Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin. Cancer Res. 2006;12:2689&#x2013;2697.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675560</ArticleId></ArticleIdList></Reference><Reference><Citation>Charneau J., Suzuki T., Shimomura M., Fujinami N., Mishima Y., Hiranuka K., Watanabe N., Yamada T., Nakamura N., Nakatsura T. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. Cancer Sci. 2022;113:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990807</ArticleId><ArticleId IdType="pubmed">35122353</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier Fran&#xe7;ois A., P&#xe9;rarnau B. HLA-A2.1&#x2013;restricted education and cytolytic activity of CD8+ T lymphocytes from &#x3b2;2 microglobulin (&#x3b2;2m) HLA-A2.1 monochain transgenic H-2Db &#x3b2;2m Double knockout mice. J. Exp. Med. 1997;185:2043&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196346</ArticleId><ArticleId IdType="pubmed">9182675</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K., Khan A.M., Yong B., Tan L., Hu Y., et al. West Nile virus T-cell ligand sequences shared with other Flaviviruses: a multitude of variant sequences as potential AlteredPeptide ligands. J. Virol. 2012;86:7616&#x2013;7624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3416302</ArticleId><ArticleId IdType="pubmed">22573867</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T., Kishimoto H., Abe R. Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model. Cancer Immunol. Immunother. 2016;65:341&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11028809</ArticleId><ArticleId IdType="pubmed">26880265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., Hosaka S., Beppu T., Ishiko T., Kamohara H., Ashihara H., Katagiri T., Furukawa Y., Fujiyama S., Ogawa M., Nakamura Y., Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun. 2003;306:16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788060</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda D., Ota S., Takazawa Y., Aburatani H., Nakagawa S., Yano T., Taketani Y., Kodama T., Fukayama M. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod. Pathol. 2009;22:824&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">19329941</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviel-Ronen S., Lau S.K., Pintilie M., Lau D., Liu N., Tsao M.S., Jothy S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod. Pathol. 2008;21:817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469798</ArticleId></ArticleIdList></Reference><Reference><Citation>Mounajjed T., Zhang L., Wu T.T. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum. Pathol. 2013;44:542&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">23079207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsura T., Kageshita T., Ito S., Wakamatsu K., Monji M., Ikuta Y., Senju S., Ono T., Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin. Cancer Res. 2004;10:6612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zynger D.L., Gupta A., Luan C., Chou P.M., Yang G.Y., Yang X.J. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum. Pathol. 2008;39:224&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">17949790</ArticleId></ArticleIdList></Reference><Reference><Citation>Toretsky J.A., Zitomersky N.L., Eskenazi A.E., Voigt R.W., Strauch E.D., Sun C.C., Huber R., Meltzer S.J., Schlessinger D. Glypican-3 expression in wilms tumor and hepatoblastoma. J. Pediatr. Hematol. Oncol. 2001;23:496&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">11878776</ArticleId></ArticleIdList></Reference><Reference><Citation>Esheba G.E., Pate L.L., Longacre T.A. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am. J. Surg. Pathol. 2008;32:600&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">18277882</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Guo H., Li J., Sui C., Qin Y., Wang J., Khan Y.H., Ye L., Xie F., Wang H., Yuan L., Ye J. Slit2 and Robo1 induce opposing effects on metastasis of hepatocellular carcinoma Sk-hep-1 cells. Int. J. Oncol. 2016;49:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">27176045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Funahashi S., Yamauchi N., Shibahara J., Midorikawa Y., Kawai S., Kinoshita Y., Watanabe A., Hippo Y., Ohtomo T., Iwanari H., Nakajima A., Makuuchi M., Fukayama M., Hirata Y., Hamakubo T., Kodama T., Tsuchiya M., Aburatani H. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin. Cancer Res. 2006;12:3257.</Citation><ArticleIdList><ArticleId IdType="pubmed">16740745</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia G., Kumar S.R., Masood R., Zhu S., Reddy R., Krasnoperov V., Quinn D.I., Henshall S.M., Sutherland R.L., Pinski J.K., Daneshmand S., Buscarini M., Stein J.P., Zhong C., Broek D., Roy-Burman P., Gill P.S. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623&#x2013;4632.</Citation><ArticleIdList><ArticleId IdType="pubmed">15930280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S.R., Singh J., Xia G., Krasnoperov V., Hassanieh L., Ley E.J., Scehnet J., Kumar N.G., Hawes D., Press M.F., Weaver F.A., Gill P.S. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am. J. Pathol. 2006;169:279&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698769</ArticleId><ArticleId IdType="pubmed">16816380</ArticleId></ArticleIdList></Reference><Reference><Citation>Masood R., Kumar S.R., Sinha U.K., Crowe D.L., Krasnoperov V., Reddy R.K., Zozulya S., Singh J., Xia G., Broek D., Schonthal A.H., Gill P.S. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int. J. Cancer. 2006;119:1236&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">16615113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S.R., Scehnet J.S., Ley E.J., Singh J., Krasnoperov V., Liu R., Manchanda P.K., Ladner R.D., Hawes D., Weaver F.A., Beart R.W., Singh G., Nguyen C., Kahn M., Gill P.S. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009;69:3736&#x2013;3745.</Citation><ArticleIdList><ArticleId IdType="pubmed">19366806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F., Tao Z., Shen Z., Wang X., Hua F. Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity. Tumour Biol. 2014;35:7225&#x2013;7232.</Citation><ArticleIdList><ArticleId IdType="pubmed">24771266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N.Y., Pasquale E.B., Owen L.B., Ethell I.M. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J. Biol. Chem. 2006;281:32574&#x2013;32586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950769</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Zhao J., Qiao J., Song C., Zhao Z. EphB4 regulates the growth and migration of pancreatic cancer cells. Tumour Biol. 2014;35:6855&#x2013;6859.</Citation><ArticleIdList><ArticleId IdType="pubmed">25051915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson B.D., Liu R., Rolle C.E., Tan Y.C., Krasnoperov V., Kanteti R., Tretiakova M.S., Cervantes G.M., Hasina R., Hseu R.D., Iafrate A.J., Karrison T., Ferguson M.K., Husain A.N., Faoro L., Vokes E.E., Gill P.S., Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013;8:e67668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699624</ArticleId><ArticleId IdType="pubmed">23844053</ArticleId></ArticleIdList></Reference><Reference><Citation>Visco Z.R., Sfakianos G., Grenier C., Boudreau M.-H., Simpson S., Rodriguez I., Whitaker R., Yao D.Y., Berchuck A., Murphy S.K., Huang Z. Epigenetic regulation of claudin-1 in the development of ovarian cancer recurrence and drug resistance. Front. Oncol. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019902</ArticleId><ArticleId IdType="pubmed">33828978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Li J., Jiang Y., Xu W., Li X., Jing W. CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. Med. Sci. Monit. 2017;23:2906&#x2013;2916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479443</ArticleId><ArticleId IdType="pubmed">28614291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong H., Li T., Qiu W., Zhu Z. Claudin-1 silencing increases sensitivity of liver cancer HepG2 cells to 5-fluorouracil by inhibiting autophagy. Oncol. Lett. 2019;18:5709&#x2013;5716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865833</ArticleId><ArticleId IdType="pubmed">31788043</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., Neff J., Washington M.K., Beauchamp R.D. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Investig. 2005;115:1765&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1150288</ArticleId><ArticleId IdType="pubmed">15965503</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku N., Sasabe E., Ueta E., Yamamoto T., Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 2006;66:5251&#x2013;5257.</Citation><ArticleIdList><ArticleId IdType="pubmed">16707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Leotlela P.D., Wade M.S., Duray P.H., Rhode M.J., Brown H.F., Rosenthal D.T., Dissanayake S.K., Earley R., Indig F.E., Nickoloff B.J., Taub D.D., Kallioniemi O.P., Meltzer P., Morin P.J., Weeraratna A.T. Claudin-1 overexpression in melanoma is regulated by pkc and contributes to melanoma cell motility. Oncogene. 2007;26:3846&#x2013;3856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17160014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Holst J. L-Type amino acid transporter and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am. J. Cancer Res. 2015;5:1281&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473310</ArticleId><ArticleId IdType="pubmed">26101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Chen G., Zhang P., Zhang J., Li X., Gan D., Cao X., Han M., Du H., Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7018038</ArticleId><ArticleId IdType="pubmed">32053643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Dai X., Dai J., Ding C., Zhang Z., Lin Z., Hu J., Lu M., Wang Z., Qi Y., Zhang L., Pan R., Zhao Z., Lu L., Liao W., Lu X. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11:822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532541</ArticleId><ArticleId IdType="pubmed">33009373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi A., Erdogan Z.M., Kim Y.J., Choi Y.L., Lu H., Katzenellenbogen B.S. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res. 2014;16:436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303117</ArticleId><ArticleId IdType="pubmed">25213081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G., Yan Z., Zhang C., Cheng M., Yan Y., Wang Y., Deng L., Lu Q., Luo S. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression. J. Exp. Clin. Cancer Res. 2019;38:188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507024</ArticleId><ArticleId IdType="pubmed">31072351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien H.C., Hsiao Y.H., Lin Y.S., Yao Y.T., Juan H.F., Kuo W.H., Hung Mien-Chie, Chang K.J., Hsieh F.J. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26:7859&#x2013;7871.</Citation><ArticleIdList><ArticleId IdType="pubmed">17603561</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempel S.A., Golembieski W.A., Ge S., Lemke N., Elisevich K., Mikkelsen T., Guti&#xe9;rrez J.A. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J. Neuropathol. Exp. Neurol. 1998;57:1112&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledda M.F., Adris S., Bravo A.I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O.L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 1997;3:171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9018235</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez M.J., Prada F., Salvatierra E., Bravo A.I., Lutzky V.P., Carbone C., Pitossi F.J., Chuluyan H., Podhajcer O.L. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res. 2005;65:5123&#x2013;5132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15958556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B.J., Chi K.P., Shen R.L., Zheng S.W., Guo Y., Li J.F., Fei J., He Y. TGFBI promotes tumor growth and is associated with poor prognosis in oral squamous cell carcinoma. J. Cancer. 2019;10:4902&#x2013;4912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6775518</ArticleId><ArticleId IdType="pubmed">31598162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Lee J., Sim W., Kim J.H. Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARgamma signalling pathway. Cell. Oncol. 2022;14:275&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">35357655</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.C., Zhu W.Y., Ren L.Y. LncRNA H19 inhibits proliferation and enhances apoptosis of nephroblastoma cells by regulating the miR-675/TGFBI axis. Eur. Rev. Med. Pharmacol. Sci. 2022;26:3800&#x2013;3806.</Citation><ArticleIdList><ArticleId IdType="pubmed">35731049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N., Xing Y., Hu Y., Chang H. Exploration of the immunotyping landscape and immune infiltration-related prognostic markers in ovarian cancer patients. Front. Oncol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307664</ArticleId><ArticleId IdType="pubmed">35880167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L., Han Z., Du Y. Identification of gene biomarkers and immune cell infiltration characteristics in rectal cancer. J Gastrointest. Oncol. 2021;12:964&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261330</ArticleId><ArticleId IdType="pubmed">34295549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Gao Q., Liu Z., Shen G., Sun X., Di X. Identification of immune and hypoxia risk classifier to estimate immune microenvironment and prognosis in cervical cancer. J. Oncol. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9593224</ArticleId><ArticleId IdType="pubmed">36304989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C., Li Z., Zhang Y., Zhang Z., Wu Z., Da L., Yang S., Wang Z., Zhang Y., Qie Y., Zhao G., Lin Y., Huang S., Zhou M., Hu H. Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer. Front. Oncol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589509</ArticleId><ArticleId IdType="pubmed">36300085</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsura T., Senju S., Yamada K., Jotsuka T., Ogawa M., Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem. Biophys. Res. Commun. 2001;281:936&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai M., Nakatsura T., Egami H., Senju S., Nishimura Y., Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol. Rep. 2003;10:1777&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534695</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone J.D., Harris D.T., Kranz D.M. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr. Opin. Immunol. 2015;33:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920053</ArticleId><ArticleId IdType="pubmed">25618219</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem M.L., Diaz-Montero C.M., El-Naggar S.A., Chen Y., Moussa O., Cole D.J. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na&#xef;ve recipient mice. Vaccine. 2009;27:549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072892</ArticleId><ArticleId IdType="pubmed">19027047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., Lambeck A.J.A, Figdor C.G. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood. 2011;118:6836&#x2013;6844.</Citation><ArticleIdList><ArticleId IdType="pubmed">21967977</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., M&#xf8;ller M., Eriksen J.A., Gaudernack G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006;55:1553&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11030882</ArticleId><ArticleId IdType="pubmed">16491401</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39931982</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-533X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Current medicinal chemistry</Title><ISOAbbreviation>Curr Med Chem</ISOAbbreviation></Journal><ArticleTitle>Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2174/0109298673361923250101072831</ELocationID><Abstract><AbstractText Label="AIM">This study aimed to screen the potential phytochemicals derived from Asparagus racemosus (Shatavari) against Thymidylate Kinase (TMPK) and D9 decapping enzyme, which is the vital target of the monkeypox virus and helps in the host-- pathogen interaction mechanism, using integrated docking, QSAR analysis, and a molecular dynamics approach.</AbstractText><AbstractText Label="BACKGROUND">The Monkeypox Virus (MPXV) is a recently emerging outbreak with ongoing infection cases. Drugs and vaccines for smallpox are being used to contain it. However, no specific drugs or vaccines are available to combat this infection.</AbstractText><AbstractText Label="METHODS">The TMPK and D9 decapping enzymes were retrieved from the MPXV virus UK strain in FASTA format. Due to the unavailability of an experimentally determined structure, the 3D structure was modelled via SWISS-MODEL and further enhanced and validated. The structure was subjected to docking analysis with the derived phytochemicals from Asparagus racemosus using a maestro module. The potential inhibitors were examined via QSAR analysis. Additionally, through MD simulation 250ns, the stability was analyzed, and the MM-GBSA was employed to calculate the binding affinities.</AbstractText><AbstractText Label="RESULTS">The molecular investigation revealed asparoside-C (PubChem ID: 158598) and asparoside-D (PubChem ID: 158597) to be potential hits among others for both targets (TMPK and D9 decapping enzyme) compared to the reference drugs, i.e., tecovirimat, brincidofovir, and cidofovir, possessing antiviral and required bioactivity analyzed via the ADME and QSAR analyses. Moreover, the simulation study of over 250ns revealed strong stability, followed by RMSD, RMSF, etc. The free energy calculation via MMGBSA exhibited strong affinities of asparoside-C and asparoside-D towards the TMPK and the D9 decapping enzyme according to their respective scores.</AbstractText><AbstractText Label="CONCLUSION">The docking, QSAR, and simulation investigation revealed dual-target inhibitors activity of phytochemicals from Asparagus racemosus towards the MPXV via targeting TMPK and D9 decapping enzyme. It has been observed that asparoside-D and asparoside-C can potentially combat MPXV.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Saurav Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, University of North Bengal, District-Darjeeling, Siliguri, 734013, West Bengal, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Anshuman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Physical Sciences, Jawaharlal Nehru University, New Delhi, 110067, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitra</LastName><ForeName>Namrata</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, University of North Bengal, District-Darjeeling, Siliguri, 734013, West Bengal, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishna</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute (CSIR-CDRI), Sector 10, Jankipuram Extension, Lucknow, India</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Nagendra</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Gautam Buddha University, Greater Noida, India</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akash</LastName><ForeName>Shopnil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Computational Biology Research Laboratory, Department of Pharmacy, Daffodil International University, Dhaka,
Bangladesh</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jardan</LastName><ForeName>Yousef A Bin</ForeName><Initials>YAB</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, King Saud University, PO Box, Riyadh, 11451, Saudi Arabia</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourhia</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Swalife Biotech Ltd, Unit 3D, North Point House, North Point Business Park, Cork, Ireland</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Georrge</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-9858-6112</Identifier><AffiliationInfo><Affiliation>Department of Bioinformatics, University of North Bengal, District-Darjeeling, Siliguri, 734013, West Bengal, India</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Med Chem</MedlineTA><NlmUniqueID>9440157</NlmUniqueID><ISSNLinking>0929-8673</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asparagus racemosus</Keyword><Keyword MajorTopicYN="N">D9 decapping enzyme.</Keyword><Keyword MajorTopicYN="N">molecular docking</Keyword><Keyword MajorTopicYN="N">monkeypox virus</Keyword><Keyword MajorTopicYN="N">thymidylate kinase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39931982</ArticleId><ArticleId IdType="doi">10.2174/0109298673361923250101072831</ArticleId><ArticleId IdType="pii">CMC-EPUB-146487</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39915566</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Comparative performance of tuberculin and defined-antigen cocktails for detecting bovine tuberculosis in BCG-vaccinated cattle in natural settings.</ArticleTitle><Pagination><StartPage>4564</StartPage><MedlinePgn>4564</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4564</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-85389-1</ELocationID><Abstract><AbstractText>Bovine tuberculosis (bTB) is a threat to cattle health and public safety. The current control programs are hampered by wildlife reservoirs and socioeconomic barriers. Vaccinating cattle with Bacillus Calmette-Gu&#xe9;rin (BCG) effectively reduces transmission, offering a potential solution for controlling bTB. A key requirement for vaccination strategies using BCG is the validation of defined antigens to differentiate infections among vaccinated animals (DIVA). We compared tuberculin with DIVA peptide cocktails (ESAT-6, CFP-10, and Rv3615c) in 67 unvaccinated and 67 BCG-vaccinated cattle exposed to M. bovis in a natural setting. The cattle were tested every 4 months with a skin test and every 2 months with interferon-gamma (IFN-&#x3b3;) release assays (IGRA) over a year of exposure. Before exposure, the DIVA skin, DIVA IGRA, and tuberculin tests showed 100% specificity in unvaccinated control calves. After exposure, the DIVA skin, DIVA IGRA, and comparative cervical tuberculin (CCT) tests had comparable sensitivities of 46% (95% CI 36, 56), 45% (95% CI 35, 55), and 47 (95% CI 37, 57), respectively, when assessed against animals positive by M. bovis culture PCR. The results suggest that test-and-slaughter control strategies using tests with low sensitivity are not expected to be effective in controlling bTB in high-prevalence herds, and highlight an urgent need to improve the sensitivity of diagnostic tests for bTB in these settings.</AbstractText><CopyrightInformation>&#xa9; 2025. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fromsa</LastName><ForeName>Abebe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia. abebe.fromsa@aau.edu.et.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Veterinary Medicine and Agriculture, Addis Ababa University, Bishoftu, Ethiopia. abebe.fromsa@aau.edu.et.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conlan</LastName><ForeName>Andrew J K</ForeName><Initials>AJK</Initials><AffiliationInfo><Affiliation>Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. ajkc2@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Sreenidhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Animal Science, The Pennsylvania State University, University Park, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Global Health Initiative, Henry Ford Health, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumi</LastName><ForeName>Balako</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedada</LastName><ForeName>Wegene</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeleke</LastName><ForeName>Miserach</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worku</LastName><ForeName>Dawit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakew</LastName><ForeName>Matios</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadesse</LastName><ForeName>Biniam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayissa</LastName><ForeName>Berecha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Veterinary Institute, Bishoftu, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirak</LastName><ForeName>Asegedech</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdela</LastName><ForeName>Musse Girma</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekonnen</LastName><ForeName>Getnet Abie</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibssa</LastName><ForeName>Tesfaye</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Animal Health Institute, Sebeta, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veerasami</LastName><ForeName>Maroudam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CisGen Biotech Discoveries Pvt Ltd, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Animal and Plant Health Agency, Weybridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vordermeier</LastName><ForeName>H Martin</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>, Woking, Surrey, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juleff</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Bill &amp; Melinda Gates Foundation, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>James L N</ForeName><Initials>JLN</Initials><AffiliationInfo><Affiliation>Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ameni</LastName><ForeName>Gobena</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aklilu Lemma Institutes of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia. gobena.ameni@uaeu.ac.ae.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University, Al Ain, UAE. gobena.ameni@uaeu.ac.ae.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapur</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, PA, USA. vxk1@psu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Animal Science, The Pennsylvania State University, University Park, PA, USA. vxk1@psu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014373">Tuberculin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014380" MajorTopicYN="Y">Tuberculosis, Bovine</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001500" MajorTopicYN="Y">BCG Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009163" MajorTopicYN="Y">Mycobacterium bovis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014374" MajorTopicYN="Y">Tuberculin Test</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014373" MajorTopicYN="N">Tuberculin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059425" MajorTopicYN="N">Interferon-gamma Release Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCG vaccination</Keyword><Keyword MajorTopicYN="N">Bovine tuberculosis</Keyword><Keyword MajorTopicYN="N">Defined antigen cocktails</Keyword><Keyword MajorTopicYN="N">IGRA and skin tests</Keyword><Keyword MajorTopicYN="N">Tuberculin</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39915566</ArticleId><ArticleId IdType="pmc">PMC11802902</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-85389-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-85389-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WOAH. Mammalian tuberculosis (infection with Mycobacterium tuberculosis complex). In Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (World Organisation for Animal Health, 2022).</Citation></Reference><Reference><Citation>Allen, A. R., Skuce, R. A. &amp; Byrne, A. W. Bovine tuberculosis in Britain and Ireland&#x2014;A perfect storm? The confluence of potential ecological and epidemiological impediments to controlling a chronic infectious disease. Front. Vet. Sci.5, 109 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008655</ArticleId><ArticleId IdType="pubmed">29951489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibhat, B. et al. Bovine tuberculosis in Ethiopia: a systematic review and meta-analysis. Prev. Vet. Med.147, 149&#x2013;157 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5739073</ArticleId><ArticleId IdType="pubmed">29254713</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaw, G. et al. The variable prevalence of bovine tuberculosis among dairy herds in Central Ethiopia provides opportunities for targeted intervention. PLoS ONE16, e0254091 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253440</ArticleId><ArticleId IdType="pubmed">34214106</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville, R. J. Australia&#x2019;s colourful path to Tuberculosis freedom. Ir. Vet. J.76, 15 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10369694</ArticleId><ArticleId IdType="pubmed">37491287</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlan, A. J. K. et al. Potential benefits of cattle vaccination as a supplementary control for bovine tuberculosis. PLoS Comput. Biol.11, e1004038 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335026</ArticleId><ArticleId IdType="pubmed">25695736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameni, G. et al. Vaccination of calves with Mycobacterium bovis bacillus Calmette-Guerin reduces the frequency and severity of lesions of bovine tuberculosis under a natural transmission setting in Ethiopia. Transbound. Emerg. Dis.65, 96&#x2013;104 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811905</ArticleId><ArticleId IdType="pubmed">28168855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameni, G., Vordermeier, M., Aseffa, A., Young, D. B. &amp; Hewinson, R. G. Field evaluation of the efficacy of Mycobacterium bovis bacillus Calmette-Gu&#xe9;rin against bovine tuberculosis in neonatal calves in Ethiopia. Clin. Vaccine Immunol.17, 1533&#x2013;1538 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953002</ArticleId><ArticleId IdType="pubmed">20719984</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlan, A. J. K., Vordermeier, M., De Jong, M. C. &amp; Wood, J. L. The intractable challenge of evaluating cattle vaccination as a control for bovine tuberculosis. eLife7, e27694 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988428</ArticleId><ArticleId IdType="pubmed">29866255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromsa, A. et al. BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination. Science383, eadl3962 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38547287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayissa, B. et al. Evaluation of the efficacy of BCG in protecting against contact challenge with bovine tuberculosis in Holstein-Friesian and Zebu crossbred calves in Ethiopia. Front. Vet. Sci.8, 702402 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339472</ArticleId><ArticleId IdType="pubmed">34368285</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan, A. O. et al. Development of a skin test for bovine tuberculosis for differentiating infected from vaccinated animals. J. Clin. Microbiol.48, 3176&#x2013;3181 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937719</ArticleId><ArticleId IdType="pubmed">20592155</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan, S. et al. A defined antigen skin test for the diagnosis of bovine tuberculosis. Sci. Adv.5, eaax4899 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636981</ArticleId><ArticleId IdType="pubmed">31328169</ArticleId></ArticleIdList></Reference><Reference><Citation>Vordermeier, H. M., Jones, G. J., Buddle, B. M., Hewinson, R. G. &amp; Villarreal-Ramos, B. Bovine tuberculosis in cattle: vaccines, DIVA tests, and host biomarker discovery. Annu. Rev. Anim. Biosci.4, 87&#x2013;109 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26884103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidders, B. et al. Screening of highly expressed mycobacterial genes identifies Rv3615c as a useful differential diagnostic antigen for the Mycobacterium tuberculosis complex. Infect. Immun.76, 3932&#x2013;3939 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519431</ArticleId><ArticleId IdType="pubmed">18519559</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Villalva, S. et al. Specificity of the tuberculin skin test is modified by use of a protein cocktail containing ESAT-6 and CFP-10 in cattle naturally infected with Mycobacterium bovis. Clin. Vaccine Immunol.19, 797&#x2013;803 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346340</ArticleId><ArticleId IdType="pubmed">22419675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayissa, B. et al. Field evaluation of specific mycobacterial protein-based skin test for the differentiation of Mycobacterium bovis&#x2010;infected and Bacillus Calmette Guerin&#x2010;vaccinated crossbred cattle in Ethiopia. Transbound. Emerg. Dis.69, 1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801543</ArticleId><ArticleId IdType="pubmed">34331511</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco, F. C. et al. Identifying bacterial and host factors involved in the interaction of Mycobacterium bovis with the bovine innate immune cells. Front. Immunol.12, 674643 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319915</ArticleId><ArticleId IdType="pubmed">34335572</ArticleId></ArticleIdList></Reference><Reference><Citation>Vordermeier, H. et al. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin. Diagn. Lab. Immunol.8, 571&#x2013;578 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC96103</ArticleId><ArticleId IdType="pubmed">11329460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, G. J. et al. Test performance data demonstrates utility of a cattle DIVA skin test reagent (DST-F) compatible with BCG vaccination. Sci. Rep.12, 12052 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9283413</ArticleId><ArticleId IdType="pubmed">35835806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Valencia, G. et al. Field evaluation of the protective efficacy of Mycobacterium bovis BCG vaccine against bovine tuberculosis. Res. Vet. Sci.88, 44&#x2013;49 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19564029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent, G., Yockney, I. J., Whitford, J., Aldwell, F. E. &amp; Buddle, B. M. Efficacy of oral BCG vaccination in protecting free-ranging cattle from natural infection by Mycobacterium bovis. Vet. Microbiol.208, 181&#x2013;189 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28888636</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent, G., Yockney, I. J., Cross, M. L. &amp; Buddle, B. M. Low-dose BCG vaccination protects free-ranging cattle against naturally-acquired bovine tuberculosis. Vaccine36, 7338&#x2013;7344 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30327211</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, S. et al. Defined antigen skin test for bovine tuberculosis retains specificity on revaccination with bacillus Calmette&#x2013;Gu&#xe9;rin. Front. Vet. Sci.9, 814227 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9043861</ArticleId><ArticleId IdType="pubmed">35498753</ArticleId></ArticleIdList></Reference><Reference><Citation>Vordermeier, H. M. et al. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun.70, 3026&#x2013;3032 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC128013</ArticleId><ArticleId IdType="pubmed">12010994</ArticleId></ArticleIdList></Reference><Reference><Citation>QIAGEN. DNeasy&#xae;Blood &amp; Tissue Handbook (2023).</Citation></Reference><Reference><Citation>Fromsa, A. et al. Bovine tuberculosis in Central Ethiopian slaughterhouses and the identification of causative mycobacteria by multiplex real-time PCR. BMC Microbiol.24, 394 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11462752</ArticleId><ArticleId IdType="pubmed">39379812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Education (MoE). National Research Ethics Review Technical Guideline (2022).</Citation></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. https://www.R-project.org/ (R Foundation for Statistical Computing, 2023).</Citation></Reference><Reference><Citation>RStudio Team. RStudio: Integrated Development for R (RStudio, 2020).</Citation></Reference><Reference><Citation>Wickham, H. ggplot2: Elegant Graphics for Data Analysis (2016).</Citation></Reference><Reference><Citation>Patil, I. Visualizations with statistical details: the &#x2018;gstatsplot&#x2019; approach. J. Open Source Softw.6, 3167 (2021).</Citation></Reference><Reference><Citation>Ranganathan, P. &amp; Aggarwal, R. Understanding the properties of diagnostic tests&#x2014;part 2: likelihood ratios. Perspect. Clin. Res.9, 99&#x2013;102 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5950618</ArticleId><ArticleId IdType="pubmed">29862204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan, P. &amp; Aggarwal, R. Common pitfalls in statistical analysis: understanding the properties of diagnostic tests&#x2014;part 1. Perspect. Clin. Res.9, 40&#x2013;43 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799952</ArticleId><ArticleId IdType="pubmed">29430417</ArticleId></ArticleIdList></Reference><Reference><Citation>Portney, L. G. Foundations of Research and Evidence: Applications to Evidence-Based Practice (F. A. Davis Company, 2020).</Citation></Reference><Reference><Citation>Drewe, J. A., Tomlinson, A. J., Walker, N. J. &amp; Delahay, R. J. Diagnostic accuracy and optimal use of three tests for tuberculosis in live badgers. PLoS ONE5, e11196 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887451</ArticleId><ArticleId IdType="pubmed">20585404</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh, M. L. Interrater reliability: the kappa statistic. Biochem. Med.10.11613/bm.2012.031 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900052</ArticleId><ArticleId IdType="pubmed">23092060</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, P. A. et al. BCG vaccination against tuberculosis in European badgers (Meles meles): a review. Comp. Immunol. Microbiol. Infect. Dis.35, 277&#x2013;287 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22340983</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton, S. et al. A molecularly defined skin test reagent for the diagnosis of bovine tuberculosis compatible with vaccination against Johne&#x2019;s disease. Sci. Rep.11, 2929 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7859399</ArticleId><ArticleId IdType="pubmed">33536465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, G. J., Whelan, A., Clifford, D., Coad, M. &amp; Vordermeier, H. M. Improved skin test for differential diagnosis of bovine tuberculosis by the addition of Rv3020c-derived peptides. Clin. Vaccine Immunol.19, 620&#x2013;622 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318272</ArticleId><ArticleId IdType="pubmed">22301696</ArticleId></ArticleIdList></Reference><Reference><Citation>Buddle, B. et al. Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle by using recombinant mycobacterial antigens. Clin. Diagn. Lab. Immunol.6, 1&#x2013;5 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC95651</ArticleId><ArticleId IdType="pubmed">9874655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulberg, S., Boysen, P. &amp; Storset, A. K. Reference values for relative numbers of natural killer cells in cattle blood. Dev. Compar. Immunol.28, 941&#x2013;948 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15183034</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen, I. et al. Bovine NK cells can produce gamma interferon in response to the secreted mycobacterial proteins ESAT-6 and MPP14 but not in response to MPB70. Infect. Immun.73, 5628&#x2013;5635 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1231097</ArticleId><ArticleId IdType="pubmed">16113280</ArticleId></ArticleIdList></Reference><Reference><Citation>Coad, M. et al. Repeat tuberculin skin testing leads to desensitisation in naturally infected tuberculous cattle which is associated with elevated interleukin-10 and decreased interleukin-1 beta responses. Vet. Res.41, 14 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785049</ArticleId><ArticleId IdType="pubmed">19840537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakew, M. et al. Utility of the intradermal skin test in a test-and-cull approach to control bovine tuberculosis: a pilot study in Ethiopia. Front. Vet. Sci.9, 823365 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940234</ArticleId><ArticleId IdType="pubmed">35330613</ArticleId></ArticleIdList></Reference><Reference><Citation>Claridge, J. et al. Fasciola hepatica is associated with the failure to detect bovine tuberculosis in dairy cattle. Nat. Commun.3, 853 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989536</ArticleId><ArticleId IdType="pubmed">22617293</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne, A. W. et al. Modelling the variation in skin-test tuberculin reactions, post-mortem lesion counts and case pathology in tuberculosis-exposed cattle: Effects of animal characteristics, histories and co-infection. Transbound. Emerg. Dis.65, 844&#x2013;858 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29363285</ArticleId></ArticleIdList></Reference><Reference><Citation>Casal, C. et al. Evaluation of two cocktails containing ESAT-6, CFP-10 and Rv-3615c in the intradermal test and the interferon-&#x3b3; assay for diagnosis of bovine tuberculosis. Prev. Vet. Med.105, 149&#x2013;154 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22391021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39915263</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-1426</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal for immunotherapy of cancer</Title><ISOAbbreviation>J Immunother Cancer</ISOAbbreviation></Journal><ArticleTitle>Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e010291</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2024-010291</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">CD4<sup>+</sup> T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4<sup>+</sup> T cell lymphocytopenia. IL-7 is a cytokine that is essential in T-cell development, proliferation and homeostasis. In PWH, IL-7 administration leads to increased numbers of circulating central memory and na&#xef;ve T-cell phenotypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this multicenter phase I study with a 3+3&#x2009;dose escalation design, participants with KS with or without HIV received up to four intramuscular injections of IL-7 (NT-I7) every 9 weeks. The primary endpoint of the study was to evaluate safety over three escalating dose levels (DL) of NT-I7 (DL1:480&#x2009;&#xb5;g/kg, DL2: 960&#x2009;&#xb5;g/kg and DL3: 1200&#x2009;&#xb5;g/kg) and identify a maximum tolerated dose. Secondary endpoints included evaluation of antitumor activity per the modified AIDS Clinical Trials Group Criteria and assessment of the effect of NT-I7 on the kinetics of CD4<sup>+</sup> and CD8<sup>+</sup> T-cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight cisgender male participants (five with HIV infection) were enrolled. Six participants were treated at DL1, and two were treated at DL2. The study was closed to accrual after enrolment of the second participant on DL2 due to termination of study funding. Four of the eight participants (three in DL1 and one in DL2) completed all four doses of the NT-I7. With regard to treatment-emergent adverse events (AEs), all participants had &lt;grade 2 AEs, which included injection site reaction and alanine aminotransferase increase. Injection site reaction was a dose-limiting toxicity in one participant at DL1. The overall KS objective response rate to NT-I7 was 42.9% (95% CI 9.9%, 81.6%) and all three responders were PWH. Absolute lymphocyte counts, CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts increased among all participants following administration of NT-I7. Participants who experienced a response had HIV and lower CD4/CD8 ratio at baseline and throughout the study as compared with those who did not have KS response to NT-I7.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preliminary data demonstrate safety and activity of IL-7 in patients with KS and activity specifically among individuals HIV-associated KS.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT04893018.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramaswami</LastName><ForeName>Ramya</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5709-4675</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA ramya.ramaswami@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kask</LastName><ForeName>Angela Shaulov</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Manoj P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lurain</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5794-7292</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarchoan</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekwede</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couey</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, University of California San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Harborview Medical Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angeldekao</LastName><ForeName>Allysson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harborview Medical Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha Lee</LastName><ForeName>Byung</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NeoImmuneTech Inc, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Judith C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheever</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uldrick</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0001-6959-0924</Identifier><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Li-Lian</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Cytel (Shanghai) Co Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fling</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Cancer Immunotherapy Trials Network (CITN), Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chia-Ching Jackie</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, University of California San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04893018</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UM1 CA154967</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA BC011954</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Immunother Cancer</MedlineTA><NlmUniqueID>101620585</NlmUniqueID><ISSNLinking>2051-1426</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508605">IL7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015851">Interleukin-7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012514" MajorTopicYN="Y">Sarcoma, Kaposi</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015851" MajorTopicYN="N">Interleukin-7</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Skin Cancer</Keyword><Keyword MajorTopicYN="N">T cell</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>Competing interests: RR, KL and RY report receiving research support from Celgene (now Bristol Myers Squibb), from CTI BioPharma (a Sobi Company), PDS Biotech, and Janssen Pharmaceuticals through CRADAs with the NCI. RR, KL and RY report receiving drug for a clinical trial from Merck through a CRADA with the NCI. RR, KL and RY report receiving drug for a clinical trial from EMD-Serano and Eli Lilly through a CRADA at the NCI. RY reports receiving preclinical material from Lentigen Technology through a CRADA or MTA with the NCI. MPM reports receiving research support from Roche through a CTA with Fred Hutchinson Cancer Research Center. TSU is currently employed by Regeneron Pharmaceuticals. TSU and RY are coinventors on US Patent 10,001,483 entitled 'Methods for the treatment of Kaposi&#x2019;s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers.' RY is also a coinventor on patents on a peptide vaccine for HIV and on the treatment of Kaposi sarcoma with IL12, and an immediate family member of RY is a coinventor on patents related to internalization of target receptors, on KSHV viral IL-6, and on the use of calreticulin and calreticulin fragments to inhibit angiogenesis. All rights, title, and interest to these patents have been or should by law be assigned to the US Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). No potential conflicts of interest were disclosed by the other authors. TSU name as a coinventor on US Provisional Patent Application 18/310,649, KSHV Oncoprotein Antigens and Epitodes for Expanding Antigen Specific T-cells.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>22</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39915263</ArticleId><ArticleId IdType="pmc">PMC11804200</ArticleId><ArticleId IdType="doi">10.1136/jitc-2024-010291</ArticleId><ArticleId IdType="pii">jitc-2024-010291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi&#x2019;s sarcoma. Science. 1994;266:1865&#x2013;9. doi: 10.1126/science.7997879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7997879</ArticleId><ArticleId IdType="pubmed">7997879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9. doi: 10.1038/s41572-019-0060-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0060-9</ArticleId><ArticleId IdType="pmc">PMC6685213</ArticleId><ArticleId IdType="pubmed">30705286</ArticleId></ArticleIdList></Reference><Reference><Citation>Labo N, Miley W, Benson CA, et al. Epidemiology of Kaposi&#x2019;s sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. AIDS. 2015;29:1217&#x2013;25. doi: 10.1097/QAD.0000000000000682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000682</ArticleId><ArticleId IdType="pmc">PMC6680245</ArticleId><ArticleId IdType="pubmed">26035321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedes DH, Operskalski E, Busch M, et al. The seroepidemiology of human herpesvirus 8 (Kaposi&#x2019;s sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918&#x2013;24. doi: 10.1038/nm0896-918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0896-918</ArticleId><ArticleId IdType="pubmed">8705863</ArticleId></ArticleIdList></Reference><Reference><Citation>Motlhale M, Sitas F, Bradshaw D, et al. Epidemiology of Kaposi&#x2019;s sarcoma in sub-Saharan Africa. Cancer Epidemiol. 2022;78:102167. doi: 10.1016/j.canep.2022.102167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2022.102167</ArticleId><ArticleId IdType="pubmed">35504064</ArticleId></ArticleIdList></Reference><Reference><Citation>Touloumi G, Hatzakis A, Potouridou I, et al. The role of immunosuppression and immune-activation in classic Kaposi&#x2019;s sarcoma. Int J Cancer. 1999;82:817&#x2013;21. doi: 10.1002/(sici)1097-0215(19990909)82:6&lt;817::aid-ijc8&gt;3.0.co;2-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0215(19990909)82:6&lt;817::aid-ijc8&gt;3.0.co;2-7</ArticleId><ArticleId IdType="pubmed">10446447</ArticleId></ArticleIdList></Reference><Reference><Citation>Unemori P, Leslie KS, Hunt PW, et al. Immunosenescence is associated with presence of Kaposi&#x2019;s sarcoma in antiretroviral treated HIV infection. AIDS. 2013;27:1735&#x2013;42. doi: 10.1097/QAD.0b013e3283601144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e3283601144</ArticleId><ArticleId IdType="pmc">PMC4063793</ArticleId><ArticleId IdType="pubmed">23435301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihl F, Mosam A, Henry LN, et al. Kaposi&#x2019;s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi&#x2019;s sarcoma. AIDS. 2007;21:1245&#x2013;52. doi: 10.1097/QAD.0b013e328182df03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e328182df03</ArticleId><ArticleId IdType="pubmed">17545700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihl F, Berger C, Chisholm JV, 3rd, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi&#x2019;s sarcoma. AIDS. 2009;23:1918&#x2013;22. doi: 10.1097/QAD.0b013e3283300a91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e3283300a91</ArticleId><ArticleId IdType="pubmed">19609199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi&#x2019;s sarcoma. J Clin Oncol. 2014;32:409&#x2013;14. doi: 10.1200/JCO.2013.51.6757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.51.6757</ArticleId><ArticleId IdType="pubmed">24378415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami R, Lurain K, Yarchoan R. Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. J Clin Oncol. 2022;40:294&#x2013;306. doi: 10.1200/JCO.21.02040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.02040</ArticleId><ArticleId IdType="pmc">PMC8769148</ArticleId><ArticleId IdType="pubmed">34890242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47:410&#x2013;7. doi: 10.1086/589865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/589865</ArticleId><ArticleId IdType="pubmed">18582203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurain K, Yarchoan R, Ramaswami R. Immunotherapy for KSHV-associated diseases. Curr Opin Virol. 2022;55:101249. doi: 10.1016/j.coviro.2022.101249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2022.101249</ArticleId><ArticleId IdType="pmc">PMC9464688</ArticleId><ArticleId IdType="pubmed">35803203</ArticleId></ArticleIdList></Reference><Reference><Citation>Krown SE, Li P, Von Roenn JH, et al. Efficacy of Low-Dose Interferon with Antiretroviral Therapy in Kaposi&#x2019;s Sarcoma: A Randomized Phase II AIDS Clinical Trials Group Study. J Interferon Cytokine Res. 2002;22:295&#x2013;303. doi: 10.1089/107999002753675712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999002753675712</ArticleId><ArticleId IdType="pubmed">12034036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami R, Polizzotto MN, Lurain K, et al. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res. 2022;28:840&#x2013;50. doi: 10.1158/1078-0432.CCR-21-3364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-3364</ArticleId><ArticleId IdType="pmc">PMC8898289</ArticleId><ArticleId IdType="pubmed">34862247</ArticleId></ArticleIdList></Reference><Reference><Citation>Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for Symptomatic Kaposi&#x2019;s Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol. 2016;34:4125&#x2013;31. doi: 10.1200/JCO.2016.69.3812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.69.3812</ArticleId><ArticleId IdType="pmc">PMC5477825</ArticleId><ArticleId IdType="pubmed">27863194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurain K, Polizzotto MN, Krug LT, et al. Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration. AIDS. 2023;37:1693&#x2013;703. doi: 10.1097/QAD.0000000000003627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003627</ArticleId><ArticleId IdType="pmc">PMC10527758</ArticleId><ArticleId IdType="pubmed">37352498</ArticleId></ArticleIdList></Reference><Reference><Citation>Delyon J, Biard L, Renaud M, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi&#x2019;s sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2022;23:491&#x2013;500. doi: 10.1016/S1470-2045(22)00097-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00097-3</ArticleId><ArticleId IdType="pubmed">35279271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurain K, Ramaswami R, Ekwede I, et al. 1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS) Ann Oncol. 2023;34 doi: 10.1016/j.annonc.2023.09.1208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.09.1208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020;26:1468&#x2013;79. doi: 10.1038/s41591-020-1006-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1006-1</ArticleId><ArticleId IdType="pmc">PMC9673009</ArticleId><ArticleId IdType="pubmed">32778827</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SA, Wu D-C, Cheung J, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1:681&#x2013;91. doi: 10.1038/s43018-020-0075-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-020-0075-x</ArticleId><ArticleId IdType="pubmed">35122038</ArticleId></ArticleIdList></Reference><Reference><Citation>Buentke E, Mathiot A, Tolaini M, et al. Do CD8 effector cells need IL-7R expression to become resting memory cells? Blood. 2006;108:1949&#x2013;56. doi: 10.1182/blood-2006-04-016857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-04-016857</ArticleId><ArticleId IdType="pubmed">16705084</ArticleId></ArticleIdList></Reference><Reference><Citation>Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20:1584&#x2013;93. doi: 10.1038/s41590-019-0479-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0479-x</ArticleId><ArticleId IdType="pubmed">31745336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolotin E, Annett G, Parkman R, et al. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999;23:783&#x2013;8. doi: 10.1038/sj.bmt.1701655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1701655</ArticleId><ArticleId IdType="pubmed">10231140</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73&#x2013;9. doi: 10.1038/83381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/83381</ArticleId><ArticleId IdType="pubmed">11135619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983&#x2013;90. doi: 10.1182/blood.v97.10.2983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v97.10.2983</ArticleId><ArticleId IdType="pubmed">11342421</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis. 2012;55:291&#x2013;300. doi: 10.1093/cid/cis383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis383</ArticleId><ArticleId IdType="pmc">PMC3381639</ArticleId><ArticleId IdType="pubmed">22550117</ArticleId></ArticleIdList></Reference><Reference><Citation>Thi&#xe9;baut R, Jarne A, Routy J-P, et al. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clin Infect Dis. 2016;62:1178&#x2013;85. doi: 10.1093/cid/ciw065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw065</ArticleId><ArticleId IdType="pmc">PMC4826452</ArticleId><ArticleId IdType="pubmed">26908786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009;113:6304&#x2013;14. doi: 10.1182/blood-2008-10-186601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-10-186601</ArticleId><ArticleId IdType="pmc">PMC2710926</ArticleId><ArticleId IdType="pubmed">19380868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg SA, Sport&#xe8;s C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29:313&#x2013;9. doi: 10.1097/01.cji.0000210386.55951.c2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cji.0000210386.55951.c2</ArticleId><ArticleId IdType="pmc">PMC1473976</ArticleId><ArticleId IdType="pubmed">16699374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Lee SW, Koh J-Y, et al. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions. Blood Adv. 2022;6:6093&#x2013;107. doi: 10.1182/bloodadvances.2021006591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006591</ArticleId><ArticleId IdType="pmc">PMC9772483</ArticleId><ArticleId IdType="pubmed">36206199</ArticleId></ArticleIdList></Reference><Reference><Citation>Krown SE, Metroka C, Wernz JC. Kaposi&#x2019;s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201&#x2013;7. doi: 10.1200/JCO.1989.7.9.1201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.1989.7.9.1201</ArticleId><ArticleId IdType="pubmed">2671281</ArticleId></ArticleIdList></Reference><Reference><Citation>Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12:191&#x2013;200. doi: 10.1038/nri3158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3158</ArticleId><ArticleId IdType="pmc">PMC3409649</ArticleId><ArticleId IdType="pubmed">22343568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L, Speiser DE, Lichterfeld M, et al. T memory stem cells in health and disease. Nat Med. 2017;23:18&#x2013;27. doi: 10.1038/nm.4241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4241</ArticleId><ArticleId IdType="pmc">PMC6354775</ArticleId><ArticleId IdType="pubmed">28060797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116:3969&#x2013;77. doi: 10.1002/cncr.25362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.25362</ArticleId><ArticleId IdType="pmc">PMC3157242</ArticleId><ArticleId IdType="pubmed">20564162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi&#x2019;s sarcoma. Oncologist. 2007;12:114&#x2013;23. doi: 10.1634/theoncologist.12-1-114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.12-1-114</ArticleId><ArticleId IdType="pubmed">17227906</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid EG, Shimabukuro K, Moore P, et al. AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. Clin Cancer Res. 2022;28:2646&#x2013;56. doi: 10.1158/1078-0432.CCR-21-0645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-0645</ArticleId><ArticleId IdType="pmc">PMC9197984</ArticleId><ArticleId IdType="pubmed">35247913</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilho JL, Bian A, Jenkins CA, et al. CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. JNCI. 2022;114:854&#x2013;62. doi: 10.1093/jnci/djac053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djac053</ArticleId><ArticleId IdType="pmc">PMC9194634</ArticleId><ArticleId IdType="pubmed">35292820</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Guti&#xe9;rrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect. 2013;66:57&#x2013;66. doi: 10.1016/j.jinf.2012.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2012.09.013</ArticleId><ArticleId IdType="pubmed">23046968</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078. doi: 10.1371/journal.ppat.1004078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004078</ArticleId><ArticleId IdType="pmc">PMC4022662</ArticleId><ArticleId IdType="pubmed">24831517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31&#x2013;46. doi: 10.1158/2159-8290.CD-21-1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1059</ArticleId><ArticleId IdType="pubmed">35022204</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S, Silva H, Cumano A, et al. Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. J Exp Med. 2005;201:971&#x2013;9. doi: 10.1084/jem.20042393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20042393</ArticleId><ArticleId IdType="pmc">PMC2213099</ArticleId><ArticleId IdType="pubmed">15767371</ArticleId></ArticleIdList></Reference><Reference><Citation>Perales M-A, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012;120:4882&#x2013;91. doi: 10.1182/blood-2012-06-437236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-06-437236</ArticleId><ArticleId IdType="pmc">PMC3520625</ArticleId><ArticleId IdType="pubmed">23012326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sport&#xe8;s C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008;205:1701&#x2013;14. doi: 10.1084/jem.20071681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20071681</ArticleId><ArticleId IdType="pmc">PMC2442646</ArticleId><ArticleId IdType="pubmed">18573906</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamichi H, Degray G, Asmuth DM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011;25:159&#x2013;64. doi: 10.1097/QAD.0b013e328340a270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e328340a270</ArticleId><ArticleId IdType="pmc">PMC3074174</ArticleId><ArticleId IdType="pubmed">21124203</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood. 2013;121:4321&#x2013;9. doi: 10.1182/blood-2012-11-465625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-11-465625</ArticleId><ArticleId IdType="pmc">PMC3663425</ArticleId><ArticleId IdType="pubmed">23589672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurain K, Ramaswami R, Ekwede I, et al. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. J Clin Oncol. 2024;0 doi: 10.1200/JCO.24.00640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.24.00640</ArticleId><ArticleId IdType="pmc">PMC11779594</ArticleId><ArticleId IdType="pubmed">39356983</ArticleId></ArticleIdList></Reference><Reference><Citation>Uldrick TS, Adams SV, Fromentin R, et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med. 2022;14:eabl3836. doi: 10.1126/scitranslmed.abl3836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl3836</ArticleId><ArticleId IdType="pmc">PMC9014398</ArticleId><ArticleId IdType="pubmed">35080914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>